{
  "file_name": "예방용+mRNA+백신+평가+가이드라인.pdf",
  "total_pages": 72,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "8.992650032043457": 2,
      "26.03999900817871": 1,
      "15.555883407592773": 1,
      "15.960000038146973": 50,
      "12.0": 3641,
      "8.772114753723145": 71,
      "17.03999900817871": 1,
      "11.039999961853027": 854,
      "14.039999961853027": 35,
      "12.960000038146973": 3,
      "20.03999900817871": 5,
      "15.0": 2,
      "24.0": 3,
      "21.959999084472656": 1,
      "11.696152687072754": 44,
      "9.960000038146973": 9
    },
    "heading_sizes": [
      24.0,
      20.03999900817871,
      15.960000038146973,
      15.0,
      14.039999961853027,
      12.960000038146973
    ]
  },
  "table_analysis": {
    "total_tables": 2,
    "tables_info": [
      {
        "bbox": [
          82.55999755859375,
          181.18429565429688,
          534.0407104492188,
          769.2283325195312
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          84.72000122070312,
          307.32000732421875,
          528.9072265625,
          655.3079833984375
        ],
        "num_rows": 5,
        "num_cols": 2
      }
    ]
  },
  "text_blocks": [
    {
      "text": "청렴한 식약처",
      "font_size": 8.992650032043457,
      "font_name": "Gungsuh",
      "bbox": [
        67.1635971069336,
        154.1060028076172,
        125.57194519042969,
        163.09617614746094
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국민 안심의 시작",
      "font_size": 8.992650032043457,
      "font_name": "Gungsuh",
      "bbox": [
        60.32730484008789,
        163.09617614746094,
        132.28829956054688,
        172.0863494873047
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방용 mRNA 백신 평가 가이드라인",
      "font_size": 26.03999900817871,
      "font_name": "T3",
      "bbox": [
        88.43999481201172,
        282.239990234375,
        506.7610168457031,
        313.4880065917969
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline on Evaluation of Prophylactic mRNA Vaccines",
      "font_size": 15.555883407592773,
      "font_name": "T4",
      "bbox": [
        98.15999603271484,
        325.44000244140625,
        496.7367248535156,
        344.5760192871094
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2022. 01. 27",
      "font_size": 15.960000038146973,
      "font_name": "T4",
      "bbox": [
        253.79998779296875,
        498.4800109863281,
        341.4287414550781,
        517.6160278320312
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오생약심사부 생물제제과",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        200.0399932861328,
        682.0994262695312,
        395.03997802734375,
        698.0603637695312
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        170.0399932861328,
        94.8128890991211,
        425.0407409667969,
        111.8528823852539
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.27999877929688,
        132.46429443359375,
        460.1913146972656,
        147.1483612060547
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방용 RNA 백신 평가 가이드라인(민원인 안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.27999877929688,
        132.46429443359375,
        460.1913146972656,
        147.1483612060547
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        167.16000366210938,
        159.34429931640625,
        428.40936279296875,
        174.0283660888672
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        71.5199966430664,
        321.70428466796875,
        115.55966186523438,
        336.38836669921875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.55999755859375,
        339.2242736816406,
        104.51966094970703,
        353.9083557128906
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        181.18429565429688,
        423.1609191894531,
        195.8683624267578
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.59999084472656,
        197.74429321289062,
        297.041015625,
        212.42835998535156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        181.7843017578125,
        507.3596496582031,
        211.82835388183594
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        181.7843017578125,
        507.3596496582031,
        211.82835388183594
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        222.8242950439453,
        531.2396240234375,
        237.50836181640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        239.38429260253906,
        535.1214599609375,
        270.62835693359375
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        239.38429260253906,
        535.1214599609375,
        270.62835693359375
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        272.38427734375,
        526.2037353515625,
        287.068359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        293.2642822265625,
        315.4010009765625,
        307.9483642578125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.59999084472656,
        309.82427978515625,
        416.4410095214844,
        341.068359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.59999084472656,
        309.82427978515625,
        416.4410095214844,
        341.068359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        302.144287109375,
        507.3596496582031,
        332.1883544921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        302.144287109375,
        507.3596496582031,
        332.1883544921875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        340.18426513671875,
        507.3596496582031,
        370.2283630371094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        340.18426513671875,
        507.3596496582031,
        370.2283630371094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        340.18426513671875,
        507.3596496582031,
        370.2283630371094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        369.3442687988281,
        451.2409362792969,
        384.0283508300781
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        384.82427978515625,
        210.0379638671875,
        399.50836181640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        369.3442687988281,
        507.3596496582031,
        399.50836181640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        369.3442687988281,
        507.3596496582031,
        399.50836181640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        398.624267578125,
        507.3596496582031,
        428.6683654785156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        398.624267578125,
        507.3596496582031,
        428.6683654785156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        398.624267578125,
        507.3596496582031,
        428.6683654785156
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        427.7842712402344,
        439.6009216308594,
        442.4683532714844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        443.2642822265625,
        252.28102111816406,
        457.9483642578125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        427.7842712402344,
        507.3596496582031,
        457.9483642578125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        427.7842712402344,
        507.3596496582031,
        457.9483642578125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        462.2242736816406,
        528.4013061523438,
        493.4683532714844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        462.2242736816406,
        528.4013061523438,
        493.4683532714844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.959999084472656,
        528.3442993164062,
        127.00350189208984,
        543.0283203125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        84.0,
        545.9843139648438,
        103.08042907714844,
        560.6683349609375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        502.9042663574219,
        447.599853515625,
        517.5883178710938
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.0,
        518.2642822265625,
        432.3637390136719,
        532.9483032226562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        502.9042663574219,
        534.0407104492188,
        532.9483032226562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        502.9042663574219,
        534.0407104492188,
        532.9483032226562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        541.42431640625,
        451.4812316894531,
        556.1083374023438
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.0,
        556.904296875,
        447.5997009277344,
        586.9483032226562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 것입니까? (민원인용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.0,
        556.904296875,
        447.5997009277344,
        586.9483032226562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        549.2243041992188,
        535.1206665039062,
        579.268310546875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        549.2243041992188,
        535.1206665039062,
        579.268310546875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기타 확인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.76000213623047,
        615.2243041992188,
        118.31999969482422,
        629.9083251953125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.55999755859375,
        632.8643188476562,
        104.51966094970703,
        647.54833984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        596.8643188476562,
        434.2002868652344,
        611.54833984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.0,
        612.2243041992188,
        336.5179748535156,
        626.9083251953125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        596.8643188476562,
        507.3596496582031,
        626.9083251953125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.79998779296875,
        596.8643188476562,
        507.3596496582031,
        626.9083251953125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        133.44000244140625,
        636.9442749023438,
        531.2415771484375,
        651.6282958984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        653.5042724609375,
        371.5350036621094,
        668.1882934570312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        215.39999389648438,
        675.7042846679688,
        381.2493591308594,
        690.3883056640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2022년   01월   27일",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        221.75999450683594,
        710.0242919921875,
        363.3600158691406,
        724.7083129882812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당자",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        329.8800048828125,
        740.2642822265625,
        404.7513122558594,
        769.2283325195312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        329.8800048828125,
        740.2642822265625,
        404.7513122558594,
        769.2283325195312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배창준",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        489.9599914550781,
        738.5842895507812,
        523.5591430664062,
        753.268310546875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김재옥",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        489.9599914550781,
        756.2243041992188,
        523.5591430664062,
        770.9083251953125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        85.19999694824219,
        93.07916259765625,
        529.5762939453125,
        111.75345611572266
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        122.47915649414062,
        529.6962890625,
        141.15345764160156
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효력을 가지는 것이 아닙니다.",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        151.87916564941406,
        259.271240234375,
        170.553466796875
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        85.19999694824219,
        191.23915100097656,
        524.7601928710938,
        209.9134521484375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        220.63916015625,
        529.6959228515625,
        239.31346130371094
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 사항이 아님을 알려드립니다. 또한, 본 안내서는 2022년 01월 27일 현재의",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        250.03916931152344,
        529.6959228515625,
        268.7134704589844
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        279.43914794921875,
        543.7359008789062,
        298.11346435546875
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        308.8391418457031,
        527.6558837890625,
        327.5134582519531
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        76.91999816894531,
        361.0146179199219,
        529.3162231445312,
        378.2524108886719
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        101.04000091552734,
        377.9346008300781,
        535.7962646484375,
        412.9324035644531
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)",
      "font_size": 12.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        101.04000091552734,
        377.9346008300781,
        535.7962646484375,
        412.9324035644531
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        62.52000045776367,
        459.37945556640625,
        498.13873291015625,
        475.34039306640625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오생약심사부 생물제제과에 문의하시기 바랍니다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        483.37945556640625,
        383.625,
        499.34039306640625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화번호 : 043-719-3451",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        507.37945556640625,
        219.12936401367188,
        523.3403930664062
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "팩스번호 : 043-719-3450",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        56.63999938964844,
        531.3794555664062,
        219.12936401367188,
        547.3403930664062
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정 이력서",
      "font_size": 20.03999900817871,
      "font_name": "MalgunGothicBold",
      "bbox": [
        230.39999389648438,
        80.30888366699219,
        364.7997741699219,
        106.9636459350586
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방용 mRNA 백신 평가 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        118.79999542236328,
        181.19430541992188,
        479.8486328125,
        201.14547729492188
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연번",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.5199966430664,
        288.37945556640625,
        452.7599792480469,
        304.34039306640625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정번호",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.5199966430664,
        288.37945556640625,
        452.7599792480469,
        304.34039306640625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발행일자",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.5199966430664,
        288.37945556640625,
        452.7599792480469,
        304.34039306640625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요내용",
      "font_size": 12.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.5199966430664,
        288.37945556640625,
        452.7599792480469,
        304.34039306640625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        77.27999877929688,
        318.25946044921875,
        439.3202819824219,
        334.22039794921875
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-1191-01",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        77.27999877929688,
        318.25946044921875,
        439.3202819824219,
        334.22039794921875
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2022.01.27",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        77.27999877929688,
        318.25946044921875,
        439.3202819824219,
        334.22039794921875
      ],
      "page_num": 4,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제정",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        77.27999877929688,
        318.25946044921875,
        439.3202819824219,
        334.22039794921875
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목",
      "font_size": 24.0,
      "font_name": "T11",
      "bbox": [
        254.39999389648438,
        81.47999572753906,
        339.6000061035156,
        110.25599670410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차",
      "font_size": 24.0,
      "font_name": "T11",
      "bbox": [
        254.39999389648438,
        81.47999572753906,
        339.6000061035156,
        110.25599670410156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어설명 ···················································································································6",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        60.959999084472656,
        147.0,
        534.2719116210938,
        163.84799194335938
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 서론 ····················································································································11",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        60.959999084472656,
        169.32000732421875,
        534.2716064453125,
        186.16799926757812
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.1. 배경 ··············································································································11",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        191.75999450683594,
        534.2716064453125,
        208.6079864501953
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.2. 목적 및 범위 ······························································································12",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        214.1999969482422,
        534.2716064453125,
        231.04798889160156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.3. 일반적 고려사항 ························································································13",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        236.52000427246094,
        534.2716064453125,
        253.3679962158203
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.4. 특이적 고려사항 ························································································15",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        258.9599914550781,
        534.2716064453125,
        275.8080139160156
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 품질 평가 ··········································································································21",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        60.959999084472656,
        281.3999938964844,
        534.2716064453125,
        298.2480163574219
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.1. 일반적 사항 ································································································21",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        303.719970703125,
        534.2716064453125,
        320.5679931640625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.2. 제조에 관한 사항 ······················································································23",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        326.15997314453125,
        534.2716064453125,
        343.00799560546875
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.3. 백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        348.5999755859375,
        534.2716064453125,
        365.447998046875
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.4. 출발물질, 원료약품, 첨가제의 관리 ······················································31",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        370.91998291015625,
        534.2716064453125,
        387.76800537109375
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.5. 공정개발 및 공정 중 관리 ······································································33",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        393.3599853515625,
        534.2716064453125,
        410.2080078125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.6. 제품 특성 분석 ··························································································33",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        415.79998779296875,
        534.2716064453125,
        432.64801025390625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.7. 제조의 일관성 ····························································································36",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        438.1199951171875,
        534.2716064453125,
        454.968017578125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8. 정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        460.5599670410156,
        534.2716064453125,
        477.4079895019531
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9. 최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        482.9999694824219,
        534.2716064453125,
        499.8479919433594
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.10. 기록 ············································································································52",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        505.3199768066406,
        534.2716064453125,
        522.16796875
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.11. 보관검체 ····································································································53",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        527.760009765625,
        534.2716064453125,
        544.6079711914062
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 비임상 평가 ······································································································54",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        60.959999084472656,
        550.2000122070312,
        534.2716064453125,
        567.0479736328125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.1. 약리작용 ······································································································54",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        572.52001953125,
        534.2716064453125,
        589.3679809570312
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.2. 독성 ··············································································································55",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        594.9600219726562,
        534.2716064453125,
        611.8079833984375
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.3. 비임상 평가의 가속화 ··············································································58",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        617.4000244140625,
        534.2716064453125,
        634.2479858398438
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 임상 평가 ··········································································································60",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        60.959999084472656,
        639.7200317382812,
        534.2716064453125,
        656.5679931640625
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.1. 안전성 및 면역원성 평가 ········································································60",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        662.1600341796875,
        534.2716064453125,
        679.0079956054688
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.2. 유효성 평가 ································································································63",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        684.6000366210938,
        534.2716064453125,
        701.447998046875
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.3. 공중 위기 맥락에서의 유효성 평가 ······················································64",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        70.91999816894531,
        706.9199829101562,
        534.2716064453125,
        723.7679443359375
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[참고문헌] ···············································································································65",
      "font_size": 14.039999961853027,
      "font_name": "T7",
      "bbox": [
        61.07999801635742,
        729.3599853515625,
        534.1524047851562,
        746.2079467773438
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어설명",
      "font_size": 24.0,
      "font_name": "T11",
      "bbox": [
        247.1999969482422,
        81.47999572753906,
        346.79998779296875,
        110.25599670410156
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다. 이 용어는 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        66.5999984741211,
        143.27999877929688,
        538.5599975585938,
        157.66799926757812
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "맥락에서는 의미가 다를 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        167.27999877929688,
        227.61599731445312,
        181.66799926757812
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        220.3199920654297,
        538.4400024414062,
        234.71998596191406
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 물질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        244.32000732421875,
        116.04000091552734,
        258.7080078125
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        278.2799987792969,
        538.4400024414062,
        292.67999267578125
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가를 받지 않은 임상시험용 백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        302.2799987792969,
        245.0399932861328,
        316.6679992675781
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        336.239990234375,
        538.5599975585938,
        350.6399841308594
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상관관계를 결정하는 구조화되고 조직화된 접근법. 이 용어는 ICH Q8(R2)에서 언급하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        360.239990234375,
        538.4400024414062,
        374.62799072265625
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        384.239990234375,
        92.01599884033203,
        398.62799072265625
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 완제의약품(drug product) : 최종 백신(final vaccine) 참조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        418.3199768066406,
        369.1199951171875,
        432.719970703125
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        452.2799987792969,
        538.5360107421875,
        466.67999267578125
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 혼합물). 단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        476.2799987792969,
        538.5599975585938,
        490.6679992675781
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        500.27996826171875,
        423.9360046386719,
        514.66796875
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        534.239990234375,
        538.4400024414062,
        548.6400146484375
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조). 이 두 가닥 RNA는 세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        558.239990234375,
        538.4400024414062,
        572.6279907226562
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다. 제조방법에 따라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        582.239990234375,
        538.5599975585938,
        596.6279907226562
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        606.239990234375,
        538.5599975585938,
        620.6279907226562
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dsRNA가 생성될 수 있다. 이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        630.239990234375,
        538.4400024414062,
        644.6279907226562
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다. 만일 제조공정 중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        654.239990234375,
        538.4400024414062,
        668.6279907226562
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        678.239990234375,
        428.7359924316406,
        692.6279907226562
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        712.3200073242188,
        538.5599975585938,
        726.7200317382812
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        736.3200073242188,
        506.0159912109375,
        750.7080078125
      ],
      "page_num": 6,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        88.31999969482422,
        538.5599975585938,
        102.72000122070312
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성요소. 대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.4400024414062,
        126.70800018310547
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려진 작용이나 효과를 발휘할 수 있다. 첨가제는 의약품의 안전한 사용을 보장하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        136.3199920654297,
        538.5599975585938,
        150.70799255371094
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다. 본 문서의 맥락에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        160.3199920654297,
        538.4400024414062,
        174.70799255371094
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        184.3199920654297,
        538.4879760742188,
        198.70799255371094
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "product)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        208.3199920654297,
        538.4400024414062,
        222.70799255371094
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        232.3199920654297,
        92.01599884033203,
        246.70799255371094
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        266.2799987792969,
        538.416015625,
        280.67999267578125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        290.2799987792969,
        538.4400024414062,
        304.6679992675781
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되어 있다. 다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        314.2799987792969,
        538.4400024414062,
        328.6679992675781
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "희석할 수 있다. 본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        338.2799987792969,
        538.4400024414062,
        352.6679992675781
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA를 지칭한다. 만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        362.2799987792969,
        538.4400024414062,
        376.6679992675781
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        386.2799987792969,
        419.0159912109375,
        400.6679992675781
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        420.239990234375,
        538.4400024414062,
        434.6399841308594
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용기들의 집합. 따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        444.239990234375,
        538.4400024414062,
        458.62799072265625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충전해야 한다. 최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        468.239990234375,
        437.0159912109375,
        482.62799072265625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        502.32000732421875,
        538.5599975585938,
        516.7200317382812
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        526.3200073242188,
        538.4400024414062,
        540.7080078125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형(dosage form)(예: 현탁액 또는 동결건조 분말). 본 문서에서는 지질나노입자 및 기타",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        550.3200073242188,
        538.4400024414062,
        564.7080078125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다. 그 외에도, 최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        574.3200073242188,
        538.5599975585938,
        588.7080078125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        598.3200073242188,
        538.5599975585938,
        612.7080078125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충전해야 한다. 다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        622.3200073242188,
        494.2560119628906,
        636.7080078125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        656.2799682617188,
        538.5599975585938,
        670.6799926757812
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        680.2799682617188,
        389.03997802734375,
        694.66796875
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        714.239990234375,
        538.4400024414062,
        728.6400146484375
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유발하는 능력",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        738.239990234375,
        140.0399932861328,
        752.6279907226562
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        88.31999969482422,
        538.4400024414062,
        102.72000122070312
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소(phage",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "polymerase))",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오시드",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3인산염(nucleoside",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.5360107421875,
        126.70800018310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "triphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        136.3199920654297,
        538.4400024414062,
        150.70799255371094
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성하는 제조공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        160.3199920654297,
        164.0399932861328,
        174.70799255371094
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        194.27999877929688,
        538.5599975585938,
        208.67999267578125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        218.27999877929688,
        538.4400024414062,
        232.66799926757812
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형. 지질 성분은 이온화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        242.27999877929688,
        538.5599975585938,
        256.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한/양이온성의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도움",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질(예,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "콜레스테롤),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        538.5360107421875,
        280.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "페길화((polyethylene-glycol-ylation(PEGylation))와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        290.2799987792969,
        538.5599975585938,
        304.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        290.2799987792969,
        538.5599975585938,
        304.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        290.2799987792969,
        538.5599975585938,
        304.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질을 포함한다(다만",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        290.2799987792969,
        538.5599975585938,
        304.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여기에 국한되는 것은 아님). LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        314.2799987792969,
        526.7760009765625,
        328.6679992675781
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        348.239990234375,
        538.4400024414062,
        362.6399841308594
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가. 식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        372.239990234375,
        538.5599975585938,
        386.62799072265625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다. 품목허가가 되면 새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.04000091552734,
        396.239990234375,
        538.4400024414062,
        410.62799072265625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        420.239990234375,
        425.0159912109375,
        434.62799072265625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 작용기작/작용기전(mode/mechanism",
      "font_size": 12.0,
      "font_name": "T4",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 12.0,
      "font_name": "T4",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "action)",
      "font_size": 12.0,
      "font_name": "T4",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포(mode)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        454.3199768066406,
        538.4400024414062,
        468.719970703125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        478.3199768066406,
        538.5360107421875,
        492.7079772949219
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        502.32000732421875,
        538.5360107421875,
        516.7080078125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "T-세포에 의한 세포독성(cytotoxicity))",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        526.3200073242188,
        264.2640075683594,
        540.7080078125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        560.2799682617188,
        538.4400024414062,
        574.6799926757812
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 우리딘(uridine))를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        584.2799682617188,
        538.5360107421875,
        598.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        584.2799682617188,
        538.5360107421875,
        598.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        584.2799682617188,
        538.5360107421875,
        598.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 자연",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        584.2799682617188,
        538.5360107421875,
        598.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        584.2799682617188,
        538.5360107421875,
        598.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변형된 뉴클레오시드(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        584.2799682617188,
        538.5360107421875,
        598.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        608.2799682617188,
        538.4400024414062,
        622.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재력이 있음. 다른 변형의 종류로는 메틸화(methylation)가 있다. 뉴클레오시드는 또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        632.2799682617188,
        538.4400024414062,
        646.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비자연적 변형을 포함하고 있을 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        656.2799682617188,
        287.0160217285156,
        670.66796875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율. 또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        690.239990234375,
        538.5599975585938,
        704.6400146484375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의 염기서열이 정확한지도 확인되어야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        714.239990234375,
        333.9360046386719,
        728.6279907226562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        288.7200012207031,
        789.0,
        306.4176330566406,
        799.791015625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        88.31999969482422,
        538.5360107421875,
        102.72000122070312
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.04000091552734,
        112.31999969482422,
        538.4400024414062,
        126.70800018310547
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        136.3199920654297,
        508.2959899902344,
        150.70799255371094
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        170.27999877929688,
        538.4400024414062,
        184.67999267578125
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        194.27999877929688,
        538.4400024414062,
        208.66799926757812
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        218.27999877929688,
        538.4400024414062,
        232.66799926757812
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제작하여) 사용하지 않는 첨가제. “새로운”이란 단어는 본 문서의 다른 부분에서 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        242.27999877929688,
        538.5599975585938,
        256.6679992675781
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어를 설명하기 위해 같은 방식으로 사용하고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        266.2799987792969,
        338.0159912109375,
        280.6679992675781
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        300.239990234375,
        538.5599975585938,
        314.6399841308594
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 기술들의 모음. mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        324.239990234375,
        538.4400024414062,
        338.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        348.239990234375,
        538.4400024414062,
        362.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        372.239990234375,
        538.4400024414062,
        386.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있을 수도 있다. 제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        396.239990234375,
        538.5599975585938,
        410.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        420.239990234375,
        538.5599975585938,
        434.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        444.239990234375,
        538.4400024414062,
        458.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다. 새로운 후보백신 개발을 위한 플랫폼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.04000091552734,
        468.239990234375,
        538.4400024414062,
        482.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        492.239990234375,
        538.5360107421875,
        506.62799072265625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        516.239990234375,
        538.5599975585938,
        530.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다. 안전한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        540.239990234375,
        538.4400024414062,
        554.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        564.239990234375,
        538.4400024414062,
        578.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.04000091552734,
        588.239990234375,
        538.4400024414062,
        602.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다. mRNA 서열과 더불어, 이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        612.239990234375,
        538.4400024414062,
        626.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        636.239990234375,
        538.5599975585938,
        650.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다. mRNA 백신을 위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        660.239990234375,
        538.4400024414062,
        674.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        684.239990234375,
        538.4400024414062,
        698.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다. 만일 근거를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        708.239990234375,
        538.5599975585938,
        722.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        732.239990234375,
        538.5599975585938,
        746.6279907226562
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간주할 수 있으며 보조자료로 평가할 수 있다. 더 나아가, 플랫폼 기술 사용에도 불구하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다. 언제나 그러하듯,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        131.27999877929688,
        413.0159912109375,
        145.66799926757812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· sa-mRNA(self-amplifying",
      "font_size": 12.0,
      "font_name": "T4",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA)",
      "font_size": 12.0,
      "font_name": "T4",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목표로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외에도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        165.239990234375,
        538.4400024414062,
        179.63998413085938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        189.239990234375,
        538.4400024414062,
        203.62799072265625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의 분자에) 코딩하는 mRNA 백신. 이러한 ORF가 세포 내 발현 시 알파바이러스의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        213.239990234375,
        538.5599975585938,
        227.62799072265625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        237.239990234375,
        538.4400024414062,
        251.62799072265625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 카피를 생산할 수 있게 된다. sa-mRNA의 목적은 생성되는 단백질 항원의 양을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        261.239990234375,
        538.4400024414062,
        275.62799072265625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다. 이러한 형태의 mRNA 백신에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        285.239990234375,
        538.4400024414062,
        299.62799072265625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        309.239990234375,
        471.9360046386719,
        323.62799072265625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        343.3199768066406,
        538.4400024414062,
        357.719970703125
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부. 다른 말로 하면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        367.3199768066406,
        538.4400024414062,
        381.7079772949219
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        391.3199768066406,
        538.5599975585938,
        405.7079772949219
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과적인 면역반응에 의해 유도될 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        415.3199768066406,
        287.0160217285156,
        429.7079772949219
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        56.63999938964844,
        449.2799987792969,
        538.5360107421875,
        463.67999267578125
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료. 본 문서에서는 예방",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        473.2799987792969,
        538.4400024414062,
        487.6679992675781
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다. 위와 같이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.04000091552734,
        497.2799987792969,
        538.4400024414062,
        511.6679992675781
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의된 치료제는 본 문서의 범위 밖이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        521.2799682617188,
        275.0160217285156,
        535.66796875
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        56.63999938964844,
        555.239990234375,
        538.4400024414062,
        569.6400146484375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.04000091552734,
        579.239990234375,
        357.5760192871094,
        593.6279907226562
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방용 mRNA 백신 평가 가이드라인",
      "font_size": 21.959999084472656,
      "font_name": "MalgunGothicBold",
      "bbox": [
        111.5999984741211,
        79.8991928100586,
        483.60076904296875,
        109.10771179199219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 서론",
      "font_size": 20.03999900817871,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        190.0800018310547,
        122.6399154663086,
        214.1079559326172
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.1. 배경",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        250.6799774169922,
        126.23949432373047,
        269.8160095214844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5599975585938,
        297.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2). 그 후 이어진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        331.32000732421875,
        538.4400024414062,
        345.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.5599975585938,
        393.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상당한 진보가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.5599975585938,
        393.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이루어졌다(3-6). mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부상하게 된 데에는 몇 가지 이유가 있다. 그러한 이유 중에는 mRNA 기반 후보 백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        444.57598876953125,
        513.7079467773438
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다루고 있다 (7~11). 또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5360107421875,
        561.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.4400024414062,
        585.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.5599975585938,
        609.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인의 긴급한 필요성이 대두되었다. 이러한 평가 시에는 (a) mRNA의 본질적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시 고려해야 한다. 생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.5360107421875,
        705.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.4400024414062,
        753.7080078125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고사항의 수립이 가능하지 않다. 따라서 현재 규제적인 유연성이 필요하며, mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5239868164062,
        97.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다. 그럼에도 본 문서에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용이 가능해질 때까지 지침을 제공하고자 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        339.5760192871094,
        193.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다. 그러나 이러한 결정은 최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의 결과적인 특성에 따라 달라질 것이다. 최종 백신의 유의한 변경으로 인해 세포의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        450.57598876953125,
        337.6679992675781
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.2. 목적 및 범위",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        366.7200012207031,
        192.59950256347656,
        385.85601806640625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다. 개발 단계별로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.4400024414062,
        437.62799072265625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다. 이 제품군에서 개발이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.4400024414062,
        461.62799072265625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.4400024414062,
        485.62799072265625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다. 그러나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.5599975585938,
        509.62799072265625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        519.239990234375,
        538.5599975585938,
        533.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하고자 한다. 그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        567.239990234375,
        538.4400024414062,
        581.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        591.239990234375,
        538.5599975585938,
        605.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        615.239990234375,
        538.4400024414062,
        629.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점에 유의해야 한다. 각각의 유익성과 위해성에 대한 평가가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        447.57598876953125,
        653.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        687.239990234375,
        538.5239868164062,
        701.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다. mRNA 백신과 제조공정의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.4400024414062,
        725.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5599975585938,
        749.6279907226562
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "채택하였다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        144.57598876953125,
        121.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한하고 있다. 지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서의 일부는 이러한 제품에도 적용할 수 있다. 복제 인자 및 바이러스 벡터, (바이러스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "속하지 않는다. 또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 제품) 역시 본 문서의 범위를 벗어나 있다. 추가로, 단클론항체를 발현하는 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5239868164062,
        313.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서의 범위 밖이다. mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.416015625,
        385.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다. 그러나 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        108.57599639892578,
        481.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요할 경우 특정 고려사항을 제공하고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        315.5760192871094,
        553.66796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다. 백신 제조 기술 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.416015625,
        601.66796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연계하여 읽어야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        198.57598876953125,
        649.66796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.3. 일반적 고려사항",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        682.6799926757812,
        218.27850341796875,
        701.8160400390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다. (규제자들이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.4400024414062,
        753.7080078125
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항들을 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        210.57598876953125,
        145.66799926757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.81124877929688
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.416015625,
        217.66799926757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다. 백신 설계의 근거에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        186.57598876953125,
        313.6679992675781
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.8112487792969
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명확하게 기술해야 한다. 마찬가지로, 표적 항원이 특정한 구조(conformation)로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적 항원의 변경을 선택한 근거를 제시해야 한다. (예상치 않은 ORF를 포함하여)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.4639892578125,
        433.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용에 대한 근거와 함께) 제공해야 한다. poly(A) tail과 같이 특정 혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조적 요소의 사용에 대한 근거를 제시해야 한다. sa-mRNA의 경우에는 전달 후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다. 특정 비코딩",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        108.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        587.2799682617188,
        538.5360107421875,
        601.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        611.2799682617188,
        527.4959716796875,
        625.66796875
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.8112182617188
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)의 제형화에 대해 기술해야 한다. 제안한 최종 백신 제품의 조성 및 첨가제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함에 대하여 적절한 근거를 제시해야 한다. 중간체와 최종 제품의 주요품질특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다. 독성 및 면역원성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가하는 것이 필요할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        107.27999877929688,
        267.5760192871094,
        121.66799926757812
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.81124877929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        445.656005859375,
        217.66799926757812
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.81124877929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명 및 근거를 제공해야 한다. 필요하면 관련된 적합성(compatability) 연구를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        186.57598876953125,
        289.6679992675781
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        96.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.8112487792969
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다. 해당 후보 백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        371.2799987792969,
        444.57598876953125,
        385.6679992675781
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.8112487792969
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될 수도 있다. 관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "HPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        515.2799682617188,
        538.5360107421875,
        529.66796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다. 다수의 질환에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        563.2799682617188,
        375.5760192871094,
        577.66796875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.4. 특이적 고려사항",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        610.6799926757812,
        218.27850341796875,
        629.8160400390625
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        643.3200073242188,
        538.5239868164062,
        657.7080078125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3). 제조는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.5599975585938,
        705.7080078125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.5599975585938,
        729.7080078125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.4400024414062,
        753.7080078125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5360107421875,
        97.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5239868164062,
        145.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형(template)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5239868164062,
        169.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5239868164062,
        169.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5239868164062,
        169.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전사하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5239868164062,
        169.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA-의존성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5239868164062,
        169.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5239868164062,
        169.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행한다. 일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5239868164062,
        217.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되어 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        159.57598876953125,
        265.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합성된 뉴클레오시드를 포함할 수 있다(3, 9). 자연 발생적 뉴클레오시드에 대한 변경의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시로는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우리딘(uridine)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "슈도우리딘(pseudouridine)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N1-메틸슈도우리딘(N1-methylpseudouridine)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된다(3,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA(tRNA)에 의한 번역을 위해). 그렇지 않으면, 단백질의 번역 속도를 낮추고 그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여 코돈을 선택할 수 있다. mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천성 면역체계의 활성을 완화하기 위해 설계되었다(4). 임상 적응증에 따라서, 체내",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소시키는 것이 바람직할 수 있다(3, 4, 14). 일부 예방 백신의 경우, 선천성 면역반응 중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA를 설계할 수 있다. 표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4639892578125,
        625.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tail이 있어야 한다(4). 효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.427978515625,
        649.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "analogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(3). 마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여 추가할 수 있다. 이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        486.57598876953125,
        745.66796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품에서 RNA가 취하는 구조이다. 일반적으로 이중 나선 형태인 DNA와는 달리,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.416015625,
        121.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대부분의 RNA는 단일 가닥이다. 그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.416015625,
        169.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5239868164062,
        193.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전체가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형태이며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감염에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5360107421875,
        241.66799926757812
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유발하지 않는다. mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        465.57598876953125,
        313.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA 기반 제품은 형태가 다를 수 있다. 가장 진전된 임상 후보 백신들 및 널리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(15, 16). 그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으므로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진전된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보백신들",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "널리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신들은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23). 지질나노입자는 조성 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24). 일부는 아직",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의 전달을 위해 사용하지 않았을 수 있다(25~28). 폴리머 및 폴리펩타이드를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다. 이러한 약물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        510.6960144042969,
        553.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        563.2799682617188,
        538.5360107421875,
        577.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부 품목의 경우 원료의약품으로 정의될 수 있다. 지질나노입자를 형성하는 지질은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 제조는 완제의약품 제조공정의 일부이다. 일부 지질나노입자는 그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화하지 않고 면역증강제로 작용할 수 있다. 그럼에도, 백신에 대하여 면역조절",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다. 이와 유사하게, 앞서 논한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바와 같이, RNA 자체가 면역조절 작용을 할 수 있다. 따라서, 두 가지 구성 요소(mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.4039916992188,
        745.66796875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        417.57598876953125,
        121.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된다. 이후 ‘1.3. 일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선례가 없는 것은 아니다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        213.57598876953125,
        241.66799926757812
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간주할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "균주(혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원)-특이적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나머지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA들에 대하여 반드시 대조해 보아야 한다. 추가로 최대내약(maximally tolerable)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4639892578125,
        385.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량의 달성을 고려해야 한다. 만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3. 비임상 평가의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가속화’, ‘4.1. 안전성 및 면역원성 평가’ 참고). 완제의약품의 적절한 품질관리를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        132.57598876953125,
        577.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의 길이 및 이차구조에 따라 달라질 수 있다. 그러므로, 다른 mRNA를 사용하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다. 따라서 최종 백신의 바람직한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이화학적 성질에 대한 고려가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        288.5760192871094,
        721.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        731.2799682617188,
        538.5239868164062,
        745.66796875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31). 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열을 지니고 있다. 그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수준의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sa-mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화한다(18). 표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있을 수 있다. 예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의 크기에 따라 달라질 수 있다. 또한, 안전성 프로파일의 차이를 가져올 수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        494.4960021972656,
        361.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(바이러스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입된)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "viral",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "replicon과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조적으로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sa-mRNA는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 또는 다른 전달 시스템으로 전달된다. 다시 말해, sa-mRNA는 세포 간의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다(18). 또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4639892578125,
        505.6679992675781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다. 따라서, 다양한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정된다. 다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된다. 그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 또는 sa-mRNA로 제한하고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        295.416015625,
        673.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다는 점에 유의해야 한다. 발현되는 표적 항원은 면역세포 특히 수지상 세포 등",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원제시세포와 같은 면역세포에 의해 제시된다. 그러나 현재 mRNA 백신의 설계는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.4400024414062,
        745.66796875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다. 앞으로의 전달",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리간드/모티프(ligand/motif)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표면에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부착할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표면을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경한(surface-modified)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역자극",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성에 추가적 영향을 줄 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        267.5760192871094,
        217.66799926757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "21/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 품질 평가",
      "font_size": 20.03999900817871,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        82.07999420166016,
        174.5998992919922,
        106.10795593261719
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.1. 일반적 사항",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        146.75999450683594,
        184.67950439453125,
        165.8960418701172
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리만큼이나 중요하다. 따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주안점을 두고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        186.57598876953125,
        289.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다. 출하 규격 및 특성 분석",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다. 품목허가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정해야 한다. 이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5360107421875,
        529.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성을 평가하는 방법이 포함될 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        300.5760192871094,
        553.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비해야 한다. 즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다. 긴급상황",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질의 사용을 고려하도록 허용할 수 있다. 생산 및 관리에 사용한 모든 시약의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다. (인간을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다. 잠재적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.4400024414062,
        745.66796875
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "22/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관심을 기울여야 한다. 엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.416015625,
        121.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격을 설정해야 한다. 원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 관리에 대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        252.57598876953125,
        217.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지해야 한다. 임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5360107421875,
        289.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4760131835938,
        337.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성 시험 결과가 포함될 것이다. 모든 백신과 마찬가지로, 핵심 임상시험의 경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5360107421875,
        409.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 예상한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        171.57598876953125,
        457.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다. 달리 말하면, 새로운 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5239868164062,
        505.6679992675781
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다. 이는 서열만",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4639892578125,
        601.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자와의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호작용은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보조자료에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        537.4559936523438,
        649.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다. 최종 제품 조성이 어떻게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(아래 ‘7. 비임상 평가’ 참조). 제조공정 변경(예: 생산 규모 증가 또는 정제 공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과물과 비교동등성(comparability) 평가를 해야 한다. 이러한 비교동등성 연구에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험, 안정성 자료가 포함될 수도 있다. 이와 관련해서는 ‘생물의약품의 제조방법",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다. 허가 후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        444.57598876953125,
        241.66799926757812
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        520.2960205078125,
        289.6679992675781
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.2. 제조에 관한 사항",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        322.67999267578125,
        226.1995086669922,
        341.8160095214844
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다르게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대부분의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물의약품은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포-기반(또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유기체-기반)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4639892578125,
        393.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증식",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성성분은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vitro",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        543.7079467773438,
        417.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "transcription(IVT)를 통해 효소 공정으로 제조한다. 생산공정에서는 재조합 효소 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5239868164062,
        465.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형을 사용하게 된다. ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.4639892578125,
        489.7079772949219
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tail의 길이를 선택한 근거를 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        316.1759948730469,
        513.7079467773438
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적으로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전사되면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정제하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디옥시리보핵산",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest). IVT 공정 중 cap과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "poly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.4400024414062,
        585.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.416015625,
        609.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5360107421875,
        657.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다. DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.4039916992188,
        681.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.5239868164062,
        705.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다. 정제 방법과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 목적에 관해 설명하고 근거를 제시해야 한다. 불순물 감소 단계로서 단백질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.5599975585938,
        753.7080078125
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5360107421875,
        97.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정개발 및 공정 중 관리’ 참고).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        260.3760070800781,
        121.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대부분은,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비록",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그보다는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전사물(transcript)에 필적하는 것이라 할지라도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정제된 mRNA는 다른 백신들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다. 이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성분(bulk",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "active",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "substance)이라고도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "볼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요소를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대부분의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규제자들에게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "친숙한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다. 그리고 다른 백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 흐름도를 제공해야 한다. 공정 흐름도에는, 제조가 원료의약품 및 최종 제형화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밝혀야 한다. 농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5360107421875,
        433.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성 프로그램에 적용해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        264.9360046386719,
        505.6679992675781
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA(원료의약품)는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형(완제의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부로서의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비)으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다. 지금까지 개발이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다. 비록 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5239868164062,
        577.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는 시스템만을 상세하게 다룰 것이다. 이 제형화는 mRNA를 안정화할 뿐",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니라,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "능동적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수동적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡입을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "달성할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진입과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포액으로의 방출을 촉진한다. 지질나노입자는 또한 면역증강 활성을 제공할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(27, 29, 30). 핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "25/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다. 따라서 제형화 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다. 예를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성 성분들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해동",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "온도뿐",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니라,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질-mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완충액/용매의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pH,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효율,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 주기 때문에, 이들에 대해 고려해야 한다. 이러한 방식으로, 지질나노입자로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하고 적합하게 밸리데이션할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        305.7359924316406,
        289.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으나,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근본적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인 코딩 서열을 지닌 sa-mRNA의 경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정에 필요한 관리 방책은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사하거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복제효소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다. 두 개의 봉입된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유도한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반감기의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차이로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설계에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상하는 안전성 및 유효성에 영향을 줄 수도 있다. 각각의 mRNA 분자들을 별도로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인 제조공정 및 품질관리를 수반해야 할 수 있다. 마찬가지로, 다가 mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다. mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "26/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당성이 제시되어야 한다는 것이다. 이는 다가 혹은 혼합 백신에서는 덜 중요할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있고 sa-mRNA 백신에서는 더 중요할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        333.6960144042969,
        145.66799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심 품질관리 사항에는 다음이 포함된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        155.27999877929688,
        315.6960144042969,
        169.66799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 출발물질,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하나 이에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국한되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않음:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "①",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.67999267578125
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA 주형(linear DNA template). ② 뉴클레오티드, ③ 효소(예: DNA-의존성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        251.27999877929688,
        538.4400024414062,
        265.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소(일반적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "T7",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "polymerase),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "캡",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형성(capping)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효소,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "O-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        103.31999969482422,
        299.2799987792969,
        538.4400024414062,
        313.67999267578125
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여겨진다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목록에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료약품에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품/백신에서 활성이 없는 원료약품이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        371.2799987792969,
        363.5760192871094,
        385.6679992675781
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 특히,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물(인간",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유래",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        521.7360229492188,
        457.6679992675781
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        96.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.8112487792969
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        491.2799987792969,
        408.33599853515625,
        505.6679992675781
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.6799926757812
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성(크기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.31999969482422,
        611.2799682617188,
        458.5199890136719,
        625.66796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        503.03997802734375,
        649.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성을 확인하기 위하여 공정을 밸리데에션해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.31999969482422,
        683.2799682617188,
        402.9360046386719,
        697.66796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "논하고 있다. 본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비공개로 간주하고 있다. 다음의 방법들은 다양한 핵심 품질관리 시점에서 특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        460.0559997558594,
        145.66799926757812
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        167.27999877929688,
        534.2639770507812,
        181.66799926757812
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술의 예시",
      "font_size": 11.696152687072754,
      "font_name": "T11",
      "bbox": [
        181.1999969482422,
        196.9199981689453,
        471.5999755859375,
        211.30799865722656
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 사용",
      "font_size": 11.696152687072754,
      "font_name": "T11",
      "bbox": [
        181.1999969482422,
        196.9199981689453,
        471.5999755859375,
        211.30799865722656
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DNA 주형 서열분석, mRNA 서열분석",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        116.04000091552734,
        220.3199920654297,
        451.8003234863281,
        234.70799255371094
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        116.04000091552734,
        220.3199920654297,
        451.8003234863281,
        234.70799255371094
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역전사효소 정량 PCR",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        158.39999389648438,
        243.59999084472656,
        473.52032470703125,
        257.98797607421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 및 함량",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        158.39999389648438,
        243.59999084472656,
        473.52032470703125,
        257.98797607421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자외선 분광법(ultraviolet spectroscopy),",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        112.31999969482422,
        266.8800048828125,
        473.52032470703125,
        298.3079833984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "형광-기반 분석(fluorescein-based assays)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        112.31999969482422,
        266.8800048828125,
        473.52032470703125,
        298.3079833984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함량 및 순도",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        112.31999969482422,
        266.8800048828125,
        473.52032470703125,
        298.3079833984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아가로스 또는 아크릴아마이드 겔 전기영동",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        103.91999816894531,
        307.32000732421875,
        321.3607482910156,
        321.7080078125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(모세관 전기영동 포함)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        154.8000030517578,
        324.3599853515625,
        270.5447692871094,
        338.74798583984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함량, 크기, RNA 완전성, 표면전하,",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        352.55999755859375,
        307.32000732421875,
        528.9072265625,
        321.7080078125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "봉입 비율(%)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        408.1199951171875,
        324.3599853515625,
        473.3451843261719,
        338.74798583984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "크로마토그래피 분석(예: 크기 배제(size-exclusion)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        85.68000030517578,
        347.6399841308594,
        339.6690368652344,
        379.0679931640625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 음이온 교환(anion-exchange), 친화성(affinity),",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        85.68000030517578,
        347.6399841308594,
        339.6690368652344,
        379.0679931640625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역상(reverse-phase))",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        163.44000244140625,
        381.7200012207031,
        261.90338134765625,
        396.1080017089844
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "mRNA 함량, 지질 함량 mRNA 품질,",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        346.91998291015625,
        356.1600036621094,
        534.5471801757812,
        370.5480041503906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나노입자 완전성",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        399.8399963378906,
        373.1999816894531,
        481.6803894042969,
        387.5879821777344
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질량 분석법(mass spectrometry)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        132.95999145507812,
        405.0,
        534.0004272460938,
        419.38800048828125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "mRNA 함량 및 지질나노입자 완전성",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        132.95999145507812,
        405.0,
        534.0004272460938,
        419.38800048828125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "dsRNA 블롯, 캡 형성(capping) 비율(%) 시험,",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        98.87999725341797,
        428.3999938964844,
        326.4671936035156,
        442.7879943847656
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "poly(A) tail 말단 전사물(transcript)의 비율(%) 및",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        89.27999877929688,
        445.44000244140625,
        336.0,
        459.8280029296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "poly(A) tail의 크기",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        164.63999938964844,
        462.47998046875,
        260.6399841308594,
        476.86798095703125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 품질 파라미터 및 순도",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        369.9599914550781,
        445.44000244140625,
        511.5600280761719,
        459.8280029296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무세포 번역 또는 세포-기반 발현 시스템",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        110.27999877929688,
        485.7599792480469,
        498.0003967285156,
        500.1479797363281
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역가 및 단백질 정확도",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        110.27999877929688,
        485.7599792480469,
        498.0003967285156,
        500.1479797363281
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광산란법(light scattering)(예: 정적 또는 동적 광산",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        87.36000061035156,
        509.03997802734375,
        337.91998291015625,
        523.427978515625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "란법), 나노입자 추적분석, 전자현미경,",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        117.36000061035156,
        526.0800170898438,
        307.9872131347656,
        540.468017578125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "크기-배제(size-exclusion) 크로마토그래피",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        111.36000061035156,
        543.1199951171875,
        314.0404052734375,
        557.5079956054688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입자크기분포",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        408.239990234375,
        517.5599975585938,
        473.2798767089844,
        531.947998046875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(순도, 일관성, 안전성)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        386.1600036621094,
        534.5999755859375,
        495.3047790527344,
        548.9879760742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "레이저 도플러 전기영동(laser doppler",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        118.19999694824219,
        575.0399780273438,
        307.01080322265625,
        589.427978515625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "electrophoresis), 동적 광산란 분석",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        127.07999420166016,
        592.0799560546875,
        298.2000427246094,
        606.4679565429688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입자 표면 특성분석",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        391.67999267578125,
        566.5199584960938,
        489.84075927734375,
        580.907958984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(크기 및 다분산, 제타 전위(zeta",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        360.9599914550781,
        583.5599975585938,
        520.5975341796875,
        597.947998046875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "potential) 포함)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        402.3599853515625,
        600.5999755859375,
        479.1047668457031,
        614.9879760742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전자현미경, 원자력 현미경, X-선 회절(XRD), 시차",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        92.87999725341797,
        623.8800048828125,
        332.400390625,
        638.2680053710938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주사 열량측정(differential scanning calorimetry) 분석",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        84.72000122070312,
        640.9199829101562,
        340.5603942871094,
        655.3079833984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이화학적 특성 분석",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        391.67999267578125,
        623.8800048828125,
        489.84002685546875,
        638.2680053710938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(표면 및 형태학적 특성 포함)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        366.6000061035156,
        640.9199829101562,
        514.8648071289062,
        655.3079833984375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무균 시험, 엔도톡신 함량",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        148.67999267578125,
        664.2000122070312,
        481.6807556152344,
        678.5880126953125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 파라미터",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        148.67999267578125,
        664.2000122070312,
        481.6807556152344,
        678.5880126953125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pH; 함습도(중량, 공비, 적정)",
      "font_size": 11.696152687072754,
      "font_name": "T7",
      "bbox": [
        140.39999389648438,
        687.5999755859375,
        462.7207336425781,
        701.9879760742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품질특성",
      "font_size": 11.696152687072754,
      "font_name": "T12",
      "bbox": [
        140.39999389648438,
        687.5999755859375,
        462.7207336425781,
        701.9879760742188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        717.239990234375,
        538.4400024414062,
        731.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여전히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충족을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        741.239990234375,
        538.4400024414062,
        755.6279907226562
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "토대로 출하할 것으로 기대하고 있다. 3상 임상시험에서 사용하는 임상시험용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        514.416015625,
        121.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘생물의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        470.7359924316406,
        217.66799926757812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.3. 백신 구조체 및 조성에 관한 일반 정보 및 설명",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        250.6799774169922,
        458.9994812011719,
        269.8160095214844
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설계와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구축,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.5599975585938,
        321.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한 정보를 제공해야 한다. 선택한 첨가제에 대한 근거 및 기능도 서술해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        331.32000732421875,
        538.5599975585938,
        345.7080078125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질의 사용에 대한 정보를 포함해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        318.5760192871094,
        393.7079772949219
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.3.1. mRNA 서열 및 요소의 배열",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        426.7200012207031,
        327.4794921875,
        445.85601806640625
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다. 표적 항원을 위한 ORF뿐",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        459.239990234375,
        538.4400024414062,
        473.62799072265625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        483.239990234375,
        538.4400024414062,
        497.62799072265625
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로모터(promoter)),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5‘",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cap",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "poly(A)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tail을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        507.239990234375,
        538.4400024414062,
        521.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 요소의 서열 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위치",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 길이를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        531.239990234375,
        538.5599975585938,
        545.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        555.239990234375,
        538.5360107421875,
        569.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다(아래의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(라)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(마)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항목",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조체에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        579.239990234375,
        538.4400024414062,
        593.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        603.239990234375,
        418.656005859375,
        617.6279907226562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        627.239990234375,
        538.5599975585938,
        641.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오시드를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        651.239990234375,
        538.5599975585938,
        665.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        675.239990234375,
        184.65599060058594,
        689.6279907226562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        699.239990234375,
        538.5599975585938,
        713.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        723.239990234375,
        538.4400024414062,
        737.6279907226562
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "29/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "삼차",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획득하거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "줄이기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코돈)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "향상하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        131.27999877929688,
        502.656005859375,
        145.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 위에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서술한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sa-mRNA는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외에도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA-의존성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합체를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조체는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "replicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며. 따라서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가시킨다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "replicon의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복제효소가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원과는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5239868164062,
        289.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적으로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위치하지만,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분리되어있다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        371.2799987792969,
        184.65599060058594,
        385.6679992675781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역조절인자(immunomodulator)(예",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이토카인)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4639892578125,
        433.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        467.2799987792969,
        130.656005859375,
        481.6679992675781
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.3.2. 제형화 및 구성성분",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        510.7200012207031,
        259.9184875488281,
        529.8560180664062
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5360107421875,
        557.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일회",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성분",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목록을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        567.239990234375,
        538.5599975585938,
        581.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질(원료의약품)이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품(최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되어",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        639.239990234375,
        538.4400024414062,
        653.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이 만들어 지는지를 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        663.239990234375,
        322.656005859375,
        677.6279907226562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        687.239990234375,
        538.4400024414062,
        701.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡입을 돕기 위해 제형화한다. 몇몇 잠재적인 전달 인자(delivery agent)(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        711.239990234375,
        538.5360107421875,
        725.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        735.239990234375,
        538.4400024414062,
        749.6279907226562
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다. 이러한 제형화의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다루어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요품질특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시 포함해야 한다. mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충분한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성분석이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여기에는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확보하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합성된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        275.2799987792969,
        538.5360107421875,
        289.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다. 따라서, 백신의 독성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        347.2799987792969,
        447.57598876953125,
        361.6679992675781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역조절 분자를 코딩할 수도 있다. 더 나아가, 별도의 면역증강제나 mRNA에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역조절(면역자극이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역억제)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화합물을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부로서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역증강제와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기여함을 증명해야 한다(12). 별도의 면역증강제를 포함한 경우, 그 품질 측면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시 다루고 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        515.2799682617188,
        256.656005859375,
        529.66796875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 추가적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원제시세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종류를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하도록",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엔도솜(endosome)으로부터의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방출이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능에 대한 증거를 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        635.2799682617188,
        298.656005859375,
        649.66796875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(보존제의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보존적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하고,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        103.68000030517578,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유해한 영향을 주지 않음을 증명해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        103.68000030517578,
        707.2799682617188,
        340.656005859375,
        721.66796875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "31/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.4. 출발물질, 원료약품, 첨가제의 관리",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        82.68000030517578,
        359.7594909667969,
        101.8160400390625
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주의를 기울여야 한다. 시약/원료약품은 내부에서 정의한 품질 시스템을 통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        139.3199920654297,
        538.5599975585938,
        153.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판매업체/공급업체로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공급받아야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        456.57598876953125,
        201.70799255371094
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.4.1. 출발물질, 원료약품, 첨가제의 품질",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        230.75999450683594,
        376.6794738769531,
        249.8960418701172
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        263.2799987792969,
        538.5360107421875,
        277.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        287.2799987792969,
        538.4400024414062,
        301.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        311.2799987792969,
        538.5599975585938,
        325.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료약품이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어느",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시점에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        359.2799987792969,
        538.5599975585938,
        373.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.4400024414062,
        397.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약전이나 이들의 규격에 대한 세부사항을 표기해야 한다. 시약 또는 출발물질(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        407.2799987792969,
        538.5360107421875,
        421.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다. mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        431.2799987792969,
        538.4039916992188,
        445.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        455.2799987792969,
        538.5599975585938,
        469.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        479.2799987792969,
        498.8160095214844,
        493.6679992675781
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        503.27996826171875,
        538.5599975585938,
        517.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(특히,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        538.4400024414062,
        541.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능하도록 충분히 상세히 기술해야 한다. 새로운 것으로 간주하지 않는 첨가제의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        575.2799682617188,
        538.4400024414062,
        589.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에도 여전히 적합한 규격을 제공해야 한다. 새로운 첨가제의 경우(예: 양이온",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        599.2799682617188,
        538.4400024414062,
        613.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능하다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질(출발물질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중간체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여기에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        671.2799682617188,
        538.4400024414062,
        685.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함될 것이다. 만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        695.2799682617188,
        538.5599975585938,
        709.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 평가를 고려해야 한다. 출발물질 및 원료약품(예: 시약 및 용제), 중간체,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        719.2799682617188,
        538.5360107421875,
        733.66796875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "32/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제(지질)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필수적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정관리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세부",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용제의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "금속",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물(elemental",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "impurities)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오염",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다(39~41).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리해야 한다. 첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구비해야 한다. 페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호작용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증강에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역할을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에(22),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "페길화된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        443.6159973144531,
        337.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "GMP",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간주한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플라스미드",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        426.57598876953125,
        433.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "곰팡이로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오염이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없음)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종자은행(seed",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "bank)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "poly(A)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tail이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플라스미드",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시행해야 한다. DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다. 미생물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        462.57598876953125,
        601.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무균이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미생물한도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엔도톡신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수준뿐",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니라,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열분석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인(genetic",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4759521484375,
        673.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "identity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "33/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 DNA 플라스미드 혹은 선형 DNA).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        307.7760009765625,
        97.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상된다는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충분히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적격한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용을 허용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        210.57598876953125,
        169.66799926757812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.4.2. 출발물질, 원료약품, 첨가제의 사용승인",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        198.71998596191406,
        410.27850341796875,
        217.8560333251953
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        231.239990234375,
        538.4400024414062,
        245.62799072265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준규격에 적합함을 확인하고 제조에 사용하여야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        255.239990234375,
        390.5760192871094,
        269.62799072265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.5. 공정개발 및 공정 중 관리",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        302.760009765625,
        292.6794738769531,
        321.8960266113281
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상업용 제조공정의 개발 이력을 제공해야 한다. 공정관리의 실시를 보장하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        359.2799987792969,
        538.4400024414062,
        373.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다. 충분히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        407.2799987792969,
        538.5599975585938,
        421.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지식을 타당한 범위 내에서 고려할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        431.2799987792969,
        324.5760192871094,
        445.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파라미터를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준수하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        455.2799987792969,
        538.4400024414062,
        469.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        479.2799987792969,
        538.5599975585938,
        493.6679992675781
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        503.27996826171875,
        538.5599975585938,
        517.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        527.2799682617188,
        453.57598876953125,
        541.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무균적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무균상태가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        551.2799682617188,
        538.5599975585938,
        565.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        575.2799682617188,
        538.5360107421875,
        589.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        599.2799682617188,
        538.5599975585938,
        613.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        120.57599639892578,
        637.66796875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.6. 제품 특성 분석",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        670.6799926757812,
        209.39950561523438,
        689.8160400390625
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출하",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA(원료의약품)와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        727.3200073242188,
        416.6159973144531,
        741.7080078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "34/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호보완적인(orthogonal)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화학적,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분자적,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물리학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한 철저한 특성분석이 핵심적일 것이다. 특성 분석이란 모든 로트에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일상적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행하지는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석이지만,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험법의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해주는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성에 대하여 중요한 지식을 획득할 수 있다. 이는 모든 로트에 대해 실시하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 중 시험 및 로트 출하 시험과 대비된다. 특히 대체 기술 사용 시 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다양한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파라미터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선택의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        396.5760192871094,
        289.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의해야 한다. 제조의 일관성은 이후 ‘2.7. 제조의 일관성’에서 더 심층적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "논하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "캡",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형성(capping)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폴리아데닐화의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5. 공정개발 및 공정 중 관리’).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5360107421875,
        385.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절단되었거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형태를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완전한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명해야 한다. 특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명되고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형태가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신생-항원이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀결될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재설계가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.416015625,
        481.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "줄 수도 있다. 특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        514.656005859375,
        625.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다. 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4639892578125,
        673.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5360107421875,
        697.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.4400024414062,
        745.66796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "35/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5360107421875,
        97.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간주해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        162.57598876953125,
        169.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유도하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성을 분석해야 한다. 추가적으로 지질나노입자가 내재적으로 면역조절 효과를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지니고 있다면, 이 역시 특성분석이 필요하다. mRNA에 다른 면역조절 요소나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역조절",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코딩된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작용기전(예;",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기여하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부분",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다(아래",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘3.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디자인을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        528.5759887695312,
        385.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하고 조사해야 한다. 이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5239868164062,
        433.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA(DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세균을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효소(예",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5239868164062,
        481.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한효소),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통합되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오티드,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잘못",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접힌",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dsRNA,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5360107421875,
        505.6679992675781
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다. 정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다. 알려진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를 수행할 것으로 기대한다. 분해된 RNA는 폴리아크릴아마이드나 아가로스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 분석 절차의 일부로서 평가할 수 있다. mRNA의 서열 및 구조의 일관성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in vitro 형질주입",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품에 대해 측정해야 할 중요한 특성들이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        366.5760192871094,
        721.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "36/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 제품 유래)는 특성 분석 및 조사되어야 한다. 이것은 또한 불순물이 적절하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        162.57598876953125,
        145.66799926757812
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.7. 제조의 일관성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        178.67999267578125,
        201.47900390625,
        197.8160400390625
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물의약품과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목허가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신청에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "앞서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다수의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연속",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5599975585938,
        249.70799255371094
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을 수행해야 한다. 한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        259.32000732421875,
        538.5599975585938,
        273.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 배치 사이의 차이에 주목하고 연구해야 한다. 이러한 연구에서 얻은 자료를,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.5360107421875,
        297.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.5599975585938,
        321.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        331.32000732421875,
        483.57598876953125,
        345.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불가능할 수 있다. 일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.4400024414062,
        393.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증강될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확증은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진전된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신청은 제출하기 이전에 실시하게 된다. 그러나 일부 경우에는, 상업적 제조를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규모",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확대를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험-규모",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목허가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동안",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하게 될 수 있다. 제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.5599975585938,
        537.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교동등성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험계획서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교동등성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전략은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘생물의약품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조방법",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교동등성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2019)’에서 논하고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        211.77598571777344,
        609.7080078125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8. 정제 mRNA 원액(원료의약품)의 제조 및 관리",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        642.719970703125,
        446.7594909667969,
        661.8560180664062
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "앞서 ‘2.2. 제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        675.239990234375,
        538.4400024414062,
        689.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        699.239990234375,
        538.5239868164062,
        713.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cap,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "poly(A)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tail,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조절",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성분(regulatory",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "element)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선택한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "37/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야 한다. 유전자 발현 또는 다른 최적화 변형(optimization modification)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 서술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨부하여 제공해야 한다. 도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리, 출하 시험에 대한 구현식 서술을 제공해야 한다. mRNA 백신의 품질 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        503.4960021972656,
        217.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들어,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다. 만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입되고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합된다면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당성이 제시되어야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        228.57598876953125,
        409.6679992675781
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1. 원액 정제 mRNA의 관리",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        438.7200012207031,
        312.719482421875,
        457.85601806640625
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        471.239990234375,
        538.4400024414062,
        485.62799072265625
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다. 사용한 분석법에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.5599975585938,
        509.62799072265625
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        519.239990234375,
        538.5360107421875,
        533.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다. 저장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건 하의 안정성에 대한 규격도 설정해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        567.239990234375,
        348.5760192871094,
        581.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가동(engineering",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "run)으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도출한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요약하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5599975585938,
        653.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야 한다. 개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.4400024414062,
        677.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        687.239990234375,
        538.4400024414062,
        701.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "강화해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.5599975585938,
        725.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다. 일부 시험은 생산 방법",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.4400024414062,
        749.6279907226562
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "38/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지식을 획득하려는 목적으로서만 필요하다. 그러므로, 원료의약품의 확인 및 순도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포괄적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        402.5760192871094,
        193.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고한다. 규격에 대한 근거를 제시해야 한다. 또한 보관조건 하에서의 안정성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 규격을 수립해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        246.57598876953125,
        289.6679992675781
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.1. 확인",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        318.7200012207031,
        165.1195068359375,
        337.85601806640625
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다. 확인시험에는 직접",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        351.239990234375,
        538.4400024414062,
        365.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        375.239990234375,
        538.5599975585938,
        389.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부만을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대표하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RT-PCR",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5239868164062,
        437.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "amplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.4400024414062,
        461.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.5599975585938,
        485.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 다른 제품에 공통된 것이어서는 안 된다. mRNA의 확인 및 순도에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        519.239990234375,
        506.4960021972656,
        533.6279907226562
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.2. 순도 및 불순물",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        566.7599487304688,
        248.2790069580078,
        585.89599609375
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        599.2799682617188,
        538.4400024414062,
        613.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리에서는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통합되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        623.2799682617188,
        538.4400024414062,
        637.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        647.2799682617188,
        538.4400024414062,
        661.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도입된 물질도 다루어야 한다. 이는 공정-관련 불순물의 제거를 확립하기 위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        671.2799682617188,
        538.4400024414062,
        685.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        695.2799682617188,
        538.416015625,
        709.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        719.2799682617188,
        538.5599975585938,
        733.66796875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "39/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려 시에는 제조공정의 설계를 참작해야 한다. 분석에는 공정 및 제품 관련",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5239868164062,
        121.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엄격한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상한(최대",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한도)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크로마토그래피",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검출법을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주형은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PCR로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량화할 수도 있다. 순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이 중요하다. 강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        108.57599639892578,
        313.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        323.2799987792969,
        538.5360107421875,
        337.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제거에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산공정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명한다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의하에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "축소하거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중단할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주기적 재밸리데이션에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지속해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도입한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기대한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용기-마개",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용출물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추출물(leachable",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.427978515625,
        505.6679992675781
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "extractable) 역시 평가하고 품목허가 신청 시 논해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        404.1360168457031,
        529.66796875
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.3. 정량화 및 물리적 상태",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        558.719970703125,
        306.719482421875,
        577.8560180664062
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완전성은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출하를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요품질특성으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간주한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        615.239990234375,
        538.4400024414062,
        629.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분절",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율(%),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dsRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율(%)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.5239868164062,
        653.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "poly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.4400024414062,
        677.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방식에 따라 달라진다. DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        687.239990234375,
        538.4639892578125,
        701.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.4400024414062,
        725.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파라미터는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데에션을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다루는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.5360107421875,
        749.6279907226562
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "40/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "겔",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전기영동",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PCR,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크로마토그래피 검출법과 같은 시험을 고려할 수도 있다. mRNA 정량화는 백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반이며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "온전한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작용기전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심이라는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명심해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량화를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법(예",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자외선",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분광광도법(UV",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "spectrophotometry))",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "온전한(intact)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량화를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        419.6159973144531,
        241.66799926757812
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.4. 안전성 특성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        270.7200012207031,
        223.4394989013672,
        289.85601806640625
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련된 안전성 시험에 대하여 기술해야 한다. 여기에는 세균과 진균에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험(함량,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미생물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동정,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명시된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유기체의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부정)과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더불어,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5360107421875,
        365.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엔도톡신 시험을 포함할 수 있다. 식약처가 요구한다면, 발열원성(pyrogenicity)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        375.239990234375,
        538.4639892578125,
        389.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다(단핵구",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있음).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5360107421875,
        437.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 윤리적 이유로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물 사용을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소화하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“대체,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.5360107421875,
        461.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.5599975585938,
        485.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        471.8160095214844,
        509.62799072265625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.5. 추가적 품질 파라미터",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        538.6799926757812,
        298.6784973144531,
        557.8160400390625
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        571.3200073242188,
        538.4400024414062,
        585.7080078125
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리해야 한다. 추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.4400024414062,
        609.7080078125
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이, 이들에 대한 관리가 필요하다(‘2.8.1.2. 순도 및 불순물’ 참조).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        449.85601806640625,
        657.7080078125
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.6. 참조물질",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        686.7599487304688,
        198.718505859375,
        705.89599609375
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        719.2799682617188,
        538.5360107421875,
        733.66796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "41/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작업용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질(working",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "standard))을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        162.57598876953125,
        145.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물학적 참조물질로 사용하기 위해 보관해야 한다. 참조물질은 적절한 형태로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조물질이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정적이라고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다. 최초 참조물질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        474.57598876953125,
        289.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조물질로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성분석을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        458.4960021972656,
        385.6679992675781
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.8.1.7. 안정성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        414.7200012207031,
        181.91900634765625,
        433.85601806640625
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가는‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2015)’에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행해야 한다. 수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.4400024414062,
        485.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도표나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그래프와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서식으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요약해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요약",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        519.239990234375,
        538.4400024414062,
        533.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액(혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중간체)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연장을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        567.239990234375,
        538.4400024414062,
        581.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 해야 한다. 만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건 하에서 수행된 운송 밸리데이션이 요구된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        615.239990234375,
        354.5760192871094,
        629.6279907226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9. 최종 제형화 백신(완제의약품)의 제조 및 관리",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        662.7599487304688,
        445.6794738769531,
        681.89599609375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "앞서 ‘2.2. 제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        695.2799682617188,
        538.4400024414062,
        709.66796875
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        719.2799682617188,
        538.4400024414062,
        733.66796875
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "42/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흐름도, 그리고 구연식 서술을 포함해야 한다. 지질나노입자의 적절한 제형화를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하기 위해 사용한 방법을 자세히 설명해야 한다. 원액 제형화 또는 원액",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정치시간(hold-time)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명시하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데에션해야 한다. 이 정치 시간 중의 이화학적 안정성 및 미생물 관리를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하는 데 적절한 고려가 필요하다. 최종 제형화 및 충전, 마감에 사용한 방법을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명하고 적절히 밸리데이션해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        294.5760192871094,
        217.66799926757812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.1. 조성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        246.71998596191406,
        153.1195068359375,
        265.85601806640625
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        279.239990234375,
        538.4400024414062,
        293.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        303.239990234375,
        538.4639892578125,
        317.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장단위",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성성분들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성성분의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능에 대해서도 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        258.57598876953125,
        365.62799072265625
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.2. 지질나노입자의 제조와 관리 그리고 mRNA 봉입",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        394.67999267578125,
        496.6794738769531,
        413.8160095214844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5360107421875,
        441.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조공정에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뒷받침하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다. 적합한 경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.5360107421875,
        513.7079467773438
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험설계(Design of Experiment) 접근법을 채택할 수도 있다. 이들의 크기 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 두 가지 모두의 영향을 받는다. 그러므로 mRNA-지질나노입자 제형화 및 최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.4400024414062,
        609.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "운영범위(operational",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "range)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탐색하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다. 원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.5599975585938,
        705.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하게 명시하고 밸리데이션해야 한다. 보관할 경우 최종 백신 생산의 중요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중간체이므로 적절하게 관리해야 한다. 이러한 정치 시간 중의 이화학적 안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.4400024414062,
        753.7080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "43/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 미생물 관리에 대해 적절한 고려가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        348.5760192871094,
        97.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용기로의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하고,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필수적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충족함을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션해야 한다. 지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기법(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접선유동여과(tangential",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "flow",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "filtration))을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준다고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5360107421875,
        289.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동결건조한다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동결건조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용해(reconstitution)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하고 타당성을 입증해야 한다. 해당되는 경우 희석제 또는 재구성 용액을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        161.85598754882812,
        361.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을 포함하게 될 것이다. (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4639892578125,
        409.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율. 일부 경우에는 제품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        536.6160278320312,
        481.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5360107421875,
        577.66796875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 요소의 영향을 결정해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        288.5760192871094,
        625.66796875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.3. 최종 백신의 제조, 충전 및 용기",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        654.719970703125,
        365.15948486328125,
        673.8560180664062
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        687.239990234375,
        538.5599975585938,
        701.6279907226562
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다. 흐름도에는 최종 제형화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.4400024414062,
        725.6279907226562
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.4400024414062,
        749.6279907226562
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "44/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계(즉, 단위 작업(unit operation))를 포함해야 한다. 흐름도에서 묘사한 각 공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계에 대한 구연식 서술을 제공해야 한다. 정보로는, 예를 들어, 각 공정 단계의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용기준이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정운영변수(process",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4759521484375,
        169.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "operational",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "parameter)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "멸균공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미생물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        162.57598876953125,
        217.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요품질특성이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지되며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충족함을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다. 용기 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다. 이를 위해, 최종 용기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.4400024414062,
        313.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        126.21599578857422,
        385.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.416015625,
        409.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BCG(bacillus",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.67999267578125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Calmette–Guérin)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.67999267578125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.67999267578125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "홍역-함유 백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.67999267578125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시처럼",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.67999267578125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용해(재구성)한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.67999267578125
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한적(time-restricted)으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오염을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방지해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용기-마개",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4639892578125,
        529.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험)가 필요할 수 있다. 다회 투여용량 바이알은 정확한 투약이 가능하도록 허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다. 다회 투여용량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최대",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "격막",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "천자(maximum",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "septum",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "puncture)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다회",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여용량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이알의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추출",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다회",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.5599975585938,
        673.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합성(comparability)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행하며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "희석",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정치",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립해야 한다. 희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5360107421875,
        721.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.4400024414062,
        745.66796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "45/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명하는 적합한 자료를 식약처에 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        354.5760192871094,
        97.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA들로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sa-mRNA),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려사항이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려사항은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려사항은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다. 둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        453.57598876953125,
        289.6679992675781
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4. 최종 백신의 관리",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        318.7200012207031,
        253.1995086669922,
        337.85601806640625
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 최종 백신 로트에서 채취한 검체를 평가해야 한다. 모든 기준 및 시험법은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        351.239990234375,
        538.4400024414062,
        365.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 승인이 필요하다. 제조사는 최종 백신에 관한 규격을 수립하고 근거를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        375.239990234375,
        538.4400024414062,
        389.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원칙적으로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.4400024414062,
        413.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다. 분석법",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.5599975585938,
        437.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.4400024414062,
        461.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술해야 한다. 시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.5599975585938,
        485.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 평가를 포함할 것을 권고한다. 개발 초기에는 규격이 제한적이며 허용기준이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.4400024414062,
        509.62799072265625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        519.239990234375,
        538.4400024414062,
        533.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "강화해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.4400024414062,
        557.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성을 확립해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        567.239990234375,
        216.57598876953125,
        581.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        591.239990234375,
        538.5360107421875,
        605.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        615.239990234375,
        538.5599975585938,
        629.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        639.239990234375,
        538.4400024414062,
        653.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트 생산 가동에 대한 요약 정보를 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        366.5760192871094,
        677.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        687.239990234375,
        538.5599975585938,
        701.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 실시할 필요는 없다. 앞서 ‘2.6. 제품 특성 분석’, ‘2.7. 제조의 일관성’에서 논한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        538.4400024414062,
        725.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        735.239990234375,
        538.4400024414062,
        749.6279907226562
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "46/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배치에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지식을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획득하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로서만",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확증을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "몇몇",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연속",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션된 방법을 사용해 시험하고 분석해야 한다. 한 로트와 다른 로트 간의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.416015625,
        193.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4639892578125,
        217.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의하기 위한 기반으로 사용해야 한다. 그러므로 mRNA 백신의 확인 및 순도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        505.0559997558594,
        337.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있을 수 있다. 이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입했는가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질나노입자을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다. 이것은 이후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다. 추가로, 혼합(mixing)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함유되어",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는가를 확인하는 데 대단히 중요하다. 총 mRNA 함량은 용량 설정의 기반이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인시험에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조소에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품으로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종전처럼",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구별하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한편,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되었는가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다루어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인시험은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼동을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방지하기 위해 대단히 중요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        258.57598876953125,
        673.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경험을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획득함에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험 및 보조자료 축소를 허용하게 될 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        354.5760192871094,
        745.66796875
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "47/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.1. 확인",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        82.68000030517578,
        165.1195068359375,
        101.8160400390625
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시설에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조했거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        139.3199920654297,
        538.4400024414062,
        153.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다가 백신) 각 mRNA의 식별을 확인해야 한다. 염기서열 분석을 통한 확인을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        162.57598876953125,
        225.70799255371094
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.2. 순도 및 불순물",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        254.75999450683594,
        248.2790069580078,
        273.8960266113281
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        287.2799987792969,
        538.4400024414062,
        301.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        311.2799987792969,
        538.4400024414062,
        325.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다. 모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        335.2799987792969,
        538.5599975585938,
        349.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다. mRNA 완전성 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        359.2799987792969,
        538.5599975585938,
        373.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입자크기,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질/폴리머",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불순물,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율/효율에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        383.2799987792969,
        538.5599975585938,
        397.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 시험을 고려해야 한다. 품목허가 신청 시에는 용기-마개 시스템의 적합성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        407.2799987792969,
        538.4400024414062,
        421.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2. 순도 및 불순물’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        431.2799987792969,
        538.5239868164062,
        445.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조). 백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        455.2799987792969,
        538.5599975585938,
        469.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        479.2799987792969,
        538.5239868164062,
        493.6679992675781
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량을 초과하지 않았는지 확인해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        503.27996826171875,
        312.5760192871094,
        517.66796875
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.3. 함량 또는 농도",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        546.719970703125,
        248.27951049804688,
        565.8560180664062
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        579.239990234375,
        538.5360107421875,
        593.6279907226562
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        603.239990234375,
        494.3760070800781,
        617.6279907226562
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.4. 안전성 특성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        646.6799926757812,
        223.4394989013672,
        665.8160400390625
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세균",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "곰팡이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무균시험(시험물질의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "살균",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        679.3200073242188,
        538.5599975585938,
        693.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부족의 제시를 포함)을 수행해야 한다. 백신을 비경구 외(non-parenteral) 투여하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        703.3200073242188,
        538.4400024414062,
        717.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        727.3200073242188,
        538.5599975585938,
        741.7080078125
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "48/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시가 필요하다. 더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구한다면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발열성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(단핵구활성시험(monocyte activation test)일 수 있음). 그러나 실시 및 허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 윤리적 이유로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물 사용을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소화하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“대체,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        471.8160095214844,
        241.66799926757812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.5. 추가적인 품질 파라미터",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        270.7200012207031,
        315.4784851074219,
        289.85601806640625
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다. 여기에는 성상(가시성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.5360107421875,
        341.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pH를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "삼투압",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도(osmolality)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.5599975585938,
        365.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점성도(viscosity) 역시 중요할 수 있다. 최종 백신(완제의약품)의 경우, 추가적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        375.239990234375,
        538.4400024414062,
        389.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파라미터에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질/폴리머",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동정(identification)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율, 다분산 지수(polydisperity index)가 포함된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        364.7760009765625,
        437.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크기와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나노입자-기반",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료제의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다지점",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        447.239990234375,
        538.5599975585938,
        461.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.4400024414062,
        485.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다. 비봉입 mRNA는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        538.5599975585938,
        509.62799072265625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        519.239990234375,
        538.4400024414062,
        533.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요품질특성으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간주해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동결-해동",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "희석으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        543.239990234375,
        538.5599975585938,
        557.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인해 변경되지 않음을 확증해야 한다. 순도나 확인을 위해 이미 수행 중인 겔",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        567.239990234375,
        538.4400024414062,
        581.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        591.239990234375,
        538.4400024414062,
        605.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        615.239990234375,
        168.57598876953125,
        629.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        639.239990234375,
        538.4400024414062,
        653.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동결건조한다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수분에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        663.239990234375,
        538.5599975585938,
        677.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        687.239990234375,
        538.4400024414062,
        701.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 기술해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        711.239990234375,
        192.57598876953125,
        725.6279907226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "49/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.6. 역가",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        82.68000030517578,
        165.1195068359375,
        101.8160400390625
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 백신의 각 로트의 역가를 결정해야 한다. 질환 특이적일 수 있는 (기능성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        139.3199920654297,
        538.4400024414062,
        153.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피접종자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성은,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(self-amplifying",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "replicon",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성성분",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.5599975585938,
        201.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포로의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전달을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성들의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5360107421875,
        249.70799255371094
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        259.32000732421875,
        538.4400024414062,
        273.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석(cell-free",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "assay)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인된(correct",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "identity)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "올바른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크기의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백질이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA로부터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현되었음을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명해줄 것이다. 그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        331.32000732421875,
        538.4400024414062,
        345.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방하고자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적응증을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하므로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.5360107421875,
        393.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질 검사항목과의 상관관계를 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        427.3199768066406,
        336.5760192871094,
        441.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        451.3199768066406,
        538.5599975585938,
        465.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 유효한지에 대해 확실히 확인하여야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        342.5760192871094,
        489.7079772949219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인간",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        503.6159973144531,
        561.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다. 시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.4400024414062,
        609.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한 바람직하다. 따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야 한다. 플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생화학",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물물리학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도들(measure)(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵산",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.5599975585938,
        705.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.5599975585938,
        729.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목표로 노력할 것을 독려한다. 그러나 이러한 척도는 mRNA에만 해당되며, 제형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.5599975585938,
        753.7080078125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "50/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다. 그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        120.57599639892578,
        169.66799926757812
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.7. 표준물질",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        198.71998596191406,
        198.718505859375,
        217.8560333251953
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        231.239990234375,
        538.5599975585938,
        245.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        255.239990234375,
        538.5599975585938,
        269.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상업적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        279.239990234375,
        538.5599975585938,
        293.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 사용해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        303.239990234375,
        216.57598876953125,
        317.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        327.239990234375,
        538.5599975585938,
        341.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준품을 개발하여 제공할 수 있다. 이러한 국제 표준품의 사용이 가능해진다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.416015625,
        365.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다. 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        375.239990234375,
        538.5599975585938,
        389.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방식으로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교를 할 수 있다. 추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.4400024414062,
        437.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.4400024414062,
        461.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.5360107421875,
        485.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코로나19",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        538.5360107421875,
        485.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        495.239990234375,
        469.656005859375,
        509.62799072265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.8. 안전성 시험, 보관 및 유효일자",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        538.6799926757812,
        368.9985046386719,
        557.8160400390625
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        571.3200073242188,
        538.4400024414062,
        585.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.4400024414062,
        609.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "’확장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관온도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건(ECTC)에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.5599975585938,
        657.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처, 2016) 역시 적용될 수도 있다. 일차 및 이차 포장재에 표기된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.4400024414062,
        705.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 승인을 위해 식약처에 제출해야 한다. 백신 바이알 모니터링에 관한 지침은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "WHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        496.656005859375,
        753.7080078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "51/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.8.1. 안정성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        82.68000030517578,
        193.79901123046875,
        101.8160400390625
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부분을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상업적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.4400024414062,
        129.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        139.3199920654297,
        538.5599975585938,
        153.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다. 안정성을 지시해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        163.3199920654297,
        538.5599975585938,
        177.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다. 측정할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.4400024414062,
        249.70799255371094
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다. 높은 온도에서의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        259.32000732421875,
        538.5599975585938,
        273.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.5599975585938,
        321.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        331.32000732421875,
        538.5599975585938,
        345.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구를 수행해야 한다. 동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.5599975585938,
        393.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        509.2560119628906,
        417.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뒷받침하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료뿐",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니라",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가속",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가혹시험(stress testing) 자료를 고려할 수 있다. 고온에서의 단기 보관 및 조제 시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.4400024414062,
        489.7079772949219
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다회 투여용량 바이알의 경우,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구되는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중 조건 하에서의 백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        547.3200073242188,
        160.29598999023438,
        561.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다. 예를 들면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        571.3200073242188,
        538.5360107421875,
        585.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.5599975585938,
        609.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다. 가속 안정성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.4400024414062,
        681.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        538.4400024414062,
        705.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발을 뒷받침할 수도 있습니다. 마찬가지로 플랫폼 기술에 대한 안정성 데이터는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        451.0559997558594,
        753.7080078125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "52/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5360107421875,
        121.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기대한다. 보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합성 포함)을 평가하고 논해야 한다. 안정성 평가는 ‘생물의약품 안정성 시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(2015)’를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준수해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        160.29598999023438,
        241.66799926757812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.8.2. 보관조건",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        270.7200012207031,
        210.5985107421875,
        289.85601806640625
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관조건을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밸리데이션해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조시설에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유통을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개시하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        303.239990234375,
        538.4400024414062,
        317.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        327.239990234375,
        538.4400024414062,
        341.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다. 최대 보관 기간은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        351.239990234375,
        538.4400024414062,
        365.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        375.239990234375,
        538.5599975585938,
        389.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명시한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        399.239990234375,
        538.5599975585938,
        413.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다. 임상시험 실시 중,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        423.239990234375,
        538.416015625,
        437.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        447.239990234375,
        538.4400024414062,
        461.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계의 지속 기간과 최소한 동일해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        471.239990234375,
        318.5760192871094,
        485.62799072265625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9.4.8.3. 유효기간",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        514.6799926757812,
        210.5985107421875,
        533.8160400390625
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        547.3200073242188,
        538.4400024414062,
        561.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받아야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효일자는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        538.5599975585938,
        609.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        619.3200073242188,
        483.57598876953125,
        633.7080078125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.10. 기록",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        666.719970703125,
        134.1595001220703,
        685.8560180664062
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        699.239990234375,
        538.4400024414062,
        713.6279907226562
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        723.239990234375,
        538.5599975585938,
        737.6279907226562
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "53/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 권고사항을 적용해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        258.57598876953125,
        97.66799926757812
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.11. 보관검체",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        130.67999267578125,
        167.75851440429688,
        149.8160400390625
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다. 보관 검체가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국한되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵심",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        211.3199920654297,
        538.5599975585938,
        225.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        235.3199920654297,
        538.5599975585938,
        249.70799255371094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비축 및 보관해야 한다. 적당한 수의 핵심 임상시험 로트의 용기를 보유할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        259.32000732421875,
        538.4400024414062,
        273.7080078125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록 사전 계획이 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        246.57598876953125,
        297.7080078125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "54/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 비임상 평가",
      "font_size": 20.03999900817871,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        82.07999420166016,
        195.5998992919922,
        106.10795593261719
      ],
      "page_num": 54,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 고려해야 한다. 제품의 약리학(면역원성 및 효력) 및 독성학과 관련된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        171.239990234375,
        538.4400024414062,
        185.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        219.239990234375,
        386.7359924316406,
        233.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        243.239990234375,
        538.4400024414062,
        257.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 있다. 이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        291.239990234375,
        538.5599975585938,
        305.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다. 그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다. mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        315.239990234375,
        538.4039916992188,
        329.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        339.239990234375,
        538.4400024414062,
        353.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않을 것이다. 그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        363.239990234375,
        538.5360107421875,
        377.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역접종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공격시험)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.4400024414062,
        401.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성을 입증하는 증거를 제공해야 한다. 예상하는 연구의 종류 및 설계, 수는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        411.239990234375,
        538.4400024414062,
        425.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 동의가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        435.239990234375,
        228.57598876953125,
        449.62799072265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.1. 약리작용",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        482.760009765625,
        159.83851623535156,
        501.8960266113281
      ],
      "page_num": 54,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018)’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이외에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음이 포함될 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        210.57598876953125,
        577.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        587.2799682617188,
        538.5599975585938,
        601.66796875
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방어",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유도와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제안된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응들.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지속성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표현형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이토카인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        659.2799682617188,
        489.6960144042969,
        673.66796875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5360107421875,
        697.66796875
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.36000061035156,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.36000061035156,
        731.2799682617188,
        522.0960083007812,
        745.66796875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "55/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.2. 독성",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        82.68000030517578,
        126.23949432373047,
        101.8160400390625
      ],
      "page_num": 55,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018)’",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이외에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        115.31999969482422,
        538.5599975585938,
        129.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항들을 다루도록 설계해야 하는가를 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        139.3199920654297,
        378.5760192871094,
        153.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 생체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔존도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우려에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증거",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터베이스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        163.3199920654297,
        538.4400024414062,
        177.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "향후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더욱",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신속히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        187.3199920654297,
        538.4400024414062,
        201.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다(3,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "44~49).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문제는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조직으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        211.3199920654297,
        538.4400024414062,
        225.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이동하는가에 따라 달라질 수 있다. 식약처는 mRNA 및 지질나노입자(또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        235.3199920654297,
        538.5599975585938,
        249.70799255371094
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        259.32000732421875,
        538.4400024414062,
        273.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다루는 비임상 연구를 기대할 수 있다. 식약처로부터 이러한 연구에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        307.32000732421875,
        538.5599975585938,
        321.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의를 구해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        331.32000732421875,
        222.57598876953125,
        345.7080078125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천성 면역체계를 통해 염증을 유발한다. mRNA 백신 내의 mRNA 분자 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        379.3199768066406,
        538.5599975585938,
        393.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        403.3199768066406,
        538.5599975585938,
        417.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        427.3199768066406,
        538.5599975585938,
        441.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(50,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "51).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유리하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        475.3199768066406,
        538.4400024414062,
        489.7079772949219
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요할 것이다. 비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        499.3199768066406,
        538.4400024414062,
        513.7079467773438
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        523.3200073242188,
        538.5599975585938,
        537.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51). 추가적으로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        547.3200073242188,
        538.5360107421875,
        561.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        595.3200073242188,
        538.4400024414062,
        609.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로파일에 영향을 줄 수 있다(52~55). 따라서 제형화를 포함한 전반적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        667.3200073242188,
        538.5360107421875,
        681.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        691.3200073242188,
        538.4400024414062,
        705.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        739.3200073242188,
        162.57598876953125,
        753.7080078125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "56/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함유한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항바이러스제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항암제는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미토콘드리아",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유발하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간지방증(liver",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "steatosis),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "췌장염(pancreatitis),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지방이영양증(lipodystropy),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        179.27999877929688,
        538.5360107421875,
        193.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고 심지어는 사망으로 이어진다. 그러나 임상적으로 관찰된 이러한 독성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물모델에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관찰되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않았다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진전된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다. 그러므로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        275.2799987792969,
        538.5360107421875,
        289.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비자연적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴클레오시드",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변형물을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우(다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.47999572753906,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는가에 대해 면밀하게 고려해야 한다(56~58).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.47999572753906,
        371.2799987792969,
        384.8160095214844,
        385.6679992675781
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전반적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전하에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "줄",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으므로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제작한 지질나노입자를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자체가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "봉입한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상이나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질(또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨가제)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함유한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운 제형화에 대하여 독성 평가를 실시해야 한다. 더 나아가, ‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및/또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICH",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S2(R1)(58)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독성 평가를 요구할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        635.2799682617188,
        270.5760192871094,
        649.66796875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        111.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 평가가 필요할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        111.5999984741211,
        707.2799682617188,
        252.57598876953125,
        721.66796875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        731.2799682617188,
        538.4400024414062,
        745.66796875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "57/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        524.4959716796875,
        97.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.81124877929688
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역전사효소(reverse",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "transcriptase)와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통합효소(integrase)를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함유한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합체의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재가 필요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        155.27999877929688,
        201.57598876953125,
        169.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        179.27999877929688,
        538.5599975585938,
        193.81124877929688
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전사를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개시하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프라이머에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA-결합",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부위를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하지 않도록 하는 것이다. 추가로, 결과 산물이 삽입되도록 역전사 후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA를 핵으로 재배치해야 할 것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        251.27999877929688,
        318.9360046386719,
        265.6679992675781
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        275.2799987792969,
        538.4400024414062,
        289.8112487792969
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "속으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들어가면",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "짧은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분해된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동안,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5360107421875,
        313.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번역되고 이후 정상적인 세포 기전에 의해 분해된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        347.2799987792969,
        399.5760192871094,
        361.6679992675781
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        371.2799987792969,
        538.5599975585938,
        385.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구를 실시할 필요는 없다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        234.57598876953125,
        409.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임신부",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가임기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여성에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "광범위하게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상되는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신들과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비암상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2014)’에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요성은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적응증에 대하여 표적 인구를 기반으로 할 것이다. 종종, 필요한 경우, 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.4400024414062,
        529.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행하는 중 또는 시험 완료 후에 실시한다. 예를 들어, 가임 여성이 포함된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록하기 전에 이용 가능해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        276.5760192871094,
        601.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        611.2799682617188,
        538.4400024414062,
        625.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.5599975585938,
        649.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻어야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        538.4400024414062,
        697.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데 동의해야 한다. 마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.4400024414062,
        745.66796875
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "58/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제제의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뒷받침할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여기에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "몰",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.5599975585938,
        169.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이하일 것이라는 것을 아는 것이 포함된다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        318.5760192871094,
        193.66799926757812
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.3. 비임상 평가의 가속화",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        226.67999267578125,
        259.79901123046875,
        245.8160400390625
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        259.32000732421875,
        538.4400024414062,
        273.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.5599975585938,
        297.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 단축 비임상 프로그램을 고려할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        336.5760192871094,
        321.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        331.32000732421875,
        538.4400024414062,
        345.85125732421875
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        355.3199768066406,
        538.5599975585938,
        369.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        379.3199768066406,
        538.4400024414062,
        393.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우(즉,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-지질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도즈",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "당",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지질나노입자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "총량이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        427.3199768066406,
        538.4400024414062,
        441.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        475.3199768066406,
        538.5599975585938,
        489.7079772949219
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가용한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우라면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동물모델을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공격-방어(challenge-protection)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한될",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        523.3200073242188,
        538.4400024414062,
        537.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        571.3200073242188,
        538.5599975585938,
        585.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "많은 안전성 자료를 수집해야 한다. 관련된 항원을 발현하는 동물용 백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        595.3200073242188,
        538.4400024414062,
        609.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        667.3200073242188,
        457.656005859375,
        681.7080078125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        691.3200073242188,
        538.5599975585938,
        705.8512573242188
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        715.3200073242188,
        538.4400024414062,
        729.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        739.3200073242188,
        538.4400024414062,
        753.7080078125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "59/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접근법은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충분하지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떤",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종류의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성/독성학",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        108.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다. 만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        131.27999877929688,
        538.5599975585938,
        145.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        155.27999877929688,
        538.5360107421875,
        169.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알레르기원성(allergenicity)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        179.27999877929688,
        538.5479736328125,
        193.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        179.27999877929688,
        538.5479736328125,
        193.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역-연관",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        179.27999877929688,
        538.5479736328125,
        193.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환강화(immune-associated",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        179.27999877929688,
        538.5479736328125,
        193.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disease",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "enhancement)로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역병리(immunopathology)와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련되어",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독성 연구가 필요할 수 있다. 자가면역은 비임상 연구에서 평가되지 않을 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        251.27999877929688,
        538.5599975585938,
        265.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다(생물의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018)).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자연적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역병리와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자연적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "거의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떻게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단축할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는가에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "논의를 진행해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        347.2799987792969,
        231.57598876953125,
        361.6679992675781
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.8112487792969
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        395.2799987792969,
        538.5599975585938,
        409.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한층",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "광범위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처와의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "논의가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        419.2799987792969,
        538.5599975585938,
        433.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다. 그러나,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.5360107421875,
        457.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        467.2799987792969,
        538.5360107421875,
        481.6679992675781
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상 연구를 개시하는 것이 가능할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        491.2799987792969,
        351.5760192871094,
        505.6679992675781
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.5599975585938,
        553.66796875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바를 항상 고려해야 한다. 관련된 제품(들)에서 도출한 임상 자료를 확보할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.5599975585938,
        577.66796875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        498.57598876953125,
        625.66796875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "60/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 임상 평가",
      "font_size": 20.03999900817871,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        82.07999420166016,
        174.5998992919922,
        106.10795593261719
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목허가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기대사항은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        147.239990234375,
        538.4400024414062,
        161.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        171.239990234375,
        538.4639892578125,
        185.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "action)(또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작용기작(mechanism",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mechanism))을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        195.239990234375,
        538.4400024414062,
        209.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        219.239990234375,
        538.4400024414062,
        233.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        243.239990234375,
        538.5599975585938,
        257.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규칙(총리령)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[별표",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4]",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        267.239990234375,
        538.4400024414062,
        281.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        291.239990234375,
        538.4400024414062,
        305.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원칙을 준수해야 한다. 또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        315.239990234375,
        538.5599975585938,
        329.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "논하고 있다. 더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        339.239990234375,
        538.5599975585938,
        353.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        363.239990234375,
        538.5360107421875,
        377.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        387.239990234375,
        538.5599975585938,
        401.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추론을 위한 면역가교의 평가 시 고려사항을 제공한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        411.239990234375,
        384.5760192871094,
        425.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        435.239990234375,
        538.5599975585938,
        449.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        459.239990234375,
        538.4400024414062,
        473.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개략적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서술하고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우려",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특별한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        483.239990234375,
        538.416015625,
        497.62799072265625
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        507.239990234375,
        453.57598876953125,
        521.6279907226562
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.1. 안전성 및 면역원성 평가",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        554.7599487304688,
        284.6394958496094,
        573.89599609375
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        587.2799682617188,
        538.4400024414062,
        601.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를 가능하게 해주는 충분한 자료를 획득해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        384.5760192871094,
        625.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 유해한 면역효과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        191.63999938964844,
        673.66796875
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중간결과에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일시적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프구의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일시적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소(1~3등급)가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고되었는데,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프구는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        707.2799682617188,
        538.5599975585938,
        721.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없었다(59). 이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유의한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이어지지는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않았다(60,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제1형",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관심을 기울여야 할 수 있다(46, 62~64). 그렇기는 하지만, 이러한 현상이 후보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으므로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백혈구",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하위군에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.4400024414062,
        241.66799926757812
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무엇보다 중요하다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        186.57598876953125,
        289.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 면역반응의 종류 및 범위",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        239.63999938964844,
        337.6679992675781
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        347.2799987792969,
        538.5599975585938,
        361.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외에도,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에서는,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        432.57598876953125,
        409.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.8112487792969
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종류의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성향이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재까지,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        467.2799987792969,
        538.5360107421875,
        481.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23). 이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        491.2799987792969,
        538.5599975585938,
        505.6679992675781
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데 유용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        515.2799682617188,
        213.57598876953125,
        529.66796875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "새로운",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        96.5999984741211,
        539.2799682617188,
        538.5360107421875,
        553.8112182617188
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        587.2799682617188,
        538.5360107421875,
        601.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하는가,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피접종자의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기존",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과라면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "악화되는가와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원인에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사를 실시해야 한다. 그렇지 않으면, 발현된 항원에 대한 반응으로 인한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        108.5999984741211,
        683.2799682617188,
        538.5599975585938,
        697.66796875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        108.5999984741211,
        707.2799682617188,
        489.33599853515625,
        721.66796875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "62/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최대내성용량(maximally",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tolerable",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dose)과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량(특히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신이거나",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sa-mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.5360107421875,
        145.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어진",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인구에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최대",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        444.57598876953125,
        193.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        203.27999877929688,
        538.4400024414062,
        217.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "빈도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중증도",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면밀한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효율적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설계를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예비",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.4400024414062,
        265.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에서 용량, 시기 및 예방 접종",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5360107421875,
        289.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "횟수(필요하다면 기초접종 및 추가 접종),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5360107421875,
        289.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다. 이러한 문제에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "논의는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2017)’에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "찾을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.5599975585938,
        337.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.4400024414062,
        361.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종이 필요하다는 결정이 내려지지 않을 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        360.5760192871094,
        385.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        91.68000030517578,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        538.4400024414062,
        433.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        443.2799987792969,
        538.4400024414062,
        457.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다(65). 아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.5599975585938,
        481.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특유한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제형화의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떤",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측면이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        538.4400024414062,
        553.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신을 접종해서는 안 된다고 조언하고 있다(66~69). 비록 생물학적 기전과 관련된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        563.2799682617188,
        538.4400024414062,
        577.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요소들은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아직",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "밝혀지지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않았지만",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심근염과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심낭염은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코로나19",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        587.2799682617188,
        538.5239868164062,
        601.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물감시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동안",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관찰되었으며",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보인다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유럽",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        611.2799682617188,
        538.5599975585938,
        625.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        635.2799682617188,
        538.4400024414062,
        649.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품청(US",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FDA)(72,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "73)의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간행물을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하여,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "몇몇",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규제당국의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최근",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        659.2799682617188,
        538.4400024414062,
        673.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        683.2799682617188,
        510.57598876953125,
        697.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2017)’에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의거하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "능동적인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물감시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        707.2799682617188,
        538.4400024414062,
        721.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획을 수립하여 실시할 것을 권고한다. 공중보건 긴급상황의 맥락에서 보급한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        731.2799682617188,
        538.5599975585938,
        745.66796875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "63/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.4400024414062,
        97.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의식 제고 캠페인 운영을 고려해야 한다. 코로나19 백신과 잠재적으로 관련된",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.5599975585938,
        121.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        528.5759887695312,
        145.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        538.4400024414062,
        193.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        203.27999877929688,
        538.5599975585938,
        217.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        227.27999877929688,
        538.5599975585938,
        241.66799926757812
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "희귀한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계속하여",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        251.27999877929688,
        538.5360107421875,
        265.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        275.2799987792969,
        538.5599975585938,
        289.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        299.2799987792969,
        538.5599975585938,
        313.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다. 추가적으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        323.2799987792969,
        538.4400024414062,
        337.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        347.2799987792969,
        538.5360107421875,
        361.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        371.2799987792969,
        538.4400024414062,
        385.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유용성 연구 수행을 고려해야 한다. 앞서 기술한 바와 같이, 이 영역은 빠르게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        395.2799987792969,
        538.4400024414062,
        409.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        419.2799987792969,
        438.57598876953125,
        433.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        443.2799987792969,
        538.5599975585938,
        457.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준품의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능해진다면,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내부",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기타",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작업용",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        467.2799987792969,
        538.4400024414062,
        481.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질(working",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "standard)을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교정하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획득한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        491.2799987792969,
        538.4400024414062,
        505.6679992675781
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교가능성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신들,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구들,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상이한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼들에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "걸쳐",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "향상하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        515.2799682617188,
        538.5599975585938,
        529.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여 IU로 표기한 결과를 보고해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        539.2799682617188,
        320.0159912109375,
        553.66796875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.2. 유효성 평가",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        586.6799926757812,
        184.67950439453125,
        605.8160400390625
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방어하고자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.5599975585938,
        633.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정되는 임상 적응증에 따라 달라진다. 백신 유효성 평가 시 고려해야 할 요소는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        426.09600830078125,
        681.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        691.3200073242188,
        538.5599975585938,
        705.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다. 위약군을 설정한 진행",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        715.3200073242188,
        538.5599975585938,
        729.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        739.3200073242188,
        538.4400024414062,
        753.7080078125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "64/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개최된 공개 회의에서 논의되었다(74~76). (적절한 대조군 선정을 포함한) 시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        83.27999877929688,
        538.5599975585938,
        97.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다. 모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        107.27999877929688,
        538.4400024414062,
        121.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후보",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마찬가지로,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이점과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "윤리적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려사항",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부문",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모두는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        131.27999877929688,
        538.4400024414062,
        145.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설계에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하며,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정은",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규제",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신청을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        155.27999877929688,
        538.4400024414062,
        169.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        179.27999877929688,
        449.3760070800781,
        193.66799926757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.3. 공중 위기 맥락에서의 유효성 평가",
      "font_size": 15.960000038146973,
      "font_name": "T11",
      "bbox": [
        61.68000030517578,
        226.67999267578125,
        359.8794860839844,
        245.8160400390625
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        259.32000732421875,
        538.5599975585938,
        273.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사의 모체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신(또는 시판",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신)에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 임상적",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성 평가변수를",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        283.32000732421875,
        538.4400024414062,
        297.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "플랫폼",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유추하기",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        307.32000732421875,
        538.4400024414062,
        321.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        331.32000732421875,
        538.5360107421875,
        345.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역가교는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동등한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역가가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떻게",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        355.3199768066406,
        538.4400024414062,
        369.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        379.3199768066406,
        538.5360107421875,
        393.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음의 두 가지 시나리오를 반드시 고려해야 한다. (1) 변이 백신이 모체 백신을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        403.3199768066406,
        538.4400024414062,
        417.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        427.3199768066406,
        538.5360107421875,
        441.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 동시에 투여하거나 순차적으로 투여할 것이다. 이러한 면역가교 연구 중의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        451.3199768066406,
        538.4400024414062,
        465.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교 안전성 자료 수집 역시 기대할 것이다. 전반적으로, 면역가교 연구에 대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        475.3199768066406,
        538.4400024414062,
        489.7079772949219
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        499.3199768066406,
        538.5599975585938,
        513.7079467773438
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        523.3200073242188,
        465.57598876953125,
        537.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        547.3200073242188,
        538.5599975585938,
        561.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        571.3200073242188,
        538.4400024414062,
        585.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규제당국들이 제공하는 지침을 고려할 수 있다(79~81).",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        595.3200073242188,
        381.6960144042969,
        609.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        91.68000030517578,
        619.3200073242188,
        538.4400024414062,
        633.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시에는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불활화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약독화",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독감",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신에",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재의",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관행을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        643.3200073242188,
        538.4400024414062,
        657.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘인플루엔자",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(식약처,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020)’을",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        81.5999984741211,
        667.3200073242188,
        538.5599975585938,
        681.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참조해야 한다.",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        81.5999984741211,
        691.3200073242188,
        162.57598876953125,
        705.7080078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "65/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[참고문헌]",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.63999938964844,
        81.26947021484375,
        131.23223876953125,
        102.49752044677734
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        120.5999984741211,
        534.3380737304688,
        133.84799194335938
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nat",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Rev",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Drug",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Discov.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2014;13(10):759–80",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(abstract:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://pubmed.ncbi.nlm.nih.gov/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        136.55999755859375,
        534.3169555664062,
        149.8079833984375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "25233993/, accessed 15 June 2021).",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.31999969482422,
        152.52000427246094,
        247.17779541015625,
        165.7569580078125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        172.55999755859375,
        534.2374877929688,
        185.7969512939453
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "transfer into mouse muscle in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1465–8.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        188.52000427246094,
        496.77789306640625,
        201.7679901123047
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. Pardi",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Hogan MJ,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Porter",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FW,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Weissman D.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA vaccines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- a",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "new era",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        208.44000244140625,
        534.3055419921875,
        221.6769561767578
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        224.39999389648438,
        384.2178955078125,
        237.64797973632812
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        244.32000732421875,
        534.3068237304688,
        257.5679931640625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of pseudouridine into mRNA yields superior nonimmunogenic vector with increased",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        260.2799987792969,
        534.2447509765625,
        305.447998046875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "translational capacity and biological stability. Mol Ther J Am Soc Gene Ther. 200810",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        260.2799987792969,
        534.2447509765625,
        305.447998046875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nov;16(11):1833–40.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        260.2799987792969,
        534.2447509765625,
        305.447998046875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. Thess",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Grund",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mui",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BL,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Hope",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MJ,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Baumhof",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "P,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Fotin-Mleczek",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "et",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "al.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        312.239990234375,
        534.2181396484375,
        325.4769592285156
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        328.1999816894531,
        534.3052978515625,
        373.3680114746094
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Effective Protein Therapy in Large Animals. Mol Ther J Am Soc Gene Ther. 2015",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        328.1999816894531,
        534.3052978515625,
        373.3680114746094
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Sep;23(9):1456–1464.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        328.1999816894531,
        534.3052978515625,
        373.3680114746094
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        380.03997802734375,
        534.2188110351562,
        393.2879943847656
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Generation and Testing of Stable and Immunogenic mRNA Vaccines. Methods Mol",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        395.9999694824219,
        534.3333740234375,
        425.2080078125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Biol Clifton NJ. 2017;1499:89–107.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        395.9999694824219,
        534.3333740234375,
        425.2080078125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al. The European",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        431.8799743652344,
        534.3053588867188,
        445.116943359375
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Regulatory Environment of RNA-Based Vaccines. In: Kramps T, Elbers K, editors.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA Vaccines: Methods and Protocols [Internet]. New York, NY: Springer; 2017 [cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "202121",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Jan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "p.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "203–22.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Methods",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Molecular",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Biology).",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        447.8399963378906,
        534.2445678710938,
        493.00799560546875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://doi.org/10.1007/978-1-4939-6481-9_13",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        495.719970703125,
        306.8161315917969,
        508.9569396972656
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. Jackson",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NAC,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Kester",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "KE,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Casimiro",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "D,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Gurunathan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DeRosa",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "The",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "promise",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        515.760009765625,
        534.30517578125,
        528.9969482421875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA24 vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020 Feb 4;5(1):11.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.43999481201172,
        531.7200317382812,
        532.4183959960938,
        544.9569702148438
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9. Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        551.6400146484375,
        534.3397216796875,
        564.876953125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Curr Top Microbiol Immunol. 2020 Jul 8;27",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        79.55999755859375,
        567.6000366210938,
        304.7775573730469,
        580.8369750976562
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials. Methods",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        587.52001953125,
        534.2310791015625,
        600.7569580078125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mol Biol Clifton NJ. 2017;1499:237–51.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        603.47998046875,
        285.3375549316406,
        616.7279663085938
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11. Hager G. Nonclinical Safety Testing of RNA Vaccines. Methods Mol Biol Clifton NJ.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        623.52001953125,
        534.2181396484375,
        636.7569580078125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2017;1499:253–72.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        639.47998046875,
        175.5379180908203,
        652.7279663085938
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12. Guidelines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nonclinical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Evaluation",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Adjuvants",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Adjuvanted",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        659.4000244140625,
        534.2426147460938,
        672.636962890625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccines,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "In:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "WHO",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Expert",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Committee",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Biological",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Standardization.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Sixty-Fourth",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        675.3599853515625,
        534.3046875,
        688.596923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Report. Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        691.3200073242188,
        534.33984375,
        736.4769287109375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Series 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        691.3200073242188,
        534.33984375,
        736.4769287109375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "accessed 1 Dec. 2020)",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        691.3200073242188,
        534.33984375,
        736.4769287109375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "66/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516–27.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        532.4175415039062,
        102.88800048828125
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14. Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        109.55999755859375,
        534.2181396484375,
        122.79695892333984
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA therapeutics deliver a hopeful message. Nano Today [Internet]. 2018 Dec 1",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        125.5199966430664,
        534.337890625,
        170.6769561767578
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited 2021 May 1];23:16–39. Available from: https://www.sciencedirect.com/science/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        125.5199966430664,
        534.337890625,
        170.6769561767578
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "article/pii/S1748013218301099",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        125.5199966430664,
        534.337890625,
        170.6769561767578
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        177.47999572753906,
        534.2364501953125,
        190.71694946289062
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dec",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "31",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Jan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5];383(27):2603–15.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://doi.org/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.3187255859375,
        222.6479949951172
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10.1056/NEJMoa2034577",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        225.36000061035156,
        207.09739685058594,
        238.59695434570312
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        245.28001403808594,
        534.2359619140625,
        258.5169677734375
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–16.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        261.239990234375,
        497.25872802734375,
        274.4880065917969
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17. Sahin",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "U,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Muik",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Derhovanessian",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "E,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vogler",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "I,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Kranz",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LM,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vormehr",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "et",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "al.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        281.15997314453125,
        534.2177734375,
        294.3969421386719
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BNT162b1",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "elicits",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "human",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "antibody",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TH1",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "T",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cell",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "responses.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        297.1199951171875,
        534.3388671875,
        310.3569641113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nature. 2020 Oct;586(7830):594–9.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        258.9378967285156,
        326.3280029296875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18. Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA. Gene Ther. 2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        333.1199951171875,
        534.2175903320312,
        346.3569641113281
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May;27(5):183–5.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        349.0799865722656,
        171.9379119873047,
        362.3280029296875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19. Bertrand",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "N,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Leroux",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "J-C.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "The",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "journey",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "drug-carrier",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "body:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "an",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        368.9999694824219,
        534.1849365234375,
        382.2369384765625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "anatomo-physiological perspective. J Control Release Off J Control Release Soc. 2012",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        384.9599914550781,
        534.2175903320312,
        414.1679992675781
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Jul 20;161(2):152–63.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        384.9599914550781,
        534.2175903320312,
        414.1679992675781
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. Safety Evaluation of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        420.8399963378906,
        534.3054809570312,
        434.07696533203125
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lipid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nanoparticle-Formulated",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Modified",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Sprague-Dawley",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Rat",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        436.79998779296875,
        534.2434692382812,
        450.0369567871094
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cynomolgus Monkey. Vet Pathol. 2018 Mar;55(2):341–54.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        381.3375549316406,
        466.00799560546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "21. Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol Pharm",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        472.79998779296875,
        534.257080078125,
        486.0369567871094
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2008",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Aug",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1];5(4):496–504.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        488.7599792480469,
        534.3381958007812,
        502.00799560546875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://doi.org/10.1021/mp800049w",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        504.7200012207031,
        268.3826599121094,
        517.9569702148438
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "22. Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al. Influence of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        524.6400146484375,
        534.184814453125,
        537.876953125
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        540.6000366210938,
        534.2275390625,
        569.7969360351562
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids. 2013 Dec 17;2:e139.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        540.6000366210938,
        534.2275390625,
        569.7969360351562
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        576.47998046875,
        534.2177734375,
        589.7169189453125
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        592.4400024414062,
        534.3375854492188,
        621.6480102539062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nov 12;383(20):1920–31.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        592.4400024414062,
        534.3375854492188,
        621.6480102539062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        628.4400024414062,
        534.2443237304688,
        641.6769409179688
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "lipid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "carriers",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "as",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "novel",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "drug",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "delivery",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "systems:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "applications,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "advantages",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        644.4000244140625,
        534.2434692382812,
        657.636962890625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disadvantages. Res Pharm Sci. 2018 Aug;13(4):288–303.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        660.3599853515625,
        370.6575622558594,
        673.6079711914062
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25. Guevara",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ML,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Persano",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Persano",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Advances",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lipid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nanoparticles",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        680.280029296875,
        534.2700805664062,
        693.5169677734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-Based Cancer Immunotherapy. Front Chem. 2020;8:589959.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        696.239990234375,
        423.2161560058594,
        709.4769287109375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "67/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "26. Hassett",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "KJ,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Benenato",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "KE,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Jacquinet",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "E,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lee",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Woods",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Yuzhakov",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "O,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "et",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "al.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2177734375,
        102.87696075439453
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Optimization",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lipid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nanoparticles",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Intramuscular",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Administration",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2973022460938,
        118.83695983886719
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccines. Mol Ther Nucleic Acids. 2019 Apr 15;15:1–11.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        121.55998992919922,
        378.2178955078125,
        134.8079833984375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27. Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.3374633789062,
        154.71694946289062
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines. 2021 Jan 19;9(1).",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        157.44000244140625,
        495.3378601074219,
        170.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28. Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. Nanoparticles as",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        177.47999572753906,
        534.2295532226562,
        190.71694946289062
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Adjuvants",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nanodelivery",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Systems",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA-Based",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccines.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Pharmaceutics",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        193.44000244140625,
        534.2305908203125,
        206.6769561767578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Jan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1];13(1):45.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3381958007812,
        222.636962890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.mdpi.com/1999-4923/13/1/45",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        225.36000061035156,
        307.2963562011719,
        238.59695434570312
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        245.28001403808594,
        534.243408203125,
        258.5169677734375
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        261.239990234375,
        534.2183227539062,
        290.447998046875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2010 Sep;31(26):6867–75.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        261.239990234375,
        534.2183227539062,
        290.447998046875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30. Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        297.1199951171875,
        534.2177734375,
        310.3680114746094
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.2174682617188,
        342.2879943847656
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "J Control Release Off J Control Release Soc. 2018 Oct 10;287:67–77.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.2174682617188,
        342.2879943847656
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "31. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.2317504882812,
        362.31695556640625
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "diseases. Gene Ther. 2020 Oct 22;49.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        365.03997802734375,
        272.377197265625,
        378.2769470214844
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32. Guidance",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Use",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "International",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nonproprietary",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Names",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(INNs)",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        384.9599914550781,
        534.2700805664062,
        398.19696044921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Pharmaceutical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        400.91998291015625,
        534.2294311523438,
        414.1569519042969
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Substances",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        400.91998291015625,
        534.2294311523438,
        414.1569519042969
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        416.8799743652344,
        533.761962890625,
        446.07696533203125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b.pdf?ua=1 accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        416.8799743652344,
        533.761962890625,
        446.07696533203125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "33. Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        452.7599792480469,
        534.2174072265625,
        466.00799560546875
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mignot G, et al. The INN global nomenclature of biological medicines: A continuous",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        468.719970703125,
        534.2359008789062,
        513.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "challenge. Biologicals [Internet]. 2019 Jul 1 [cited 2021 May 1];60:15–23. Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        468.719970703125,
        534.2359008789062,
        513.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from: https://www.sciencedirect.com/science/article/pii/S104510561930048X",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        468.719970703125,
        534.2359008789062,
        513.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "34. Arbuthnot P, Ely",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        520.6799926757812,
        534.3053588867188,
        533.9169311523438
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A, Bloom K. A convenient method to generate and maintain",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        520.6799926757812,
        534.3053588867188,
        533.9169311523438
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "poly(A)-encoding",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sequences",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "required",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vitro",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "transcription",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.3370361328125,
        549.876953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BioTechniques. 2019 Jan;66(1):37–9.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        552.6000366210938,
        267.0975646972656,
        565.8480224609375
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "35. Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        572.52001953125,
        534.230224609375,
        585.7569580078125
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "significantly",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "reduce",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "recombination",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "plasmid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "without",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "affecting",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        588.47998046875,
        534.2973022460938,
        601.7169189453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "translation",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "efficiency",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "or",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "half-life.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "25:507–518.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3375244140625,
        617.68798828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        387.5758361816406,
        633.636962890625
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        640.3200073242188,
        534.236572265625,
        653.5569458007812
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the Cold Reality of mRNA Vaccine Stability. J Pharm Sci [Internet]. 2021 Mar 1 [cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "WHO/BS/2021.2402",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Feb",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19];110(3):997–1001.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        656.280029296875,
        534.3381958007812,
        685.4879760742188
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.sciencedirect.com/science/article/pii/S0022354920307851",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        688.2000122070312,
        439.78173828125,
        701.4369506835938
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "68/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "37. Muralidhara",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BK,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Baid",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "R,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Bishop",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SM,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Huang",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Wang",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "W,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nema",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Critical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2128295898438,
        102.87696075439453
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "considerations for developing nucleic acid macromolecule based drug products. Drug",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2353515625,
        134.8079833984375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Discov Today. 2016 Mar;21(3):430–44.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        534.2353515625,
        134.8079833984375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "38. Poveda",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "C,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Biter",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AB,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Bottazzi",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ME,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Strych",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "U.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Establishing",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Preferred",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Product",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        141.47999572753906,
        534.2173461914062,
        154.71694946289062
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Characterization for the Evaluation of RNA Vaccine Antigens. Vaccines. 2019 Sep 27;7(4).",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        157.44000244140625,
        533.3773193359375,
        170.6769561767578
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "39. ICH Q3C(R6). Impurities: guideline for residual solvents. 2016. https://database.ich.org/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        177.47999572753906,
        534.1971435546875,
        190.71694946289062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.83999633789062,
        193.44000244140625,
        433.9797058105469,
        206.6769561767578
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40. ICH",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Q3D(R1).",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "elemental",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "impurities.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2019.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://database.ich.org/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        213.36000061035156,
        534.3184204101562,
        226.59695434570312
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        229.32000732421875,
        463.145751953125,
        242.5569610595703
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "41. ICH",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "guideline",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S2",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(R1)",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "genotoxicity",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "testing",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "data",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "interpretation",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        249.24000549316406,
        534.2700805664062,
        262.4769592285156
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pharmaceuticals",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "intended",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "human",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.ema.europa.eu/en/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        265.1999816894531,
        534.199951171875,
        278.43695068359375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        281.15997314453125,
        533.95654296875,
        310.3569641113281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        281.15997314453125,
        533.95654296875,
        310.3569641113281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42. WHO Getting started with vaccine vial monitors. 2002. https://apps.who.int/iris/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        317.15997314453125,
        534.3189697265625,
        330.3969421386719
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        333.1199951171875,
        431.0173034667969,
        346.3569641113281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "43. WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        353.03997802734375,
        534.2186279296875,
        366.2769470214844
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccines.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        368.9999694824219,
        534.3091430664062,
        382.2369384765625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        368.9999694824219,
        534.3091430664062,
        382.2369384765625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.who.int/publications/m/item/bar-codes-qr-codes-and-",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        368.9999694824219,
        534.3091430664062,
        382.2369384765625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        384.9599914550781,
        486.57720947265625,
        398.19696044921875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "44. Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al. Nonclinical safety",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        404.8799743652344,
        534.2351684570312,
        418.116943359375
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "assessment",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "repeated",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "administration",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "biodistribution",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "novel",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "rabies",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        420.8399963378906,
        534.2303466796875,
        434.07696533203125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "self-amplifying mRNA vaccine in rats. Regul Toxicol Pharmacol RTP. 2020 Jun;113:104648.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        436.79998779296875,
        533.0214233398438,
        450.0369567871094
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "45. Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. Delivery of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        456.8399658203125,
        534.184814453125,
        470.0769348144531
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        472.79998779296875,
        534.2088012695312,
        502.00799560546875
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "lipid selection. J Control Release Off J Control Release Soc. 2020 Sep 10;325:370–9.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        472.79998779296875,
        534.2088012695312,
        502.00799560546875
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "46. Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        508.6799621582031,
        534.2434692382812,
        521.9169311523438
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        524.6400146484375,
        534.2434692382812,
        553.8480224609375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "H7N9 Influenza Viruses. Mol Ther J Am Soc Gene Ther. 2017 Jun 7;25(6):1316–27.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        524.6400146484375,
        534.2434692382812,
        553.8480224609375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "47. Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al. Efficient Targeting",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        560.52001953125,
        534.2362670898438,
        573.7680053710938
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        576.47998046875,
        534.2382202148438,
        605.6769409179688
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Administration in Rhesus",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        576.47998046875,
        534.2382202148438,
        605.6769409179688
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Macaques. Mol Ther J Am",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        576.47998046875,
        534.2382202148438,
        605.6769409179688
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Soc Gene Ther. 2017 Dec",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        576.47998046875,
        534.2382202148438,
        605.6769409179688
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6;25(12):2635–47.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        608.4000244140625,
        171.8175811767578,
        621.6480102539062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "48. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        628.4400024414062,
        534.18408203125,
        641.6769409179688
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        644.4000244140625,
        534.236083984375,
        657.636962890625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "to mice by",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        644.4000244140625,
        534.236083984375,
        657.636962890625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "various routes. J Controlled Release [Internet]. 2015 Nov 10 [cited 2021 May 1];217:345–",
      "font_size": 11.039999961853027,
      "font_name": "T16",
      "bbox": [
        84.72000122070312,
        660.3599853515625,
        534.239990234375,
        689.5569458007812
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "51. Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        660.3599853515625,
        534.239990234375,
        689.5569458007812
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "49. EMA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assessment",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "report",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Comirnaty,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "December",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "21,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "page",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "47",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        696.239990234375,
        534.2175903320312,
        709.4769287109375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        712.2000122070312,
        533.9961547851562,
        741.39697265625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "sment-report_en.pdf Accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        712.2000122070312,
        533.9961547851562,
        741.39697265625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "69/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "50. Obeid MA, Tate RJ, Mullen AB, Ferro VA. Chapter 8 - Lipid-based nanoparticles for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.2700805664062,
        102.87696075439453
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cancer treatment. In: Grumezescu AM, editor. Lipid Nanocarriers for Drug Targeting",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.95999908447266,
        105.5999984741211,
        534.235595703125,
        150.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet]. William Andrew Publishing; 2018 [cited 2021 May 27]. p. 313–59. Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.95999908447266,
        105.5999984741211,
        534.235595703125,
        150.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from: https://www.sciencedirect.com/science/article/pii/B9780128136874000086",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.95999908447266,
        105.5999984741211,
        534.235595703125,
        150.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "51. Marlowe",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "JL,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Akopian",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "V,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Karmali",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "P,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Kornbrust",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "D,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lockridge",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "J,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Semple",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        157.44000244140625,
        534.2174072265625,
        170.6769561767578
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Recommendations",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Oligonucleotide",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Safety",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Working",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Group’s",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Formulated",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        173.40000915527344,
        534.242919921875,
        186.636962890625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Oligonucleotide",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Subcommittee",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Safety",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assessment",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Formulated",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        189.36000061035156,
        534.242919921875,
        202.59695434570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Oligonucleotide-Based Therapeutics. Nucleic Acid Ther. 2017 Aug;27(4):183–96.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        205.32000732421875,
        494.1375427246094,
        218.5679931640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "52. CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        225.36000061035156,
        534.243408203125,
        238.59695434570312
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "drug",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "products",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "pediatric",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "population",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.ema.europa.eu/en/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        241.32000732421875,
        534.3202514648438,
        254.5569610595703
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "chmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        257.2799987792969,
        534.0669555664062,
        286.4769592285156
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "drug-products Accessed June 1, 2021.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        257.2799987792969,
        534.0669555664062,
        286.4769592285156
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "53. Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of Biopharmaceuticals: A",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        293.15997314453125,
        534.2980346679688,
        306.3969421386719
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Review",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Chemistry",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nonclinical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Safety",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Information",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Drugs.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "J",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        309.1199951171875,
        534.3052978515625,
        322.3569641113281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Pharm Sci. 2016 Feb;105(2):460–75.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        325.0799865722656,
        265.7775573730469,
        338.3280029296875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "54. Turecek PL, Siekmann J. 4 - PEG–protein conjugates: nonclinical and clinical toxicity",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        344.9999694824219,
        534.2362060546875,
        358.24798583984375
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "considerations. In: Pasut G, Zalipsky S, editors. Polymer-Protein Conjugates [Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Elsevier;",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "p.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61–101.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        360.9599914550781,
        534.3403930664062,
        390.1679992675781
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.sciencedirect.com/science/article/pii/B978044464081900004830",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        392.8799743652344,
        468.1015625,
        406.116943359375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "55. Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al. Cytotoxicity study of polyethylene",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        412.91998291015625,
        534.1143188476562,
        426.1569519042969
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "glycol derivatives. RSC Adv [Internet]. 2017 Mar 24 [cited 2021 May 27];7(30):18252–9.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        428.8799743652344,
        534.3383178710938,
        458.07696533203125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.72000122070312,
        428.8799743652344,
        534.3383178710938,
        458.07696533203125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "56. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        464.7599792480469,
        534.3054809570312,
        477.9969482421875
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3331298828125,
        509.9280090332031
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Chem. 2001 Nov 2;276(44):40847–57.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3331298828125,
        509.9280090332031
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "57. Moyle",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "G.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Toxicity",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "antiretroviral",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nucleoside",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nucleotide",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "analogues:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "is",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2301635742188,
        529.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mitochondrial toxicity the only mechanism? Drug Saf. 2000 Dec;23(6):467–81.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        532.5599975585938,
        485.8575439453125,
        545.8079833984375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "58. Nucleoside",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Analogues.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "In:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LiverTox:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Clinical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Research",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Information",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.3055419921875,
        565.8369750976562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Digestive",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Kidney",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Diseases;",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.3381958007812,
        597.7569580078125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "http://www.ncbi.nlm.nih.gov/books/NBK548938/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        600.47998046875,
        339.4381408691406,
        613.7169189453125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "59. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        620.4000244140625,
        534.1168212890625,
        633.636962890625
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature [Internet]. 2020 Oct",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27];586(7830):589–93.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.nature.com/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.217041015625,
        665.5679931640625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "articles/ s41586-020-2639-4",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        668.280029296875,
        218.73715209960938,
        681.5169677734375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "60. Bovay A, Speiser DE, Marraco SAF. Early drop of circulating T cells negatively",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        688.2000122070312,
        534.2364501953125,
        701.4369506835938
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "correlates with the protective immune response to Yellow Fever vaccination. Hum",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Immunother",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dec",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mar",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20];16(12):3103–10.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        704.1600341796875,
        534.2571411132812,
        733.3679809570312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available from: https://doi.org/10.1080/21645515.2020.1750249",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        736.0800170898438,
        403.65447998046875,
        749.3169555664062
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61. Faguet GB. The effect of killed influenza virus vaccine on the kinetics of normal",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3325805664062,
        102.87696075439453
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "human lymphocytes. J Infect Dis. 1981 Feb;143(2):252–8.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        105.5999984741211,
        377.737548828125,
        118.8479995727539
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "62. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2434692382812,
        138.7569580078125
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "immunogenicity",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mRNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "rabies",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "healthy",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "adults:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "an",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "open-label,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        534.2186279296875,
        154.71694946289062
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet Lond Engl.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        157.44000244140625,
        534.3377075195312,
        186.6479949951172
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2017 Sep 23;390(10101):1511–20.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        157.44000244140625,
        534.3377075195312,
        186.6479949951172
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "63. Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. Vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        193.44000244140625,
        534.238525390625,
        206.6769561767578
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell. 2017 Jul",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3328247070312,
        238.6079864501953
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13;170(2):273–283.e12.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        534.3328247070312,
        238.6079864501953
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "64. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al. A novel",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        245.28001403808594,
        534.2132568359375,
        258.5169677734375
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA-based adjuvant combines strong immunostimulatory capacities with a favorable",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        261.239990234375,
        534.2362060546875,
        290.447998046875
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "safety profile. Int J Cancer. 2015 Jul 15;137(2):372–84.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        261.239990234375,
        534.2362060546875,
        290.447998046875
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "65. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        297.1199951171875,
        534.1773071289062,
        310.3569641113281
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA [Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mar",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1];325(11):1101.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3403930664062,
        342.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://jamanetwork.com/journals/jama/fullarticle/2776557",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        344.9999694824219,
        387.5792541503906,
        358.2369384765625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "66. Public",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assessment",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Report",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "National",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Procedure:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Moderna,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.20",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        365.03997802734375,
        534.3375854492188,
        378.2769470214844
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "mg/mL dispersion for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        380.9999694824219,
        534.2212524414062,
        394.2369384765625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "injection",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        380.9999694824219,
        534.2212524414062,
        394.2369384765625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(COVID-19 mRNA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        380.9999694824219,
        534.2212524414062,
        394.2369384765625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        380.9999694824219,
        534.2212524414062,
        394.2369384765625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[nucleoside-modified]),",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        380.9999694824219,
        534.2212524414062,
        394.2369384765625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PLGB 53720/0002, Moderna Biotech Spain, S.L. [cited 2021 May 1]. Available from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        396.9599914550781,
        534.3381958007812,
        458.07696533203125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        396.9599914550781,
        534.3381958007812,
        458.07696533203125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        396.9599914550781,
        534.3381958007812,
        458.07696533203125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AR__-__final.pdf",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        396.9599914550781,
        534.3381958007812,
        458.07696533203125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "67. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        464.7599792480469,
        534.3052978515625,
        477.9969482421875
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Med",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Feb",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1];384(7):643–9.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        480.719970703125,
        534.3381958007812,
        493.9679870605469
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://doi.org/10.1056/NEJMra2035343",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        496.67999267578125,
        288.0967712402344,
        509.9169616699219
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "68. Sellaturay",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "P,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nasser",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ewan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "P.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Polyethylene",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Glycol-Induced",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Systemic",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Allergic",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        516.6000366210938,
        534.2105102539062,
        529.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2021 Feb;9(2):670–5.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        532.5599975585938,
        480.2175598144531,
        545.8079833984375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "69. FDA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "presentation",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "to",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "their",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Related",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Biological",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Products",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Advisory",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        552.6000366210938,
        534.2357788085938,
        565.8369750976562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Committee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.2188720703125,
        597.7569580078125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.fda.gov/media/144585/download, accessed June 1, 2021.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        568.5599975585938,
        534.2188720703125,
        597.7569580078125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "70. EMA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assessment",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Report.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccine",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Report",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Moderna.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Jan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        604.4400024414062,
        534.3375244140625,
        617.6769409179688
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        533.9531860351562,
        649.596923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a-epar-public-assessment-report_en.pdf",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        533.9531860351562,
        649.596923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "71. UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        656.280029296875,
        534.3375854492188,
        669.5169677734375
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        672.239990234375,
        534.006103515625,
        717.39697265625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        672.239990234375,
        534.006103515625,
        717.39697265625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CH__15Dec2020.pdf Accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        672.239990234375,
        534.006103515625,
        717.39697265625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "71/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "72. US",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FDA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Review",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Memorandum:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Pfizer-BioNTech",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        89.63999938964844,
        534.3375244140625,
        102.87696075439453
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        84.23999786376953,
        105.5999984741211,
        529.41748046875,
        118.83695983886719
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "73. US",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FDA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Review",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Memorandum:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Moderna",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        125.5199966430664,
        534.2175903320312,
        138.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.fda.gov/media/144673/download",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        141.47999572753906,
        326.0433654785156,
        154.71694946289062
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "74. Goodman",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Considerations",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "placebo-controlled",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "trial",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "design",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "if",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "an",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "unlicensed",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        161.52000427246094,
        534.2451171875,
        174.7569580078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine becomes available. Presentation to US FDA Vaccines and Related Biological",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Products",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Advisory",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Committee",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "December",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        177.47999572753906,
        534.3375244140625,
        206.6769561767578
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.fda.gov/media/144354/download, accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        209.40000915527344,
        444.69757080078125,
        222.636962890625
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75. Goodman",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Considerations",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "placebo-controlled",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "trial",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "design",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "if",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "an",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "unlicensed",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        229.32000732421875,
        534.2451171875,
        242.5569610595703
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vaccine becomes available. Presentation to US FDA Vaccines and Related Biological",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Products",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Advisory",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Committee",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "December",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        245.28001403808594,
        534.3375244140625,
        274.4769592285156
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.fda.gov/media/144582/download Accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        277.1999816894531,
        445.05755615234375,
        290.43695068359375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "76. Expert consultation on the use of placebos in vaccine trials. Meeting report. Geneva:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        297.1199951171875,
        534.339111328125,
        310.3569641113281
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "World Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3170166015625,
        342.2769470214844
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9789241506250_eng.pdf Accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        313.0799865722656,
        534.3170166015625,
        342.2769470214844
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "77. Guideline",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "on",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Influenza",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vaccines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Non-clinical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Clinical",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Module.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":31.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        349.0799865722656,
        534.3375244140625,
        362.31695556640625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non-",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        365.03997802734375,
        533.7178344726562,
        394.2369384765625
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "clinical-clinical-module_en.pdf Accessed June 1, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        365.03997802734375,
        533.7178344726562,
        394.2369384765625
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "78. Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        400.91998291015625,
        534.2373657226562,
        414.1569519042969
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "United States. Influenza Other Respir Viruses. 2016 Sep;10(5):354–60.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        416.8799743652344,
        443.3775634765625,
        430.12799072265625
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "79. Marta DJ. Reflection paper on the regulatory requirements for vaccines intended to",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        436.79998779296875,
        534.2680053710938,
        450.0369567871094
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "provide",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "protection",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "against",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "variant",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "strain(s)",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SARS-CoV-2.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":7.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        452.7599792480469,
        534.337890625,
        465.9969482421875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        468.719970703125,
        534.2443237304688,
        497.9169616699219
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        468.719970703125,
        534.2443237304688,
        497.9169616699219
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Accessed",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        468.719970703125,
        534.2443237304688,
        497.9169616699219
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "June 7, 2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        500.6399841308594,
        148.17758178710938,
        513.876953125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80. Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        520.6799926757812,
        534.2312622070312,
        533.9169311523438
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "HSA.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        536.6400146484375,
        534.2178344726562,
        549.876953125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        552.6000366210938,
        533.9530639648438,
        581.7969360351562
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ce-strain-changes-in-authorised-covid-19-vaccines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        552.6000366210938,
        533.9530639648438,
        581.7969360351562
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "81. ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        65.87999725341797,
        588.47998046875,
        534.2321166992188,
        601.7169189453125
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Regulatory",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Authorities",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(ICMRA)",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Internet].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[cited",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "May",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1].",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Available",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "from:",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        604.4400024414062,
        534.3381958007812,
        617.6769409179688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "http://www.icmra.info/drupal/en/covid-19/10february2021.Gruber",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        534.3384399414062,
        633.636962890625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M,",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        534.3384399414062,
        633.636962890625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cavileri",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        534.3384399414062,
        633.636962890625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        620.4000244140625,
        534.3384399414062,
        633.636962890625
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Co-chairs)",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICMRA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Virus",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Variants",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Workshop",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "report.",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2021",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICMRA",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        636.3599853515625,
        534.2979125976562,
        649.596923828125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "COVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        652.3200073242188,
        534.23583984375,
        681.5169677734375
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Authorities (ICMRA) (accessed 3/8/2021).",
      "font_size": 11.039999961853027,
      "font_name": "T7",
      "bbox": [
        85.08000183105469,
        652.3200073242188,
        534.23583984375,
        681.5169677734375
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "72/72",
      "font_size": 8.772114753723145,
      "font_name": "T7",
      "bbox": [
        286.67999267578125,
        789.0,
        308.57818603515625,
        799.791015625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방용 mRNA 백신 평가 가이드라인",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        175.55999755859375,
        98.51431274414062,
        422.03997802734375,
        118.46548461914062
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        143.63999938964844,
        261.1199951171875,
        158.0279998779297
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.15999603271484,
        143.63999938964844,
        261.1199951171875,
        158.0279998779297
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        143.63999938964844,
        261.1199951171875,
        158.0279998779297
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2022년 01월 27일",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        143.63999938964844,
        261.1199951171875,
        158.0279998779297
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        172.67999267578125,
        420.3599853515625,
        187.0679931640625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.15999603271484,
        172.67999267578125,
        420.3599853515625,
        187.0679931640625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        172.67999267578125,
        420.3599853515625,
        187.0679931640625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원장 서경원",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        172.67999267578125,
        420.3599853515625,
        187.0679931640625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편집위 원장",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        201.59999084472656,
        514.199951171875,
        215.9879913330078
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.15999603271484,
        201.59999084472656,
        514.199951171875,
        215.9879913330078
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편 집 위 원",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        230.63999938964844,
        532.416015625,
        279.8280029296875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        230.63999938964844,
        532.416015625,
        279.8280029296875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.15999603271484,
        230.63999938964844,
        532.416015625,
        279.8280029296875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신진영, 이",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        230.63999938964844,
        532.416015625,
        279.8280029296875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        230.63999938964844,
        532.416015625,
        279.8280029296875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 사전상담과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        165.47999572753906,
        288.6000061035156,
        411.9599914550781,
        320.38800048828125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오상연, 민아름",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        165.47999572753906,
        288.6000061035156,
        411.9599914550781,
        320.38800048828125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        165.47999572753906,
        329.2799987792969,
        529.3200073242188,
        361.0679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "윤경은, 엄소영",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        165.47999572753906,
        329.2799987792969,
        529.3200073242188,
        361.0679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        165.47999572753906,
        369.8399963378906,
        488.5199890136719,
        401.62799072265625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기경, 양준영",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        165.47999572753906,
        369.8399963378906,
        488.5199890136719,
        401.62799072265625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도움주신 분",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        416.2799987792969,
        131.90399169921875,
        448.0679931640625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(실무작업반)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.15999603271484,
        416.2799987792969,
        131.90399169921875,
        448.0679931640625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환),",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        165.47999572753906,
        416.2799987792969,
        530.3040161132812,
        448.0679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁)",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        165.47999572753906,
        416.2799987792969,
        530.3040161132812,
        448.0679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발 행 부 서",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        462.5999755859375,
        525.239990234375,
        476.98797607421875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        462.5999755859375,
        525.239990234375,
        476.98797607421875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        502.91998291015625,
        525.239990234375,
        517.3079833984375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "락",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        502.91998291015625,
        525.239990234375,
        517.3079833984375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        502.91998291015625,
        525.239990234375,
        517.3079833984375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과",
      "font_size": 12.0,
      "font_name": "T12",
      "bbox": [
        65.15999603271484,
        502.91998291015625,
        525.239990234375,
        517.3079833984375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전 화 번 호",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.15999603271484,
        531.9599609375,
        239.0159912109375,
        546.3479614257812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "043) 719-3451",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.15999603271484,
        531.9599609375,
        239.0159912109375,
        546.3479614257812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "팩 스 번 호",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        65.15999603271484,
        561.0,
        239.0159912109375,
        575.3880004882812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "043) 719-3450",
      "font_size": 12.0,
      "font_name": "T7",
      "bbox": [
        65.15999603271484,
        561.0,
        239.0159912109375,
        575.3880004882812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.",
      "font_size": 9.960000038146973,
      "font_name": "T18",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로",
      "font_size": 9.960000038146973,
      "font_name": "T18",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신고하여 주시기 바랍니다. 신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편",
      "font_size": 9.960000038146973,
      "font_name": "T18",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.",
      "font_size": 9.960000038146973,
      "font_name": "T18",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공익신고자 보호제도란?",
      "font_size": 9.960000038146973,
      "font_name": "T19",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익",
      "font_size": 9.960000038146973,
      "font_name": "T18",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호조치, 신변보호조치 등을 통하여 보호하는 제도",
      "font_size": 9.960000038146973,
      "font_name": "T19",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※보호조치요구방법",
      "font_size": 9.960000038146973,
      "font_name": "T19",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고",
      "font_size": 9.960000038146973,
      "font_name": "T19",
      "bbox": [
        65.15999603271484,
        603.1199340820312,
        532.319091796875,
        731.2319946289062
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    }
  ],
  "markdown_content": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022. 01. 27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까?**\n| Oligonucleotide-Based Therapeutics. Nucleic Acid Ther. 2017 Aug;27(4):183–96. | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다. |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다.**\n**of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–16.**\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다. |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다. | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? |\n**Nature. 2020 Oct;586(7830):594–9.**\n| Pharm Sci. 2016 Feb;105(2):460–75. | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다. | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다. | 번역되고 이후 정상적인 세포 기전에 의해 분해된다. | 논의를 진행해야 한다. |\n| May;27(5):183–5. | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases. Gene Ther. 2020 Oct 22;49. | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다. | 서술해야 한다. | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다. | 수 있는가에 대해 면밀하게 고려해야 한다(56~58). | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021. | 내용입니까? |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States. Influenza Other Respir Viruses. 2016 Sep;10(5):354–60. | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats. Regul Toxicol Pharmacol RTP. 2020 Jun;113:104648.**\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다. | 정리한 자료입니까? | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey. Vet Pathol. 2018 Mar;55(2):341–54.**\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | poly(A) tail의 크기 |\n**한다.**\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다. | 임상 연구를 개시하는 것이 가능할 수 있다. |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다. | 데 유용할 수 있다. |\n| 사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism? Drug Saf. 2000 Dec;23(6):467–81. | Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2021 Feb;9(2):670–5. | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques. 2019 Jan;66(1):37–9. | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다. | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ. 2017;1499:237–51. | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다. |\n| 6;25(12):2635–47. | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다. | 민원인을 구속하는 내용이 있습니까? |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118. | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다. | 독성 평가를 요구할 수 있다. | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72. | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다.**\n| disadvantages. Res Pharm Sci. 2018 Aug;13(4):288–303. | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다. |\n| 백신이 만들어 지는지를 기술해야 한다. | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다. | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다. | 상기 사항에 대하여 확인하였음. |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다.**\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy. Front Chem. 2020;8:589959.**\n| 유해한 영향을 주지 않음을 증명해야 한다. | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다. | 및 평가가 필요할 것이다. |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다.**\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다. | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n<!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다. 또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n<!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1. 서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1. 배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2. 목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3. 일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4. 특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2. 품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1. 일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2. 제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3. 백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4. 출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5. 공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6. 제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7. 제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8. 정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9. 최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10. 기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11. 보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3. 비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1. 약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2. 독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3. 비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4. 임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1. 안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2. 유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3. 공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다. 이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n· 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법. 이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n· 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물). 단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n· dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조). 이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다. 제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다. 이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다. 만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n· 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소. 대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다. 첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다. 본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n· 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다. 다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다. 본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다. 만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n· 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합. 따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다. 최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n· 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말). 본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다. 그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다. 다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n· 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형. 지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님). LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n· 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가. 식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다. 품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n· 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음. 다른 변형의 종류로는 메틸화(methylation)가 있다. 뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n· mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율. 또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\nmRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n· 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제. “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n· 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음. mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다. 제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다. 새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다. 안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다. mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다. mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다. 만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다. 더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다. 언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n· sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신. 이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다. sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다. 이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n· 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부. 다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n· 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료. 본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다. 위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n· tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1. 서론\n\n<!-- PAGE_11 -->\n### 1.1. 배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2). 그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6). mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다. 그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11). 또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다. 이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다. 생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다. 따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다. 그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다. 그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다. 최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n<!-- PAGE_12 -->\n### 1.2. 목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다. 개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다. 이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다. 그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다. 그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다. 각각의 유익성과 위해성에 대한 평가가 필요하다.\n\nmRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다. mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다. 지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다. 복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다. 또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다. 추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다. mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다. 그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다. 백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n<!-- PAGE_13 -->\n### 1.3. 일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다. (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\nŸ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다. 여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다. 백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다. 마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다. (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다. poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다. sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다. 특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다. 제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다. 중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다. 독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\nŸ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다. 필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다. 해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다. 관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다. 다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4. 특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3). 제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\nRNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다. 일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9). 자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해). 그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다. mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4). 임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14). 일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다. 표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4). 효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3). 마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다. 이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다. 일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다. 그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다. mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\nRNA 기반 제품은 형태가 다를 수 있다. 가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16). 그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23). 지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24). 일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28). 폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다. 이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다. 지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다. 일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다. 그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다. 이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다. 따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다. 그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다. 이후 ‘1.3. 일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다. 추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다. 만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3. 비임상 평가의\n\n가속화’, ‘4.1. 안전성 및 면역원성 평가’ 참고). 완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\nmRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다. 그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다. 따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31). 이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다. 그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18). 표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다. 예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다. 또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n(바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다. 다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18). 또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다. 따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다. 다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다. 그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다. 발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다. 그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다. 앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n21/72\n\n<!-- PAGE_21 -->\n## 2. 품질 평가\n\n<!-- PAGE_21 -->\n### 2.1. 일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다. 따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다. 출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다. 품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다. 이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다. 즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다. 긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다. 생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다. (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다. 잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다. 엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다. 원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다. 임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다. 모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다. 달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다. 이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다. 최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7. 비임상 평가’ 참조). 제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다. 이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다. 이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다. 허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n<!-- PAGE_23 -->\n### 2.2. 제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다. 생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다. ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest). IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\nDNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다. DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다. 정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다. 불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n공정개발 및 공정 중 관리’ 참고).\n\n대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다. 이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다. 그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다. 공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다. 농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다. 다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\nmRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다. 지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다. 비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다. 이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다. 지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30). 핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다. 지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다. 따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다. 예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다. 이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다. 두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다. 발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다. 각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다. 마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다. mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다. 이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n핵심 품질관리 사항에는 다음이 포함된다.\n\n가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template). ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다. 본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다. 다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n표 1. 여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다. 3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n<!-- PAGE_28 -->\n### 2.3. 백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다. 선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다. 해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n<!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다. 표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며. 따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2. 제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다. 몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다. 이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다. mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다. 따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다. 더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12). 별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4. 출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다. 시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n<!-- PAGE_31 -->\n### 2.4.1. 출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다. 이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다. 시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다. mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다. 새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다. 새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다. 만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다. 출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다. 첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다. 페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다. DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다. 미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다. 초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n<!-- PAGE_33 -->\n### 2.4.2. 출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n<!-- PAGE_33 -->\n### 2.5. 공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다. 공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다. 충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다. 이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n<!-- PAGE_33 -->\n### 2.6. 제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다. 특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다. 이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다. 특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다. 제조의 일관성은 이후 ‘2.7. 제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5. 공정개발 및 공정 중 관리’).\n\n절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다. 특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다. 특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다. 이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다. 추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다. mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n비임상\n\n평가’\n\n참조).\n\n이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다. 이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다. 정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다. 알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다. 분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다. mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다. 이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n<!-- PAGE_36 -->\n### 2.7. 제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다. 한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다. 이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다. 일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다. 그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다. 제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n<!-- PAGE_36 -->\n### 2.8. 정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2. 제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다. 유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다. 도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다. mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\nsa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다. 만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n<!-- PAGE_37 -->\n### 2.8.1. 원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다. 사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다. 저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다. 개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다. 일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다. 그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다. 규격에 대한 근거를 제시해야 한다. 또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n<!-- PAGE_38 -->\n### 2.8.1.1. 확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다. 확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다. mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n<!-- PAGE_38 -->\n### 2.8.1.2. 순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다. 이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다. 분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다. 순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다. 강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n<!-- PAGE_39 -->\n### 2.8.1.3. 정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다. DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다. mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n<!-- PAGE_40 -->\n### 2.8.1.4. 안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다. 여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다. 식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n<!-- PAGE_40 -->\n### 2.8.1.5. 추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다. 추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2. 순도 및 불순물’ 참조).\n\n<!-- PAGE_40 -->\n### 2.8.1.6. 참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다. 참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다. 최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n<!-- PAGE_41 -->\n### 2.8.1.7. 안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다. 수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다. 만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n<!-- PAGE_41 -->\n### 2.9. 최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2. 제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다. 지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다. 원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다. 이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다. 최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n<!-- PAGE_42 -->\n### 2.9.1. 조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n<!-- PAGE_42 -->\n### 2.9.2. 지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다. 적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다. 이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다. 그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다. 이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다. 원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다. 보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다. 이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다. 지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다. 해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다. (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율. 일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\nmRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n<!-- PAGE_43 -->\n### 2.9.3. 최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다. 흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다. 흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다. 정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다. 용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다. 이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다. 또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다. 다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다. 다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다. 희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다. 둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n<!-- PAGE_45 -->\n### 2.9.4. 최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다. 모든 기준 및 시험법은\n\n식약처의 승인이 필요하다. 제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다. 분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다. 시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다. 개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다. 앞서 ‘2.6. 제품 특성 분석’, ‘2.7. 제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다. 한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다. 그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다. 이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다. 이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다. 추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다. 총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1. 확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다. 백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다. 염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n<!-- PAGE_47 -->\n### 2.9.4.2. 순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다. 전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다. 모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다. mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다. 품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2. 순도 및 불순물’\n\n참조). 백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n<!-- PAGE_47 -->\n### 2.9.4.3. 함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n<!-- PAGE_47 -->\n### 2.9.4.4. 안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다. 백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다. 더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음). 그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n<!-- PAGE_48 -->\n### 2.9.4.5. 추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다. 여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다. 최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다. 비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다. 순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6. 역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다. 질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다. 그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\nmRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다. 시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다. 따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다. 플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다. 제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다. 그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다. 그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n<!-- PAGE_50 -->\n### 2.9.4.7. 표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다. 이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다. 이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다. 추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n<!-- PAGE_50 -->\n### 2.9.4.8. 안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다. 일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다. 백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1. 안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다. 안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다. 측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다. 높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다. 동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다. 고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다. 예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다. 가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다. 마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다. 보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다. 안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n<!-- PAGE_52 -->\n### 2.9.4.8.2. 보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다. 최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다. 임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n<!-- PAGE_52 -->\n### 2.9.4.8.3. 유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n<!-- PAGE_52 -->\n### 2.10. 기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n<!-- PAGE_53 -->\n### 2.11. 보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다. 보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다. 적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n54/72\n\n<!-- PAGE_54 -->\n## 3. 비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다. 제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\nmRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다. 이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다. 그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다. mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다. 그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다. 예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n<!-- PAGE_54 -->\n### 3.1. 약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n- (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2. 독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n- (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다. 식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다. 식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다. mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다. 비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51). 추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55). 따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다. 그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다. 그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다. 더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\nŸ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\nŸ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다. 추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다. 종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다. 예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다. 마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n<!-- PAGE_58 -->\n### 3.3. 비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\nŸ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다. 관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다. 사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다. 만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다. 자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다. 그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다. 관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n60/72\n\n<!-- PAGE_60 -->\n## 4. 임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다. 또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다. 더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n<!-- PAGE_60 -->\n### 4.1. 안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n- (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59). 이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\nRNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64). 그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다. 따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n- (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\nŸ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23). 이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다. 그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다. 이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\nmRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65). 아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69). 비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다. 공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다. 코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다. 추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다. 앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n<!-- PAGE_63 -->\n### 4.2. 유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다. 백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\nmRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다. 위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76). (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다. 모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n<!-- PAGE_64 -->\n### 4.3. 공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n다음의 두 가지 시나리오를 반드시 고려해야 한다. (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다. 이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다. 전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\nNat\n\nRev\n\nDrug\n\nDiscov.\n\n2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n- 2. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene\ntransfer into mouse muscle in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1465–8.\n\n- 3. Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.\n\n- 4. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability. Mol Ther J Am Soc Gene Ther. 200810\n\nNov;16(11):1833–40.\n\n- 5. Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\nSequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals. Mol Ther J Am Soc Gene Ther. 2015\n\nSep;23(9):1456–1464.\n\n- 6. Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines. Methods Mol\n\nBiol Clifton NJ. 2017;1499:89–107.\n\n- 7. Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al. The European\nRegulatory Environment of RNA-Based Vaccines. In: Kramps T, Elbers K, editors.\n\nRNA Vaccines: Methods and Protocols [Internet]. New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\np.\n\n203–22.\n\n(Methods\n\nin\n\nMolecular\n\nBiology).\n\nAvailable\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8. Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020 Feb 4;5(1):11.\n\n- 9. Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\nCurr Top Microbiol Immunol. 2020 Jul 8;27\n\n- 10. Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials. Methods\n- 11. Hager G. Nonclinical Safety Testing of RNA Vaccines. Methods Mol Biol Clifton NJ.\n- 12. Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\nSixty-Fourth\n\nReport. Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec. 2020)\n\n66/72\n\n- 13. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516–27.\n- 14. Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\nmRNA therapeutics deliver a hopeful message. Nano Today [Internet]. 2018 Dec 1\n\n[cited 2021 May 1];23:16–39. Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet].\n\n2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\nAvailable\n\nfrom:\n\nhttps://doi.org/\n\n- 16. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety\n- 17. Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\nCOVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n- 18. Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA. Gene Ther. 2020\n- 19. Bertrand\nN,\n\nLeroux\n\nJ-C.\n\nThe\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective. J Control Release Off J Control Release Soc. 2012\n\nJul 20;161(2):152–63.\n\n- 20. Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21. Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol Pharm\n[Internet].\n\n2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\nAvailable\n\nfrom:\n\n- 22. Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al. Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids. 2013 Dec 17;2:e139.\n\n- 23. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\nAn mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020\n\nNov 12;383(20):1920–31.\n\n- 24. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25. Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26. Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\nOptimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines. Mol Ther Nucleic Acids. 2019 Apr 15;15:1–11.\n\n- 27. Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines. Vaccines. 2021 Jan 19;9(1).\n\n- 28. Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\nPharmaceutics\n\n[Internet].\n\n2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\nAvailable\n\nfrom:\n\n- 29. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials.\n\n2010 Sep;31(26):6867–75.\n\n- 30. Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\nCationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\nJ Control Release Off J Control Release Soc. 2018 Oct 10;287:67–77.\n\n- 31. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32. Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33. Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al. The INN global nomenclature of biological medicines: A continuous\n\nchallenge. Biologicals [Internet]. 2019 Jul 1 [cited 2021 May 1];60:15–23. Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34. Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n- 35. Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\nRNA\n\n2020,\n\n25:507–518.\n\n- 36. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability. J Pharm Sci [Internet]. 2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\nAvailable\n\nfrom:\n\n68/72\n\n- 37. Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products. Drug\n\nDiscov Today. 2016 Mar;21(3):430–44.\n\n- 38. Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens. Vaccines. 2019 Sep 27;7(4).\n\n- 39. ICH Q3C(R6). Impurities: guideline for residual solvents. 2016. https://database.ich.org/\n- 40. ICH\nQ3D(R1).\n\nGuideline\n\nfor\n\nelemental\n\nimpurities.\n\n- 2019.\nhttps://database.ich.org/\n\n- 41. ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n- 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42. WHO Getting started with vaccine vial monitors. 2002. https://apps.who.int/iris/\n- 43. WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44. Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al. Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45. Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection. J Control Release Off J Control Release Soc. 2020 Sep 10;325:370–9.\n\n- 46. Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses. Mol Ther J Am Soc Gene Ther. 2017 Jun 7;25(6):1316–27.\n\n- 47. Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al. Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques. Mol Ther J Am\n\nSoc Gene Ther. 2017 Dec\n\n- 48. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes. J Controlled Release [Internet]. 2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51. Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49. EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50. Obeid MA, Tate RJ, Mullen AB, Ferro VA. Chapter 8 - Lipid-based nanoparticles for\ncancer treatment. In: Grumezescu AM, editor. Lipid Nanocarriers for Drug Targeting\n\n[Internet]. William Andrew Publishing; 2018 [cited 2021 May 27]. p. 313–59. Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51. Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52. CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n- 53. Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\nJ\n\n- 54. Turecek PL, Siekmann J. 4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations. In: Pasut G, Zalipsky S, editors. Polymer-Protein Conjugates [Internet].\n\nElsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\np.\n\n61–101.\n\nAvailable\n\nfrom:\n\n- 55. Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al. Cytotoxicity study of polyethylene\nglycol derivatives. RSC Adv [Internet]. 2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\nAvailable from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol\n\nChem. 2001 Nov 2;276(44):40847–57.\n\n- 57. Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58. Nucleoside\nAnalogues.\n\nIn:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\nAvailable\n\nfrom:\n\n- 59. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature [Internet]. 2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\nAvailable\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60. Bovay A, Speiser DE, Marraco SAF. Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination. Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n70/72\n\n- 61. Faguet GB. The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes. J Infect Dis. 1981 Feb;143(2):252–8.\n\n- 62. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial. Lancet Lond Engl.\n\n2017 Sep 23;390(10101):1511–20.\n\n- 63. Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease. Cell. 2017 Jul\n\n13;170(2):273–283.e12.\n\n- 64. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al. A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile. Int J Cancer. 2015 Jul 15;137(2):372–84.\n\n- 65. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA [Internet].\n\n2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\nAvailable\n\nfrom:\n\n- 66. Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L. [cited 2021 May 1]. Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J\nMed\n\n[Internet].\n\n2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\nAvailable\n\nfrom:\n\n- 68. Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69. FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\nhttps://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n- 70. EMA\nAssessment\n\nReport.\n\nCOVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n6\n\nJan\n\n- 2021.\n- 71. UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72. US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73. US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74. Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n- 75. Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n- 76. Expert consultation on the use of placebos in vaccine trials. Meeting report. Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77. Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n:31.\n\n- 78. Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the\n- 79. Marta DJ. Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n:7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80. Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\nHSA.\n\n[cited\n\n2021\n\nMay\n\n2].\n\nAvailable\n\nfrom:\n\n- 81. ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n[cited\n\n2021\n\nMay\n\n1].\n\nAvailable\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n(Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다. 신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n공익신고자 보호제도란?\n\n공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 123,
        "word_count": 22,
        "page_number": 1,
        "window_text": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022.  01.  27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까?",
        "original_sentence": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "01. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 1,
        "window_text": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022.  01.  27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까? **\n| Oligonucleotide-Based Therapeutics. ",
        "original_sentence": "01. "
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 107,
        "word_count": 20,
        "page_number": 1,
        "window_text": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022.  01.  27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까? **\n| Oligonucleotide-Based Therapeutics.  Nucleic Acid Ther. ",
        "original_sentence": "27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까?",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 274,
        "word_count": 55,
        "page_number": 1,
        "window_text": "청렴한 식약처\n\n국민 안심의 시작\n\n예방용 mRNA 백신 평가 가이드라인\n\nGuideline on Evaluation of Prophylactic mRNA Vaccines\n\n<!-- PAGE_1 -->\n### 2022.  01.  27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까? **\n| Oligonucleotide-Based Therapeutics.  Nucleic Acid Ther.  2017 Aug;27(4):183–96. ",
        "original_sentence": "등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까?"
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "**\n| Oligonucleotide-Based Therapeutics. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 41,
        "word_count": 4,
        "page_number": 26,
        "window_text": "01.  27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까? **\n| Oligonucleotide-Based Therapeutics.  Nucleic Acid Ther.  2017 Aug;27(4):183–96.  | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다. ",
        "original_sentence": "**\n| Oligonucleotide-Based Therapeutics. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "Nucleic Acid Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 19,
        "word_count": 3,
        "page_number": 65,
        "window_text": "27\n\n바이오생약심사부 생물제제과\n\n2/72\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n예방용 RNA 백신 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까? **\n| Oligonucleotide-Based Therapeutics.  Nucleic Acid Ther.  2017 Aug;27(4):183–96.  | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.  |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다.",
        "original_sentence": "Nucleic Acid Ther. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "2017 Aug;27(4):183–96. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 23,
        "word_count": 2,
        "page_number": 4,
        "window_text": "등록대상\n\n**[표 시작]**\n\n| 예방용 mRNA 백신 평가 가이드라인(민원인 안내서) | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- |\n**본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술**\n| sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf | 기술의 예시 | 잠재적 사용 |\n**지침서ㆍ안내서가 있습니까? **\n| Oligonucleotide-Based Therapeutics.  Nucleic Acid Ther.  2017 Aug;27(4):183–96.  | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.  |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다. **\n**of the mRNA-1273 SARS-CoV-2 Vaccine. ",
        "original_sentence": "2017 Aug;27(4):183–96. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 15,
        "window_text": "**\n| Oligonucleotide-Based Therapeutics.  Nucleic Acid Ther.  2017 Aug;27(4):183–96.  | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.  |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다. **\n**of the mRNA-1273 SARS-CoV-2 Vaccine.  N Engl J Med. ",
        "original_sentence": "| 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "|\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 338,
        "word_count": 46,
        "page_number": 4,
        "window_text": "Nucleic Acid Ther.  2017 Aug;27(4):183–96.  | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.  |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다. **\n**of the mRNA-1273 SARS-CoV-2 Vaccine.  N Engl J Med.  2021 Feb 4;384(5):403–16.",
        "original_sentence": "|\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다."
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "**\n**of the mRNA-1273 SARS-CoV-2 Vaccine. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 42,
        "word_count": 6,
        "page_number": 4,
        "window_text": "2017 Aug;27(4):183–96.  | 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.  |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다. **\n**of the mRNA-1273 SARS-CoV-2 Vaccine.  N Engl J Med.  2021 Feb 4;384(5):403–16. **\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다. ",
        "original_sentence": "**\n**of the mRNA-1273 SARS-CoV-2 Vaccine. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "N Engl J Med. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 66,
        "window_text": "| 식약처의 요구가 있다면 안전성약리시험 자료)를 제공해야 한다.  |\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다. **\n**of the mRNA-1273 SARS-CoV-2 Vaccine.  N Engl J Med.  2021 Feb 4;384(5):403–16. **\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다.  |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다. ",
        "original_sentence": "N Engl J Med. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "2021 Feb 4;384(5):403–16.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 4,
        "window_text": "|\n**https://www.fda.gov/media/144354/download, accessed June 1, 2021**\n| DNA 주형 서열분석, mRNA 서열분석 | 확인 |\n| 10.1056/NEJMoa2034577 | https://www.mdpi.com/1999-4923/13/1/45 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n**sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf**\n| 역전사효소 정량 PCR | 확인 및 함량 |\n**RNA를 핵으로 재배치해야 할 것이다. **\n**of the mRNA-1273 SARS-CoV-2 Vaccine.  N Engl J Med.  2021 Feb 4;384(5):403–16. **\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다.  |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다.  | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "2021 Feb 4;384(5):403–16."
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "**\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 242,
        "word_count": 26,
        "page_number": 26,
        "window_text": "**\n**of the mRNA-1273 SARS-CoV-2 Vaccine.  N Engl J Med.  2021 Feb 4;384(5):403–16. **\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다.  |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다.  | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |\n**Nature. ",
        "original_sentence": "**\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "|\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 247,
        "word_count": 24,
        "page_number": 23,
        "window_text": "N Engl J Med.  2021 Feb 4;384(5):403–16. **\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다.  |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다.  | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |\n**Nature.  2020 Oct;586(7830):594–9.",
        "original_sentence": "|\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "| □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 111,
        "word_count": 29,
        "page_number": 2,
        "window_text": "2021 Feb 4;384(5):403–16. **\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다.  |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다.  | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |\n**Nature.  2020 Oct;586(7830):594–9. **\n| Pharm Sci. ",
        "original_sentence": "| □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "|\n**Nature. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 12,
        "word_count": 2,
        "page_number": 65,
        "window_text": "**\n| 자외선 분광법(ultraviolet spectroscopy), | 형광-기반 분석(fluorescein-based assays) | 함량 및 순도 |\n**(사유 :                                                                 )**\n| https://www.fda.gov/media/144582/download Accessed June 1, 2021 | 수행해야 한다.  |\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다.  | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |\n**Nature.  2020 Oct;586(7830):594–9. **\n| Pharm Sci.  2016 Feb;105(2):460–75. ",
        "original_sentence": "|\n**Nature. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "2020 Oct;586(7830):594–9.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 25,
        "word_count": 2,
        "page_number": 8,
        "window_text": "|\n| documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-data-interpretation | -pharmaceuticals-intended-human-use-step_en.pdf, accessed 27 June 2021 |\n| 식품의약품안전처 식품의약품안전평가원 사전상담과 | 오상연, 민아름 |\n**□ 법령(법ㆍ시행령ㆍ시행규칙) 또는**\n| 기술해야 한다.  | □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |\n**Nature.  2020 Oct;586(7830):594–9. **\n| Pharm Sci.  2016 Feb;105(2):460–75.  | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다. ",
        "original_sentence": "2020 Oct;586(7830):594–9."
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "**\n| Pharm Sci. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 66,
        "window_text": "| □ 예 | ■ 아니오 |\n| 아가로스 또는 아크릴아마이드 겔 전기영동 | 함량, 크기, RNA 완전성, 표면전하, |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |\n**Nature.  2020 Oct;586(7830):594–9. **\n| Pharm Sci.  2016 Feb;105(2):460–75.  | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다.  | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "**\n| Pharm Sci. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "2016 Feb;105(2):460–75. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 4,
        "window_text": "|\n**Nature.  2020 Oct;586(7830):594–9. **\n| Pharm Sci.  2016 Feb;105(2):460–75.  | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다.  | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다. ",
        "original_sentence": "2016 Feb;105(2):460–75. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 25,
        "window_text": "2020 Oct;586(7830):594–9. **\n| Pharm Sci.  2016 Feb;105(2):460–75.  | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다.  | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.  | 번역되고 이후 정상적인 세포 기전에 의해 분해된다. ",
        "original_sentence": "| (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 157,
        "word_count": 20,
        "page_number": 31,
        "window_text": "**\n| Pharm Sci.  2016 Feb;105(2):460–75.  | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다.  | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.  | 번역되고 이후 정상적인 세포 기전에 의해 분해된다.  | 논의를 진행해야 한다. ",
        "original_sentence": "| 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "| □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 114,
        "word_count": 18,
        "page_number": 2,
        "window_text": "2016 Feb;105(2):460–75.  | (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다.  | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.  | 번역되고 이후 정상적인 세포 기전에 의해 분해된다.  | 논의를 진행해야 한다.  |\n| May;27(5):183–5. ",
        "original_sentence": "| □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 번역되고 이후 정상적인 세포 기전에 의해 분해된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 23,
        "window_text": "| (모세관 전기영동 포함) | 봉입 비율(%) |\n| 동의를 구해야 한다.  | 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.  | 번역되고 이후 정상적인 세포 기전에 의해 분해된다.  | 논의를 진행해야 한다.  |\n| May;27(5):183–5.  | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases. ",
        "original_sentence": "| 번역되고 이후 정상적인 세포 기전에 의해 분해된다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "| 논의를 진행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 27,
        "window_text": "| 식품의약품안전처 식품의약품안전평가원 의료제품연구부 바이오의약품연구과 | 윤경은, 엄소영 |\n**bitstream/handle/10665/67806/WHO_V-B_02.35_eng.pdf;sequence=1**\n| 여부 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.  | 번역되고 이후 정상적인 세포 기전에 의해 분해된다.  | 논의를 진행해야 한다.  |\n| May;27(5):183–5.  | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases.  Gene Ther. ",
        "original_sentence": "| 논의를 진행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "|\n| May;27(5):183–5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 4,
        "window_text": "| □ 예 | ■ 아니오 |\n| https://jamanetwork.com/journals/jama/fullarticle/2776557 | 서술하고, 그 영향(긍정적 또는 부정적)에 대해 고려해야 한다.  | 번역되고 이후 정상적인 세포 기전에 의해 분해된다.  | 논의를 진행해야 한다.  |\n| May;27(5):183–5.  | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases.  Gene Ther.  2020 Oct 22;49. ",
        "original_sentence": "|\n| May;27(5):183–5. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 96,
        "word_count": 13,
        "page_number": 8,
        "window_text": "| 번역되고 이후 정상적인 세포 기전에 의해 분해된다.  | 논의를 진행해야 한다.  |\n| May;27(5):183–5.  | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases.  Gene Ther.  2020 Oct 22;49.  | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다. ",
        "original_sentence": "| 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "Gene Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 11,
        "word_count": 2,
        "page_number": 65,
        "window_text": "| 논의를 진행해야 한다.  |\n| May;27(5):183–5.  | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases.  Gene Ther.  2020 Oct 22;49.  | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다.  | 서술해야 한다. ",
        "original_sentence": "Gene Ther. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "2020 Oct 22;49. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 66,
        "window_text": "|\n| May;27(5):183–5.  | 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases.  Gene Ther.  2020 Oct 22;49.  | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다.  | 서술해야 한다.  | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다. ",
        "original_sentence": "2020 Oct 22;49. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 172,
        "word_count": 14,
        "page_number": 8,
        "window_text": "| 크로마토그래피 분석(예: 크기 배제(size-exclusion) | 또는 음이온 교환(anion-exchange), 친화성(affinity), |\n| diseases.  Gene Ther.  2020 Oct 22;49.  | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다.  | 서술해야 한다.  | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.  | 수 있는가에 대해 면밀하게 고려해야 한다(56~58). ",
        "original_sentence": "| https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "| 서술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 27,
        "window_text": "Gene Ther.  2020 Oct 22;49.  | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다.  | 서술해야 한다.  | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.  | 수 있는가에 대해 면밀하게 고려해야 한다(56~58).  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021. ",
        "original_sentence": "| 서술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "| 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 15,
        "window_text": "2020 Oct 22;49.  | https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다.  | 서술해야 한다.  | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.  | 수 있는가에 대해 면밀하게 고려해야 한다(56~58).  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.  | 내용입니까? ",
        "original_sentence": "| 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "| 수 있는가에 대해 면밀하게 고려해야 한다(56~58). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 8,
        "window_text": "| https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non- | clinical-clinical-module_en.pdf Accessed June 1, 2021 |\n| 완제의약품/백신에서 활성이 없는 원료약품이다.  | 서술해야 한다.  | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.  | 수 있는가에 대해 면밀하게 고려해야 한다(56~58).  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.  | 내용입니까?  |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "| 수 있는가에 대해 면밀하게 고려해야 한다(56~58). "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 218,
        "word_count": 34,
        "page_number": 2,
        "window_text": "| 서술해야 한다.  | 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.  | 수 있는가에 대해 면밀하게 고려해야 한다(56~58).  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.  | 내용입니까?  |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States. ",
        "original_sentence": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "| 내용입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 2,
        "window_text": "| 효율적 개발을 보장하기 위해 식약처와의 조기 상담은 필요하다.  | 수 있는가에 대해 면밀하게 고려해야 한다(56~58).  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.  | 내용입니까?  |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States.  Influenza Other Respir Viruses. ",
        "original_sentence": "| 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "|\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 108,
        "word_count": 9,
        "page_number": 8,
        "window_text": "| 수 있는가에 대해 면밀하게 고려해야 한다(56~58).  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.  | 내용입니까?  |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States.  Influenza Other Respir Viruses.  2016 Sep;10(5):354–60. ",
        "original_sentence": "|\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "| □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 196,
        "word_count": 29,
        "page_number": 2,
        "window_text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 식품의약품안전처 식품의약품안전평가원 독성평가연구부 독성연구과 | 정기경, 양준영 | □ 예 | ■ 아니오 |\n**나노입자 완전성**\n**역상(reverse-phase))**\n| vaccine-vial-monitors-in-the-context-of-covid-19-vaccines Accessed June 1, 2021.  | 내용입니까?  |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States.  Influenza Other Respir Viruses.  2016 Sep;10(5):354–60.  | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats. ",
        "original_sentence": "| □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "Influenza Other Respir Viruses. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 32,
        "word_count": 4,
        "page_number": 65,
        "window_text": "| 내용입니까?  |\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States.  Influenza Other Respir Viruses.  2016 Sep;10(5):354–60.  | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats.  Regul Toxicol Pharmacol RTP. ",
        "original_sentence": "Influenza Other Respir Viruses. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "2016 Sep;10(5):354–60. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 23,
        "word_count": 2,
        "page_number": 4,
        "window_text": "|\n**https://www.sciencedirect.com/science/article/pii/B978044464081900004830**\n| □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States.  Influenza Other Respir Viruses.  2016 Sep;10(5):354–60.  | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats.  Regul Toxicol Pharmacol RTP.  2020 Jun;113:104648.",
        "original_sentence": "2016 Sep;10(5):354–60. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "| 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 216,
        "word_count": 40,
        "page_number": 29,
        "window_text": "| □ 예 | ■ 아니오 |\n| 질량 분석법(mass spectrometry) | mRNA 함량 및 지질나노입자 완전성 |\n| https://www.who.int/medicines/services/inn/FINAL_WHO_PHARM_S_NOM_1570_we | b.pdf?ua=1 accessed June 1, 2021 | United States.  Influenza Other Respir Viruses.  2016 Sep;10(5):354–60.  | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats.  Regul Toxicol Pharmacol RTP.  2020 Jun;113:104648. **\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다. ",
        "original_sentence": "| 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "Regul Toxicol Pharmacol RTP. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 29,
        "word_count": 4,
        "page_number": 66,
        "window_text": "Influenza Other Respir Viruses.  2016 Sep;10(5):354–60.  | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats.  Regul Toxicol Pharmacol RTP.  2020 Jun;113:104648. **\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.  | 정리한 자료입니까? ",
        "original_sentence": "Regul Toxicol Pharmacol RTP. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "2020 Jun;113:104648.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 20,
        "word_count": 2,
        "page_number": 4,
        "window_text": "2016 Sep;10(5):354–60.  | 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats.  Regul Toxicol Pharmacol RTP.  2020 Jun;113:104648. **\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.  | 정리한 자료입니까?  | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey. ",
        "original_sentence": "2020 Jun;113:104648."
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "**\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 8,
        "window_text": "| 녹십자(이상빈), 아이진(안한나), 에스케이바이오사이언스(신진환), | 에스티팜(양주성), 진원생명과학(정문섭), 큐라티스(최유화), 한미약품(양준혁) |\n| dsRNA 블롯, 캡 형성(capping) 비율(%) 시험, | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n**self-amplifying mRNA vaccine in rats.  Regul Toxicol Pharmacol RTP.  2020 Jun;113:104648. **\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.  | 정리한 자료입니까?  | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey.  Vet Pathol. ",
        "original_sentence": "**\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "| 정리한 자료입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 2,
        "window_text": "Regul Toxicol Pharmacol RTP.  2020 Jun;113:104648. **\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.  | 정리한 자료입니까?  | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey.  Vet Pathol.  2018 Mar;55(2):341–54.",
        "original_sentence": "| 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "| 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 41,
        "word_count": 9,
        "page_number": 8,
        "window_text": "2020 Jun;113:104648. **\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.  | 정리한 자료입니까?  | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey.  Vet Pathol.  2018 Mar;55(2):341–54. **\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "| 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "Vet Pathol. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 12,
        "word_count": 2,
        "page_number": 65,
        "window_text": "**\n| poly(A) tail 말단 전사물(transcript)의 비율(%) 및 | 첨가제는 적절한 외부 조달 및 관리시험, 위해성 평가를 통해 관리해야 한다.  | 정리한 자료입니까?  | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey.  Vet Pathol.  2018 Mar;55(2):341–54. **\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "Vet Pathol. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "2018 Mar;55(2):341–54.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 22,
        "word_count": 2,
        "page_number": 4,
        "window_text": "| 정리한 자료입니까?  | 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey.  Vet Pathol.  2018 Mar;55(2):341–54. **\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | poly(A) tail의 크기 |\n**한다.",
        "original_sentence": "2018 Mar;55(2):341–54."
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "**\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 2,
        "window_text": "| 기타 품질 파라미터 및 순도 |\n**Cynomolgus Monkey.  Vet Pathol.  2018 Mar;55(2):341–54. **\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | poly(A) tail의 크기 |\n**한다. **\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다. ",
        "original_sentence": "**\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 2,
        "window_text": "Vet Pathol.  2018 Mar;55(2):341–54. **\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | poly(A) tail의 크기 |\n**한다. **\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.  | 임상 연구를 개시하는 것이 가능할 수 있다. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "| poly(A) tail의 크기 |\n**한다.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 27,
        "window_text": "2018 Mar;55(2):341–54. **\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | poly(A) tail의 크기 |\n**한다. **\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.  | 임상 연구를 개시하는 것이 가능할 수 있다.  |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다. ",
        "original_sentence": "| poly(A) tail의 크기 |\n**한다."
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "**\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 78,
        "word_count": 23,
        "page_number": 8,
        "window_text": "**\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | poly(A) tail의 크기 |\n**한다. **\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.  | 임상 연구를 개시하는 것이 가능할 수 있다.  |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다.  | 데 유용할 수 있다. ",
        "original_sentence": "**\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "| 임상 연구를 개시하는 것이 가능할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | poly(A) tail의 크기 |\n**한다. **\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.  | 임상 연구를 개시하는 것이 가능할 수 있다.  |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다.  | 데 유용할 수 있다.  |\n| 사무의 세부기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| 임상 연구를 개시하는 것이 가능할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "|\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 216,
        "word_count": 34,
        "page_number": 4,
        "window_text": "| poly(A) tail의 크기 |\n**한다. **\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.  | 임상 연구를 개시하는 것이 가능할 수 있다.  |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다.  | 데 유용할 수 있다.  |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism? ",
        "original_sentence": "|\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "| 데 유용할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 6,
        "window_text": "**\n| 무세포 번역 또는 세포-기반 발현 시스템 | 역가 및 단백질 정확도 |\n| 확인 또는 관리를 보장하는 데에 주의를 기울여야 한다.  | 임상 연구를 개시하는 것이 가능할 수 있다.  |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다.  | 데 유용할 수 있다.  |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism?  Drug Saf. ",
        "original_sentence": "| 데 유용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "|\n| 사무의 세부기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 5,
        "window_text": "| 임상 연구를 개시하는 것이 가능할 수 있다.  |\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다.  | 데 유용할 수 있다.  |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism?  Drug Saf.  2000 Dec;23(6):467–81. ",
        "original_sentence": "|\n| 사무의 세부기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "(공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 90,
        "word_count": 14,
        "page_number": 27,
        "window_text": "|\n**https://doi.org/10.1056/NEJMra2035343**\n**June 7, 2021**\n| https://doi.org/10.1021/mp800049w | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | □ 예(☞지침서) | ■ 아니오 |\n**광산란법(light scattering)(예: 정적 또는 동적 광산**\n| 역시 다루고 기술해야 한다.  | 데 유용할 수 있다.  |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism?  Drug Saf.  2000 Dec;23(6):467–81.  | Reactions (Anaphylaxis). ",
        "original_sentence": "(공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism? "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "Drug Saf. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 65,
        "window_text": "| 데 유용할 수 있다.  |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism?  Drug Saf.  2000 Dec;23(6):467–81.  | Reactions (Anaphylaxis).  J Allergy Clin Immunol Pract. ",
        "original_sentence": "Drug Saf. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "2000 Dec;23(6):467–81. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 23,
        "word_count": 2,
        "page_number": 4,
        "window_text": "|\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism?  Drug Saf.  2000 Dec;23(6):467–81.  | Reactions (Anaphylaxis).  J Allergy Clin Immunol Pract.  2021 Feb;9(2):670–5. ",
        "original_sentence": "2000 Dec;23(6):467–81. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| Reactions (Anaphylaxis). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 27,
        "word_count": 3,
        "page_number": 65,
        "window_text": "(공무원용) | 입자크기분포 |\n**란법), 나노입자 추적분석, 전자현미경,**\n| mitochondrial toxicity the only mechanism?  Drug Saf.  2000 Dec;23(6):467–81.  | Reactions (Anaphylaxis).  J Allergy Clin Immunol Pract.  2021 Feb;9(2):670–5.  | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques. ",
        "original_sentence": "| Reactions (Anaphylaxis). "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "J Allergy Clin Immunol Pract. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 23,
        "window_text": "Drug Saf.  2000 Dec;23(6):467–81.  | Reactions (Anaphylaxis).  J Allergy Clin Immunol Pract.  2021 Feb;9(2):670–5.  | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques.  2019 Jan;66(1):37–9. ",
        "original_sentence": "J Allergy Clin Immunol Pract. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "2021 Feb;9(2):670–5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 21,
        "word_count": 2,
        "page_number": 4,
        "window_text": "2000 Dec;23(6):467–81.  | Reactions (Anaphylaxis).  J Allergy Clin Immunol Pract.  2021 Feb;9(2):670–5.  | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques.  2019 Jan;66(1):37–9.  | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
        "original_sentence": "2021 Feb;9(2):670–5. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "| (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 116,
        "word_count": 22,
        "page_number": 8,
        "window_text": "| Reactions (Anaphylaxis).  J Allergy Clin Immunol Pract.  2021 Feb;9(2):670–5.  | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques.  2019 Jan;66(1):37–9.  | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다. ",
        "original_sentence": "| (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "2019 Jan;66(1):37–9. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 21,
        "word_count": 2,
        "page_number": 4,
        "window_text": "J Allergy Clin Immunol Pract.  2021 Feb;9(2):670–5.  | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques.  2019 Jan;66(1):37–9.  | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.  | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ. ",
        "original_sentence": "2019 Jan;66(1):37–9. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 188,
        "word_count": 15,
        "page_number": 8,
        "window_text": "2021 Feb;9(2):670–5.  | (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques.  2019 Jan;66(1):37–9.  | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.  | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ.  2017;1499:237–51. ",
        "original_sentence": "| https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "(민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 6,
        "window_text": "| (순도, 일관성, 안전성) |\n**□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서**\n| 구분 | 크기-배제(size-exclusion) 크로마토그래피 |\n| BioTechniques.  2019 Jan;66(1):37–9.  | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.  | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ.  2017;1499:237–51.  | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다. ",
        "original_sentence": "(민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "| 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 242,
        "word_count": 44,
        "page_number": 27,
        "window_text": "2019 Jan;66(1):37–9.  | https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.  | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ.  2017;1499:237–51.  | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.  |\n| 6;25(12):2635–47. ",
        "original_sentence": "| 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "2017;1499:237–51. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 18,
        "word_count": 1,
        "page_number": 4,
        "window_text": "| https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access/guidan | ce-strain-changes-in-authorised-covid-19-vaccines | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.  | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ.  2017;1499:237–51.  | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.  |\n| 6;25(12):2635–47.  | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다. ",
        "original_sentence": "2017;1499:237–51. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "| 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 8,
        "window_text": "(민원인용) |\n| 혼합 백신 개발에 관한 지침서 역시 고려할 수 있다.  | 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ.  2017;1499:237–51.  | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.  |\n| 6;25(12):2635–47.  | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.  | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "|\n| 6;25(12):2635–47. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 22,
        "word_count": 3,
        "page_number": 4,
        "window_text": "| 입자 표면 특성분석 |\n**레이저 도플러 전기영동(laser doppler**\n**(크기 및 다분산, 제타 전위(zeta**\n**electrophoresis), 동적 광산란 분석**\n| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| http://www.ncbi.nlm.nih.gov/books/NBK548938/ | potential) 포함) |\n| Mol Biol Clifton NJ.  2017;1499:237–51.  | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.  |\n| 6;25(12):2635–47.  | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.  | 민원인을 구속하는 내용이 있습니까?  |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118. ",
        "original_sentence": "|\n| 6;25(12):2635–47. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 85,
        "word_count": 23,
        "page_number": 8,
        "window_text": "2017;1499:237–51.  | 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.  |\n| 6;25(12):2635–47.  | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.  | 민원인을 구속하는 내용이 있습니까?  |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.  | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다. ",
        "original_sentence": "| 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 2,
        "window_text": "| 포함된 추가 서열의 존재 및 기능에 대해 기술해야 한다.  |\n| 6;25(12):2635–47.  | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.  | 민원인을 구속하는 내용이 있습니까?  |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.  | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다.  | 독성 평가를 요구할 수 있다. ",
        "original_sentence": "| 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "|\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 62,
        "word_count": 3,
        "page_number": 4,
        "window_text": "|\n| 6;25(12):2635–47.  | 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.  | 민원인을 구속하는 내용이 있습니까?  |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.  | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다.  | 독성 평가를 요구할 수 있다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72. ",
        "original_sentence": "|\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "| https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 202,
        "word_count": 25,
        "page_number": 8,
        "window_text": "| 불순물의 제거에 대한 관리 또는 밸리데이션 중의 한 가지를 포함 | mRNA에 코딩된 각 유전자 서열에 대해 예상하는 기능과 목적을 제시해야 한다.  | 민원인을 구속하는 내용이 있습니까?  |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.  | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다.  | 독성 평가를 요구할 수 있다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72.  | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
        "original_sentence": "| https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "| 독성 평가를 요구할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 6,
        "window_text": "| 민원인을 구속하는 내용이 있습니까?  |\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.  | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다.  | 독성 평가를 요구할 수 있다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72.  | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다. **\n| disadvantages. ",
        "original_sentence": "| 독성 평가를 요구할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 117,
        "word_count": 21,
        "page_number": 2,
        "window_text": "|\n| http://www.rnajournal.org/cgi/doi/10.1261/rna.069286.118.  | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다.  | 독성 평가를 요구할 수 있다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72.  | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다. **\n| disadvantages.  Res Pharm Sci. ",
        "original_sentence": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72. "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "| (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 2,
        "window_text": "| https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-modern | a-epar-public-assessment-report_en.pdf |\n| 전자현미경, 원자력 현미경, X-선 회절(XRD), 시차 | 이화학적 특성 분석 |\n| 사항 | 기능에 대한 증거를 제공해야 한다.  | 독성 평가를 요구할 수 있다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72.  | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다. **\n| disadvantages.  Res Pharm Sci.  2018 Aug;13(4):288–303. ",
        "original_sentence": "| (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다."
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "**\n| disadvantages. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 20,
        "word_count": 3,
        "page_number": 66,
        "window_text": "| 독성 평가를 요구할 수 있다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72.  | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다. **\n| disadvantages.  Res Pharm Sci.  2018 Aug;13(4):288–303.  | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다. ",
        "original_sentence": "**\n| disadvantages. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "Res Pharm Sci. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 66,
        "window_text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ |\n| 주사 열량측정(differential scanning calorimetry) 분석 | 2017;1499:253–72.  | (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다. **\n| disadvantages.  Res Pharm Sci.  2018 Aug;13(4):288–303.  | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.  |\n| 백신이 만들어 지는지를 기술해야 한다. ",
        "original_sentence": "Res Pharm Sci. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "2018 Aug;13(4):288–303. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 4,
        "window_text": "| (표면 및 형태학적 특성 포함) |\n**안내서 제ㆍ개정 절차를 진행하시기 바랍니다. **\n| disadvantages.  Res Pharm Sci.  2018 Aug;13(4):288–303.  | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.  |\n| 백신이 만들어 지는지를 기술해야 한다.  | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다. ",
        "original_sentence": "2018 Aug;13(4):288–303. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 6,
        "window_text": "**\n| disadvantages.  Res Pharm Sci.  2018 Aug;13(4):288–303.  | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.  |\n| 백신이 만들어 지는지를 기술해야 한다.  | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.  | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다. ",
        "original_sentence": "| 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "|\n| 백신이 만들어 지는지를 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 8,
        "window_text": "Res Pharm Sci.  2018 Aug;13(4):288–303.  | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.  |\n| 백신이 만들어 지는지를 기술해야 한다.  | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.  | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다.  | 상기 사항에 대하여 확인하였음. ",
        "original_sentence": "|\n| 백신이 만들어 지는지를 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 19,
        "window_text": "2018 Aug;13(4):288–303.  | 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.  |\n| 백신이 만들어 지는지를 기술해야 한다.  | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.  | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다.  | 상기 사항에 대하여 확인하였음.  |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다.",
        "original_sentence": "| 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 277,
        "word_count": 26,
        "page_number": 4,
        "window_text": "| 잔존도(persistence) 및 면역반응을 조사하는 데 도움을 줄 수도 있다.  |\n| 백신이 만들어 지는지를 기술해야 한다.  | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.  | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다.  | 상기 사항에 대하여 확인하였음.  |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다. **\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy. ",
        "original_sentence": "| 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "| 상기 사항에 대하여 확인하였음. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 2,
        "window_text": "|\n| 백신이 만들어 지는지를 기술해야 한다.  | 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.  | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다.  | 상기 사항에 대하여 확인하였음.  |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다. **\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy.  Front Chem. ",
        "original_sentence": "| 상기 사항에 대하여 확인하였음. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "|\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 24,
        "window_text": "| 생체분포 연구 자료) 역시 식약처가 고려하도록 제공해야 한다.  | 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다.  | 상기 사항에 대하여 확인하였음.  |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다. **\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy.  Front Chem.  2020;8:589959.",
        "original_sentence": "|\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다."
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "**\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 139,
        "word_count": 14,
        "page_number": 8,
        "window_text": "| 무균 시험, 엔도톡신 함량 | 안전성 파라미터 |\n| articles/ s41586-020-2639-4 | https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme | nt_data/file/944544/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTE | CH__15Dec2020.pdf Accessed June 1, 2021 |\n| 포함해야 한다.  | 상기 사항에 대하여 확인하였음.  |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다. **\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy.  Front Chem.  2020;8:589959. **\n| 유해한 영향을 주지 않음을 증명해야 한다. ",
        "original_sentence": "**\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy. "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "Front Chem. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 12,
        "word_count": 2,
        "page_number": 65,
        "window_text": "| 상기 사항에 대하여 확인하였음.  |\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다. **\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy.  Front Chem.  2020;8:589959. **\n| 유해한 영향을 주지 않음을 증명해야 한다.  | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다. ",
        "original_sentence": "Front Chem. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "2020;8:589959.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 14,
        "word_count": 1,
        "page_number": 8,
        "window_text": "|\n**일관성을 확인하기 위하여 공정을 밸리데에션해야 한다. **\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy.  Front Chem.  2020;8:589959. **\n| 유해한 영향을 주지 않음을 증명해야 한다.  | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.  | 및 평가가 필요할 것이다. ",
        "original_sentence": "2020;8:589959."
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "**\n| 유해한 영향을 주지 않음을 증명해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 27,
        "window_text": "**\n| https://www.sciencedirect.com/science/article/pii/S0022354920307851 | pH; 함습도(중량, 공비, 적정) | 품질특성 |\n**mRNA-Based Cancer Immunotherapy.  Front Chem.  2020;8:589959. **\n| 유해한 영향을 주지 않음을 증명해야 한다.  | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.  | 및 평가가 필요할 것이다.  |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다.",
        "original_sentence": "**\n| 유해한 영향을 주지 않음을 증명해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 48,
        "word_count": 9,
        "page_number": 6,
        "window_text": "Front Chem.  2020;8:589959. **\n| 유해한 영향을 주지 않음을 증명해야 한다.  | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.  | 및 평가가 필요할 것이다.  |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다. **\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다. ",
        "original_sentence": "| 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| 및 평가가 필요할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 17,
        "word_count": 5,
        "page_number": 8,
        "window_text": "2020;8:589959. **\n| 유해한 영향을 주지 않음을 증명해야 한다.  | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.  | 및 평가가 필요할 것이다.  |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다. **\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다.  | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
        "original_sentence": "| 및 평가가 필요할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "|\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다.",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 197,
        "word_count": 25,
        "page_number": 8,
        "window_text": "**\n| 유해한 영향을 주지 않음을 증명해야 한다.  | 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.  | 및 평가가 필요할 것이다.  |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다. **\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다.  | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
        "original_sentence": "|\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다."
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "**\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 77,
        "word_count": 6,
        "page_number": 4,
        "window_text": "| 항원결정기 모방(epitopic mimicry)에 관하여 조사가 필요할 수 있다.  | 및 평가가 필요할 것이다.  |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다. **\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다.  | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n",
        "original_sentence": "**\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 2,
        "window_text": "| 및 평가가 필요할 것이다.  |\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다. **\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다.  | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n <!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다. ",
        "original_sentence": "| 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 2,
        "window_text": "|\n| :https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-asses | sment-report_en.pdf Accessed June 1, 2021 | 2022년   01월   27일 |\n**추가 접종이나 순차적 접종의 필요성(또는 그 시기)에 영향을 줄 수도 있다. **\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다.  | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n <!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 208,
        "word_count": 43,
        "page_number": 3,
        "window_text": "**\n**Available from: https://doi.org/10.1080/21645515.2020.1750249**\n| 중요하다.  | 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n <!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n",
        "original_sentence": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "<!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 107,
        "word_count": 20,
        "page_number": 3,
        "window_text": "| 담당자 | 확  인(부서장) | 배창준 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n <!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n 전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1. ",
        "original_sentence": "<!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 163,
        "word_count": 37,
        "page_number": 3,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n <!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n 전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1.  서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1. ",
        "original_sentence": "또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "<!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 259,
        "word_count": 49,
        "page_number": 3,
        "window_text": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n김재옥\n\n3/72\n\n<!-- PAGE_3 -->\n##### 이 안내서는 예방용 mRNA 백신 평가 시 고려사항에 대하여 알기 쉽게\n\n<!-- PAGE_3 -->\n##### 설명하거나 식품의약품안전처의 입장을 기술한 것으로 대외적으로 법적\n\n<!-- PAGE_3 -->\n##### 효력을 가지는 것이 아닙니다.\n\n <!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n 전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1.  서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1.  배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 352,
        "word_count": 44,
        "page_number": 4,
        "window_text": "<!-- PAGE_3 -->\n##### 방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야\n\n<!-- PAGE_3 -->\n##### 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n 전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1.  서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1.  배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2.  목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3. ",
        "original_sentence": "전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 150,
        "word_count": 7,
        "page_number": 5,
        "window_text": "또한, 본 안내서는 2022년 01월 27일 현재의\n\n<!-- PAGE_3 -->\n##### 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신\n\n<!-- PAGE_3 -->\n##### 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n 전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1.  서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1.  배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2.  목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3.  일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4. ",
        "original_sentence": "서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 144,
        "word_count": 7,
        "page_number": 5,
        "window_text": "<!-- PAGE_3 -->\n###### ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기\n\n<!-- PAGE_3 -->\n###### 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을\n\n<!-- PAGE_3 -->\n###### 기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n바이오생약심사부 생물제제과에 문의하시기 바랍니다.\n\n 전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1.  서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1.  배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2.  목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3.  일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4.  특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2. ",
        "original_sentence": "배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 133,
        "word_count": 9,
        "page_number": 5,
        "window_text": "전화번호 : 043-719-3451\n\n팩스번호 : 043-719-3450\n\n4/72\n\n<!-- PAGE_4 -->\n## 제·개정 이력서\n\n연번\n\n제·개정번호\n\n발행일자\n\n주요내용\n\n1\n\n안내서-1191-01\n\n- 2022.01.27\n제정\n\n5/72\n\n<!-- PAGE_5 -->\n# 목\n\n<!-- PAGE_5 -->\n# 차\n\n<!-- PAGE_5 -->\n##### 용어설명 ···················································································································6\n\n<!-- PAGE_5 -->\n##### 1.  서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1.  배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2.  목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3.  일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4.  특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2.  품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1. ",
        "original_sentence": "목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 128,
        "word_count": 8,
        "page_number": 5,
        "window_text": "서론 ····················································································································11\n\n<!-- PAGE_5 -->\n##### 1.1.  배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2.  목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3.  일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4.  특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2.  품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1.  일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2. ",
        "original_sentence": "일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 126,
        "word_count": 8,
        "page_number": 5,
        "window_text": "배경 ··············································································································11\n\n<!-- PAGE_5 -->\n##### 1.2.  목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3.  일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4.  특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2.  품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1.  일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2.  제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3. ",
        "original_sentence": "특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 143,
        "word_count": 8,
        "page_number": 5,
        "window_text": "목적 및 범위 ······························································································12\n\n<!-- PAGE_5 -->\n##### 1.3.  일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4.  특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2.  품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1.  일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2.  제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4. ",
        "original_sentence": "품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 134,
        "word_count": 8,
        "page_number": 5,
        "window_text": "일반적 고려사항 ························································································13\n\n<!-- PAGE_5 -->\n##### 1.4.  특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2.  품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1.  일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2.  제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4.  출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5. ",
        "original_sentence": "일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 127,
        "word_count": 9,
        "page_number": 5,
        "window_text": "특이적 고려사항 ························································································15\n\n<!-- PAGE_5 -->\n##### 2.  품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1.  일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2.  제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4.  출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5.  공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6. ",
        "original_sentence": "제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 88,
        "word_count": 15,
        "page_number": 5,
        "window_text": "품질 평가 ··········································································································21\n\n<!-- PAGE_5 -->\n##### 2.1.  일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2.  제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4.  출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5.  공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6.  제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7. ",
        "original_sentence": "백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 105,
        "word_count": 10,
        "page_number": 5,
        "window_text": "일반적 사항 ································································································21\n\n<!-- PAGE_5 -->\n##### 2.2.  제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4.  출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5.  공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6.  제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7.  제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8. ",
        "original_sentence": "출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 116,
        "word_count": 11,
        "page_number": 5,
        "window_text": "제조에 관한 사항 ······················································································23\n\n<!-- PAGE_5 -->\n##### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4.  출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5.  공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6.  제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7.  제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9. ",
        "original_sentence": "공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 130,
        "word_count": 9,
        "page_number": 5,
        "window_text": "백신 구조체 및 조성에 관한 일반 정보 및 설명 ······························28\n\n<!-- PAGE_5 -->\n##### 2.4.  출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5.  공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6.  제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7.  제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10. ",
        "original_sentence": "제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 131,
        "word_count": 8,
        "page_number": 5,
        "window_text": "출발물질, 원료약품, 첨가제의 관리 ······················································31\n\n<!-- PAGE_5 -->\n##### 2.5.  공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6.  제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7.  제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10.  기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11. ",
        "original_sentence": "제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 91,
        "word_count": 12,
        "page_number": 5,
        "window_text": "공정개발 및 공정 중 관리 ······································································33\n\n<!-- PAGE_5 -->\n##### 2.6.  제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7.  제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10.  기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11.  보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3. ",
        "original_sentence": "정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 91,
        "word_count": 12,
        "page_number": 5,
        "window_text": "제품 특성 분석 ··························································································33\n\n<!-- PAGE_5 -->\n##### 2.7.  제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10.  기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11.  보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3.  비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1. ",
        "original_sentence": "최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 143,
        "word_count": 7,
        "page_number": 5,
        "window_text": "제조의 일관성 ····························································································36\n\n<!-- PAGE_5 -->\n##### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10.  기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11.  보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3.  비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1.  약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2. ",
        "original_sentence": "기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 134,
        "word_count": 7,
        "page_number": 5,
        "window_text": "정제 mRNA 원액(원료의약품)의 제조 및 관리 ·································36\n\n<!-- PAGE_5 -->\n##### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10.  기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11.  보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3.  비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1.  약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2.  독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3. ",
        "original_sentence": "보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 140,
        "word_count": 8,
        "page_number": 5,
        "window_text": "최종 제형화 백신(완제의약품)의 제조 및 관리 ·································42\n\n<!-- PAGE_5 -->\n##### 2.10.  기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11.  보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3.  비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1.  약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2.  독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3.  비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4. ",
        "original_sentence": "비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 138,
        "word_count": 7,
        "page_number": 5,
        "window_text": "기록 ············································································································52\n\n<!-- PAGE_5 -->\n##### 2.11.  보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3.  비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1.  약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2.  독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3.  비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4.  임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1. ",
        "original_sentence": "약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 144,
        "word_count": 7,
        "page_number": 5,
        "window_text": "보관검체 ····································································································53\n\n<!-- PAGE_5 -->\n##### 3.  비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1.  약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2.  독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3.  비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4.  임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1.  안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2. ",
        "original_sentence": "독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 119,
        "word_count": 9,
        "page_number": 5,
        "window_text": "비임상 평가 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.1.  약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2.  독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3.  비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4.  임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1.  안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2.  유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3. ",
        "original_sentence": "비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 143,
        "word_count": 8,
        "page_number": 5,
        "window_text": "약리작용 ······································································································54\n\n<!-- PAGE_5 -->\n##### 3.2.  독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3.  비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4.  임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1.  안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2.  유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3.  공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다. ",
        "original_sentence": "임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 117,
        "word_count": 10,
        "page_number": 5,
        "window_text": "독성 ··············································································································55\n\n<!-- PAGE_5 -->\n##### 3.3.  비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4.  임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1.  안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2.  유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3.  공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다.  이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n",
        "original_sentence": "안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 134,
        "word_count": 8,
        "page_number": 5,
        "window_text": "비임상 평가의 가속화 ··············································································58\n\n<!-- PAGE_5 -->\n##### 4.  임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1.  안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2.  유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3.  공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다.  이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n · 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법. ",
        "original_sentence": "유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 286,
        "word_count": 26,
        "page_number": 5,
        "window_text": "임상 평가 ··········································································································60\n\n<!-- PAGE_5 -->\n##### 4.1.  안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2.  유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3.  공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다.  이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n · 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법.  이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n",
        "original_sentence": "공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 6,
        "window_text": "안전성 및 면역원성 평가 ········································································60\n\n<!-- PAGE_5 -->\n##### 4.2.  유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3.  공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다.  이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n · 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법.  이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n · 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물). ",
        "original_sentence": "이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "· 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 230,
        "word_count": 48,
        "page_number": 5,
        "window_text": "유효성 평가 ································································································63\n\n<!-- PAGE_5 -->\n##### 4.3.  공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다.  이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n · 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법.  이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n · 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물).  단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n",
        "original_sentence": "· 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 6,
        "window_text": "공중 위기 맥락에서의 유효성 평가 ······················································64\n\n<!-- PAGE_5 -->\n##### [참고문헌] ···············································································································65\n\n6/72\n\n<!-- PAGE_6 -->\n# 용어설명\n\n아래에 제시하는 정의는 본 문서에서 사용되는 용어에 적용된다.  이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n · 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법.  이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n · 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물).  단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n · dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조). ",
        "original_sentence": "이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "· 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 119,
        "word_count": 21,
        "page_number": 6,
        "window_text": "이 용어는 다른\n\n맥락에서는 의미가 다를 수 있다.\n\n · 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법.  이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n · 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물).  단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n · dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조).  이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다. ",
        "original_sentence": "· 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물). "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 77,
        "word_count": 17,
        "page_number": 4,
        "window_text": "· 면역증강제(adjuvant) : 적절한 면역반응과 이후 백신의 임상적 유효성 강화를 목적으로\n\n하는 물질\n\n· 후보백신(candidate vaccine) : 연구 및 임상 개발 단계에 있으며, 식약처로부터 승인이나\n\n허가를 받지 않은 임상시험용 백신\n\n· 실험설계(design of experiments) : 공정에 영향을 미치는 요소와 그 공정 결과 간의\n\n상관관계를 결정하는 구조화되고 조직화된 접근법.  이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n · 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물).  단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n · dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조).  이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다.  제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다. ",
        "original_sentence": "단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "· dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 97,
        "word_count": 20,
        "page_number": 5,
        "window_text": "이 용어는 ICH Q8(R2)에서 언급하고\n\n있다.\n\n · 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물).  단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n · dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조).  이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다.  제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다.  이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다. ",
        "original_sentence": "· dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조). "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 6,
        "window_text": "· 완제의약품(drug product) : 최종 백신(final vaccine) 참조\n\n· 원료의약품(drug substance) : 최종 제형화 이전 정제된 mRNA(일부 품목의 경우,\n\n지질나노입자 혼합물).  단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n · dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조).  이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다.  제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다.  이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다.  만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n",
        "original_sentence": "이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 89,
        "word_count": 16,
        "page_number": 8,
        "window_text": "단일한 균질 생산 배치로 준비하여, 지정된 1가지 이상의 용기에\n\n보관하며, 최종 제형(최종 백신 또는 완제의약품)의 준비에 사용된다.\n\n · dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조).  이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다.  제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다.  이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다.  만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n · 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n",
        "original_sentence": "제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 74,
        "word_count": 16,
        "page_number": 8,
        "window_text": "· dsRNA(두 가닥 RNA) : 어떤 바이러스는 특정 부위(예: mRNA의 이차구조)보다는 전장에\n\n걸쳐 완전하게 두 가닥 RNA를 형성한다(예, mRNA의 이차구조).  이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다.  제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다.  이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다.  만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n · 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n 7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소. ",
        "original_sentence": "이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 6,
        "window_text": "이 두 가닥 RNA는 세포\n\n내 수용체에 의해 감지되어 선천성 면역반응을 일으킬 수 있다.  제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다.  이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다.  만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n · 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n 7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소.  대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다. ",
        "original_sentence": "만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "· 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 107,
        "word_count": 22,
        "page_number": 6,
        "window_text": "제조방법에 따라\n\n다르겠으나, 어떤 mRNA 백신에서 in vitro transcription(IVT) 제조공정 중 부산물로서\n\ndsRNA가 생성될 수 있다.  이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다.  만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n · 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n 7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소.  대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다.  첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다. ",
        "original_sentence": "· 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 5,
        "window_text": "이러한 dsRNA는 제조공정 중 mRNA와 분리하여 제거해야\n\n하는 불순물이며, 최소한 제품 내에서의 양을 확정하고 관리해야 한다.  만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n · 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n 7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소.  대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다.  첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다.  본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n",
        "original_sentence": "7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 64,
        "word_count": 15,
        "page_number": 10,
        "window_text": "만일 제조공정 중\n\ndsRNA가 생성되지 않는다면 이러한 공정관리가 필요한 것은 아니다.\n\n · 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n 7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소.  대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다.  첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다.  본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n · 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다. ",
        "original_sentence": "대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 8,
        "window_text": "· 공정개발용 생산(engineering run(s)) : GMP 생산공정을 확증하거나 증진 시키기 위한\n\n공정을 개발하는 데 이용된 생산 단위로 사람에게서의 사용을 목적으로 하지 않는다.\n\n 7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소.  대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다.  첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다.  본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n · 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다.  다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다. ",
        "original_sentence": "첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 118,
        "word_count": 21,
        "page_number": 10,
        "window_text": "7/72\n\n· 첨가제(excipient) : 특정한 목적을 위해 제형화에 추가된, 활성 성분 외의 의약품의\n\n구성요소.  대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다.  첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다.  본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n · 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다.  다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다.  본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다. ",
        "original_sentence": "본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "· 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 132,
        "word_count": 24,
        "page_number": 7,
        "window_text": "대부분의 첨가제는 비활성 성분으로 간주하는 반면, 일부는 특정 상황에서\n\n알려진 작용이나 효과를 발휘할 수 있다.  첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다.  본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n · 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다.  다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다.  본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다.  만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n",
        "original_sentence": "· 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 6,
        "window_text": "첨가제는 의약품의 안전한 사용을 보장하기\n\n위하여 반드시 제품의 라벨 정보 및 첨부문서에 표시해야 한다.  본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n · 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다.  다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다.  본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다.  만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n · 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합. ",
        "original_sentence": "다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 50,
        "word_count": 11,
        "page_number": 8,
        "window_text": "본 문서의 맥락에서는\n\n지질나노입자를 형성하는 지질이 첨가제이지만, 지질나노입자 혼합물은 완제의약품(drug\n\nproduct)의 생산에서 중간체로 정의되나, 일부 품목의 경우 원료의약품으로 정의될 수\n\n있다.\n\n · 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다.  다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다.  본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다.  만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n · 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합.  따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다. ",
        "original_sentence": "본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 77,
        "word_count": 18,
        "page_number": 18,
        "window_text": "· 최종 원액(final formulated bulk) : 최종 백신(final vaccine)의 제조공정 중의 중간체로서,\n\n일차 용기에 충전할 농도의 최종 제형화된 균질한 원료의약품 및 첨가제(excipient)로\n\n구성되어 있다.  다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다.  본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다.  만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n · 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합.  따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다.  최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n",
        "original_sentence": "만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "· 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 69,
        "word_count": 18,
        "page_number": 7,
        "window_text": "다른 방식으로는, 최종 원액을 더 높은 농도로 보관하고 충전 직전에\n\n희석할 수 있다.  본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다.  만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n · 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합.  따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다.  최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n · 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말). ",
        "original_sentence": "· 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 17,
        "window_text": "본 문서에서는 지질나노입자 및 필요에 따라 다른 첨가제로 제형화한\n\nmRNA를 지칭한다.  만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n · 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합.  따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다.  최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n · 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말).  본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다. ",
        "original_sentence": "따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 6,
        "window_text": "만일 다가 혹은 혼합 백신에서처럼 2개 이상의 원료의약품이 혼합될\n\n경우, 이러한 과정은 최종원액의 준비과정 중에 이루어질 수도 있다.\n\n · 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합.  따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다.  최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n · 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말).  본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다.  그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다. ",
        "original_sentence": "최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "· 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 148,
        "word_count": 28,
        "page_number": 7,
        "window_text": "· 최종 로트(final lot) : 충진 중 제품의 조성 및 오염 방지와 관련하여 균일하게 밀봉한 최종\n\n용기들의 집합.  따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다.  최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n · 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말).  본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다.  그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다.  다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n",
        "original_sentence": "· 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말). "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 62,
        "word_count": 14,
        "page_number": 8,
        "window_text": "따라서 최종 로트는 반드시 단일 연속 작업 세션에서 최종 원액으로부터\n\n충전해야 한다.  최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n · 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말).  본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다.  그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다.  다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n · 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형. ",
        "original_sentence": "본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 71,
        "word_count": 18,
        "page_number": 8,
        "window_text": "최종원액을 두 개 이상의 최종 로트에 충전할 수도 있다.\n\n · 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말).  본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다.  그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다.  다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n · 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형.  지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님). ",
        "original_sentence": "그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 45,
        "word_count": 5,
        "page_number": 7,
        "window_text": "· 최종 백신(final vaccine) (또는 완제의약품(drug product)) : 일반적으로 첨가제와 함께\n\n제형화하고 사용을 위해 봉입된 한 개 이상의 원료의약품(활성 성분)을 함유한 최종\n\n제형(dosage form)(예: 현탁액 또는 동결건조 분말).  본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다.  그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다.  다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n · 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형.  지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님).  LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n",
        "original_sentence": "다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "· 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 532,
        "word_count": 101,
        "page_number": 5,
        "window_text": "본 문서에서는 지질나노입자 및 기타\n\n첨가제와 함께 제형화하여 최종 용기에 충전된 mRNA 부유액을 일컫는다.  그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다.  다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n · 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형.  지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님).  LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n · 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가. ",
        "original_sentence": "· 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형. "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 145,
        "word_count": 19,
        "page_number": 8,
        "window_text": "그 외에도, 최종\n\n용기는 (각 용기가 다회 투여량을 담고 있을 수 있을지라도) 임상 용량에 해당하는 농도로\n\n충전해야 한다.  다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n · 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형.  지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님).  LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n · 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가.  식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다. ",
        "original_sentence": "지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님). "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 6,
        "window_text": "다른 문서에서는“최종화된 제품(finished product)”으로도 칭한다.\n\n · 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형.  지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님).  LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n · 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가.  식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다.  품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n",
        "original_sentence": "LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "· 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 73,
        "word_count": 11,
        "page_number": 5,
        "window_text": "· 의약품 제조 및 품질관리기준(GMP) : 제품의 사용 의도에 적합한 품질기준 및 품목허가\n\n요건에 따른 일관적인 제품의 생산 및 관리를 보장하는 시스템\n\n· 면역원성(immunogenicity) : 백신이 표적 항원에 대하여 측정 가능한 후천성 면역반응을\n\n유발하는 능력\n\n8/72\n\n· in vitro transcribed (IVT) mRNA : DNA-의존적 RNA 중합효소(예: T7, T3 또는 Sp6 파지\n\nRNA\n\n중합효소(phage\n\nRNA\n\npolymerase))\n\n및\n\n뉴클레오시드\n\n3인산염(nucleoside\n\ntriphosphate)을 사용하여 선형 DNA 주형(template)으로부터 mRNA를 in vitro 환경에서\n\n생성하는 제조공정\n\n· 지질나노입자(Lipid nanoparticle, LNP) : 예를 들면, 세포 밖에서 분해되는 것을 피하고\n\nmRNA의 세포 내 진입 및 세포질(cytosol)로의 방출을 촉진할 목적으로, mRNA의 안정화\n\n및 봉입화를 보장하기 위하여 다양한 구성요소로 이루어진 전달 제형.  지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님).  LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n · 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가.  식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다.  품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n · 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음. ",
        "original_sentence": "· 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 83,
        "word_count": 21,
        "page_number": 5,
        "window_text": "지질 성분은 이온화\n\n가능한/양이온성의\n\n지질,\n\n도움\n\n지질(예,\n\n인지질\n\n및/또는\n\n콜레스테롤),\n\n페길화((polyethylene-glycol-ylation(PEGylation))와\n\n같은\n\n변형\n\n지질을 포함한다(다만\n\n여기에 국한되는 것은 아님).  LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n · 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가.  식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다.  품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n · 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음.  다른 변형의 종류로는 메틸화(methylation)가 있다. ",
        "original_sentence": "식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 52,
        "word_count": 11,
        "page_number": 2,
        "window_text": "LNP 및/또는 지질 성분은 면역증강제 활성을 지닐 수 있다.\n\n · 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가.  식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다.  품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n · 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음.  다른 변형의 종류로는 메틸화(methylation)가 있다.  뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n",
        "original_sentence": "품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "· 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 390,
        "word_count": 56,
        "page_number": 8,
        "window_text": "· 품목허가(marketing authorization/approval) : (백신을 포함한) 의약품의 시판을 위한 공식\n\n허가.  식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다.  품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n · 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음.  다른 변형의 종류로는 메틸화(methylation)가 있다.  뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n · mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율. ",
        "original_sentence": "· 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "다른 변형의 종류로는 메틸화(methylation)가 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 34,
        "word_count": 5,
        "page_number": 6,
        "window_text": "식약처가 새로운 의약품의 품목허가 신청을 승인하면 이 의약품은 시판할 수 있으며\n\n의사의 처방 및/또는 공중보건 사용을 위해 제공할 수 있게 된다.  품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n · 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음.  다른 변형의 종류로는 메틸화(methylation)가 있다.  뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n · mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율.  또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n",
        "original_sentence": "다른 변형의 종류로는 메틸화(methylation)가 있다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 6,
        "window_text": "품목허가가 되면 새로운\n\n의약품은 허가사항에 따라 제조되고 관리되며 표시 기재되어야 한다.\n\n · 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음.  다른 변형의 종류로는 메틸화(methylation)가 있다.  뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n · mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율.  또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n 9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n",
        "original_sentence": "뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "· mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 8,
        "window_text": "· 작용기작/작용기전(mode/mechanism\n\nof\n\naction)\n\n:\n\n백신이\n\n세포(mode)\n\n또는\n\n분자(mechanism) 수준에서 유도한 후천성 면역반응이 병원체에 대하여 방어하는 방식(예:\n\n중화항체에 의한 중화작용(neutralization), 옵소닌 항체에 의한 옵소닌작용(opsonization),\n\nT-세포에 의한 세포독성(cytotoxicity))\n\n· 변형된 뉴클리오시드(modified nucleoside) : mRNA 제작 시 일반적인 뉴클리오시드(이\n\n경우, 우리딘(uridine))를\n\n대체할\n\n수\n\n있는 자연\n\n발생적인\n\n변형된 뉴클레오시드(예:\n\n슈도우리딘(pseudouridine))로서 결과적으로 염증 활성의 감소 및/또는 안정성 증가\n\n잠재력이 있음.  다른 변형의 종류로는 메틸화(methylation)가 있다.  뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n · mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율.  또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n 9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n",
        "original_sentence": "· mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 8,
        "window_text": "다른 변형의 종류로는 메틸화(methylation)가 있다.  뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n · mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율.  또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n 9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n · 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제. ",
        "original_sentence": "또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 66,
        "word_count": 13,
        "page_number": 8,
        "window_text": "뉴클레오시드는 또한\n\n비자연적 변형을 포함하고 있을 수도 있다.\n\n · mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율.  또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n 9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n · 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제.  “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n",
        "original_sentence": "9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n"
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 120,
        "word_count": 24,
        "page_number": 8,
        "window_text": "· mRNA 완전성 : 정확한 크기와 5’ cap 및 poly(A) tail을 포함하는 mRNA의 비율.  또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n 9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n · 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제.  “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n · 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음. ",
        "original_sentence": "mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "· 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 179,
        "word_count": 40,
        "page_number": 8,
        "window_text": "또한\n\nmRNA의 염기서열이 정확한지도 확인되어야 한다.\n\n 9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n · 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제.  “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n · 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음.  mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다. ",
        "original_sentence": "· 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "“새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 8,
        "window_text": "9/72\n\n· mRNA(messenger RNA) : 세포의 세포질에서 단백질로 번역되는 단일 가닥의 RNA 분자.\n\n mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n · 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제.  “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n · 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음.  mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다.  제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다. ",
        "original_sentence": "“새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "· 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 78,
        "word_count": 17,
        "page_number": 8,
        "window_text": "mRNA는 단백질(백신의 경우, 표적 항원)을 코딩하는 오픈 리딩 프레임(ORF), 주변을 둘러싼\n\n비번역 부위(UTR), 5‘ cap(또는 대체물) 및 poly(A) tail과 같은 3’ 서열을 포함하고 있다.\n\n · 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제.  “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n · 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음.  mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다.  제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다.  새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다. ",
        "original_sentence": "· 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 145,
        "word_count": 35,
        "page_number": 8,
        "window_text": "· 새로운 첨가제(novel excipient) : 인체 투여를 위해 허가 또는 승인된 의약품에서 이전에\n\n사용된 적이 없는 첨가제(예: 지질), 또는 인체 투여를 위해 허가나 승인된 제품에서 이전에\n\n사용되었다면, 허가 또는 승인된 투여경로와 동일하게 (그리고/또는 더 높은 농도로\n\n제작하여) 사용하지 않는 첨가제.  “새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n · 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음.  mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다.  제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다.  새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다.  안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다. ",
        "original_sentence": "mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 168,
        "word_count": 37,
        "page_number": 8,
        "window_text": "“새로운”이란 단어는 본 문서의 다른 부분에서 다른\n\n용어를 설명하기 위해 같은 방식으로 사용하고 있다.\n\n · 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음.  mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다.  제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다.  새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다.  안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다.  mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다. ",
        "original_sentence": "제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 162,
        "word_count": 42,
        "page_number": 24,
        "window_text": "· 플랫폼 기술(platform technology) : 기존과 다른 적용 및 공정, 기술의 개발을 위한 토대로\n\n사용되는 기술들의 모음.  mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다.  제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다.  새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다.  안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다.  mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다.  mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다. ",
        "original_sentence": "새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 147,
        "word_count": 29,
        "page_number": 8,
        "window_text": "mRNA 백신의 맥락에서, 다양한 질환(개별 각각의 백신 또는\n\n혼합 백신)이나 동일 질환에 대한 병원체 균주(개별 단가 혹은 혼합 다가 백신)에 대한\n\n백신(또는 치료제) 개발을 위한 기반으로써 제조사는 한 가지 이상의 플랫폼을 보유하고\n\n있을 수도 있다.  제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다.  새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다.  안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다.  mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다.  mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다.  만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다. ",
        "original_sentence": "안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 103,
        "word_count": 24,
        "page_number": 8,
        "window_text": "제조 방법이 본질적으로 변경되지 않고(그러나 각 특이적 백신 후보에\n\n대해 최적화될 수 있음), 기준 및 시험법(확인시험, 역가시험, 안정성시험은 제외)과\n\n허용기준은 변경되지 않았으며, 면역조절 복합체나 요소가 변경되지 않았고, GMP 준수의\n\n변경이 없는 경우, 플랫폼을 고려할 수 있을 것이다.  새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다.  안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다.  mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다.  mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다.  만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다.  더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다. ",
        "original_sentence": "mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 96,
        "word_count": 23,
        "page_number": 8,
        "window_text": "새로운 후보백신 개발을 위한 플랫폼\n\n기술 사용에 따른 한 가지 영향은, 획득한 경험과 지식 및 생성된 자료(제조 및 관리,\n\n안정성, 비임상), 변경되지 않은 방법에 대한 밸리데이션을 모두 더욱 신속한 새로운 후보\n\n백신의 평가 및 개발을 위한 보조자료로 사용할 수 있게 된다는 것이다.  안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다.  mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다.  mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다.  만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다.  더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다.  언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n",
        "original_sentence": "mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 88,
        "word_count": 21,
        "page_number": 17,
        "window_text": "안전한\n\n시작용량(starting dose) 또는 내약용량(tolerable dose)과 관련하여 플랫폼에서 얻은 임상\n\n및 비임상 자료는 또한 이 플랫폼으로 이미 내약성이 있다고 파악된 용량에서 새로운\n\n후보백신의 임상시험을 개시하도록 뒷받침해 줄 수도 있다.  mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다.  mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다.  만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다.  더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다.  언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n · sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신. ",
        "original_sentence": "만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 64,
        "word_count": 15,
        "page_number": 25,
        "window_text": "mRNA 서열과 더불어, 이\n\n플랫폼 기술에 변경된 측면이 있다면, 초기 플랫폼으로 생성된 자료가 새로운 후보 백신을\n\n뒷받침해준다고 간주해야 하는 이유에 대해 근거를 제시해야 한다.  mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다.  만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다.  더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다.  언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n · sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신.  이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다. ",
        "original_sentence": "더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 48,
        "word_count": 10,
        "page_number": 10,
        "window_text": "mRNA 백신을 위해\n\n사용하는 생산 및 관리 방법은 제조사 간에 아직 표준화되지 않았기 때문에, 다른\n\n제조사에서 생성한 정보가 플랫폼 기술을 뒷받침해주지 못할 것이다.  만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다.  더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다.  언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n · sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신.  이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다.  sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다. ",
        "original_sentence": "언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "· sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 147,
        "word_count": 23,
        "page_number": 5,
        "window_text": "만일 근거를\n\n제시하고 그 근거가 강력하다면, 이러한 정보는 제품군에 대한 정보와 유사한 것으로\n\n10/72\n\n간주할 수 있으며 보조자료로 평가할 수 있다.  더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다.  언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n · sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신.  이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다.  sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다.  이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n",
        "original_sentence": "· sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 99,
        "word_count": 25,
        "page_number": 17,
        "window_text": "더 나아가, 플랫폼 기술 사용에도 불구하고\n\n현재 표준화의 부재로 인하여 규제적 유연성을 발휘가 타당한 상황이다.  언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n · sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신.  이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다.  sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다.  이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n · 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부. ",
        "original_sentence": "이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다. "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 62,
        "word_count": 13,
        "page_number": 5,
        "window_text": "언제나 그러하듯,\n\n사례별 접근법이 타당하며 식약처와 논의하고 동의를 구해야 한다.\n\n · sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신.  이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다.  sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다.  이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n · 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부.  다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n",
        "original_sentence": "sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 65,
        "word_count": 13,
        "page_number": 2,
        "window_text": "· sa-mRNA(self-amplifying\n\nmRNA)\n\n:\n\n목표로\n\n하는\n\n항원의\n\n코딩\n\n외에도,\n\n특정\n\n알파바이러스의 비구조단백질(nonstructural protein)을 또한 (항원과 동일한 분자에 또는\n\n별도의 분자에) 코딩하는 mRNA 백신.  이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다.  sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다.  이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n · 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부.  다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n · 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료. ",
        "original_sentence": "이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "· 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 90,
        "word_count": 24,
        "page_number": 10,
        "window_text": "이러한 ORF가 세포 내 발현 시 알파바이러스의\n\n복제 기전을 지닌 단백질을 생산하며, 이를 통해 세포는 항원 단백질을 코딩하는 다수의\n\nmRNA 카피를 생산할 수 있게 된다.  sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다.  이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n · 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부.  다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n · 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료.  본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다. ",
        "original_sentence": "· 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 85,
        "word_count": 22,
        "page_number": 8,
        "window_text": "sa-mRNA의 목적은 생성되는 단백질 항원의 양을\n\n증가함으로써 mRNA 백신의 체내 역가를 높이는 것이다.  이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n · 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부.  다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n · 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료.  본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다.  위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n",
        "original_sentence": "다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "· 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 96,
        "word_count": 21,
        "page_number": 8,
        "window_text": "이러한 형태의 mRNA 백신에는\n\n다른 명칭이 주어졌으나, 이 문서에서는 sa-mRNA라는 용어를 사용할 것이다.\n\n · 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부.  다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n · 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료.  본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다.  위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n · tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n",
        "original_sentence": "· 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료. "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 24,
        "window_text": "· 표적 항원 : 백신 접종에 의한 면역반응은 하나 이상의 병원체 혹은 계통에 대한 예방을\n\n기대하는 mRNA 백신의 mRNA에서 코딩된 단백질 혹은 그 일부.  다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n · 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료.  본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다.  위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n · tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n 11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1. ",
        "original_sentence": "본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 10,
        "window_text": "다른 말로 하면\n\n병원체가 원인이 되는 질병 (또는 감염)에 대한 예방은 백신 접종으로 표적 항원에 대한\n\n결과적인 면역반응에 의해 유도될 수 있다.\n\n · 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료.  본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다.  위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n · tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n 11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1.  서론\n\n<!-- PAGE_11 -->\n### 1.1. ",
        "original_sentence": "위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "· tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 93,
        "word_count": 16,
        "page_number": 8,
        "window_text": "· 치료제(therapeutic) : 감염성 유기체에 대한 노출 발생 이전의 질병 예방과 대비하여,\n\n질병이나 병태(또는 이들의 징후나 증상)가 증명된 후 제공되는 치료.  본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다.  위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n · tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n 11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1.  서론\n\n<!-- PAGE_11 -->\n### 1.1.  배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2). ",
        "original_sentence": "· tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 52,
        "word_count": 11,
        "page_number": 11,
        "window_text": "본 문서에서는 예방\n\n백신은 치료제로 간주하지 않으나, 일부 규제 관할지역의 정의는 다를 수 있다.  위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n · tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n 11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1.  서론\n\n<!-- PAGE_11 -->\n### 1.1.  배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2).  그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6). ",
        "original_sentence": "11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "서론\n\n<!-- PAGE_11 -->\n### 1.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 11,
        "window_text": "위와 같이\n\n정의된 치료제는 본 문서의 범위 밖이다.\n\n · tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n 11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1.  서론\n\n<!-- PAGE_11 -->\n### 1.1.  배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2).  그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6).  mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다. ",
        "original_sentence": "서론\n\n<!-- PAGE_11 -->\n### 1.1. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 163,
        "word_count": 30,
        "page_number": 4,
        "window_text": "· tRNA(transfer RNA) : 리보솜에 의해 사용되는 RNA 분자이며, mRNA상의 코돈을\n\n단백질로 번역하는 데에 관여하는 어댑터(adaptor)이다.\n\n 11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1.  서론\n\n<!-- PAGE_11 -->\n### 1.1.  배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2).  그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6).  mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다.  그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n",
        "original_sentence": "배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2). "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 117,
        "word_count": 29,
        "page_number": 8,
        "window_text": "11/72\n\n예방용 mRNA 백신 평가 가이드라인\n\n<!-- PAGE_11 -->\n## 1.  서론\n\n<!-- PAGE_11 -->\n### 1.1.  배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2).  그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6).  mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다.  그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n 수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11). ",
        "original_sentence": "그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6). "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 8,
        "window_text": "서론\n\n<!-- PAGE_11 -->\n### 1.1.  배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2).  그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6).  mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다.  그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n 수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11).  또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다. ",
        "original_sentence": "mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 164,
        "word_count": 36,
        "page_number": 8,
        "window_text": "배경\n\nRNA의 면역자극 효과는 1960년대 초부터 알려져 왔으나(1), 단백질(항원 포함) 발현\n\n유전자를 일시적으로 도입하기 위한 in vitro transcribed(IVT) mRNA의 직접적인 체내\n\n투여 가능성은 “naked” 핵산의 직접 주입 이후인 1990년에 증명되었다(2).  그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6).  mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다.  그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n 수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11).  또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다.  이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다. ",
        "original_sentence": "그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 8,
        "window_text": "그 후 이어진\n\nmRNA 안정화 및 RNA 기반 제품의 제조 실행 가능성 제고, RNA 연관 염증반응 감소\n\n부문의 개선을 통해 mRNA 기반 백신 및 치료제의 개발에는\n\n상당한 진보가\n\n이루어졌다(3-6).  mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다.  그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n 수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11).  또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다.  이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다.  생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다. ",
        "original_sentence": "수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11). "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 154,
        "word_count": 35,
        "page_number": 4,
        "window_text": "mRNA 기반 플랫폼 기술이 잠재적인 백신 기술로서 가장 앞서\n\n부상하게 된 데에는 몇 가지 이유가 있다.  그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n 수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11).  또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다.  이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다.  생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다.  따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다. ",
        "original_sentence": "또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 145,
        "word_count": 31,
        "page_number": 8,
        "window_text": "그러한 이유 중에는 mRNA 기반 후보 백신을\n\n구축하고 제조하는 빠른 속도, 동물원성 독감 바이러스 균주 및 지카 바이러스, 가장\n\n최근의 코로나19의 원인 인자인 코로나19 바이러스(SARS-CoV-2)와 같이 새롭게\n\n출현하는 병원체에 대한 신속한 백신 개발의 필요성이 포함되어 있다.\n\n 수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11).  또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다.  이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다.  생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다.  따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다.  그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n",
        "original_sentence": "이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 155,
        "word_count": 32,
        "page_number": 8,
        "window_text": "수많은 논문에서 이러한 신기술과 관련된 일부 안전성, 생산 및 규제 문제에 대해\n\n다루고 있다 (7~11).  또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다.  이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다.  생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다.  따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다.  그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n 어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다. ",
        "original_sentence": "생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 114,
        "word_count": 28,
        "page_number": 8,
        "window_text": "또한, 코로나19 후보 백신에 대해 임상시험이 진행되는 속도,\n\n식약처의 승인이나 허가 그리고 이후 이들의 광범위한 사용으로 인하여, 인간에게\n\n발생하는 전염성 질환 예방을 위한 mRNA 제품의 품질 및 안전성, 유효성 평가에 관한\n\n가이드라인의 긴급한 필요성이 대두되었다.  이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다.  생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다.  따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다.  그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n 어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다.  그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다. ",
        "original_sentence": "따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 89,
        "word_count": 21,
        "page_number": 8,
        "window_text": "이러한 평가 시에는 (a) mRNA의 본질적인\n\n면역학 및 이화학, 구조적 특성, (b) 지질나노입자와 같은 안정성과 효율적인 전달을\n\n보장하기 위한 특별한 제형의 필요성, 그리고 (c) 새로운 무세포(cell-free) 효소 공정을\n\n반드시 고려해야 한다.  생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다.  따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다.  그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n 어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다.  그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다.  최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n",
        "original_sentence": "그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 127,
        "word_count": 30,
        "page_number": 8,
        "window_text": "생산에 사용되는 방법에 대한 상세한 정보가 알려지지 않았고,\n\n안전하고 효과적인 mRNA 백신을 위한 관리가 표준화되지 않았으며, 특정 세부 사항은\n\n특허정보로 남아 공개되지 않았으므로 현시점에서는 구체적인 국제적 가이드라인이나\n\n12/72\n\n권고사항의 수립이 가능하지 않다.  따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다.  그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n 어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다.  그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다.  최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n <!-- PAGE_12 -->\n### 1.2. ",
        "original_sentence": "어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 17,
        "window_text": "따라서 현재 규제적인 유연성이 필요하며, mRNA\n\n백신의 품질, 안전성, 유효성에 영향을 줄 수 있는 중요한 변경은 물론, 세부적 생산 및\n\n관리 절차는 사례별로 식약처와 논의하고 승인을 받아야 한다.  그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n 어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다.  그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다.  최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n <!-- PAGE_12 -->\n### 1.2.  목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다. ",
        "original_sentence": "그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 127,
        "word_count": 24,
        "page_number": 17,
        "window_text": "그럼에도 본 문서에서\n\n기술하는 핵심 원칙은 일반적으로 mRNA 백신에 적용 가능하며 더 많은 세부 정보의\n\n사용이 가능해질 때까지 지침을 제공하고자 한다.\n\n 어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다.  그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다.  최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n <!-- PAGE_12 -->\n### 1.2.  목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다.  개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다. ",
        "original_sentence": "최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "<!-- PAGE_12 -->\n### 1.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 12,
        "window_text": "어떠한 제조사의 mRNA 백신이든 결과적인 새로운 제품의 제조이나 관리를 반드시\n\n변경해야 할 필요 없이(확인 및 역가에 대한 면역원-특이적 시험은 제외) 번역영역을\n\n수월하게 변경할 수 있는 플랫폼 기술로써 여겨질 수 있다.  그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다.  최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n <!-- PAGE_12 -->\n### 1.2.  목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다.  개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다.  이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다. ",
        "original_sentence": "<!-- PAGE_12 -->\n### 1.2. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 97,
        "word_count": 26,
        "page_number": 5,
        "window_text": "그러나 이러한 결정은 최종\n\n백신의 결과적인 특성에 따라 달라질 것이다.  최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n <!-- PAGE_12 -->\n### 1.2.  목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다.  개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다.  이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다.  그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다. ",
        "original_sentence": "목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 8,
        "window_text": "최종 백신의 유의한 변경으로 인해 세포의\n\n상호반응뿐 아니라 주요품질특성(Critical Quality Attributes, CQAs)이 변경된다면 이\n\n제품의 제조공정 및 관리, 시험에 대한 추가적인 고려가 필요할 것이다.\n\n <!-- PAGE_12 -->\n### 1.2.  목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다.  개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다.  이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다.  그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다.  그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다. ",
        "original_sentence": "개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 103,
        "word_count": 23,
        "page_number": 4,
        "window_text": "<!-- PAGE_12 -->\n### 1.2.  목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다.  개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다.  이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다.  그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다.  그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다.  각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n",
        "original_sentence": "이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 108,
        "word_count": 25,
        "page_number": 4,
        "window_text": "목적 및 범위\n\n본 문서는 인체 투여를 위한 예방용 mRNA 백신의 제조 및 품질관리 그리고 비임상\n\n및 임상 평가의 핵심적 측면과 관련된 정보와 규제 고려사항을 제공한다.  개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다.  이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다.  그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다.  그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다.  각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다. ",
        "original_sentence": "그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 141,
        "word_count": 34,
        "page_number": 8,
        "window_text": "개발 단계별로\n\n적절하고 진전을 이룰 수 있는 충분한 정보가 제공되어야 한다.  이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다.  그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다.  그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다.  각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다.  mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n",
        "original_sentence": "그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 12,
        "window_text": "이 제품군에서 개발이\n\n가장 진전된 백신은 코로나19 백신이며, 본문에서 예시로 사용하고 있을지라도 이\n\n문서가 코로나19 백신에만 특이적인 지침을 제공하는 것으로 보아서는 안 된다.  그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다.  그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다.  각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다.  mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n 본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다. ",
        "original_sentence": "각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 128,
        "word_count": 29,
        "page_number": 8,
        "window_text": "그러나\n\n현재의 코로나19 대유행과 이에 대응하는 mRNA 백신 개발의 속도의 관점에서, 본\n\n문서는 이러한 예방용 mRNA 백신에 대한 특별 고려사항을 가능한 한 신속하게\n\n제공하고자 한다.  그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다.  각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다.  mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n 본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다.  지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다. ",
        "original_sentence": "mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 117,
        "word_count": 25,
        "page_number": 8,
        "window_text": "그럼에도 불구하고 특정 mRNA 백신이 예방하려는 질병에 대해\n\n성공적이고 광범위하게 관련성이 있으며 지속적으로 효능을 발휘하는 데 필요할 수\n\n있는 면역원성의 유형 및 양에 대한 과학적 이해에 있어서 여전히 지식 격차가 있다는\n\n점에 유의해야 한다.  각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다.  mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n 본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다.  지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다.  복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다. ",
        "original_sentence": "mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 10,
        "window_text": "각각의 유익성과 위해성에 대한 평가가 필요하다.\n\n mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다.  mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n 본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다.  지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다.  복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다.  또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다. ",
        "original_sentence": "본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 70,
        "word_count": 17,
        "page_number": 8,
        "window_text": "mRNA 백신은 새로운 백신이며 다른 종류의 백신들(심지어 플라스미드 DNA 백신과\n\n같은 다른 형태의 핵산 백신)과도 다르기 때문에 유용하다고 판단되는 경우 mRNA\n\n백신 특이적인 주제에 대하여 간략한 개론을 제공하고 있다.  mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n 본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다.  지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다.  복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다.  또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다.  추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다. ",
        "original_sentence": "지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 86,
        "word_count": 18,
        "page_number": 8,
        "window_text": "mRNA 백신과 제조공정의\n\n신규성으로 인하여 제조사가 이러한 종류의 제품을 개발하고 규제자들이 이러한\n\n13/72\n\n제품을 평가할 때 모든 관련된 측면들을 고려할 수 있도록 포괄적인 접근법을\n\n채택하였다.\n\n 본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다.  지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다.  복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다.  또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다.  추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다.  mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n",
        "original_sentence": "복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 121,
        "word_count": 29,
        "page_number": 5,
        "window_text": "본 문서의 범위는 감염성 질환의 예방을 위한 능동적 면역접종과 관련된 표적 항원을\n\n코딩하는 서열을 체내로 전달하기 위해 지질나노입자로 봉입된 mRNA 및 sa-mRNA로\n\n제한하고 있다.  지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다.  복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다.  또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다.  추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다.  mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n 품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다. ",
        "original_sentence": "또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 82,
        "word_count": 19,
        "page_number": 8,
        "window_text": "지질나노입자 외에 다른 제형의 mRNA 및 sa-mRNA도 개발 중이며 본\n\n문서의 일부는 이러한 제품에도 적용할 수 있다.  복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다.  또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다.  추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다.  mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n 품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다.  그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n",
        "original_sentence": "추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 85,
        "word_count": 18,
        "page_number": 8,
        "window_text": "복제 인자 및 바이러스 벡터, (바이러스\n\n단백질로 봉입되었거나 플라스미드 DNA로 코딩된) RNA replicon은 본 문서의 범위에\n\n속하지 않는다.  또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다.  추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다.  mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n 품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다.  그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n 다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n",
        "original_sentence": "mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n"
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 6,
        "window_text": "또한, 치료 목적의 mRNA 및 sa-mRNA(즉, 제품이 감염병을 포함하여\n\n질병의 예방을 위한 능동적 면역접종이 아닌, 이들의 치료 또는 완화, 치유를 목적으로\n\n하는 제품) 역시 본 문서의 범위를 벗어나 있다.  추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다.  mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n 품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다.  그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n 다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n 본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다. ",
        "original_sentence": "품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 105,
        "word_count": 26,
        "page_number": 8,
        "window_text": "추가로, 단클론항체를 발현하는 mRNA\n\n제품 역시 (질병에 대한 예방을 위한 능동 면역으로 작용하든 또는 치료제이든) 본\n\n문서의 범위 밖이다.  mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n 품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다.  그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n 다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n 본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다.  백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n",
        "original_sentence": "그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 132,
        "word_count": 27,
        "page_number": 8,
        "window_text": "mRNA 기반 치료제(단클론항체를 발현하는 이러한 제품들을\n\n포함)의 제조 단계는 백신에 관해 서술한 내용과 유사하기 때문에, 본 가이드라인의 ‘2.\n\n 품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다.  그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n 다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n 본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다.  백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n <!-- PAGE_13 -->\n### 1.3. ",
        "original_sentence": "다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 13,
        "window_text": "품질 평가’에서 논하는 일부 측면이 이러한 제품에 적용될 수 있다.  그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n 다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n 본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다.  백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n <!-- PAGE_13 -->\n### 1.3.  일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다. ",
        "original_sentence": "본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 125,
        "word_count": 31,
        "page_number": 8,
        "window_text": "그러나 이러한\n\n치료용 제품의 비임상 및 임상 평가는 이들의 치료 적응증을 기반으로 해야 할\n\n것이므로, 본 문서에 이러한 제품에 대한 규제적 고려사항을 수록하는 것은 타당하지\n\n않다.\n\n 다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n 본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다.  백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n <!-- PAGE_13 -->\n### 1.3.  일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다.  (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n",
        "original_sentence": "백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "<!-- PAGE_13 -->\n### 1.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 13,
        "window_text": "다가(multivalent) mRNA 백신을 개발하거나 어떠한 병원체(예 : 독감 바이러스 또는\n\nSARS-CoV-2)에 대하여 기존 백신 균주를 변경해야 할 수 있으므로, 본 문서에서는\n\n필요할 경우 특정 고려사항을 제공하고 있다.\n\n 본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다.  백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n <!-- PAGE_13 -->\n### 1.3.  일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다.  (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다. ",
        "original_sentence": "<!-- PAGE_13 -->\n### 1.3. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 98,
        "word_count": 23,
        "page_number": 2,
        "window_text": "본 문서는 현재까지의 가용한 지식의 관점에서 작성하였다.  백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n <!-- PAGE_13 -->\n### 1.3.  일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다.  (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다.  여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다. ",
        "original_sentence": "일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "(규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 129,
        "word_count": 31,
        "page_number": 4,
        "window_text": "백신 제조 기술 및\n\n임상시험 설계 분야 모두 빠르게 변화하고 있는 점을 고려할 때, 본 문서는, 가용한 경우,\n\n식약처의 질환 특이적 가이드라인 및 권고사항을 포함하여, 관련된 최근 가이드라인과\n\n연계하여 읽어야 한다.\n\n <!-- PAGE_13 -->\n### 1.3.  일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다.  (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다.  여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다.  백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다. ",
        "original_sentence": "(규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 51,
        "word_count": 13,
        "page_number": 8,
        "window_text": "<!-- PAGE_13 -->\n### 1.3.  일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다.  (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다.  여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다.  백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다.  마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다. ",
        "original_sentence": "Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 146,
        "word_count": 32,
        "page_number": 8,
        "window_text": "일반적 고려사항\n\n모든 백신과 마찬가지로, 표적 병원체, 선택한 항원, 예방하고자 하는 질환 및 표적\n\n인구를 포함하여, mRNA의 계획한 임상적 사용에 관해 기술해야 한다.  (규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다.  여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다.  백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다.  마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다.  (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다. ",
        "original_sentence": "여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 205,
        "word_count": 48,
        "page_number": 8,
        "window_text": "(규제자들이\n\n14/72\n\n친숙한 기존의 승인된 백신 유형과 대비하여) mRNA 후보 백신의 새로운 구조 및\n\n제조를 감안할 때, 품질 및 안전성, 유효성에 대한 mRNA 백신 평가 시에는 다음과 같은\n\n사항들을 고려해야 한다.\n\n Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다.  여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다.  백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다.  마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다.  (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다.  poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다. ",
        "original_sentence": "백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 10,
        "window_text": "Ÿ 특히, 특정 mRNA 기술의 사용에 따른 연관성 있는 생물학적 특성을 설명해야\n\n한다.  여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다.  백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다.  마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다.  (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다.  poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다.  sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다. ",
        "original_sentence": "마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "(예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 92,
        "word_count": 23,
        "page_number": 22,
        "window_text": "여기에는, 예를 들면, 해당 mRNA의 표적 항원-특이적 반응뿐 아니라 선천성\n\n면역반응 유발 능력, 면역반응의 질과 양, 편향(예 : type 1 T helper(Th1) 또는 type\n\n2 T helper(Th2) 세포의 표현형), 생물 안정성이 포함된다.  백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다.  마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다.  (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다.  poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다.  sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다.  특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다. ",
        "original_sentence": "(예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 99,
        "word_count": 25,
        "page_number": 8,
        "window_text": "백신 설계의 근거에\n\n대한 타당성을 제시하기 위하여, 특정 병원체 및 질환과 관련이 있다고 판단되는\n\n면역의 종류(예방적 및 면역 병인적)에 대해 알려졌거나 사용 가능한 모든 정보를\n\nŸ 표적 항원이나 그 일부 그리고 코딩된 모든 단백질(예; 사이토카인)의 선택 및\n\n제안한 작용기전(제안한 방어기제)에 이들이 기여하는 바에 대하여 근거를\n\n명확하게 기술해야 한다.  마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다.  (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다.  poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다.  sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다.  특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다.  제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다. ",
        "original_sentence": "poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 114,
        "word_count": 23,
        "page_number": 8,
        "window_text": "마찬가지로, 표적 항원이 특정한 구조(conformation)로\n\n접히도록 하는 데 사용되는 코딩 서열과 같이, 표적 항원에 추가된 코딩 서열이나\n\n표적 항원의 변경을 선택한 근거를 제시해야 한다.  (예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다.  poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다.  sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다.  특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다.  제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다.  중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다. ",
        "original_sentence": "sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 122,
        "word_count": 29,
        "page_number": 8,
        "window_text": "(예상치 않은 ORF를 포함하여)\n\n모든 ORF를 확인해주는 주석을 단 전체 서열, 그리고 모든 기타 서열 요소를 (그\n\n사용에 대한 근거와 함께) 제공해야 한다.  poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다.  sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다.  특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다.  제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다.  중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다.  독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n",
        "original_sentence": "특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 8,
        "window_text": "poly(A) tail과 같이 특정 혹은\n\n특이적으로 설계된 비코딩 서열 및 선택한 5’ cap 구조 혹은 그 대체재와 같은\n\n구조적 요소의 사용에 대한 근거를 제시해야 한다.  sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다.  특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다.  제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다.  중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다.  독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다. ",
        "original_sentence": "제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 102,
        "word_count": 25,
        "page_number": 5,
        "window_text": "sa-mRNA의 경우에는 전달 후\n\n인체 세포 내에서 mRNA의 증폭이 가능하도록 백신 구조체 안에 코딩된 바이러스\n\n복제효소 유전자(viral replicase gene)에 대해 상세히 기술해야 한다.  특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다.  제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다.  중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다.  독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다.  필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다. ",
        "original_sentence": "중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 82,
        "word_count": 20,
        "page_number": 4,
        "window_text": "특정 비코딩\n\n및 구조적 요소들과 이들이 전반적인 작용기전에 기여하는 바에 대한 설명과 함께,\n\nŸ 최종 백신 제품 및 모든 첨가제(지질나노입자의 생성에 사용한 모든 구성성분을\n\n포함)의 제형화에 대해 기술해야 한다.  제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다.  중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다.  독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다.  필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다.  해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다. ",
        "original_sentence": "독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 204,
        "word_count": 49,
        "page_number": 15,
        "window_text": "제안한 최종 백신 제품의 조성 및 첨가제\n\n포함에 대하여 적절한 근거를 제시해야 한다.  중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다.  독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다.  필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다.  해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다.  관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다. ",
        "original_sentence": "Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 160,
        "word_count": 36,
        "page_number": 8,
        "window_text": "중간체와 최종 제품의 주요품질특성\n\n및 공정 중 관리, 멸균 절차에 대한 정보를 포함하여 지질나노입자 및 최종 백신\n\n제품(완제의약품)의 생산 방법에 대한 정보 또한 제공해야 한다.  독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다.  필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다.  해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다.  관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다.  다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4. ",
        "original_sentence": "필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 68,
        "word_count": 18,
        "page_number": 10,
        "window_text": "독성 및 면역원성\n\n15/72\n\n평가 시 지질나노입자에 대한 단독군을 포함해 독성 및 면역원성에 미치는 영향을\n\n평가하는 것이 필요할 수 있다.\n\n Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다.  필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다.  해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다.  관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다.  다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4.  특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3). ",
        "original_sentence": "해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 264,
        "word_count": 65,
        "page_number": 8,
        "window_text": "Ÿ 각 새로운 첨가제의 경우(정의에 대해서는 용어 참조), 이러한 첨가제 포함의\n\n근거에 대한 상세한 자료, 생산 방법(출발물질, 중간체, 원료에 대한 세부 사항 및\n\n관리를 포함), 안전성에 관한 비임상 및/또는 임상 연구에서 얻은 자료(그리고\n\nŸ 희석에 필요한 희석제뿐 아니라 계획한 투여, 투여경로, 새로운 투여기기에 대한\n\n설명 및 근거를 제공해야 한다.  필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다.  해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다.  관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다.  다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4.  특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3).  제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n",
        "original_sentence": "관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 15,
        "window_text": "필요하면 관련된 적합성(compatability) 연구를\n\nŸ 어떤 제조사의 mRNA 백신 제품은 표적 항원의 서열만을 변경했더라도 플랫폼\n\n기술로 간주될 수 있으나 각 백신의 관리 및 비임상시험, 임상 개발은 개별적으로\n\n고려해야 하며, 이 후보 백신의 독특한 특성을 감안해야 한다.  해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다.  관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다.  다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4.  특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3).  제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다. ",
        "original_sentence": "다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 148,
        "word_count": 32,
        "page_number": 2,
        "window_text": "해당 후보 백신의\n\nŸ 다가 후보 백신의 개발과 관련하여, 선례인 제품들의 개발을 참고하는 것이 도움이\n\n될 수도 있다.  관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다.  다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4.  특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3).  제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다.  일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n",
        "original_sentence": "특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3). "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 154,
        "word_count": 30,
        "page_number": 8,
        "window_text": "관련 예시로는, (a) 다가 백신이며 연례 균주 변경을 실시하는 계절\n\n독감 바이러스 백신, (b) 최초 허가 이후 9가 백신으로 변경된 4가 백신과 같은\n\nHPV 백신 및 3가 폴리오 백신, 다가 로타바이러스 백신, 다가 폐렴상구균\n\n백신으로, 이들은 동일한 (또는 관련된) 질환을 유발하는 서로 다른 균주들에 대해\n\n사용되며, 또는 (c) 디프테리아 및 파상풍-톡소이드 함유 백신이나 홍역, 이하선염,\n\n풍진 백신으로, 서로 다른 표적 질환에 대한 혼합 백신이 있다.  다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4.  특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3).  제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다.  일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n 제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9). ",
        "original_sentence": "제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 209,
        "word_count": 36,
        "page_number": 8,
        "window_text": "다수의 질환에 대한\n\n<!-- PAGE_15 -->\n### 1.4.  특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3).  제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다.  일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n 제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9).  자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n",
        "original_sentence": "RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 115,
        "word_count": 25,
        "page_number": 8,
        "window_text": "특이적 고려사항\n\n현재 임상 개발에서 혹은 코로나19 예방으로 널리 이용되고 있는 가장 진전된 mRNA\n\n백신은 생물학적 방식의 세포 배양보다 효소를 기반으로 생산되며, 따라서 개발자나\n\n규제당국자에게 친숙한 대부분의 다른 생물의약품의 생산과는 다르다(1, 3).  제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다.  일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n 제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9).  자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n 또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해). ",
        "original_sentence": "일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 72,
        "word_count": 14,
        "page_number": 8,
        "window_text": "제조는\n\n(플라스미드 DNA 백신과 같은 생물의약품을 생산하는 방식과 유사하게) 박테리아에서\n\n생산된 선형화된 DNA 플라스미드로 시작하거나, 또는 중합효소 연쇄반응(PCR) 혹은\n\n16/72\n\n다른 새로운 합성방식의 효소학적으로 생산된 선형 DNA 분자로 시작하게 된다.\n\n RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다.  일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n 제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9).  자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n 또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해).  그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다. ",
        "original_sentence": "제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9). "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 137,
        "word_count": 15,
        "page_number": 8,
        "window_text": "RNA의 제조를 플라스미드 DNA로부터 형성된 선형 분자에서 또는 다른 방식으로\n\n이미 생성된 선형 DNA 서열에서 시작하는가와는 관계없이, mRNA 생산은 선형 DNA\n\n주형(template)을\n\nmRNA\n\n분자로\n\n전사하는\n\nDNA-의존성\n\nRNA\n\n중합효소(DNA-dependent RNA polymerase)를 도구로 삼아 효소학적으로 in vitro로\n\n진행한다.  일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n 제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9).  자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n 또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해).  그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다.  mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4). ",
        "original_sentence": "자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n"
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 126,
        "word_count": 29,
        "page_number": 10,
        "window_text": "일반적으로 mRNA 서열은 코딩 영역, mRNA 전사를 조절하는 5’ 및 3’\n\n비번역영역(UTR), 5’ cap 및 3’ poly(A) tail과 같은 세포 mRNA의 일반적인 요소로\n\n구성되어 있다.\n\n 제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9).  자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n 또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해).  그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다.  mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4).  임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14). ",
        "original_sentence": "또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해). "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 102,
        "word_count": 22,
        "page_number": 10,
        "window_text": "제조에 사용되는 뉴클레오티드에는 자연 발생적인 뉴클레오시드 또는 변형되었거나\n\n합성된 뉴클레오시드를 포함할 수 있다(3, 9).  자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n 또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해).  그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다.  mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4).  임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14).  일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다. ",
        "original_sentence": "그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 8,
        "window_text": "자연 발생적 뉴클레오시드에 대한 변경의\n\n예시로는\n\n우리딘(uridine)을\n\n대체하는\n\n슈도우리딘(pseudouridine)\n\n또는\n\nN1-메틸슈도우리딘(N1-methylpseudouridine)의\n\n사용이\n\n포함된다(3,\n\n4,\n\n14).\n\n 또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해).  그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다.  mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4).  임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14).  일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다.  표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4). ",
        "original_sentence": "mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4). "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 107,
        "word_count": 19,
        "page_number": 23,
        "window_text": "또한\n\n(코딩된 아미노산의 변경 없이) 코돈 사용의 변경이나 최적화는 안정성에 영향을 주고\n\n인체 내의 mRNA 번역을 향상할 수 있다(예: 인체 세포에서 더 빈번하게 발견되는 운반\n\nRNA(tRNA)에 의한 번역을 위해).  그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다.  mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4).  임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14).  일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다.  표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4).  효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3). ",
        "original_sentence": "임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14). "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 10,
        "window_text": "그렇지 않으면, 단백질의 번역 속도를 낮추고 그\n\n결과 원하는 단백질 접힘(protein folding)이 가능해지도록, 빈도가 더 낮은 tRNA를\n\n위하여 코돈을 선택할 수 있다.  mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4).  임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14).  일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다.  표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4).  효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3).  마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다. ",
        "original_sentence": "일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 8,
        "window_text": "mRNA에 대한 일부 변경은 mRNA의 안정성을 높이고\n\n선천성 면역체계의 활성을 완화하기 위해 설계되었다(4).  임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14).  일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다.  표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4).  효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3).  마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다.  이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n",
        "original_sentence": "표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4). "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 113,
        "word_count": 19,
        "page_number": 8,
        "window_text": "임상 적응증에 따라서, 체내\n\n염증성 반응원성(inflammatory reactogenicity)을 유발할 수도 있는 선천성 면역반응을\n\n감소시키는 것이 바람직할 수 있다(3, 4, 14).  일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다.  표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4).  효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3).  마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다.  이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n 17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다. ",
        "original_sentence": "효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3). "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 10,
        "window_text": "일부 예방 백신의 경우, 선천성 면역반응 중\n\n일부는 원하는 후천성 면역반응을 증강하는 데 유용하다고 볼 수 있으며, 이에 맞추어\n\nmRNA를 설계할 수 있다.  표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4).  효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3).  마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다.  이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n 17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다.  일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다. ",
        "original_sentence": "마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 77,
        "word_count": 17,
        "page_number": 8,
        "window_text": "표적 항원을 코딩하는 유전자 서열은 개시 및 종결코돈을\n\n포함하고, 3’과 5‘ 비번역 부위(UTR)로 둘러싸여 있으며, 일반적으로 5’ cap 및 ‘ poly(A)\n\ntail이 있어야 한다(4).  효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3).  마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다.  이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n 17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다.  일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다.  그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n",
        "original_sentence": "이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 76,
        "word_count": 18,
        "page_number": 2,
        "window_text": "효소 처리를 통해, 또는 적절한 캡 유사체(appropriate cap\n\nanalogue)를 사용하여 in vitro transcription(IVT) 중에 mRNA에 cap을 추가할 수\n\n있다(3).  마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다.  이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n 17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다.  일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다.  그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n 이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n",
        "original_sentence": "17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 8,
        "window_text": "마찬가지로, 3’ poly(A) tail을 DNA 주형에 코딩하거나 IVT 이후 효소를\n\n사용하여 추가할 수 있다.  이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n 17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다.  일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다.  그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n 이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n 그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다. ",
        "original_sentence": "일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 8,
        "window_text": "이러한 설계상의 특징은 mRNA 원료의약품 및/또는 최종\n\n백신 완제의약품의 주요품질특성, 제조방법 및 관리시험에 영향을 줄 수 있다.\n\n 17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다.  일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다.  그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n 이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n 그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다.  mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n",
        "original_sentence": "그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 155,
        "word_count": 26,
        "page_number": 8,
        "window_text": "17/72\n\nmRNA 기반 백신의 안전성 및 유효성에 관한 규제 고려사항과 연관이 있는 것은 백신\n\n제품에서 RNA가 취하는 구조이다.  일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다.  그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n 이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n 그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다.  mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n RNA 기반 제품은 형태가 다를 수 있다. ",
        "original_sentence": "이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 8,
        "window_text": "일반적으로 이중 나선 형태인 DNA와는 달리,\n\n대부분의 RNA는 단일 가닥이다.  그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n 이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n 그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다.  mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n RNA 기반 제품은 형태가 다를 수 있다.  가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16). ",
        "original_sentence": "그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 81,
        "word_count": 18,
        "page_number": 8,
        "window_text": "그러나 RNA는, 그 서열에 따라서, 다양한 단일 가닥의\n\n고리(loop)를 사이에 두고 짧은 두 가닥의 분절로 구성된 복잡한 구조를 형성할 수 있다.\n\n 이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n 그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다.  mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n RNA 기반 제품은 형태가 다를 수 있다.  가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16).  그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23). ",
        "original_sentence": "mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "RNA 기반 제품은 형태가 다를 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 6,
        "window_text": "이것이 관련성이 있는 이유는, 엄밀하게 이중 가닥인 RNA(dsRNA)는 일부 RNA\n\n바이러스의\n\n유전체가\n\n취하는\n\n형태이며,\n\n세포가\n\n바이러스\n\n감염에\n\n대한\n\n선천적\n\n반응으로써 면역 반응원성(immune reactogenicity)을 촉발하도록 유도하기 때문이다.\n\n 그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다.  mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n RNA 기반 제품은 형태가 다를 수 있다.  가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16).  그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23).  지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24). ",
        "original_sentence": "RNA 기반 제품은 형태가 다를 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 81,
        "word_count": 19,
        "page_number": 4,
        "window_text": "그러나 내인성 세포 RNA는 부분적으로 두 가닥인 분절에도 불구하고 이런 효과를\n\n유발하지 않는다.  mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n RNA 기반 제품은 형태가 다를 수 있다.  가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16).  그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23).  지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24).  일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28). ",
        "original_sentence": "가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16). "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 133,
        "word_count": 24,
        "page_number": 8,
        "window_text": "mRNA 후보백신의 체내 효과(선천성 면역 촉발 가능성을 포함)는\n\n특성을 분석하고, 백신 설계 및 비임상 연구, 임상시험에서 다루어야 한다.\n\n RNA 기반 제품은 형태가 다를 수 있다.  가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16).  그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23).  지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24).  일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28).  폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다. ",
        "original_sentence": "그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23). "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 55,
        "word_count": 12,
        "page_number": 8,
        "window_text": "RNA 기반 제품은 형태가 다를 수 있다.  가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16).  그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23).  지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24).  일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28).  폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다.  이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n",
        "original_sentence": "지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24). "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 8,
        "window_text": "가장 진전된 임상 후보 백신들 및 널리\n\n사용되고 있는 코로나19 백신들은 표적 항원을 코딩하는 mRNA의 형태를 취하고\n\n있다(15, 16).  그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23).  지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24).  일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28).  폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다.  이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n 지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다. ",
        "original_sentence": "일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28). "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 108,
        "word_count": 26,
        "page_number": 8,
        "window_text": "그러나 mRNA(그리고 일반적으로 RNA)는 뉴클레아제에 의해 분해될 수\n\n있으므로,\n\n가장\n\n진전된\n\nmRNA\n\n후보백신들\n\n및\n\n널리\n\n사용되고\n\n있는\n\n백신들은\n\n지질나노입자로 제형화하여 안정성과 전달을 돕는다(13, 17~23).  지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24).  일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28).  폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다.  이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n 지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다.  지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n",
        "original_sentence": "폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 57,
        "word_count": 16,
        "page_number": 8,
        "window_text": "지질나노입자는 조성 및\n\n채택한 지질의 종류, 사용한 제조공정에 따라서 다른 종류가 있다(24).  일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28).  폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다.  이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n 지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다.  지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n 서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다. ",
        "original_sentence": "이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 78,
        "word_count": 14,
        "page_number": 17,
        "window_text": "일부는 아직\n\nmRNA의 전달을 위해 사용하지 않았을 수 있다(25~28).  폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다.  이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n 지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다.  지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n 서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다.  일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다. ",
        "original_sentence": "지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 44,
        "word_count": 7,
        "page_number": 8,
        "window_text": "폴리머 및 폴리펩타이드를\n\n사용하는 다른 안정화 및 전달 시스템, 그리고 다른 지질-기반 시스템, 또는 폴리머와\n\n지질-기반 시스템들의 결합 역시 미래에 mRNA 전달을 위해 개발될 수 있다.  이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n 지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다.  지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n 서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다.  일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다.  그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다. ",
        "original_sentence": "지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 52,
        "word_count": 10,
        "page_number": 10,
        "window_text": "이러한 약물\n\n전달 시스템은 또한 필요 시 맞춤형 세포성 반응을 위해 표면 변형이 가능할 수 있다.\n\n 지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다.  지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n 서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다.  일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다.  그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다.  이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다. ",
        "original_sentence": "서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 91,
        "word_count": 19,
        "page_number": 8,
        "window_text": "지질나노입자 혼합물은 완제의약품(drug product)의 생산에서 중간체로 정의되나,\n\n일부 품목의 경우 원료의약품으로 정의될 수 있다.  지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n 서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다.  일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다.  그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다.  이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다.  따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n",
        "original_sentence": "일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 10,
        "window_text": "지질나노입자를 형성하는 지질은\n\n최종\n\n백신이나\n\n완제의약품의\n\n첨가제이다.\n\n 서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다.  일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다.  그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다.  이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다.  따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n 일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다. ",
        "original_sentence": "그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 48,
        "word_count": 13,
        "page_number": 6,
        "window_text": "서로\n\n다른\n\n지질을\n\n기반으로\n\n하는\n\n지질나노입자 제조는 완제의약품 제조공정의 일부이다.  일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다.  그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다.  이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다.  따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n 일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다.  그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다. ",
        "original_sentence": "이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 112,
        "word_count": 25,
        "page_number": 4,
        "window_text": "일부 지질나노입자는 그\n\n조성에 따라서 면역조절 효과도 발휘할 수 있으며(27~30), 일부 지질은 지질나노입자로\n\n제형화하지 않고 면역증강제로 작용할 수 있다.  그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다.  이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다.  따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n 일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다.  그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다.  이후 ‘1.3. ",
        "original_sentence": "따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 50,
        "word_count": 13,
        "page_number": 6,
        "window_text": "그럼에도, 백신에 대하여 면역조절\n\n작용을 하는 백신 면역증강제는 또한 첨가제로 간주한다.  이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다.  따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n 일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다.  그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다.  이후 ‘1.3.  일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n",
        "original_sentence": "일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 100,
        "word_count": 24,
        "page_number": 8,
        "window_text": "이와 유사하게, 앞서 논한\n\n바와 같이, RNA 자체가 면역조절 작용을 할 수 있다.  따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n 일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다.  그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다.  이후 ‘1.3.  일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n 다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n",
        "original_sentence": "그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "이후 ‘1.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 4,
        "window_text": "따라서, 두 가지 구성 요소(mRNA\n\n18/72\n\n및 지질나노입자에서 지질)는 모두 백신의 작용기전에 기여할 수 있으며, 이에 따른\n\n영향을 주요품질특성과 비임상 및 임상 평가에서 고려해야 한다.\n\n 일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다.  그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다.  이후 ‘1.3.  일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n 다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n 다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다. ",
        "original_sentence": "이후 ‘1.3. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 2,
        "window_text": "일부 후보 백신은 서로 다른 항원을 코딩하는 다양한 mRNA를 함유하고 있을 수\n\n있다.  그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다.  이후 ‘1.3.  일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n 다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n 다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다.  추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다. ",
        "original_sentence": "일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 8,
        "window_text": "그 예시로는 동일한 병원체에서 추출한 다수의 항원, 또는 동일한 병원체의 서로\n\n다른 균주나 혈청형을 대표하는 동일 항원, 서로 다른 병원체에서 추출한 다수의 항원이\n\n포함된다.  이후 ‘1.3.  일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n 다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n 다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다.  추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다.  만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3. ",
        "original_sentence": "다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 194,
        "word_count": 43,
        "page_number": 8,
        "window_text": "이후 ‘1.3.  일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n 다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n 다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다.  추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다.  만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3.  비임상 평가의\n\n가속화’, ‘4.1. ",
        "original_sentence": "다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 97,
        "word_count": 19,
        "page_number": 8,
        "window_text": "일반적 고려사항’에서 논하고 있는 바와 같이, 이러한 백신 개발의\n\n선례가 없는 것은 아니다.\n\n 다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n 다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다.  추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다.  만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3.  비임상 평가의\n\n가속화’, ‘4.1.  안전성 및 면역원성 평가’ 참고). ",
        "original_sentence": "추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 116,
        "word_count": 28,
        "page_number": 8,
        "window_text": "다른 혼합 백신이나 다가 백신과 마찬가지로, 각각의 mRNA는 최종 완제의약품에서\n\n혼합되는\n\n각각의\n\n원료의약품으로\n\n간주할\n\n것이다.\n\n 다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다.  추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다.  만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3.  비임상 평가의\n\n가속화’, ‘4.1.  안전성 및 면역원성 평가’ 참고).  완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n",
        "original_sentence": "만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "비임상 평가의\n\n가속화’, ‘4.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 21,
        "word_count": 4,
        "page_number": 4,
        "window_text": "다른\n\n혼합\n\n백신이나\n\n다가\n\n백신에서처럼 각 표적 항원에 대한 mRNA의 양, 그리고 각각의 발현 효율 및 결과적인\n\n면역반응은, 모든 표적 항원의 발현과 면역반응에 대한 간섭을 방지하고 전체 백신에\n\n대한\n\n필요한\n\n균주(혹은\n\n항원)-특이적\n\n면역반응을\n\n보장하기\n\n위해,\n\n나머지\n\n다른\n\nmRNA들에 대하여 반드시 대조해 보아야 한다.  추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다.  만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3.  비임상 평가의\n\n가속화’, ‘4.1.  안전성 및 면역원성 평가’ 참고).  완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다. ",
        "original_sentence": "비임상 평가의\n\n가속화’, ‘4.1. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "안전성 및 면역원성 평가’ 참고). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 8,
        "window_text": "추가로 최대내약(maximally tolerable)\n\nmRNA (및 지질나노입자) 총량을 초과함 없이, 각 코딩된 표적 항원에 대한 적절한\n\n용량의 달성을 고려해야 한다.  만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3.  비임상 평가의\n\n가속화’, ‘4.1.  안전성 및 면역원성 평가’ 참고).  완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다.  그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다. ",
        "original_sentence": "안전성 및 면역원성 평가’ 참고). "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 122,
        "word_count": 28,
        "page_number": 8,
        "window_text": "만일 다가 백신 혹은 혼합 백신이 플랫폼 기술에\n\n기반한다면 주어진 집단에서의 최대내약용량은 그 플랫폼에 기반한 이전의 백신 혹은\n\n후보 백신에 의해 제안될 수 있다(이에 대한 추가적인 논의사항은 ‘3.3.  비임상 평가의\n\n가속화’, ‘4.1.  안전성 및 면역원성 평가’ 참고).  완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다.  그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다.  따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n",
        "original_sentence": "완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 73,
        "word_count": 16,
        "page_number": 8,
        "window_text": "비임상 평가의\n\n가속화’, ‘4.1.  안전성 및 면역원성 평가’ 참고).  완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다.  그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다.  따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n 일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31). ",
        "original_sentence": "mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 100,
        "word_count": 22,
        "page_number": 8,
        "window_text": "안전성 및 면역원성 평가’ 참고).  완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다.  그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다.  따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n 일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31).  이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다. ",
        "original_sentence": "그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 86,
        "word_count": 20,
        "page_number": 8,
        "window_text": "완제의약품의 적절한 품질관리를\n\n보장하고, 최종 백신 내의 각 mRNA 성분(각 원료의약품)의 관리를 위해 사용한\n\n분석법의 적합성 확인을 위해, 다가 백신의 제조, 관리 및 안전성 역시 추가적인 고려가\n\n필요하다.\n\n mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다.  그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다.  따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n 일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31).  이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다.  그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n",
        "original_sentence": "따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 121,
        "word_count": 19,
        "page_number": 8,
        "window_text": "mRNA와 지질나노입자 사이의 상호작용은 지질나노입자의 지질 조성뿐 아니라\n\nmRNA의 길이 및 이차구조에 따라 달라질 수 있다.  그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다.  따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n 일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31).  이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다.  그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n 현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18). ",
        "original_sentence": "일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31). "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 126,
        "word_count": 24,
        "page_number": 8,
        "window_text": "그러므로, 다른 mRNA를 사용하는\n\n경우, mRNA를 감싸는 지질나노입자 결과물의 입자크기 및 형태학적 특성, 표면\n\n특성(예: 전하), 그리고 봉입 효율이 변경될 수도 있다.  따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n 일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31).  이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다.  그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n 현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18).  표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다. ",
        "original_sentence": "이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다. "
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 8,
        "window_text": "따라서 최종 백신의 바람직한\n\n특성에 대한 이해를 위해 mRNA와 지질나노입자 두 가지 모두의 주요품질특성 및\n\n이화학적 성질에 대한 고려가 필요하다.\n\n 일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31).  이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다.  그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n 현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18).  표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다.  예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다. ",
        "original_sentence": "그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 38,
        "word_count": 5,
        "page_number": 4,
        "window_text": "일부 후보 제품은 mRNA의 자가 증폭(self-amplifying)(소위 self-amplifying mRNA\n\n19/72\n\n또는 sa-mRNA)을 허용하는 데 필요한 구성성분을 포함하고 있다(8, 18, 31).  이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다.  그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n 현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18).  표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다.  예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다.  또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n",
        "original_sentence": "현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18). "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 99,
        "word_count": 24,
        "page_number": 8,
        "window_text": "이러한\n\n제품은, 표적 항원 외에도, 동일한 또는 다른 mRNA 분자 중 한 곳에 (현재까지는\n\n알파바이러스(alphavirus) 유래) 복제효소 단백질(replicase protein)을 위한 유전자\n\n서열을 지니고 있다.  그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n 현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18).  표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다.  예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다.  또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n (바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다. ",
        "original_sentence": "표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 8,
        "window_text": "그 결과, 항원을 코딩하는 mRNA는 체내 복제가 가능하며, 높은\n\n수준의\n\n표적\n\n항원\n\n발현이\n\n진행된다.\n\n 현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18).  표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다.  예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다.  또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n (바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다.  다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18). ",
        "original_sentence": "예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 173,
        "word_count": 45,
        "page_number": 5,
        "window_text": "현재의\n\nsa-mRNA\n\n역시\n\n지질나노입자로\n\n제형화한다(18).  표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다.  예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다.  또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n (바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다.  다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18).  또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다. ",
        "original_sentence": "또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "(바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 87,
        "word_count": 14,
        "page_number": 17,
        "window_text": "표적 항원이 별도의 mRNA 분자, 또는 복제효소 유전자 서열과 동일한\n\n분자에 코딩되어 있다면, sa-mRNA의 설계로 인해 백신 안전성 및 유효성에 영향이\n\n있을 수 있다.  예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다.  또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n (바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다.  다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18).  또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다.  따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다. ",
        "original_sentence": "(바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 143,
        "word_count": 27,
        "page_number": 8,
        "window_text": "예를 들면 지질나노입자의 입자크기 및 형태학적 특성은 봉입된\n\nmRNA의 크기에 따라 달라질 수 있다.  또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n (바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다.  다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18).  또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다.  따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다.  다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다. ",
        "original_sentence": "다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18). "
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 130,
        "word_count": 31,
        "page_number": 8,
        "window_text": "또한, 안전성 프로파일의 차이를 가져올 수도\n\n있고 그래서 백신 설계 및 평가에 있어서 고려될 수 있는 dsRNA의 양, 선천성 면역반응,\n\nmRNA 반감기 등뿐 아니라 발현 효율 정도의 차이로 인해, 동일한 수준의 유효성\n\n달성을 위해 필요한 mRNA의 총량은 위의 두 가지 설계 사이에 달라질 수 있다.\n\n (바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다.  다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18).  또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다.  따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다.  다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다.  그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n",
        "original_sentence": "또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다. "
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 61,
        "word_count": 14,
        "page_number": 5,
        "window_text": "(바이러스\n\n구조\n\n단백질로\n\n봉입된)\n\nviral\n\nreplicon과\n\n대조적으로,\n\nsa-mRNA는\n\n지질나노입자 또는 다른 전달 시스템으로 전달된다.  다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18).  또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다.  따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다.  다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다.  그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n 현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다. ",
        "original_sentence": "따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 147,
        "word_count": 32,
        "page_number": 8,
        "window_text": "다시 말해, sa-mRNA는 세포 간의\n\n전달을 위해 제형에 의존하는 반면, virus replicon은 바이러스 수용체를 통해 세포에\n\n진입하기 때문에, sa-mRNA를 흡입하는 세포와 viral replicon을 흡입하는 세포는 다를\n\n것이다(18).  또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다.  따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다.  다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다.  그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n 현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다.  발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다. ",
        "original_sentence": "다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 64,
        "word_count": 12,
        "page_number": 8,
        "window_text": "또한 RNA 기반 제품은 벡터 백신이나 생백신으로 사용되는 바이러스의\n\n구조 단백질을 코딩하는 유전자를 포함하고 있지 않기 때문에, (RNA 바이러스에 대한)\n\n바이러스 벡터 백신 및 바이러스 생백신 두 가지 모두와 대조를 이룬다.  따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다.  다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다.  그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n 현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다.  발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다.  그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다. ",
        "original_sentence": "그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 63,
        "word_count": 15,
        "page_number": 8,
        "window_text": "따라서, 다양한\n\n유사 제품이 개발 중이며, 이들 사이의 차이점은 대체로 생물학이나 설계에 따라\n\n결정된다.  다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다.  그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n 현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다.  발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다.  그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다.  앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n",
        "original_sentence": "현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 8,
        "window_text": "다른 유사한 기술로는 개발 중인 원형 RNA 제품, cap 대신 내부 리보솜 진입\n\n부위(IRES)를 사용하는 mRNA, 그리고 폴리머와 폴리펩티드 시스템(또는 폴리머와\n\n지질-기반 시스템의 결합)을 사용한 다른 약물 전달 시스템으로 봉입된 RNA가\n\n포함된다.  그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n 현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다.  발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다.  그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다.  앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n 다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n",
        "original_sentence": "발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 8,
        "window_text": "그러나 현 가이드라인의 범위는 지금으로서는 지질나노입자로 봉입된\n\nmRNA 또는 sa-mRNA로 제한하고 있다.\n\n 현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다.  발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다.  그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다.  앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n 다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n 21/72\n\n<!-- PAGE_21 -->\n## 2. ",
        "original_sentence": "그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 151,
        "word_count": 23,
        "page_number": 8,
        "window_text": "현재의 mRNA 백신은 발현을 위해 근육 혹은 면역세포로 흡수되는 것으로 제안되고\n\n있다는 점에 유의해야 한다.  발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다.  그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다.  앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n 다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n 21/72\n\n<!-- PAGE_21 -->\n## 2.  품질 평가\n\n<!-- PAGE_21 -->\n### 2.1. ",
        "original_sentence": "앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n"
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 90,
        "word_count": 20,
        "page_number": 8,
        "window_text": "발현되는 표적 항원은 면역세포 특히 수지상 세포 등\n\n항원제시세포와 같은 면역세포에 의해 제시된다.  그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다.  앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n 다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n 21/72\n\n<!-- PAGE_21 -->\n## 2.  품질 평가\n\n<!-- PAGE_21 -->\n### 2.1.  일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다. ",
        "original_sentence": "다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "21/72\n\n<!-- PAGE_21 -->\n## 2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 21,
        "window_text": "그러나 현재 mRNA 백신의 설계는\n\n20/72\n\n오로지 이러한 세포들만을 표적으로 삼도록 제한한 것은 아니다.  앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n 다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n 21/72\n\n<!-- PAGE_21 -->\n## 2.  품질 평가\n\n<!-- PAGE_21 -->\n### 2.1.  일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다.  따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n",
        "original_sentence": "21/72\n\n<!-- PAGE_21 -->\n## 2. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "품질 평가\n\n<!-- PAGE_21 -->\n### 2.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 21,
        "window_text": "앞으로의 전달\n\n시스템은 mRNA가 특정 세포나 조직을 겨냥할 수 있도록 설계할 것으로 예상된다(예:\n\n리간드/모티프(ligand/motif)를\n\n지질나노입자\n\n표면에\n\n부착할\n\n수도\n\n있는\n\n표면을\n\n변경한(surface-modified)\n\n지질나노입자를\n\n사용).\n\n 다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n 21/72\n\n<!-- PAGE_21 -->\n## 2.  품질 평가\n\n<!-- PAGE_21 -->\n### 2.1.  일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다.  따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n 이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다. ",
        "original_sentence": "품질 평가\n\n<!-- PAGE_21 -->\n### 2.1. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 113,
        "word_count": 24,
        "page_number": 2,
        "window_text": "다른\n\n선천성\n\n면역자극\n\n효과를\n\n불러오는 이화학적 특성에 대한 변경은 mRNA 또는 sa-mRNA 백신의 안전성이나\n\n유효성에 추가적 영향을 줄 수 있다.\n\n 21/72\n\n<!-- PAGE_21 -->\n## 2.  품질 평가\n\n<!-- PAGE_21 -->\n### 2.1.  일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다.  따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n 이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다.  출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다. ",
        "original_sentence": "일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 92,
        "word_count": 22,
        "page_number": 2,
        "window_text": "21/72\n\n<!-- PAGE_21 -->\n## 2.  품질 평가\n\n<!-- PAGE_21 -->\n### 2.1.  일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다.  따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n 이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다.  출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다.  품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다. ",
        "original_sentence": "따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 169,
        "word_count": 40,
        "page_number": 21,
        "window_text": "품질 평가\n\n<!-- PAGE_21 -->\n### 2.1.  일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다.  따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n 이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다.  출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다.  품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다.  이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n",
        "original_sentence": "이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 5,
        "window_text": "일반적 사항\n\n모든 mRNA 백신은 생물의약품으로 규제하며, 다른 생물의약품과 마찬가지로\n\n출발물질 및 원료약품, 첨가제 그리고 제조공정에 대한 적절한 관리는 최종 제품에 대한\n\n관리만큼이나 중요하다.  따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n 이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다.  출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다.  품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다.  이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n 여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n",
        "original_sentence": "출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 104,
        "word_count": 23,
        "page_number": 5,
        "window_text": "따라서 규제 고려사항은 원료의약품과 최종 백신 자체에 대한\n\n포괄적인 특성분석 및 출하 시험뿐 아니라 백신의 관리전략 및 제조공정에 상당한\n\n주안점을 두고 있다.\n\n 이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다.  출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다.  품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다.  이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n 여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n 임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다. ",
        "original_sentence": "품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 82,
        "word_count": 20,
        "page_number": 8,
        "window_text": "이러한 공정을 통하여, 제조 개시부터 종료까지 각 배치나 로트에 대해 품질\n\n모니터링이 가능하도록, (적용 가능하다면, 핵심 및 비핵심적 품질특성을 측정하는\n\n공정 중 시험을 포함하여) (허용 가능한 기준을 설정한) 다수의 공정 중 모니터링\n\n및/또는 관리 시험을 위험 기반 접근법으로 수립해야 한다.  출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다.  품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다.  이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n 여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n 임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다.  즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다. ",
        "original_sentence": "이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 21,
        "window_text": "출하 규격 및 특성 분석\n\n방법은 임상시험 승인이나 품목허가 일부로서 식약처의 동의가 필요하다.  품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다.  이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n 여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n 임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다.  즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다.  긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다. ",
        "original_sentence": "여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 8,
        "window_text": "품목허가를\n\n위한 원료의약품 및 완제의약품의 출하 규격은 임상시험에서 사용한 로트에 대해\n\n획득한 결과뿐 아니라 상업적 제조공정으로 제조한 제품에 대한 시험을 기반으로\n\n설정해야 한다.  이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n 여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n 임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다.  즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다.  긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다.  생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다. ",
        "original_sentence": "임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 81,
        "word_count": 22,
        "page_number": 5,
        "window_text": "이러한 규격 및 특성분석 방법에서는 안전하고 효과적인 백신을\n\n제공하는 데 필요한 일관된 품질을 보장할 수 있는 핵심 파라미터를 다루어야 한다.\n\n 여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n 임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다.  즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다.  긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다.  생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다.  (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다. ",
        "original_sentence": "즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 79,
        "word_count": 17,
        "page_number": 8,
        "window_text": "여기에는 함량, 확인, 순도, mRNA 완전성, 역가, 기타 품질 및 안전성 파라미터,\n\n안정성을 평가하는 방법이 포함될 것이다.\n\n 임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다.  즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다.  긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다.  생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다.  (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다.  잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다. ",
        "original_sentence": "긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 8,
        "window_text": "임상시험에서 사용할 mRNA 백신 역시 임상 개발 단계에 적합한 GMP 조건 하에서\n\n준비해야 한다.  즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다.  긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다.  생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다.  (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다.  잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다.  엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n",
        "original_sentence": "생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "(인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 18,
        "window_text": "즉, 제조 및 관리 절차가 개발 중이며 아직 밸리데이션되지 않았을 수\n\n있는 초기 개발 단계에서는 완전한 GMP 준수가 가능하지 않을 수 있다.  긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다.  생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다.  (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다.  잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다.  엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n 임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다. ",
        "original_sentence": "(인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 78,
        "word_count": 16,
        "page_number": 8,
        "window_text": "긴급상황\n\n하에서 그리고 유익성/위해성 평가를 토대로, 완전한 GMP 준수하에 준비되지 못한\n\n출발물질의 사용을 고려하도록 허용할 수 있다.  생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다.  (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다.  잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다.  엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n 임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다.  원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n",
        "original_sentence": "잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 79,
        "word_count": 20,
        "page_number": 8,
        "window_text": "생산 및 관리에 사용한 모든 시약의\n\n품질 및 정확한 확인(identity)을 확보하는 데에 적절한 주의를 기울여야 한다.  (인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다.  잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다.  엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n 임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다.  원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n 규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다. ",
        "original_sentence": "엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 8,
        "window_text": "(인간을\n\n포함한) 동물 유래 성분의 기원/유래에 구매에 특별한 주의가 필요하다.  잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다.  엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n 임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다.  원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n 규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다.  임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n",
        "original_sentence": "임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 104,
        "word_count": 24,
        "page_number": 8,
        "window_text": "잠재적인\n\n외래성 인자의 부정(freedom)이나 관리 역시 적절한 증거 및 위해성 평가로 뒷받침하며\n\n22/72\n\n관심을 기울여야 한다.  엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n 임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다.  원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n 규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다.  임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n 예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다. ",
        "original_sentence": "원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 2,
        "window_text": "엔도톡신 및 안정성, 무균에 대한 시험과 같이 생물의약품의\n\n품질관리를 위한 일반 요건 중 많은 부분이 mRNA 백신에도 적용될 수 있다.\n\n 임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다.  원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n 규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다.  임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n 예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다.  모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n",
        "original_sentence": "규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 81,
        "word_count": 17,
        "page_number": 8,
        "window_text": "임상시험에서 수용 가능한 성능을 증명한 로트에 대한 시험 결과를 기반으로 상업적\n\n규격을 설정해야 한다.  원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n 규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다.  임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n 예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다.  모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n 모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다. ",
        "original_sentence": "임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 223,
        "word_count": 53,
        "page_number": 8,
        "window_text": "원료약품 및 첨가제에 대한 관리 그리고 제조 중간체에 대한\n\n공정 중 관리를 포함하여 지질나노입자로 제형화한 mRNA 또는 sa-mRNA에 특이적인\n\n추가 관리에 대해 기술해야 한다.\n\n 규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다.  임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n 예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다.  모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n 모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다.  달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다. ",
        "original_sentence": "예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다. "
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 88,
        "word_count": 19,
        "page_number": 8,
        "window_text": "규제당국이 요구하는 세부사항의 수준은 제품 개발이 진전됨에 따라 증가함을\n\n인지해야 한다.  임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n 예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다.  모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n 모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다.  달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다.  이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n",
        "original_sentence": "모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 79,
        "word_count": 20,
        "page_number": 8,
        "window_text": "임상 개발의 시작 단계에서는, 임상시험 신청서에 수록한 정보는\n\n완제의약품 및 제조공정에서 유래하는 위해성의 평가가 가능하도록 적합해야 한다.\n\n 예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다.  모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n 모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다.  달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다.  이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n 보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n",
        "original_sentence": "모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 149,
        "word_count": 32,
        "page_number": 8,
        "window_text": "예를 들면, 공정 중 사용한 모든 물질에 대한 동정(identification) 및 규격, 생물학적\n\n원천의 물질에서 유래하는 위해성의 평가, 제조시설의 인증 또는 단계에 적합한 GMP\n\n준수, 공정 및 시험에 대한 간략한 설명, 제안한 임상시험에 사용할 백신 로트(그리고\n\n적용 가능하다면 임상시험 시 접종을 위한 위약 혹은 다른 대조약)의 시험 결과, 예비\n\n안정성 시험 결과가 포함될 것이다.  모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n 모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다.  달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다.  이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n 보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n 임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다. ",
        "original_sentence": "달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 95,
        "word_count": 18,
        "page_number": 5,
        "window_text": "모든 백신과 마찬가지로, 핵심 임상시험의 경우,\n\nmRNA 백신의 품질(제조 및 관리)에 관해 제공하는 세부정보의 수준이 상당히 상향될\n\n것으로 예상한다.\n\n 모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다.  달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다.  이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n 보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n 임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다.  최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7. ",
        "original_sentence": "이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 8,
        "window_text": "모든 mRNA 백신이 플랫폼 기술을 기반으로 제작된다고 볼 수는 없는 반면, 특정\n\n제조사의 기술은 어느 범위까지는 그렇다고 볼 수도 있다.  달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다.  이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n 보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n 임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다.  최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7.  비임상 평가’ 참조). ",
        "original_sentence": "보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 148,
        "word_count": 31,
        "page_number": 8,
        "window_text": "달리 말하면, 새로운 mRNA\n\n후보백신은, (비록 각 후보 백신에 대한 최적화를 통한) 제조공정이나 시험(확인시험\n\n혹은 역가시험은 제외), 규격이 본질적으로 변경되지 않는다면, 이전의 mRNA 후보\n\n백신이나 허가된 백신으로 획득한 자료로써 뒷받침할 수도 있다.  이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n 보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n 임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다.  최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7.  비임상 평가’ 참조).  제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다. ",
        "original_sentence": "임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 79,
        "word_count": 17,
        "page_number": 8,
        "window_text": "이는 서열만\n\n변경되었으나(이 변경이 새로운 mRNA 결과물의 크기나 이차구조를 변경할 수 있음)\n\n지질나노입자와의\n\n상호작용은\n\n변경하지\n\n않은\n\n경우에\n\n해당된다.\n\n 보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n 임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다.  최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7.  비임상 평가’ 참조).  제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다.  이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다. ",
        "original_sentence": "최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "비임상 평가’ 참조). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 23,
        "window_text": "보조자료에는\n\n제조공정, 시험, 규격, 비임상 및 임상 안전성에 대하여 획득한 자료가 포함될 수도 있다.\n\n 임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다.  최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7.  비임상 평가’ 참조).  제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다.  이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다.  이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다. ",
        "original_sentence": "비임상 평가’ 참조). "
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 115,
        "word_count": 24,
        "page_number": 8,
        "window_text": "임상 로트 제조 중 제품 조성(product composition)에 대한 변경(예: mRNA 서열 변경\n\n또는 결합가(valency) 증가, 첨가제 변경, 보존제 추가) 또는 제조 변경(예: 공정이나\n\n제조소, 제조 규모의 변경)에 대하여 적절히 서술해야 한다.  최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7.  비임상 평가’ 참조).  제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다.  이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다.  이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다.  허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n",
        "original_sentence": "제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 88,
        "word_count": 22,
        "page_number": 8,
        "window_text": "최종 제품 조성이 어떻게\n\n변경되었는가에 따라(예: 새로운 첨가제 추가), 새로운 비임상 연구가 필요할 수도\n\n23/72\n\n있다(아래 ‘7.  비임상 평가’ 참조).  제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다.  이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다.  이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다.  허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n 백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n",
        "original_sentence": "이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 67,
        "word_count": 12,
        "page_number": 28,
        "window_text": "비임상 평가’ 참조).  제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다.  이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다.  이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다.  허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n 백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n <!-- PAGE_23 -->\n### 2.2. ",
        "original_sentence": "이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 23,
        "window_text": "제조공정 변경(예: 생산 규모 증가 또는 정제 공정\n\n변경)의 경우, 변경을 적용한 원료의약품 및 완제의약품을 이전 공정을 사용해 생산한\n\n결과물과 비교동등성(comparability) 평가를 해야 한다.  이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다.  이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다.  허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n 백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n <!-- PAGE_23 -->\n### 2.2.  제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n",
        "original_sentence": "허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 100,
        "word_count": 21,
        "page_number": 8,
        "window_text": "이러한 비교동등성 연구에는\n\n동물모델에서 도출한 면역원성 자료 및 이화학적 분석 결과, 공정 및 제품 관련 불순물\n\n시험, 안정성 자료가 포함될 수도 있다.  이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다.  허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n 백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n <!-- PAGE_23 -->\n### 2.2.  제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n 대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다. ",
        "original_sentence": "백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n"
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "<!-- PAGE_23 -->\n### 2.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 23,
        "window_text": "이와 관련해서는 ‘생물의약품의 제조방법\n\n변경에 따른 비교동등성 평가 가이드라인(식약처, 2019)’를 참고해야 한다.  허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n 백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n <!-- PAGE_23 -->\n### 2.2.  제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n 대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다.  생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다. ",
        "original_sentence": "<!-- PAGE_23 -->\n### 2.2. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 2,
        "window_text": "허가 후\n\n제품에 실시한 변경은 동 가이드라인에서 열거한 요건을 따라야 한다.\n\n 백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n <!-- PAGE_23 -->\n### 2.2.  제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n 대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다.  생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다.  ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n",
        "original_sentence": "제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 124,
        "word_count": 19,
        "page_number": 8,
        "window_text": "백신에 활성 원료의약품으로 사용된 정의된 재조합 핵산은, 그 유래가 생물학적이든\n\n또는 합성된 것이든, 요청 시에는 국제 비특허명(INN)을 부여받을 수도 있다(32, 33).\n\n <!-- PAGE_23 -->\n### 2.2.  제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n 대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다.  생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다.  ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n 일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest). ",
        "original_sentence": "대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 77,
        "word_count": 16,
        "page_number": 8,
        "window_text": "<!-- PAGE_23 -->\n### 2.2.  제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n 대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다.  생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다.  ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n 일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest).  IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n",
        "original_sentence": "생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 19,
        "window_text": "제조에 관한 사항\n\nmRNA 기반 제품은 새로운 생물의약품 제품군을 대표하며 전통적인 생물의약품과\n\n다르게\n\n제조된다.\n\n 대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다.  생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다.  ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n 일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest).  IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다. ",
        "original_sentence": "ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 90,
        "word_count": 12,
        "page_number": 8,
        "window_text": "대부분의\n\n이러한\n\n생물의약품은\n\n세포-기반(또는\n\n유기체-기반)\n\n시스템으로\n\n증식\n\n또는\n\n생산하는\n\n반면\n\nmRNA\n\n구성성분은\n\nin\n\nvitro\n\ntranscription(IVT)를 통해 효소 공정으로 제조한다.  생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다.  ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n 일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest).  IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다.  DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다. ",
        "original_sentence": "일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest). "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 128,
        "word_count": 30,
        "page_number": 8,
        "window_text": "생산공정에서는 재조합 효소 및\n\n뉴클레오시드 3인산염으로 DNA-의존성 RNA 전사를 이끌기 위하여 선형 DNA\n\n주형을 사용하게 된다.  ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n 일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest).  IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다.  DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다.  정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다. ",
        "original_sentence": "IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n"
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 145,
        "word_count": 32,
        "page_number": 23,
        "window_text": "ORF뿐 아니라 UTR의 구조와 서열, 그리고 cap과 poly(A)\n\ntail의 길이를 선택한 근거를 제시해야 한다.\n\n 일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest).  IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다.  DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다.  정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다.  불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n",
        "original_sentence": "DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 92,
        "word_count": 22,
        "page_number": 8,
        "window_text": "일반적으로,\n\nmRNA가\n\n전사되면,\n\nmRNA를\n\n정제하기\n\n전에\n\n디옥시리보핵산\n\n가수분해효소(DNase)를 사용하여 주형 DNA를 절단한다(digest).  IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다.  DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다.  정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다.  불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n 공정개발 및 공정 중 관리’ 참고).\n\n",
        "original_sentence": "DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 5,
        "window_text": "IVT 공정 중 cap과\n\npoly(A) tail 요소를 추가하지 않거나, 또는 더 긴 poly(A) tail이 필요하다면, 이들을\n\n합성 이후 그러나 정제 이전에 효소 반응을 통해 추가할 수 있다(8, 14, 34, 35).\n\n DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다.  DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다.  정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다.  불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n 공정개발 및 공정 중 관리’ 참고).\n\n 대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다. ",
        "original_sentence": "정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 71,
        "word_count": 15,
        "page_number": 4,
        "window_text": "DNA 주형 제거 외에도, 부착되지 않은 cap, 통합되지 않은 뉴클레오티드 및 생산에\n\n사용한 효소(예: RNA 중합효소), 그리고 모든 공정-관련 및 제품-관련 불순물(예:\n\ndsRNA 및 크기가 부정확한 mRNA 분자)도 가능한 범위까지 제거해야 한다.  DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다.  정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다.  불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n 공정개발 및 공정 중 관리’ 참고).\n\n 대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다.  이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다. ",
        "original_sentence": "불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n"
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "공정개발 및 공정 중 관리’ 참고).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 24,
        "window_text": "DNA\n\n중합효소 및 제한효소와 같이, (만일 DNA 주형 수준에서 조절되지 않는다면) DNA\n\n주형의 생성에 관여할 수 있는 효소의 제거에 주의를 기울여야 한다.  정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다.  불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n 공정개발 및 공정 중 관리’ 참고).\n\n 대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다.  이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다.  그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다. ",
        "original_sentence": "공정개발 및 공정 중 관리’ 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 165,
        "word_count": 28,
        "page_number": 8,
        "window_text": "정제 방법과\n\n그 목적에 관해 설명하고 근거를 제시해야 한다.  불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n 공정개발 및 공정 중 관리’ 참고).\n\n 대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다.  이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다.  그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다.  공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다. ",
        "original_sentence": "대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 209,
        "word_count": 35,
        "page_number": 8,
        "window_text": "불순물 감소 단계로서 단백질\n\n24/72\n\n효소를 이용한 단백질 분해와 같은 정제 공정 밸리데이션을 증명해야 한다(‘2.5.\n\n 공정개발 및 공정 중 관리’ 참고).\n\n 대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다.  이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다.  그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다.  공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다.  농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다. ",
        "original_sentence": "이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 134,
        "word_count": 30,
        "page_number": 8,
        "window_text": "공정개발 및 공정 중 관리’ 참고).\n\n 대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다.  이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다.  그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다.  공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다.  농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다.  다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n",
        "original_sentence": "그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 131,
        "word_count": 32,
        "page_number": 8,
        "window_text": "대부분은,\n\n비록\n\nmRNA가\n\n실제\n\n항원이\n\n아니며,\n\n그보다는\n\n항원을\n\n코딩하는\n\n전사물(transcript)에 필적하는 것이라 할지라도,\n\n정제된 mRNA는 다른 백신들의\n\n경우 명명하는 “정제된 원액 항원(purified bulk antigen)”에 상응하는 것으로 간주할\n\n것이다.  이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다.  그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다.  공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다.  농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다.  다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다. ",
        "original_sentence": "공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 97,
        "word_count": 19,
        "page_number": 8,
        "window_text": "이것은 또한 원액 생물학적 물질(bulk biological substance) 또는 원액 활성\n\n성분(bulk\n\nactive\n\nsubstance)이라고도\n\n볼\n\n수\n\n있으며,\n\n본\n\n문서에서는\n\n백신\n\n내의\n\n생물학적\n\n활성\n\n요소를\n\n기술하는\n\n데에\n\n대부분의\n\n제조사와\n\n규제자들에게\n\n친숙한\n\n용어를 사용하기 위해 원료의약품(drug substance)이라 칭한다.  그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다.  공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다.  농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다.  다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다.  지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다. ",
        "original_sentence": "농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 61,
        "word_count": 14,
        "page_number": 8,
        "window_text": "그리고 다른 백신에\n\n대해서도 예상하는 바와 같이, 각 공정 단계 및 이 단계에서 채취한 검체, 그리고\n\n어떤 공정 중 관리시험(in-process control test)을 위해 검체를 채취하는가를 표시한\n\n공정 흐름도를 제공해야 한다.  공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다.  농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다.  다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다.  지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다.  비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다. ",
        "original_sentence": "다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 81,
        "word_count": 13,
        "page_number": 8,
        "window_text": "공정 흐름도에는, 제조가 원료의약품 및 최종 제형화\n\n원액, 최종 충전된 백신(완제의약품)의 단계에 도달하는 공정 상의 단계, 그리고 공정\n\n중 관리 및 출하시험을 위해 검체 채취가 진행되는 흐름도 상의 단계를 명확히\n\n밝혀야 한다.  농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다.  다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다.  지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다.  비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다.  이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다. ",
        "original_sentence": "mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 48,
        "word_count": 10,
        "page_number": 17,
        "window_text": "농축 정제된 mRNA(원료의약품) 또는 유지하거나 저장되는 중간체(예:\n\n최종 제형화 원액)의 저장 기간은 정치 시간(hold time)/안정성 연구로 뒷받침할 수\n\n있다.  다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다.  지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다.  비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다.  이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다.  지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30). ",
        "original_sentence": "지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 78,
        "word_count": 17,
        "page_number": 8,
        "window_text": "다른 백신에 대해 기대하는 바와 같이, 동의한 원료의약품 로트의 개수를\n\n안정성 프로그램에 적용해야 한다.\n\n mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다.  지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다.  비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다.  이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다.  지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30).  핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다. ",
        "original_sentence": "비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 92,
        "word_count": 20,
        "page_number": 8,
        "window_text": "mRNA(원료의약품)는\n\n특정\n\n제형(완제의약품\n\n생산의\n\n일부로서의\n\n준비)으로\n\n보호하고 전달하지 않는다면 임상적 사용에는 적합하지 못하다.  지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다.  비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다.  이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다.  지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30).  핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다.  지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다. ",
        "original_sentence": "이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 8,
        "window_text": "지금까지 개발이\n\n가장 진전된 후보백신을 위해 선택한 제형화는 지질나노입자 기반이다.  비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다.  이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다.  지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30).  핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다.  지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다.  따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다. ",
        "original_sentence": "지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30). "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 143,
        "word_count": 29,
        "page_number": 8,
        "window_text": "비록 mRNA\n\n기반 제품의 봉입을 위한 다른 접근법들이 있으나, 본 문서에서는 지질나노입자를\n\n사용하는 시스템만을 상세하게 다룰 것이다.  이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다.  지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30).  핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다.  지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다.  따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다.  예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다. ",
        "original_sentence": "핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 16,
        "window_text": "이 제형화는 mRNA를 안정화할 뿐\n\n아니라,\n\n능동적\n\n또는\n\n수동적\n\n흡입을\n\n통해\n\n달성할\n\n수도\n\n있는\n\n세포\n\n내\n\n진입과\n\n세포액으로의 방출을 촉진한다.  지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30).  핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다.  지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다.  따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다.  예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다.  이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n",
        "original_sentence": "지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 8,
        "window_text": "지질나노입자는 또한 면역증강 활성을 제공할 수\n\n있다(27, 29, 30).  핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다.  지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다.  따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다.  예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다.  이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n 비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n",
        "original_sentence": "따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 200,
        "word_count": 38,
        "page_number": 17,
        "window_text": "핵산 분해 효소(nuclease)에 의한 분해로부터 mRNA를 방어하기\n\n위해, 핵산 분해 효소가 접근하지 못하도록 지질나노입자로 보호해야 하지만, 일단\n\n표적 세포 안에 진입했다면 지질나노입자는 반드시 mRNA를 방출할 수도 있어야\n\n25/72\n\n한다.  지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다.  따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다.  예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다.  이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n 비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n 표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n",
        "original_sentence": "예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 89,
        "word_count": 20,
        "page_number": 8,
        "window_text": "지질나노입자는 또한 표적 세포에 의한 최적의 흡입을 위해 바람직한 표면\n\n특성과 함께 반드시 크기가 적절한 범위에 해당되어야 한다.  따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다.  예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다.  이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n 비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n 표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n 그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다. ",
        "original_sentence": "이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 166,
        "word_count": 33,
        "page_number": 8,
        "window_text": "따라서 제형화 및\n\n제조공정 두 가지 모두의 최적화에 관하여 제품 개발 자료를 제공해야 한다.  예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다.  이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n 비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n 표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n 그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다.  두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다. ",
        "original_sentence": "비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 111,
        "word_count": 23,
        "page_number": 8,
        "window_text": "예를\n\n들면,\n\n서로\n\n다른\n\n구성 성분들의\n\n해동\n\n온도뿐\n\n아니라,\n\n서로\n\n다른\n\n지질의\n\n농도,\n\n지질-mRNA의\n\n비율,\n\n완충액/용매의\n\npH,\n\nmRNA\n\n봉입\n\n효율,\n\n지질과\n\nmRNA의\n\n유속(flow rate) 및 혼합비율(mixing rate)은 모두 최종 백신(완제의약품)의 품질에\n\n영향을 주기 때문에, 이들에 대해 고려해야 한다.  이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n 비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n 표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n 그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다.  두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다.  발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다. ",
        "original_sentence": "표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 153,
        "word_count": 28,
        "page_number": 8,
        "window_text": "이러한 방식으로, 지질나노입자로\n\n봉입하는 공정을 주의 깊게 관리할 수 있으며, 생산 방법과 관리 방책을 적절하게\n\n기술하고 적합하게 밸리데이션할 수 있다.\n\n 비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n 표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n 그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다.  두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다.  발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다.  각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다. ",
        "original_sentence": "그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 8,
        "window_text": "비록 sa-mRNA에는 이것의 체내 증폭(그러나 바이러스 비구조 유전자가 필요한\n\n봉입(packaging)은 제외)을 허용하는 추가적 단백질에 대한 코딩 서열을 포함하고\n\n있으나,\n\nIVT 이후 정제 및 지질나노입자 제형화를 실시하는 제조 방법은 앞서\n\n기술한\n\n내용과\n\n근본적으로\n\n동일하다.\n\n 표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n 그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다.  두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다.  발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다.  각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다.  마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다. ",
        "original_sentence": "두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 175,
        "word_count": 43,
        "page_number": 5,
        "window_text": "표적\n\n항원\n\n코딩\n\n서열과\n\n동일한\n\n분자에\n\n추가적인 코딩 서열을 지닌 sa-mRNA의 경우,\n\n제조공정에 필요한 관리 방책은\n\nmRNA\n\n백신의\n\n경우와\n\n유사하거나\n\n동일할\n\n수도\n\n있다.\n\n 그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다.  두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다.  발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다.  각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다.  마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다.  mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다. ",
        "original_sentence": "발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 141,
        "word_count": 35,
        "page_number": 2,
        "window_text": "그러나\n\n복제효소\n\n유전자(replicase gene)가 별도의 mRNA 분자에 코딩되어 있다면, 추가적인 제조공정\n\n및\n\n품질관리가\n\n필요할\n\n수\n\n있으며,\n\n필요한\n\nmRNA가\n\n지질나노입자에\n\n적절하게\n\n봉입되도록 보장하기 위해 이러한 사항들에 관하여 기술해야 한다.  두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다.  발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다.  각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다.  마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다.  mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다.  이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n",
        "original_sentence": "각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 67,
        "word_count": 16,
        "page_number": 8,
        "window_text": "두 개의 봉입된\n\nmRNA의 분자량 비율 정보 및 그 타당성 그리고 밸리데이션 방법이 제공되어야\n\n한다.  발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다.  각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다.  마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다.  mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다.  이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n 핵심 품질관리 사항에는 다음이 포함된다.\n\n",
        "original_sentence": "마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 5,
        "window_text": "발현 효율의 정도 역시 이 두 접근법 사이에 차이가 있을 수 있으며(예: 한\n\n가지 mRNA 사용과 대조적으로 두 가지 mRNA를 사용), 이는 dsRNA의 함량 및\n\n유도한\n\n선천성\n\n면역반응,\n\nmRNA\n\n반감기의\n\n차이로\n\n인하여\n\n백신\n\n설계에\n\n대해\n\n예상하는 안전성 및 유효성에 영향을 줄 수도 있다.  각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다.  마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다.  mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다.  이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n 핵심 품질관리 사항에는 다음이 포함된다.\n\n 가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template). ",
        "original_sentence": "mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 57,
        "word_count": 15,
        "page_number": 8,
        "window_text": "각각의 mRNA 분자들을 별도로\n\n봉입하고 봉입 이전에 혼합하지 않는다면, 이 사항 역시 기술해야 할 것이며, 두\n\n가지(또는 그 이상의) mRNA의 적절한 혼합 및 적합한 비율을 보장하기 위해\n\n추가적인 제조공정 및 품질관리를 수반해야 할 수 있다.  마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다.  mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다.  이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n 핵심 품질관리 사항에는 다음이 포함된다.\n\n 가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template).  ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n",
        "original_sentence": "이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "핵심 품질관리 사항에는 다음이 포함된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 26,
        "window_text": "마찬가지로, 다가 mRNA의\n\n경우, 봉입 이전 또는 이후의 혼합 단계에 관해 기술해야 하며 적절히 관리가\n\n필요하다.  mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다.  이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n 핵심 품질관리 사항에는 다음이 포함된다.\n\n 가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template).  ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n 선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n",
        "original_sentence": "핵심 품질관리 사항에는 다음이 포함된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 174,
        "word_count": 36,
        "page_number": 8,
        "window_text": "mRNA가 봉입되고 혼합된 경우 주목해야 할 중요한 점은 각각이 생체\n\n26/72\n\n내에서 동일한 세포에 의해 흡수되어야 하는 방법 또는 필요 여부에 대한 확실한\n\n타당성이 제시되어야 한다는 것이다.  이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n 핵심 품질관리 사항에는 다음이 포함된다.\n\n 가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template).  ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n 선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n 목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n",
        "original_sentence": "가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template). "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 155,
        "word_count": 24,
        "page_number": 8,
        "window_text": "이는 다가 혹은 혼합 백신에서는 덜 중요할 수\n\n있고 sa-mRNA 백신에서는 더 중요할 수 있다.\n\n 핵심 품질관리 사항에는 다음이 포함된다.\n\n 가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template).  ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n 선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n 목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n 첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n",
        "original_sentence": "② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n"
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 26,
        "window_text": "핵심 품질관리 사항에는 다음이 포함된다.\n\n 가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template).  ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n 선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n 목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n 첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n 또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다. ",
        "original_sentence": "선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 44,
        "word_count": 8,
        "page_number": 5,
        "window_text": "가) 출발물질,\n\n원료약품\n\n및\n\n첨가제\n\n- -\n다음을\n\n포함하나 이에\n\n국한되지\n\n않음:\n\n- ①\n효소적으로 혹은 합성적으로 생성된 산물(예, PCR 혹은 새로운 방법)이거나\n\n(일반적으로 제한 뉴클레아제로) 선형화한 플라스미드 DNA일 수도 있는 선형\n\nDNA 주형(linear DNA template).  ② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n 선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n 목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n 첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n 또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다.  본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다. ",
        "original_sentence": "목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 255,
        "word_count": 58,
        "page_number": 8,
        "window_text": "② 뉴클레오티드, ③ 효소(예: DNA-의존성\n\nRNA\n\n중합효소(일반적으로\n\nT7\n\npolymerase),\n\n캡\n\n형성(capping)\n\n효소,\n\n2’\n\nO-methyltransferase, poly(A) 중합효소, DNase), ④ 완충액, ⑤ 용제 및/또는 ⑥\n\n지질.\n\n 선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n 목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n 첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n 또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다.  본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다.  다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n",
        "original_sentence": "첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 282,
        "word_count": 62,
        "page_number": 8,
        "window_text": "선형\n\nDNA\n\n주형은\n\n원료의약품\n\n제조의\n\n출발물질로\n\n여겨진다.\n\n 목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n 첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n 또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다.  본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다.  다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n 표 1. ",
        "original_sentence": "또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 52,
        "word_count": 11,
        "page_number": 23,
        "window_text": "목록에\n\n제시되지\n\n않은\n\n제조에\n\n사용되는\n\n것도\n\n원료약품에\n\n포함된다.\n\n 첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n 또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다.  본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다.  다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n 표 1.  여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n",
        "original_sentence": "본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 73,
        "word_count": 16,
        "page_number": 27,
        "window_text": "첨가제는\n\nŸ 특히,\n\n동물(인간\n\n포함)\n\n유래\n\n출발물질이나\n\n원료약품\n\n또는\n\n첨가제,\n\n또는\n\n동물(인간 포함) 유래 원료를 사용하여 생산된 출발물질이나 원료약품 또는\n\nŸ 타당한 증거 및 위해성 평가로 뒷받침하면서 잠재적인 외인성 인자의 부재\n\n나) 제조공정 및 중간체의 공정 중 관리 – 최종 제형화 원액의 제형화(지질나노입자\n\n제조 및 봉입 단계) 및 충전뿐 아니라 원액 mRNA 성분(원료의약품)의 제조를\n\n위해\n\n실시한\n\n공정을\n\n포함.\n\n 또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다.  본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다.  다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n 표 1.  여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n 여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다. ",
        "original_sentence": "다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n"
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "표 1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 4,
        "window_text": "또한,\n\n지질나노입자\n\n제형화의\n\n일관성(크기\n\n및\n\n다분산(polydisperity)), mRNA 봉입의 일관성, 그리고 부분적 mRNA, dsRNA\n\n다) 제조 후 mRNA 백신 원료의약품 및 최종 충전된 백신(완제의약품)의 출하\n\n라) 공정 밸리데이션 - 원하는 품질 프로파일을 가진 상업용 최종 완제의약품의 공정\n\n이러한 핵심 품질관리 사항 중 일부를 평가하기 위해 고려할 수도 있는 분석\n\n방법은 정확한 방법 및 기준이 아직 일반에 공유된 상태는 아니지만, 문헌에서\n\n27/72\n\n논하고 있다.  본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다.  다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n 표 1.  여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n 여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다.  3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n",
        "original_sentence": "표 1. "
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 136,
        "word_count": 33,
        "page_number": 27,
        "window_text": "본 문서 작성 시점에서는, 이러한 방법들은 제조사들이 기업비밀이자\n\n비공개로 간주하고 있다.  다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n 표 1.  여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n 여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다.  3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n 임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n",
        "original_sentence": "여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 8,
        "window_text": "다음의 방법들은 다양한 핵심 품질관리 시점에서 특성\n\n분석이나 관리를 위한 잠재적인 방법의 예시로 간주할 수 있다(36~38).\n\n 표 1.  여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n 여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다.  3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n 임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n 임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n",
        "original_sentence": "여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 66,
        "word_count": 14,
        "page_number": 10,
        "window_text": "표 1.  여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n 여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다.  3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n 임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n 임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n ‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n",
        "original_sentence": "3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 95,
        "word_count": 25,
        "page_number": 8,
        "window_text": "여러 핵심 품질관리 관점에서 특성 분석 혹은 관리를 위한 잠재적 기술의 예시(잠재적 사용)\n\nmRNA 함량, 지질 함량 mRNA 품질,\n\n임상시험 중 사용을 위해서는 mRNA를 임상 개발 단계에 적절한 GMP 조건\n\n하에\n\n제조해야\n\n한다.\n\n 여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다.  3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n 임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n 임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n ‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n <!-- PAGE_28 -->\n### 2.3. ",
        "original_sentence": "임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 8,
        "window_text": "여전히\n\n임상시험\n\n물질은\n\n적절한\n\n품질관리\n\n기준\n\n충족을\n\n28/72\n\n토대로 출하할 것으로 기대하고 있다.  3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n 임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n 임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n ‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n <!-- PAGE_28 -->\n### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다. ",
        "original_sentence": "임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 52,
        "word_count": 8,
        "page_number": 4,
        "window_text": "3상 임상시험에서 사용하는 임상시험용\n\n의약품 그리고 상업적 제조에 대해서는 GMP를 완전히 준수할 것을 기대한다.\n\n 임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n 임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n ‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n <!-- PAGE_28 -->\n### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다.  선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다. ",
        "original_sentence": "‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "<!-- PAGE_28 -->\n### 2.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 28,
        "window_text": "임상 개발 중 도입한 제조 변경은, 특히 핵심 안전성 및 유효성 시험 완료 후\n\n그리고 품목허가 신청 이전에 실시했다면, 이에 대하여 서술하고 근거를 제시해야\n\n한다.\n\n 임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n ‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n <!-- PAGE_28 -->\n### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다.  선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다.  해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n",
        "original_sentence": "<!-- PAGE_28 -->\n### 2.3. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 147,
        "word_count": 35,
        "page_number": 8,
        "window_text": "임상적으로\n\n검증된\n\n배치와\n\n비교\n\n분석을\n\n수행해야\n\n한다.\n\n ‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n <!-- PAGE_28 -->\n### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다.  선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다.  해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n <!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다. ",
        "original_sentence": "백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 8,
        "window_text": "‘생물의약품의\n\n제조방법 변경에 따른 비교동등성 가이드라인(식약처, 2019)’를 따른다.\n\n <!-- PAGE_28 -->\n### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다.  선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다.  해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n <!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다.  표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n",
        "original_sentence": "선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 8,
        "window_text": "<!-- PAGE_28 -->\n### 2.3.  백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다.  선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다.  해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n <!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다.  표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n 추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n",
        "original_sentence": "해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "<!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 78,
        "word_count": 18,
        "page_number": 28,
        "window_text": "백신 구조체 및 조성에 관한 일반 정보 및 설명\n\nmRNA\n\n원료의약품\n\n및\n\n제형화한\n\nmRNA\n\n백신에\n\n대하여,\n\n그\n\n설계와\n\n구축,\n\n조성(예: 지질 및 기타 첨가제), 사용한 각 첨가제의 함량, mRNA 서열과 관련하여\n\n기술한 정보를 제공해야 한다.  선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다.  해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n <!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다.  표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n 추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n 구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n",
        "original_sentence": "<!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 173,
        "word_count": 36,
        "page_number": 8,
        "window_text": "선택한 첨가제에 대한 근거 및 기능도 서술해야\n\n한다.  해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n <!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다.  표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n 추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n 구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n 이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n",
        "original_sentence": "표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 99,
        "word_count": 21,
        "page_number": 8,
        "window_text": "해당되는 경우, 사용한 지질의 구조 및 분자량 그리고 백신 제형화 시\n\n지질의 사용에 대한 정보를 포함해야 한다.\n\n <!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다.  표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n 추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n 구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n 이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n 라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n",
        "original_sentence": "추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n"
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 298,
        "word_count": 59,
        "page_number": 8,
        "window_text": "<!-- PAGE_28 -->\n### 2.3.1. mRNA 서열 및 요소의 배열\n\n가) 주석을 첨부한 DNA 주형의 서열을 제공해야 한다.  표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n 추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n 구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n 이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n 라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n 이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며. ",
        "original_sentence": "구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n"
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 29,
        "window_text": "표적 항원을 위한 ORF뿐\n\n아니라, 개시 및 종결 코돈, 둘러싼 UTR, 조절 요소(예: RNA 중합효소를 위한\n\n프로모터(promoter)),\n\n5‘\n\ncap\n\n및\n\n3’\n\npoly(A)\n\ntail을\n\n포함하여,\n\nmRNA\n\n안에\n\n포함된\n\n모든 요소의 서열 및\n\n위치\n\n또는 길이를\n\n제시해야\n\n한다.\n\n 추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n 구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n 이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n 라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n 이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며.  따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n",
        "original_sentence": "이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 95,
        "word_count": 18,
        "page_number": 8,
        "window_text": "추가적인\n\n단백질을 코딩한다면(예: 자가 증폭 구조체 또는 사이토카인을 위한 단백질),\n\n이들의\n\n서열을\n\n제공해야\n\n한다(아래의\n\n- (라)\n및\n\n- (마)\n항목\n\n참조).\n\n 구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n 이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n 라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n 이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며.  따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n 이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n",
        "original_sentence": "라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 8,
        "window_text": "구조체에\n\n나) 백신 mRNA는 자연발생적인 또는 변형이나 합성된 뉴클레오시드를 포함하여\n\n제조가\n\n가능하기\n\n때문에,\n\n서열\n\n정보에는\n\n사용된\n\n특정\n\n뉴클레오시드를\n\n다) 또한, 병원체의 유전체 내의 천연(naive) 코돈보다는 최적화된 코돈(예: 인체\n\n세포 내의 적절한 tRNA의 빈도에 더 잘 매칭되거나, mRNA의 특정한 이차\n\n29/72\n\n또는\n\n삼차\n\n구조를\n\n획득하거나\n\n선천성\n\n면역반응을\n\n줄이기\n\n위해\n\n사용되는\n\n코돈)을\n\n사용할\n\n수\n\n있다(예:\n\nmRNA의\n\n생체\n\n내\n\n안정성을\n\n향상하기\n\n위해).\n\n 이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n 라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n 이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며.  따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n 이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n 복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n",
        "original_sentence": "이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며. "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 24,
        "window_text": "이러한 최적화된 코돈의 사용에 대해 기술하고 타당성을 제시해야 한다.\n\n 라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n 이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며.  따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n 이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n 복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n 일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2. ",
        "original_sentence": "따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 50,
        "word_count": 9,
        "page_number": 23,
        "window_text": "라) 위에\n\n서술한\n\n바와\n\n같이,\n\nsa-mRNA는\n\n표적\n\n항원의\n\n코딩\n\n외에도,\n\n바이러스\n\nRNA-의존성\n\nRNA\n\n중합효소\n\n복합체를\n\n코딩할\n\n수\n\n있다.\n\n 이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며.  따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n 이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n 복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n 일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2.  제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n",
        "original_sentence": "이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 81,
        "word_count": 17,
        "page_number": 8,
        "window_text": "이러한\n\n구조체는\n\nreplicon을 구성하며, 결과적으로, 피접종자의 세포 내 전달 및 세포에 의한\n\n흡입 시 항원을 코딩하는 mRNA 카피를 다수 생성할 수 있으며.  따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n 이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n 복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n 일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2.  제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n 일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n",
        "original_sentence": "복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 254,
        "word_count": 43,
        "page_number": 29,
        "window_text": "따라서\n\n잠재적으로\n\n백신의\n\n역가를\n\n증가시킨다.\n\n 이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n 복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n 일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2.  제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n 일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n 한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n",
        "original_sentence": "일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 66,
        "word_count": 15,
        "page_number": 8,
        "window_text": "이러한\n\nreplicon의\n\n서열\n\n정보를\n\n제공하고\n\n그\n\n기능을\n\n설명해야\n\n한다.\n\n 복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n 일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2.  제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n 일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n 한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n 만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다. ",
        "original_sentence": "제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 5,
        "window_text": "복제효소가\n\n항원과는\n\n별도의\n\nmRNA\n\n분자에 제공된다면, 각 구성성분의 제조 및 관리에 대하여 도해와 서술식\n\n설명을\n\n제공해야\n\n한다.\n\n 일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2.  제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n 일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n 한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n 만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다.  몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다. ",
        "original_sentence": "일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 27,
        "window_text": "일반적으로,\n\n이러한\n\n코딩\n\n서열은\n\n동일한\n\n분자에\n\n위치하지만,\n\n만일\n\n분리되어있다면,\n\n추가적인\n\n관리가\n\n필요하며\n\n이에\n\n대해\n\n마) mRNA\n\n백신이\n\n다른\n\n면역조절인자(immunomodulator)(예\n\n:\n\n사이토카인)를\n\n코딩하는 서열 또는 면역조절인자로서 작용하도록 의도한 비코딩(non-coding)\n\n서열을 포함하고 있다면, 이러한 서열과 이들의 목적에 대한 정보를 제공해야\n\n<!-- PAGE_29 -->\n### 2.3.2.  제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n 일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n 한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n 만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다.  몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다.  이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n",
        "original_sentence": "한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 186,
        "word_count": 38,
        "page_number": 8,
        "window_text": "제형화 및 구성성분\n\n가) 배치 조성(batch formula) : 상업적 생산을 위한 배치 조성을 제공해야 한다.\n\n 일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n 한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n 만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다.  몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다.  이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n 지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다. ",
        "original_sentence": "만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다. "
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 170,
        "word_count": 28,
        "page_number": 8,
        "window_text": "일회\n\n접종량\n\n중\n\n각\n\n성분\n\n함량의\n\n목록을\n\n제시해야\n\n한다.\n\n 한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n 만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다.  몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다.  이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n 지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다.  mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n",
        "original_sentence": "몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 120,
        "word_count": 26,
        "page_number": 8,
        "window_text": "한\n\n배치의\n\n전체\n\n용량을\n\n정의해야\n\n한다.\n\n 만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다.  몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다.  이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n 지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다.  mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n 여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다. ",
        "original_sentence": "이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 17,
        "window_text": "만일\n\n2종\n\n이상의\n\nmRNA\n\n물질(원료의약품)이\n\n완제의약품(최종\n\n백신)에\n\n포함되어\n\n있다면\n\n각각의\n\nmRNA가\n\n동시에\n\n혹은\n\n개별적으로 지질나노입자에 봉입되어 sa-mRNA 백신, 다가 백신 혹은 혼합\n\n나) 화학적 특성 및 제형화 : mRNA는 원칙적으로 안정성을 향상하고 세포 내\n\n흡입을 돕기 위해 제형화한다.  몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다.  이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n 지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다.  mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n 여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다.  따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다. ",
        "original_sentence": "지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 57,
        "word_count": 11,
        "page_number": 8,
        "window_text": "몇몇 잠재적인 전달 인자(delivery agent)(예:\n\n프로타민 복합체(protamine complex), 양이온성 리포솜, 지질-, 폴리머- 또는\n\n30/72\n\n지질/폴리머-기반 나노입자)가 있으나, 현재 사용 중이거나 임상시험이 가장\n\n진전된 mRNA 후보백신들은 지질나노입자로 봉입한 것이다.  이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n 지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다.  mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n 여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다.  따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다.  더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n",
        "original_sentence": "mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 164,
        "word_count": 27,
        "page_number": 8,
        "window_text": "이러한 제형화의\n\n화학적 특성분석 및 구조적 제형화(예: 나노입자)에 대한 물리적 파라미터와\n\n관련된 특성분석에 대해 서술해야 하며, 제형화와 최종 제품의 일관성 및\n\n안정성과\n\n같은\n\n특성을\n\n다루어야\n\n한다.\n\n 지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다.  mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n 여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다.  따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다.  더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n 면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12). ",
        "original_sentence": "여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 123,
        "word_count": 30,
        "page_number": 8,
        "window_text": "지질과\n\n완제의약품의\n\n주요품질특성\n\n역시 포함해야 한다.  mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n 여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다.  따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다.  더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n 면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12).  별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4. ",
        "original_sentence": "따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 100,
        "word_count": 17,
        "page_number": 8,
        "window_text": "mRNA-지질나노입자 복합체 및 표적 세포 내로의 흡입에\n\n대하여\n\n충분한\n\n특성분석이\n\n필요하다.\n\n 여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다.  따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다.  더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n 면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12).  별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4.  출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다. ",
        "original_sentence": "더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 77,
        "word_count": 14,
        "page_number": 23,
        "window_text": "여기에는,\n\nmRNA의\n\n적절한\n\n보호와\n\n백신에\n\n요구되는\n\n안정성을\n\n확보하기\n\n위하여,\n\n합성된\n\nmRNA-지질나노입자\n\n복합체의 표면 화학(surface chemistry) 및 크기, 다분산(polydisperity), 형태,\n\n전하, 단백질 결합 특성에 대한 이해가 포함되어야 한다.  따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다.  더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n 면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12).  별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4.  출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다.  시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n",
        "original_sentence": "면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12). "
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 340,
        "word_count": 69,
        "page_number": 31,
        "window_text": "따라서, 백신의 독성\n\n및 이상사례, 면역반응, 유효성에 영향을 줄 수 있는 제형화의 특성에 대해\n\n다) 추가적 면역조절인자 및 면역증강제 : mRNA는 또한 사이토카인 같은 특정한\n\n면역조절 분자를 코딩할 수도 있다.  더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n 면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12).  별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4.  출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다.  시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n 이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n",
        "original_sentence": "별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 78,
        "word_count": 18,
        "page_number": 10,
        "window_text": "더 나아가, 별도의 면역증강제나 mRNA에\n\n코딩하지\n\n않은\n\n면역조절(면역자극이나\n\n면역억제)\n\n화합물을\n\n제형화에\n\n또는\n\n지질나노입자의\n\n일부로서\n\n추가할\n\n수도\n\n있다.\n\n 면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12).  별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4.  출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다.  시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n 이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n <!-- PAGE_31 -->\n### 2.4.1. ",
        "original_sentence": "출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 67,
        "word_count": 11,
        "page_number": 24,
        "window_text": "면역증강제와\n\n함께\n\n제형화한\n\n백신에 관한 일반원칙으로서, 이러한 면역증강제 추가가 백신의 면역원성에\n\n기여함을 증명해야 한다(12).  별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4.  출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다.  시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n 이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n <!-- PAGE_31 -->\n### 2.4.1.  출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n",
        "original_sentence": "시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 47,
        "word_count": 9,
        "page_number": 23,
        "window_text": "별도의 면역증강제를 포함한 경우, 그 품질 측면\n\n라) 추가적\n\n서열\n\n:\n\nmRNA가\n\n항원제시세포\n\n혹은\n\n다른\n\n특이적인\n\n세포\n\n종류를\n\n표적으로\n\n하도록\n\n또는\n\n엔도솜(endosome)으로부터의\n\nmRNA\n\n방출이\n\n증가하도록 추가 서열을 포함했다면, 이러한 추가 부분의 서열 및 기능에\n\n대해 서술하고, 추가 서열에 대해 제안한 작용기전을 뒷받침하기 위해 이들의\n\n마) 추가적 첨가제(예: 보존제) : 이러한 추가된 첨가제의 조성, 필요성, 그리고\n\n(보존제의\n\n경우)\n\n보존적\n\n유효성에\n\n대해\n\n기술하고,\n\n지질나노입자의\n\n특성에\n\n31/72\n\n<!-- PAGE_31 -->\n### 2.4.  출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다.  시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n 이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n <!-- PAGE_31 -->\n### 2.4.1.  출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n 각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다. ",
        "original_sentence": "이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "<!-- PAGE_31 -->\n### 2.4.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 31,
        "window_text": "출발물질, 원료약품, 첨가제의 관리\n\n다른 백신과 마찬가지로, 생산에 사용하는 모든 시약의 구매 및 품질에 특별한\n\n주의를 기울여야 한다.  시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n 이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n <!-- PAGE_31 -->\n### 2.4.1.  출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n 각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다.  이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다. ",
        "original_sentence": "<!-- PAGE_31 -->\n### 2.4.1. "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 178,
        "word_count": 37,
        "page_number": 8,
        "window_text": "시약/원료약품은 내부에서 정의한 품질 시스템을 통해\n\n제조사가\n\n승인한\n\n판매업체/공급업체로부터\n\n공급받아야\n\n한다.\n\n 이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n <!-- PAGE_31 -->\n### 2.4.1.  출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n 각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다.  이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다.  시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다. ",
        "original_sentence": "출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 86,
        "word_count": 18,
        "page_number": 26,
        "window_text": "이러한\n\n물질의\n\n공급업체는 제조사가 적절한 품질검증 프로그램으로 관리해야 한다.\n\n <!-- PAGE_31 -->\n### 2.4.1.  출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n 각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다.  이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다.  시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다.  mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n",
        "original_sentence": "각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 72,
        "word_count": 16,
        "page_number": 23,
        "window_text": "<!-- PAGE_31 -->\n### 2.4.1.  출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n 각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다.  이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다.  시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다.  mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n 지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다. ",
        "original_sentence": "이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 8,
        "window_text": "출발물질, 원료약품, 첨가제의 품질\n\nmRNA를 생산하기 위해 사용한 출발물질, 원료약품 및 첨가제(예: DNA 주형,\n\n뉴클레오티드(변형된 뉴클레오시드 함유 가능), 효소, 완충액, 용제, 정제 시 사용한\n\n컬럼 등) 및 지질나노입자에서 지질을 포함하여, 출발물질, 원료약품 및 첨가제에\n\n대해\n\n기술해야\n\n한다.\n\n 각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다.  이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다.  시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다.  mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n 지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다.  새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다. ",
        "original_sentence": "시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 92,
        "word_count": 22,
        "page_number": 8,
        "window_text": "각\n\n출발물질과\n\n원료약품이\n\n제조공정의\n\n어느\n\n시점에서\n\n사용되는가를 포함하여, 이들의 출처 및 품질, 관리, 안정성, 역할에 대해 서술해야\n\n한다.  이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다.  시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다.  mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n 지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다.  새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다.  새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n",
        "original_sentence": "mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 159,
        "word_count": 35,
        "page_number": 8,
        "window_text": "이러한 물질들은 GMP 생산에 적합해야 하며, 참고한 국제적으로 공인된\n\n약전이나 이들의 규격에 대한 세부사항을 표기해야 한다.  시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다.  mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n 지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다.  새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다.  새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n 여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다. ",
        "original_sentence": "지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 22,
        "window_text": "시약 또는 출발물질(예:\n\n선형 DNA 주형)의 추출을 위해 사용한 공정 정보 역시 제공해야 한다.  mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n 지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다.  새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다.  새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n 여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다.  만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다. ",
        "original_sentence": "새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 103,
        "word_count": 20,
        "page_number": 8,
        "window_text": "mRNA\n\n백신의 생산을 위한 출발물질은 선형 DNA 주형이나 그 주형은 재조합 세포\n\n은행에서 증식된 DNA 플라스미드와 같은 상류 물질로부터 유래할 수 있다.\n\n 지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다.  새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다.  새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n 여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다.  만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다.  출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n",
        "original_sentence": "새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 8,
        "window_text": "지질나노입자 관련하여 지질나노입자 제조에 사용한 지질의 출처 및 품질은\n\n(특히,\n\n이전에\n\n비임상\n\n및\n\n임상적으로\n\n연구된\n\n적이\n\n없는\n\n지질나노입자\n\n내에\n\n존재하는 새로운 지질인 경우), 이들의 안전성 및 품질에 대한 유의한 평가가\n\n가능하도록 충분히 상세히 기술해야 한다.  새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다.  새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n 여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다.  만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다.  출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n 용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n",
        "original_sentence": "여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다. "
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 58,
        "word_count": 11,
        "page_number": 8,
        "window_text": "새로운 것으로 간주하지 않는 첨가제의\n\n경우에도 여전히 적합한 규격을 제공해야 한다.  새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n 여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다.  만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다.  출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n 용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n 물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다. ",
        "original_sentence": "만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 116,
        "word_count": 23,
        "page_number": 2,
        "window_text": "새로운 첨가제의 경우(예: 양이온\n\n지질),\n\n가능하다면,\n\n이\n\n새로운\n\n지질(출발물질\n\n및\n\n중간체\n\n포함)의\n\n제조공정\n\n및\n\n관리에\n\n대한\n\n상세\n\n내용을\n\n제공해야\n\n한다.\n\n 여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다.  만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다.  출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n 용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n 물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다.  첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n",
        "original_sentence": "출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 89,
        "word_count": 14,
        "page_number": 8,
        "window_text": "여기에는\n\n새로운\n\n첨가제의\n\n합성에\n\n사용되는 제안한 출발물질 및 모든 중간체에 대한 정보 그리고 타당한 근거가\n\n포함될 것이다.  만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다.  출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n 용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n 물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다.  첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n 정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n",
        "original_sentence": "용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n"
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 53,
        "word_count": 11,
        "page_number": 17,
        "window_text": "만일 관련이 있다면 (양이온성) 지질에서 수행되는 nitrosamine의\n\n위해 평가를 고려해야 한다.  출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n 용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n 물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다.  첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n 정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n 제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다. ",
        "original_sentence": "물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 8,
        "window_text": "출발물질 및 원료약품(예: 시약 및 용제), 중간체,\n\n32/72\n\n최종\n\n첨가제(지질)에\n\n대한\n\n필수적인\n\n공정관리\n\n및\n\n규격과\n\n함께,\n\n제조소\n\n및\n\n제조공정의\n\n세부\n\n사항을\n\n제공해야\n\n한다.\n\n 용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n 물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다.  첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n 정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n 제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다.  페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n",
        "original_sentence": "첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 8,
        "window_text": "용제의\n\n사용\n\n및\n\n관리\n\n그리고\n\n금속\n\n불순물(elemental\n\nimpurities)에\n\n의한\n\n잠재적\n\n오염\n\n역시\n\n고려해야\n\n한다(39~41).\n\n 물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다.  첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n 정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n 제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다.  페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n 위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n",
        "original_sentence": "정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 116,
        "word_count": 26,
        "page_number": 16,
        "window_text": "물질/시약/용제의 재활용을 제안한 경우, 이에 대한 근거를 제시하고 적절하게\n\n관리해야 한다.  첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n 정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n 제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다.  페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n 위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n 플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n",
        "original_sentence": "제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 127,
        "word_count": 26,
        "page_number": 8,
        "window_text": "첨가제와 관련된 불순물의 수준 또한 적절하게 관리하고 타당성을\n\n입증해야\n\n한다.\n\n 정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n 제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다.  페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n 위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n 플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n 세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n",
        "original_sentence": "페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 67,
        "word_count": 13,
        "page_number": 8,
        "window_text": "정제\n\n및\n\n분리\n\n단계를\n\n상세히\n\n설명해야\n\n한다.\n\n 제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다.  페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n 위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n 플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n 세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n 종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n",
        "original_sentence": "위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 114,
        "word_count": 26,
        "page_number": 8,
        "window_text": "제안한\n\n새로운\n\n첨가제의 품질을 보장하기 위해, 해당 제조사는 또한 이 물질의 특성 분석, 안정성\n\n모니터링,\n\n배치\n\n분석을\n\n위해\n\n사용한\n\n분석법에\n\n대하여\n\n가용한\n\n관련\n\n정보를\n\n구비해야 한다.  페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n 위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n 플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n 세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n 종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n 만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다. ",
        "original_sentence": "플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 73,
        "word_count": 14,
        "page_number": 24,
        "window_text": "페길화된 지질의 포함은 지질나노입자의 안전성 제공 및 세포와의\n\n상호작용\n\n증강에\n\n핵심적\n\n역할을\n\n수행하기\n\n때문에(22),\n\n페길화된\n\n지질에\n\n대해\n\n적절한 관리(예: 분자량 및 다분산에 대한 관리)를 실시해야 한다.\n\n 위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n 플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n 세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n 종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n 만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다.  DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다. ",
        "original_sentence": "세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 46,
        "word_count": 7,
        "page_number": 27,
        "window_text": "위에서\n\n설명한\n\n바와\n\n같이\n\n선형\n\nDNA\n\n주형은\n\nmRNA의\n\nGMP\n\n생산을\n\n위한\n\n출발물질로\n\n간주한다.\n\n 플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n 세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n 종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n 만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다.  DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다.  미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n",
        "original_sentence": "종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 87,
        "word_count": 17,
        "page_number": 10,
        "window_text": "플라스미드\n\nDNA로부터\n\n선형\n\nDNA가\n\n준비되는\n\n경우\n\n세포은행 확립 및 플라스미드 DNA 제조를 위한 절차는 이후 GMP 제조 시\n\n사용하기 위한 물질의 생산과 일관된 방식으로 실시해야 한다.\n\n 세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n 종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n 만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다.  DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다.  미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n 만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다. ",
        "original_sentence": "만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 81,
        "word_count": 18,
        "page_number": 8,
        "window_text": "세포은행 시스템을 확립하고, 이에 관해 기술하며 미생물 순도 시험(세균이나\n\n곰팡이로부터\n\n오염이\n\n없음)을\n\n실시해야\n\n한다.\n\n 종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n 만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다.  DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다.  미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n 만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다.  초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n",
        "original_sentence": "DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 8,
        "window_text": "종자은행(seed\n\nbank)의\n\n유전적\n\n안정성을\n\n반드시\n\n증명해야\n\n한다.\n\n 만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다.  DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다.  미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n 만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다.  초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n 핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n",
        "original_sentence": "미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 255,
        "word_count": 51,
        "page_number": 8,
        "window_text": "만일\n\npoly(A)\n\ntail이\n\n플라스미드\n\nDNA로부터\n\n코딩이 된다면 특별히 DNA 플라스미드에서 그 부분에 대한 재조합률 시험을\n\n시행해야 한다.  DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다.  미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n 만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다.  초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n 핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n <!-- PAGE_33 -->\n### 2.4.2. ",
        "original_sentence": "만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 75,
        "word_count": 17,
        "page_number": 3,
        "window_text": "DNA 플라스미드로부터의 불순물(예 : RNA 및 숙주-세포 DNA,\n\n단백질, 지질, 다당류)을 줄이기 위해 정제 공정을 또한 실시해야 한다.  미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n 만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다.  초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n 핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n <!-- PAGE_33 -->\n### 2.4.2.  출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n",
        "original_sentence": "초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n"
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 110,
        "word_count": 26,
        "page_number": 8,
        "window_text": "미생물\n\n오염의 위험을 최소화하기 위한 방식으로 제조공정을 수립해야 한다.\n\n 만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다.  초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n 핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n <!-- PAGE_33 -->\n### 2.4.2.  출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n <!-- PAGE_33 -->\n### 2.5. ",
        "original_sentence": "핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "<!-- PAGE_33 -->\n### 2.4.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 33,
        "window_text": "만일 선형 DNA를 만드는 데 사용된다면 DNA 플라스미드 및 선형 주형에\n\n대한\n\n시험에는\n\n잔여\n\n유전체\n\nDNA\n\n및\n\nRNA,\n\n단백질,\n\n무균이나\n\n허용\n\n가능한\n\n미생물한도,\n\n엔도톡신\n\n수준뿐\n\n아니라,\n\n서열분석을\n\n통한\n\n유전적\n\n확인(genetic\n\nidentity) 및 완전성(integrity)(목적하는 코딩된 항원 서열 및 조절/통제 서열의\n\n확증을 포함), 적절한 표준품을 사용한 선형 DNA 비율에 대한 시험도 포함해야\n\n한다.  초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n 핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n <!-- PAGE_33 -->\n### 2.4.2.  출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n <!-- PAGE_33 -->\n### 2.5.  공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다. ",
        "original_sentence": "<!-- PAGE_33 -->\n### 2.4.2. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 99,
        "word_count": 20,
        "page_number": 17,
        "window_text": "초기 개발과정에서 시험은 둘 중 하나에 대해서만 제공될 수 있다(사용되는\n\n33/72\n\n경우 DNA 플라스미드 혹은 선형 DNA).\n\n 핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n <!-- PAGE_33 -->\n### 2.4.2.  출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n <!-- PAGE_33 -->\n### 2.5.  공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다.  공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다. ",
        "original_sentence": "출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "<!-- PAGE_33 -->\n### 2.5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 33,
        "window_text": "핵심 임상시험 및 상업적 제조를 뒷받침하기 위해 관리가 한층 강화될 것으로\n\n예상된다는\n\n조건\n\n하에\n\n초기\n\n임상\n\n개발\n\n시에는\n\n품질이\n\n충분히\n\n적격한\n\n물질의\n\n사용을 허용할 수 있다.\n\n <!-- PAGE_33 -->\n### 2.4.2.  출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n <!-- PAGE_33 -->\n### 2.5.  공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다.  공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다.  충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_33 -->\n### 2.5. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 42,
        "word_count": 11,
        "page_number": 8,
        "window_text": "<!-- PAGE_33 -->\n### 2.4.2.  출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n <!-- PAGE_33 -->\n### 2.5.  공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다.  공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다.  충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n 제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다. ",
        "original_sentence": "공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 101,
        "word_count": 25,
        "page_number": 17,
        "window_text": "출발물질, 원료약품, 첨가제의 사용승인\n\n다른 백신과 마찬가지로, 제조사가 모든 출발물질, 원료약품 및 첨가제가 정해진\n\n기준규격에 적합함을 확인하고 제조에 사용하여야 한다.\n\n <!-- PAGE_33 -->\n### 2.5.  공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다.  공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다.  충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n 제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다.  이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n",
        "original_sentence": "공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 17,
        "window_text": "<!-- PAGE_33 -->\n### 2.5.  공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다.  공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다.  충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n 제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다.  이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n 무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n",
        "original_sentence": "충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 94,
        "word_count": 18,
        "page_number": 8,
        "window_text": "공정개발 및 공정 중 관리\n\n상업용 제조공정의 개발 이력을 제공해야 한다.  공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다.  충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n 제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다.  이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n 무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n <!-- PAGE_33 -->\n### 2.6. ",
        "original_sentence": "제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 80,
        "word_count": 18,
        "page_number": 8,
        "window_text": "공정관리의 실시를 보장하고\n\n공정 관리에 대한 피드백을 제공하기 위하여, 제조공정 중 중요 단계의 경고 및\n\n조치 한계에 관한 시험 및 허용기준을 개발하고 타당성을 입증해야 한다.  충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n 제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다.  이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n 무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n <!-- PAGE_33 -->\n### 2.6.  제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n",
        "original_sentence": "이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 140,
        "word_count": 28,
        "page_number": 8,
        "window_text": "충분히\n\n확립된 플랫폼 기술을 사용하고 있는 경우에는, 허가된 제품의 제조에서 얻은\n\n지식을 타당한 범위 내에서 고려할 수 있다.\n\n 제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다.  이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n 무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n <!-- PAGE_33 -->\n### 2.6.  제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n 34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다. ",
        "original_sentence": "무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "<!-- PAGE_33 -->\n### 2.6. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 33,
        "window_text": "제조공정\n\n밸리데이션을\n\n통해,\n\n제조공정의\n\n중요,\n\n핵심\n\n파라미터를\n\n준수하고\n\n있으며 사전 정의한 품질특성을 일관되게 충족하는 제품을 생산함을 증명해야\n\n한다.  이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n 무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n <!-- PAGE_33 -->\n### 2.6.  제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n 34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다.  특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다. ",
        "original_sentence": "<!-- PAGE_33 -->\n### 2.6. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 97,
        "word_count": 20,
        "page_number": 8,
        "window_text": "이때에는 공정- 및 제품-관련 불순물에 대해 사람에게 의도된 용도에 허용\n\n가능한 수준으로, 재현 가능하며 일관되게 제거함을 증명해야 한다.\n\n 무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n <!-- PAGE_33 -->\n### 2.6.  제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n 34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다.  특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다.  이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다. ",
        "original_sentence": "제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 85,
        "word_count": 13,
        "page_number": 4,
        "window_text": "무균적\n\n공정과\n\n같은\n\n중요\n\n단계\n\n및\n\n완제의약품의\n\n무균상태가\n\n임상시험용\n\n의약품의 제조 시에 관리되고 있음을 밸리데이션하거나 적절히 증명해야 하지만,\n\n공정 밸리데에션은 초기 임상시험에서 사용되는 후보 백신에 대해서는 요구하지\n\n않는다.\n\n <!-- PAGE_33 -->\n### 2.6.  제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n 34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다.  특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다.  이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다.  특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n",
        "original_sentence": "34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 148,
        "word_count": 32,
        "page_number": 8,
        "window_text": "<!-- PAGE_33 -->\n### 2.6.  제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n 34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다.  특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다.  이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다.  특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n 상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n",
        "original_sentence": "특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 8,
        "window_text": "제품 특성 분석\n\n공정\n\n중\n\n시험\n\n및\n\n로트\n\n출하\n\n시험에\n\n추가적으로\n\nmRNA(원료의약품)와\n\n최종\n\n백신(완제의약품)의 특성 분석에 대한 요약을 제공해야 한다.\n\n 34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다.  특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다.  이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다.  특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n 상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n 제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다. ",
        "original_sentence": "이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 114,
        "word_count": 27,
        "page_number": 8,
        "window_text": "34/72\n\n상호보완적인(orthogonal)\n\n화학적,\n\n분자적,\n\n물리학적\n\n그리고\n\n생물학적\n\n방법을\n\n사용한 철저한 특성분석이 핵심적일 것이다.  특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다.  이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다.  특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n 상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n 제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다.  제조의 일관성은 이후 ‘2.7. ",
        "original_sentence": "특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 34,
        "window_text": "특성 분석이란 모든 로트에 대해\n\n일상적으로\n\n수행하지는\n\n않은\n\n연구와\n\n분석이지만,\n\n제조사는\n\n특성\n\n분석을\n\n통해\n\n공정과\n\n시험법의\n\n개발\n\n및\n\n개선에\n\n지침을\n\n제공해주는\n\n제품의\n\n구조\n\n및\n\n성능,\n\n안전성에 대하여 중요한 지식을 획득할 수 있다.  이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다.  특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n 상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n 제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다.  제조의 일관성은 이후 ‘2.7.  제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n",
        "original_sentence": "상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 58,
        "word_count": 10,
        "page_number": 8,
        "window_text": "이는 모든 로트에 대해 실시하는\n\n공정 중 시험 및 로트 출하 시험과 대비된다.  특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n 상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n 제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다.  제조의 일관성은 이후 ‘2.7.  제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n 캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5. ",
        "original_sentence": "제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "제조의 일관성은 이후 ‘2.7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 26,
        "window_text": "특히 대체 기술 사용 시 다른\n\n결과를 얻게 될 가능성이 있을 때(예: 다른 방법을 사용한 입자크기 측정)에는\n\n다양한\n\n파라미터\n\n결정을\n\n위한\n\n분석법\n\n선택의\n\n타당성\n\n입증을\n\n고려해야\n\n한다.\n\n 상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n 제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다.  제조의 일관성은 이후 ‘2.7.  제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n 캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5.  공정개발 및 공정 중 관리’).\n\n",
        "original_sentence": "제조의 일관성은 이후 ‘2.7. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 6,
        "window_text": "상호보완적 방법을 권고하는 것은 이러한 이유 때문이다.\n\n 제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다.  제조의 일관성은 이후 ‘2.7.  제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n 캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5.  공정개발 및 공정 중 관리’).\n\n 절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다. ",
        "original_sentence": "제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 76,
        "word_count": 14,
        "page_number": 8,
        "window_text": "제조한 mRNA군(population)의 서열을 확인하고 적절한 서열의 일관성 정도를\n\n정의해야 한다.  제조의 일관성은 이후 ‘2.7.  제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n 캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5.  공정개발 및 공정 중 관리’).\n\n 절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다.  특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n",
        "original_sentence": "캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5. "
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "공정개발 및 공정 중 관리’).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 8,
        "window_text": "제조의 일관성은 이후 ‘2.7.  제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n 캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5.  공정개발 및 공정 중 관리’).\n\n 절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다.  특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n 지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다. ",
        "original_sentence": "공정개발 및 공정 중 관리’).\n\n"
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 57,
        "word_count": 11,
        "page_number": 10,
        "window_text": "제조의 일관성’에서 더 심층적으로\n\n논하고\n\n있다.\n\n 캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5.  공정개발 및 공정 중 관리’).\n\n 절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다.  특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n 지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다.  특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n",
        "original_sentence": "절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 135,
        "word_count": 29,
        "page_number": 19,
        "window_text": "캡\n\n형성(capping)\n\n및\n\n폴리아데닐화의\n\n일관성\n\n정도\n\n역시\n\n특성\n\n분석되어야 하고 밸리데이션이 필요할 수 있다(‘2.5.  공정개발 및 공정 중 관리’).\n\n 절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다.  특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n 지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다.  특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n 지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다. ",
        "original_sentence": "특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 208,
        "word_count": 45,
        "page_number": 8,
        "window_text": "공정개발 및 공정 중 관리’).\n\n 절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다.  특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n 지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다.  특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n 지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다.  이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n",
        "original_sentence": "지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 93,
        "word_count": 15,
        "page_number": 8,
        "window_text": "절단되었거나\n\n대체\n\n형태를\n\n포함하지\n\n않은\n\n코딩된\n\n완전한\n\n단백질의\n\n발현을\n\n증명해야 한다.  특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n 지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다.  특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n 지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다.  이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n 지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n",
        "original_sentence": "특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 10,
        "window_text": "특히 특성 분석 연구 중 표적 항원이 절단되었거나 대체 형태의\n\n발현이\n\n증명되고\n\n이러한\n\n대체\n\n형태가\n\n신생-항원이나\n\n원하지\n\n않는\n\n면역반응\n\n발생으로\n\n귀결될\n\n수\n\n있다면,\n\nmRNA\n\n서열의\n\n재설계가\n\n필요할\n\n수\n\n있다.\n\n 지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다.  특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n 지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다.  이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n 지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n 이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n",
        "original_sentence": "지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 99,
        "word_count": 17,
        "page_number": 8,
        "window_text": "지질나노입자를 사용한 mRNA 봉입의 일관성 정도 역시 특성 분석에서 다루어야\n\n하며, 한편으로는 입자 흡입(particle uptake) 연구가 입자를 흡수하는 세포 타입의\n\n확인, 흡수 기작, 흡수 효율, 이러한 작용의 평가를 위한 최적의 무세포 혹은 체내\n\n시험법의 선택을 통해 잠재적인 역가 척도(potency measure)의 특성분석에 도움을\n\n줄 수도 있다.  특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n 지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다.  이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n 지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n 이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n 표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n",
        "original_sentence": "이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 153,
        "word_count": 31,
        "page_number": 8,
        "window_text": "특성분석 중에는, 이러한 특성 중 어느 것을 중요품질특성 및/또는\n\n안정성-지시(stability-indicating) 파라미터로 관리해야 하는가를 결정해야 한다.\n\n 지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다.  이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n 지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n 이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n 표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n 제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다. ",
        "original_sentence": "지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 35,
        "window_text": "지질나노입자의 특정 측면들은 매우 면밀하게 특성을 분석해야 한다.  이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n 지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n 이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n 표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n 제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다.  추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다. ",
        "original_sentence": "이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 54,
        "word_count": 11,
        "page_number": 8,
        "window_text": "이러한\n\n측면에는, mRNA를 함유한 지질나노입자의 형태학적 그리고 치수적(dimensional)\n\n특성을 탐색하기 위해 다른 분석기술을 활용하여 확인한 입자크기가 포함된다.\n\n 지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n 이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n 표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n 제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다.  추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다.  mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n",
        "original_sentence": "표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 105,
        "word_count": 22,
        "page_number": 17,
        "window_text": "지질나노입자 내 PEG(polyethylene glycol)의 밀도 및 분포는 제품의 안정성 및\n\n세포와의 상호작용, 면역학적 반응 특성에 영향을 주기 때문에, 이들에 대한 정보\n\n35/72\n\n역시 mRNA-지질나노입자 복합체의 표면 특성의 이해를 돕는데 유용할 것이다.\n\n 이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n 표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n 제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다.  추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다.  mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n 비임상\n\n평가’\n\n참조).\n\n",
        "original_sentence": "제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 56,
        "word_count": 11,
        "page_number": 19,
        "window_text": "이러한 정보는 또한 제조한 백신의 일관성을 확증하는 데 도움을 줄 것이다.\n\n 표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n 제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다.  추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다.  mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n 비임상\n\n평가’\n\n참조).\n\n 이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n",
        "original_sentence": "추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 184,
        "word_count": 36,
        "page_number": 8,
        "window_text": "표면전하 측정(예: 제타 전위) 또한 지질나노입자의 특성분석을 위한 방법으로\n\n간주해야 한다.\n\n 제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다.  추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다.  mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n 비임상\n\n평가’\n\n참조).\n\n 이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n 출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다. ",
        "original_sentence": "mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n"
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "비임상\n\n평가’\n\n참조).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 28,
        "window_text": "제품에서 이러한 특성의 중요성 때문에 제품의 특성분석과 그에 대한 이해를\n\n위해\n\n비임상\n\n연구에서는\n\nmRNA로\n\n코딩된\n\n표적\n\n항원이\n\n유도하는\n\n면역원성의\n\n특성을 분석해야 한다.  추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다.  mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n 비임상\n\n평가’\n\n참조).\n\n 이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n 출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다.  이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다. ",
        "original_sentence": "비임상\n\n평가’\n\n참조).\n\n"
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 2,
        "window_text": "추가적으로 지질나노입자가 내재적으로 면역조절 효과를\n\n지니고 있다면, 이 역시 특성분석이 필요하다.  mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n 비임상\n\n평가’\n\n참조).\n\n 이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n 출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다.  이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다.  정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다. ",
        "original_sentence": "이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 8,
        "window_text": "mRNA에 다른 면역조절 요소나\n\n유전자가 포함된 모든 경우에는, 특성분석을 실시한 제품 설계에 이들을 포함한\n\n바에\n\n대하여\n\n타당성을\n\n제시하기\n\n위해,\n\n이러한\n\n면역조절\n\n요소\n\n또는\n\n유전자가\n\nmRNA로\n\n코딩된\n\n표적\n\n항원의\n\n작용기전(예;\n\n면역원성)에\n\n기여하는\n\n부분\n\n또한\n\n측정해야\n\n한다(아래\n\n‘3.\n\n 비임상\n\n평가’\n\n참조).\n\n 이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n 출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다.  이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다.  정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다.  알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다. ",
        "original_sentence": "출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 241,
        "word_count": 49,
        "page_number": 23,
        "window_text": "비임상\n\n평가’\n\n참조).\n\n 이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n 출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다.  이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다.  정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다.  알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다.  분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다. ",
        "original_sentence": "이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 82,
        "word_count": 21,
        "page_number": 8,
        "window_text": "이러한\n\n사항은\n\n제품\n\n디자인을\n\n최적화하고 적절한 관리방법을 발전시키려는 제품 이해와 지식을 위해 중요하다.\n\n 출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다.  이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다.  정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다.  알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다.  분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다.  mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n",
        "original_sentence": "정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 67,
        "word_count": 16,
        "page_number": 8,
        "window_text": "출발물질 및 정제된 mRNA 내의 잠재적 제품 혹은 공정 유래 불순물에 대해\n\n기술하고 조사해야 한다.  이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다.  정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다.  알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다.  분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다.  mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n 완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다. ",
        "original_sentence": "알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다. "
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 97,
        "word_count": 20,
        "page_number": 8,
        "window_text": "이러한 불순물에는 잔여 세균 숙주-세포 단백질(DNA\n\n주형의 제조에 사용한 경우), 엔도톡신, 잔여 세균 숙주-세포 RNA 및 염색체\n\nDNA(DNA\n\n주형의\n\n제조에\n\n세균을\n\n사용한\n\n경우),\n\n효소(예\n\n:\n\nDNA\n\n및\n\nRNA\n\n중합효소,\n\n제한효소),\n\n통합되지\n\n않은\n\n뉴클레오티드,\n\n잘못\n\n접힌\n\nRNA,\n\ndsRNA,\n\n불완전하거나 크기가 다른 RNA, 그리고 제조공정에 사용된 기타 물질이 포함될\n\n수 있다.  정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다.  알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다.  분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다.  mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n 완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다.  이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n",
        "original_sentence": "분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 104,
        "word_count": 22,
        "page_number": 8,
        "window_text": "정제된 RNA에 존재하는 불순물에 대한 정보를, 이들의 최대 허용 가능\n\n또는 최저 달성 가능 수준에 대해 설정된 규격과 더불어, 제공해야 한다.  알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다.  분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다.  mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n 완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다.  이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n <!-- PAGE_36 -->\n### 2.7. ",
        "original_sentence": "mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 78,
        "word_count": 18,
        "page_number": 6,
        "window_text": "알려진\n\n또는 잠재적인 독성 효과가 있는 불순물 및 잔여물의 경우, 독성학적인 위해성\n\n평가를 수행할 것으로 기대한다.  분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다.  mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n 완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다.  이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n <!-- PAGE_36 -->\n### 2.7.  제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다. ",
        "original_sentence": "완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 16,
        "window_text": "분해된 RNA는 폴리아크릴아마이드나 아가로스\n\n겔 전기영동 및/또는 고성능 액체 크로마토그래피(HPLC), 모세 겔 전기영동과\n\n같은 분석 절차의 일부로서 평가할 수 있다.  mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n 완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다.  이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n <!-- PAGE_36 -->\n### 2.7.  제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다.  한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다. ",
        "original_sentence": "이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "<!-- PAGE_36 -->\n### 2.7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 36,
        "window_text": "mRNA의 서열 및 구조의 일관성\n\n정도\n\n그리고\n\nmRNA가\n\n세포로\n\nin vitro 형질주입\n\n시\n\n일관된\n\n단백질의\n\n발현은\n\n완제의약품에 대해 측정해야 할 중요한 특성들이다.\n\n 완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다.  이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n <!-- PAGE_36 -->\n### 2.7.  제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다.  한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다.  이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n",
        "original_sentence": "<!-- PAGE_36 -->\n### 2.7. "
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 113,
        "word_count": 24,
        "page_number": 5,
        "window_text": "완제의약품의 제조에 사용되는 지질로부터 유래할 수 있는 잠재적 불순물(공정\n\n36/72\n\n및 제품 유래)는 특성 분석 및 조사되어야 한다.  이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n <!-- PAGE_36 -->\n### 2.7.  제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다.  한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다.  이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n 초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다. ",
        "original_sentence": "제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 5,
        "window_text": "이것은 또한 불순물이 적절하게\n\n통제되고 임상적으로 결정된 허용 범위 내에서 제안된 규격 한계의 타당성을\n\n허용할 것이다.\n\n <!-- PAGE_36 -->\n### 2.7.  제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다.  한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다.  이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n 초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다.  일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n",
        "original_sentence": "한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 110,
        "word_count": 23,
        "page_number": 8,
        "window_text": "<!-- PAGE_36 -->\n### 2.7.  제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다.  한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다.  이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n 초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다.  일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n 로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다. ",
        "original_sentence": "이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 8,
        "window_text": "제조의 일관성\n\n다른\n\n생물의약품과\n\n마찬가지로,\n\n품목허가\n\n신청에\n\n앞서\n\n다수의\n\n연속\n\n배치에\n\n대하여 제조의 일관성을 확정하기 위해 밸리데에션된 방법을 사용해 시험 및\n\n분석을 수행해야 한다.  한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다.  이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n 초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다.  일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n 로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다.  그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다. ",
        "original_sentence": "초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 10,
        "window_text": "한 배치와 시험한 파라미터의 허용 가능 범위를 벗어난\n\n다른 배치 사이의 차이에 주목하고 연구해야 한다.  이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n 초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다.  일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n 로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다.  그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다.  제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n",
        "original_sentence": "일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 98,
        "word_count": 20,
        "page_number": 8,
        "window_text": "이러한 연구에서 얻은 자료를,\n\n제품과 공정에 대한 지식 및 일정한 특성상의 변동의 위험도(criticality) 평가와\n\n더불어, 선택한 규격의 타당성을 입증하기 위한 기반으로 사용해야 한다.\n\n 초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다.  일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n 로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다.  그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다.  제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n 비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n",
        "original_sentence": "로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 86,
        "word_count": 19,
        "page_number": 22,
        "window_text": "초기 임상 개발 중에는, 로트 생산이 적어 생산의 일관성 증명이 제한적이거나\n\n불가능할 수 있다.  일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n 로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다.  그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다.  제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n 비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n <!-- PAGE_36 -->\n### 2.8. ",
        "original_sentence": "그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 87,
        "word_count": 20,
        "page_number": 8,
        "window_text": "일관성을 증명하는 능력은 제품 개발 중 제조 경험을 획득함에\n\n따라\n\n증강될\n\n것이다.\n\n 로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다.  그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다.  제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n 비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n <!-- PAGE_36 -->\n### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2. ",
        "original_sentence": "제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 103,
        "word_count": 17,
        "page_number": 8,
        "window_text": "로트의\n\n일관성\n\n확증은\n\n일반적으로\n\n개발이\n\n진전된\n\n단계이지만(예: 상업적 제조를 위해 제조공정의 규모가 확대된 시점) 품목허가\n\n신청은 제출하기 이전에 실시하게 된다.  그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다.  제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n 비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n <!-- PAGE_36 -->\n### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다. ",
        "original_sentence": "비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "<!-- PAGE_36 -->\n### 2.8. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 36,
        "window_text": "그러나 일부 경우에는, 상업적 제조를\n\n위한\n\n생산\n\n규모\n\n확대를\n\n임상시험-규모\n\n물질에\n\n대해\n\n품목허가를\n\n구하는\n\n동안\n\n실시하게 될 수 있다.  제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n 비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n <!-- PAGE_36 -->\n### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다.  유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n",
        "original_sentence": "<!-- PAGE_36 -->\n### 2.8. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 8,
        "window_text": "제조공정에 변경을 실시할 때마다, 특히 핵심 연구에 사용한\n\n로트 및 계획한 상업적 공정으로 제조한 로트에 대하여 로트의 비교동등성을\n\n입증해야\n\n한다.\n\n 비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n <!-- PAGE_36 -->\n### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다.  유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n 완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다. ",
        "original_sentence": "정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2. "
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 180,
        "word_count": 36,
        "page_number": 2,
        "window_text": "비교동등성\n\n시험계획서\n\n및\n\n비교동등성\n\n증명을\n\n위한\n\n전략은\n\n‘생물의약품의\n\n제조방법\n\n변경에\n\n따른\n\n비교동등성\n\n평가\n\n가이드라인(식약처,\n\n2019)’에서 논하고 있다.\n\n <!-- PAGE_36 -->\n### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다.  유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n 완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다.  도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다. ",
        "original_sentence": "제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 63,
        "word_count": 10,
        "page_number": 8,
        "window_text": "<!-- PAGE_36 -->\n### 2.8.  정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다.  유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n 완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다.  도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다.  mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n",
        "original_sentence": "유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 8,
        "window_text": "정제 mRNA 원액(원료의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다.  유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n 완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다.  도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다.  mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n",
        "original_sentence": "완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 64,
        "word_count": 17,
        "page_number": 8,
        "window_text": "제조에 관한 사항’에서 기술한 바와 같이, mRNA의 개발 및 제조에\n\n관한 개요에는 표적 항원 유전자 및 mRNA 서열에 포함된 다른 유전자(들), UTR, 5’\n\ncap,\n\n3’\n\npoly(A)\n\ntail,\n\n사용된\n\n조절\n\n성분(regulatory\n\nelement)을\n\n선택한\n\n근거를\n\n37/72\n\n포함해야 한다.  유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n 완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다.  도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다.  mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n 예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다. ",
        "original_sentence": "도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 108,
        "word_count": 29,
        "page_number": 5,
        "window_text": "유전자 발현 또는 다른 최적화 변형(optimization modification)에\n\n대하여 서술해야 한다.\n\n 완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다.  도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다.  mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n 예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다.  만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n",
        "original_sentence": "mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 127,
        "word_count": 25,
        "page_number": 8,
        "window_text": "완전한 DNA 주형 및 mRNA의 서열에 대하여 주석을\n\n첨부하여 제공해야 한다.  도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다.  mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n 예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다.  만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n <!-- PAGE_37 -->\n### 2.8.1. ",
        "original_sentence": "sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 103,
        "word_count": 22,
        "page_number": 8,
        "window_text": "도해식이며 주석을 덧붙인 흐름도 그리고 제조 및 공정 중\n\n관리, 출하 시험에 대한 구현식 서술을 제공해야 한다.  mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n 예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다.  만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n <!-- PAGE_37 -->\n### 2.8.1.  원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다. ",
        "original_sentence": "예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 113,
        "word_count": 25,
        "page_number": 8,
        "window_text": "mRNA 백신의 품질 및\n\n안전성, 유효성에 영향을 줄 수 있는 생산 및 관리 절차에 대한 유의한 변경과 함께,\n\n세부적인 생산 및 관리 절차에 대하여 식약처와 논의하고 승인을 받아야 한다.\n\n sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n 예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다.  만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n <!-- PAGE_37 -->\n### 2.8.1.  원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다.  사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n",
        "original_sentence": "만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "<!-- PAGE_37 -->\n### 2.8.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 37,
        "window_text": "sa-mRNA의 경우, 복제효소와 표적 항원이 별도의 mRNA에 발현된다면, 이에\n\n대해 기술하고 제공되는 흐름도에서 명확히 설명해야 하며, 여기에는 추가적인\n\n제조공정\n\n및/또는\n\n품질관리\n\n시험\n\n역시\n\n포함해야\n\n한다.\n\n 예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다.  만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n <!-- PAGE_37 -->\n### 2.8.1.  원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다.  사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n 상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다. ",
        "original_sentence": "<!-- PAGE_37 -->\n### 2.8.1. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 95,
        "word_count": 23,
        "page_number": 8,
        "window_text": "예를\n\n들어,\n\n만일\n\n복제효소-코딩 mRNA 분자와 표적-항원-코딩 mRNA 분자 두 가지 모두를 동일한\n\n지질나노입자에 봉입했다면, 이 분자들의 비율에 대한 관리를 고려해야 한다.  만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n <!-- PAGE_37 -->\n### 2.8.1.  원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다.  사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n 상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다.  저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n",
        "original_sentence": "원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 55,
        "word_count": 13,
        "page_number": 8,
        "window_text": "만일\n\n각각의\n\nmRNA가\n\n봉입되고\n\n혼합된다면\n\n각각이\n\n생체\n\n내에서\n\n동일한\n\n세포에서\n\n흡수되어야 하는 방법 및 필요 여부와 효능 및 면역원성에 대한 의미에 대한\n\n타당성이 제시되어야 한다.\n\n <!-- PAGE_37 -->\n### 2.8.1.  원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다.  사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n 상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다.  저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n 개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다. ",
        "original_sentence": "사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 27,
        "window_text": "<!-- PAGE_37 -->\n### 2.8.1.  원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다.  사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n 상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다.  저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n 개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다.  개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n",
        "original_sentence": "상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 17,
        "window_text": "원액 정제 mRNA의 관리\n\n원액 정제 mRNA의 확인 및 순도, 함량, 물리적 상태, 안전성, 품질에 대한\n\n중요품질특성 관련 규격을 확립하고 타당성을 입증해야 한다.  사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n 상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다.  저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n 개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다.  개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n 제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다. ",
        "original_sentence": "저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 152,
        "word_count": 31,
        "page_number": 27,
        "window_text": "사용한 분석법에\n\n대해 설명하고, 허용 한계의 정의 및 분석법 밸리데에션에 대해 기술해야 한다.\n\n 상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다.  저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n 개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다.  개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n 제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다.  일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다. ",
        "original_sentence": "개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 104,
        "word_count": 24,
        "page_number": 8,
        "window_text": "상업적 규모로 생산한 모든 배치의 시험 결과를 요약하여 제공해야 한다.  저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n 개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다.  개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n 제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다.  일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다.  그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n",
        "original_sentence": "개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 10,
        "window_text": "저장\n\n조건 하의 안정성에 대한 규격도 설정해야 한다.\n\n 개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다.  개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n 제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다.  일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다.  그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n 그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n",
        "original_sentence": "제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다. "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 87,
        "word_count": 21,
        "page_number": 8,
        "window_text": "개발 초기에, 임상시험 승인을 뒷받침하기 위하여, GMP에 따라 제조한 배치\n\n시험의 결과와 확보 가능하다면, 제조 절차 확립을 위해 실시한 생산 점검용\n\n가동(engineering\n\nrun)으로\n\n생산한\n\n배치의\n\n시험에서\n\n도출한\n\n결과를\n\n요약하여\n\n제공해야 한다.  개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n 제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다.  일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다.  그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n 그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n 원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다. ",
        "original_sentence": "일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 95,
        "word_count": 21,
        "page_number": 8,
        "window_text": "개발 초기에는 규격이 제한적이며 허용기준은 다소 광범위할 수\n\n있으나, 제조공정 및 분석법에 대한 경험을 획득함에 따라, 적절한 경우, 규격 및\n\n기준을\n\n검토하고\n\n강화해야\n\n한다.\n\n 제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다.  일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다.  그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n 그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n 원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다.  규격에 대한 근거를 제시해야 한다. ",
        "original_sentence": "그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 27,
        "window_text": "제품\n\n특성\n\n분석\n\n중\n\n진행하는\n\n모든\n\n시험을\n\n출하시험으로서 각 백신 배치에 대해 실시할 필요는 없다.  일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다.  그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n 그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n 원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다.  규격에 대한 근거를 제시해야 한다.  또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n",
        "original_sentence": "그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 97,
        "word_count": 25,
        "page_number": 8,
        "window_text": "일부 시험은 생산 방법\n\n38/72\n\n및 생산의 일관성 확립을 위하여 제한적인 일련의 배치에 대해 제품 및 공정\n\n지식을 획득하려는 목적으로서만 필요하다.  그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n 그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n 원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다.  규격에 대한 근거를 제시해야 한다.  또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n <!-- PAGE_38 -->\n### 2.8.1.1. ",
        "original_sentence": "원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다. "
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "규격에 대한 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 17,
        "window_text": "그러므로, 원료의약품의 확인 및 순도,\n\n품질, 안전성, 안정성과 관련하여 일관성 확립을 위해 최초의 상업적 생산 배치에\n\n대해\n\n포괄적인\n\n분석을\n\n실시해야\n\n한다.\n\n 그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n 원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다.  규격에 대한 근거를 제시해야 한다.  또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n <!-- PAGE_38 -->\n### 2.8.1.1.  확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다. ",
        "original_sentence": "규격에 대한 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 8,
        "window_text": "그\n\n후\n\n식약처가\n\n동의한\n\n바에\n\n따라\n\n품질관리를 위한 제한적인 일련의 시험이 적절할 수 있다.\n\n 원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다.  규격에 대한 근거를 제시해야 한다.  또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n <!-- PAGE_38 -->\n### 2.8.1.1.  확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다.  확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n",
        "original_sentence": "또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "<!-- PAGE_38 -->\n### 2.8.1.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 38,
        "window_text": "원액 정제 mRNA에 관한 규격에는 최소한 mRNA의 확인, 순도 및 물리적\n\n상태와 양, 엔도톡신 함량 및 무균, 미생물 한도에 대한 평가를 포함해야 할 것을\n\n권고한다.  규격에 대한 근거를 제시해야 한다.  또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n <!-- PAGE_38 -->\n### 2.8.1.1.  확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다.  확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n 확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다. ",
        "original_sentence": "<!-- PAGE_38 -->\n### 2.8.1.1. "
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 8,
        "window_text": "규격에 대한 근거를 제시해야 한다.  또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n <!-- PAGE_38 -->\n### 2.8.1.1.  확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다.  확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n 확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다.  mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n",
        "original_sentence": "확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 123,
        "word_count": 22,
        "page_number": 8,
        "window_text": "또한 보관조건 하에서의 안정성에\n\n대하여 규격을 수립해야 한다.\n\n <!-- PAGE_38 -->\n### 2.8.1.1.  확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다.  확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n 확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다.  mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n <!-- PAGE_38 -->\n### 2.8.1.2. ",
        "original_sentence": "확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 165,
        "word_count": 37,
        "page_number": 8,
        "window_text": "<!-- PAGE_38 -->\n### 2.8.1.1.  확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다.  확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n 확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다.  mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n <!-- PAGE_38 -->\n### 2.8.1.2.  순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n",
        "original_sentence": "확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 8,
        "window_text": "확인\n\n원액 정제 mRNA 각 배치의 확인시험을 수행해야 한다.  확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n 확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다.  mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n <!-- PAGE_38 -->\n### 2.8.1.2.  순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n 불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다. ",
        "original_sentence": "mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "<!-- PAGE_38 -->\n### 2.8.1.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 38,
        "window_text": "확인시험에는 직접\n\nRNA 서열분석, 또는 RT-PCR 산물의 서열분석(또는 이 산물의 존재나 부재를\n\n측정), 초고속 차세대(high-throughput) 서열분석을 통한 mRNA 염기서열 판정을\n\n포함해야\n\n한다.\n\n 확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다.  mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n <!-- PAGE_38 -->\n### 2.8.1.2.  순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n 불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다.  이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_38 -->\n### 2.8.1.2. "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 8,
        "window_text": "확인이\n\n전체\n\nmRNA\n\n서열\n\n중\n\n일부만을\n\n대표하는\n\nRT-PCR\n\namplicon을 기반으로 한다면, 선택한 서열은 해당 mRNA 제품(부속 및 조절 영역\n\n포함)에 고유한 것이어야 하며, 동일 시설이나 동일 장비를 이용하여 제조했을 수\n\n있는 다른 제품에 공통된 것이어서는 안 된다.  mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n <!-- PAGE_38 -->\n### 2.8.1.2.  순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n 불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다.  이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n 모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다. ",
        "original_sentence": "순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 101,
        "word_count": 21,
        "page_number": 22,
        "window_text": "mRNA의 확인 및 순도에 대한\n\n검증을 위해서는 전체 mRNA 염기서열을 분석하는 것이 더 적절할 수 있다.\n\n <!-- PAGE_38 -->\n### 2.8.1.2.  순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n 불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다.  이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n 모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다.  분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n",
        "original_sentence": "불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 71,
        "word_count": 18,
        "page_number": 8,
        "window_text": "<!-- PAGE_38 -->\n### 2.8.1.2.  순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n 불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다.  이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n 모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다.  분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n 크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n",
        "original_sentence": "이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 81,
        "word_count": 17,
        "page_number": 8,
        "window_text": "순도 및 불순물\n\n모원액 정제 mRNA의 각 배치를 순도에 대해 시험해야 하며, 결과는 확립된\n\n한도\n\n내에\n\n포함되어야\n\n한다.\n\n 불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다.  이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n 모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다.  분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n 크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n 잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다. ",
        "original_sentence": "모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 115,
        "word_count": 27,
        "page_number": 8,
        "window_text": "불순물\n\n관리에서는,\n\nDNA\n\n주형,\n\n통합되지\n\n않은\n\n뉴클레오티드, 통합되지 않은 cap, 효소, mRNA 분절, dsRNA와 같은, 제조 중\n\n도입된 물질도 다루어야 한다.  이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n 모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다.  분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n 크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n 잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다.  순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다. ",
        "original_sentence": "분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 6,
        "window_text": "이는 공정-관련 불순물의 제거를 확립하기 위한\n\n공정 밸리데이션 또는 잔류 불순물에 대한 출하 시험을 통해 완수할 수 있다.\n\n 모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다.  분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n 크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n 잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다.  순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다.  강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n",
        "original_sentence": "크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 6,
        "window_text": "모든 공정에서 dsRNA가 생성되지는 않기 때문에, dsRNA에 대한 시험의 필요성\n\n39/72\n\n고려 시에는 제조공정의 설계를 참작해야 한다.  분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n 크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n 잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다.  순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다.  강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n 품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n",
        "original_sentence": "잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 84,
        "word_count": 19,
        "page_number": 8,
        "window_text": "분석에는 공정 및 제품 관련\n\n불순물에 대한 민감하고 신뢰할 수 있는 시험을 포함해야 하며, 원액 정제 mRNA\n\n내의\n\n함량에\n\n대하여\n\n엄격한\n\n상한(최대\n\n허용\n\n가능\n\n한도)을\n\n명시해야\n\n한다.\n\n 크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n 잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다.  순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다.  강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n 품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n 공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n",
        "original_sentence": "순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 141,
        "word_count": 32,
        "page_number": 8,
        "window_text": "크로마토그래피\n\n검출법을\n\n고려할\n\n수\n\n있다.\n\n 잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다.  순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다.  강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n 품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n 공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n 공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n",
        "original_sentence": "강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 139,
        "word_count": 26,
        "page_number": 8,
        "window_text": "잔여\n\nDNA\n\n주형은\n\n정량\n\nPCR로\n\n정량화할 수도 있다.  순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다.  강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n 품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n 공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n 공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n 공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n",
        "original_sentence": "품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 49,
        "word_count": 10,
        "page_number": 8,
        "window_text": "순도를 증명하고 불순물을 측정하기 위해 사용하는 기술은\n\n가능한 한 광범위한 이화학적 및/또는 생물학적 분자적 특성을 기반으로 하는\n\n것이 중요하다.  강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n 품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n 공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n 공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n 공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n 용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n",
        "original_sentence": "공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 75,
        "word_count": 16,
        "page_number": 8,
        "window_text": "강제 분해(forced degradation) 연구와 같은 방법의 결과에 대해\n\n고려함으로써, 출하 시 및/또는 안정성 시험계획서에서, 생산 중 순도시험을 통해\n\n시험 및/또는 측정이 필요한 제픔 유래 불순물에 대한 결정 시 지침을 얻을 수\n\n있다.\n\n 품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n 공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n 공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n 공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n 용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n <!-- PAGE_39 -->\n### 2.8.1.3. ",
        "original_sentence": "공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 76,
        "word_count": 16,
        "page_number": 8,
        "window_text": "품질관리의 일환으로서 공정- 또는 제품-관련 잔여 불순물 수준에 대한 시험은,\n\n불순물의\n\n적절한\n\n제거에\n\n대하여\n\n생산공정을\n\n적절하게\n\n밸리데이션하고\n\n생산의\n\n일관성을\n\n증명한다면,\n\n식약처의\n\n동의하에\n\n축소하거나\n\n중단할\n\n수\n\n있다.\n\n 공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n 공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n 공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n 용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n <!-- PAGE_39 -->\n### 2.8.1.3.  정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n",
        "original_sentence": "공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 90,
        "word_count": 16,
        "page_number": 8,
        "window_text": "공정의\n\n주기적 재밸리데이션에\n\n관한\n\n계획\n\n및\n\n규격에\n\n대해\n\n기술해야\n\n한다.\n\n 공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n 공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n 용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n <!-- PAGE_39 -->\n### 2.8.1.3.  정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n 따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n",
        "original_sentence": "용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "<!-- PAGE_39 -->\n### 2.8.1.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 39,
        "window_text": "공정이\n\n밸리데이션될 때까지, 식약처가 동의한 바와 같이 다수의 로트에 대하여 불순물\n\n시험\n\n및/또는\n\n측정을\n\n지속해야\n\n한다.\n\n 공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n 용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n <!-- PAGE_39 -->\n### 2.8.1.3.  정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n 따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n 3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다. ",
        "original_sentence": "<!-- PAGE_39 -->\n### 2.8.1.3. "
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 63,
        "word_count": 12,
        "page_number": 8,
        "window_text": "공정에\n\n중요한\n\n변경을\n\n도입한\n\n경우,\n\n식약처가 동의한 다수의 로트에 대하여 재검정이나 지속적인 측정을 시행할 것을\n\n기대한다.\n\n 용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n <!-- PAGE_39 -->\n### 2.8.1.3.  정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n 따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n 3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다.  DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n",
        "original_sentence": "정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 116,
        "word_count": 24,
        "page_number": 8,
        "window_text": "용기-마개\n\n시스템\n\n적합성\n\n그리고\n\n용출물\n\n및\n\n추출물(leachable\n\nand\n\nextractable) 역시 평가하고 품목허가 신청 시 논해야 한다.\n\n <!-- PAGE_39 -->\n### 2.8.1.3.  정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n 따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n 3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다.  DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n 40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n",
        "original_sentence": "따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 8,
        "window_text": "<!-- PAGE_39 -->\n### 2.8.1.3.  정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n 따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n 3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다.  DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n 40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n 이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다. ",
        "original_sentence": "3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다. "
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 138,
        "word_count": 29,
        "page_number": 8,
        "window_text": "정량화 및 물리적 상태\n\nmRNA\n\n구조의\n\n완전성은\n\nmRNA\n\n출하를\n\n위한\n\n중요품질특성으로\n\n간주한다.\n\n 따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n 3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다.  DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n 40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n 이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다.  mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n",
        "original_sentence": "DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 77,
        "word_count": 15,
        "page_number": 8,
        "window_text": "따라서 mRNA의 완전성, 5’ cap 형성 효율, 3’ poly(A) tail의 존재 및 길이, 순도\n\n시험,\n\nmRNA\n\n분절\n\n비율(%),\n\ndsRNA\n\n비율(%)\n\n등에\n\n대한\n\n관리가\n\n필요하다.\n\n 3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다.  DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n 40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n 이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다.  mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n 따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n",
        "original_sentence": "40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 61,
        "word_count": 13,
        "page_number": 5,
        "window_text": "3’\n\npoly(A) tail의 존재 및 길이 측정에 대한 필요성은 mRNA에 이 서열을 추가하는\n\n방식에 따라 달라진다.  DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n 40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n 이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다.  mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n 따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.4. ",
        "original_sentence": "이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 75,
        "word_count": 14,
        "page_number": 8,
        "window_text": "DNA 주형에 코딩되어 있다면, 전장 mRNA에 3’ poly(A)\n\ntail이 포함되어 있어야 하지만, IVT 이후 효소 처리를 통해 추가한 경우라면, 이\n\n파라미터는\n\n시험이나\n\n공정\n\n밸리데에션을\n\n통해\n\n다루는\n\n것이\n\n적절할\n\n것이다.\n\n 40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n 이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다.  mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n 따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.4.  안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다. ",
        "original_sentence": "mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 140,
        "word_count": 23,
        "page_number": 8,
        "window_text": "40/72\n\n마찬가지로, dsRNA는 사용한 공정이 dsRNA를 불순물로서 생성할 수 있는가에\n\n따라\n\n그\n\n존재\n\n여부가\n\n결정된다.\n\n 이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다.  mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n 따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.4.  안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다.  여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다. ",
        "original_sentence": "따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "<!-- PAGE_40 -->\n### 2.8.1.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 40,
        "window_text": "이러한\n\n목적으로\n\n겔\n\n전기영동\n\n또는\n\nPCR,\n\n크로마토그래피 검출법과 같은 시험을 고려할 수도 있다.  mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n 따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.4.  안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다.  여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다.  식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n",
        "original_sentence": "<!-- PAGE_40 -->\n### 2.8.1.4. "
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 14,
        "window_text": "mRNA 정량화는 백신\n\n용량\n\n설정의\n\n기반이며\n\n온전한\n\nmRNA는\n\n백신의\n\n작용기전에\n\n핵심이라는\n\n점을\n\n명심해야\n\n한다.\n\n 따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.4.  안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다.  여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다.  식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n 그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n",
        "original_sentence": "안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 133,
        "word_count": 29,
        "page_number": 17,
        "window_text": "따라서\n\nmRNA\n\n정량화를\n\n위해\n\n사용하는\n\n방법(예\n\n:\n\n자외선\n\n분광광도법(UV\n\nspectrophotometry))\n\n그리고\n\n온전한(intact)\n\nmRNA의\n\n정량화를\n\n위해 사용하는 방법(예 : 겔 전기영동)에 대해 기술해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.4.  안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다.  여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다.  식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n 그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n",
        "original_sentence": "여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 70,
        "word_count": 10,
        "page_number": 8,
        "window_text": "<!-- PAGE_40 -->\n### 2.8.1.4.  안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다.  여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다.  식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n 그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.5. ",
        "original_sentence": "식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n"
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 8,
        "window_text": "안전성 특성\n\n관련된 안전성 시험에 대하여 기술해야 한다.  여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다.  식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n 그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.5.  추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다. ",
        "original_sentence": "그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 142,
        "word_count": 33,
        "page_number": 8,
        "window_text": "여기에는 세균과 진균에 대한\n\n무균시험(시험 물질 내의 세균과 진균의 비활성 증명을 포함) 또는 미생물 한도\n\n시험(함량,\n\n미생물\n\n동정,\n\n그리고\n\n명시된\n\n불필요한\n\n유기체의\n\n부정)과\n\n더불어,\n\n엔도톡신 시험을 포함할 수 있다.  식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n 그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.5.  추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다.  추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2. ",
        "original_sentence": "과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "<!-- PAGE_40 -->\n### 2.8.1.5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 40,
        "window_text": "식약처가 요구한다면, 발열원성(pyrogenicity)\n\n시험을\n\n수행해야\n\n한다(단핵구\n\n활성화\n\n시험일\n\n수\n\n있음).\n\n 그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.5.  추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다.  추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2.  순도 및 불순물’ 참조).\n\n",
        "original_sentence": "<!-- PAGE_40 -->\n### 2.8.1.5. "
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 69,
        "word_count": 15,
        "page_number": 8,
        "window_text": "그러나\n\n실시\n\n및\n\n허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.5.  추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다.  추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2.  순도 및 불순물’ 참조).\n\n <!-- PAGE_40 -->\n### 2.8.1.6. ",
        "original_sentence": "추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 120,
        "word_count": 25,
        "page_number": 8,
        "window_text": "과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_40 -->\n### 2.8.1.5.  추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다.  추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2.  순도 및 불순물’ 참조).\n\n <!-- PAGE_40 -->\n### 2.8.1.6.  참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n",
        "original_sentence": "추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2. "
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "순도 및 불순물’ 참조).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "<!-- PAGE_40 -->\n### 2.8.1.5.  추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다.  추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2.  순도 및 불순물’ 참조).\n\n <!-- PAGE_40 -->\n### 2.8.1.6.  참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n 원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n",
        "original_sentence": "순도 및 불순물’ 참조).\n\n"
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "<!-- PAGE_40 -->\n### 2.8.1.6. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 40,
        "window_text": "추가적 품질 파라미터\n\n추가적인 중요한 품질특성(예: 성상, pH, 그리고, 해당 시, 점도)을 수립하고\n\n관리해야 한다.  추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2.  순도 및 불순물’ 참조).\n\n <!-- PAGE_40 -->\n### 2.8.1.6.  참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n 원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n 적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다. ",
        "original_sentence": "<!-- PAGE_40 -->\n### 2.8.1.6. "
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 104,
        "word_count": 15,
        "page_number": 8,
        "window_text": "추가로, mRNA와 관련된 다수의 주요품질특성(예: poly(A) tail의\n\n길이 및 캡 형성 효율)이 있으며, 순도 및 불순물과 관련하여 앞서 언급한 바와\n\n같이, 이들에 대한 관리가 필요하다(‘2.8.1.2.  순도 및 불순물’ 참조).\n\n <!-- PAGE_40 -->\n### 2.8.1.6.  참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n 원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n 적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다.  참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n",
        "original_sentence": "참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 5,
        "window_text": "순도 및 불순물’ 참조).\n\n <!-- PAGE_40 -->\n### 2.8.1.6.  참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n 원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n 적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다.  참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n 참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다. ",
        "original_sentence": "원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 120,
        "word_count": 28,
        "page_number": 8,
        "window_text": "<!-- PAGE_40 -->\n### 2.8.1.6.  참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n 원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n 적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다.  참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n 참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다.  최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n",
        "original_sentence": "적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 27,
        "window_text": "참조물질\n\n분석시험의 표준화 및 비교동등성 평가에 사용할 내부(in-house) 참조물질(즉,\n\n41/72\n\n작업용\n\n표준물질(working\n\nstandard))을\n\n확립해야\n\n한다.\n\n 원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n 적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다.  참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n 참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다.  최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n 개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n",
        "original_sentence": "참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 72,
        "word_count": 14,
        "page_number": 23,
        "window_text": "원액\n\n정제\n\nmRNA의\n\n시험에 사용하는 표준물질 또는 참조물질에 대한 정보를 품목허가 신청 시까지\n\n제공해야 한다.\n\n 적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다.  참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n 참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다.  최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n 개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n <!-- PAGE_41 -->\n### 2.8.1.7. ",
        "original_sentence": "참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 18,
        "window_text": "적합한 배치(즉, 임상적으로 평가한 배치)를 그 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전한 특성분석을 실시하고, 적합한 검체를 화학 및\n\n생물학적 참조물질로 사용하기 위해 보관해야 한다.  참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n 참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다.  최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n 개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n <!-- PAGE_41 -->\n### 2.8.1.7.  안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다. ",
        "original_sentence": "최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 180,
        "word_count": 40,
        "page_number": 8,
        "window_text": "참조물질은 적절한 형태로\n\n제형화해야\n\n한다.\n\n 참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다.  최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n 개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n <!-- PAGE_41 -->\n### 2.8.1.7.  안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다.  수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n",
        "original_sentence": "개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "<!-- PAGE_41 -->\n### 2.8.1.7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 41,
        "window_text": "참조물질이\n\n안정적이라고\n\n증명된\n\n조건에서\n\n저장해야\n\n하며\n\n이러한 안정성 모니터링을 위한 일상적 프로그램을 실시해야 한다.  최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n 개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n <!-- PAGE_41 -->\n### 2.8.1.7.  안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다.  수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n 요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n",
        "original_sentence": "<!-- PAGE_41 -->\n### 2.8.1.7. "
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 64,
        "word_count": 10,
        "page_number": 4,
        "window_text": "최초 참조물질\n\n소진 시 이를 대체하기 위한 계획에 대하여 식약처의 동의가 필요하다.\n\n 개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n <!-- PAGE_41 -->\n### 2.8.1.7.  안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다.  수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n 요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n 원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다. ",
        "original_sentence": "안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 82,
        "word_count": 18,
        "page_number": 8,
        "window_text": "개발 초기에는(예: 초기 임상시험), 개발 후기(예: 핵심 임상시험) 및 상업적 제조\n\n시\n\n참조물질로\n\n사용하기\n\n위해\n\n적합한\n\n임상시험\n\n배치를\n\n확인하고\n\n특성분석을\n\n완료할 때까지, 생산 점검용 생산 배치 또는 핵심 비임상 연구에서 사용하는\n\nmRNA 백신 로트가 만들어지는 배치를 참조물질로 사용할 수 있다.\n\n <!-- PAGE_41 -->\n### 2.8.1.7.  안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다.  수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n 요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n 원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다.  만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n",
        "original_sentence": "수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 8,
        "window_text": "<!-- PAGE_41 -->\n### 2.8.1.7.  안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다.  수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n 요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n 원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다.  만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n <!-- PAGE_41 -->\n### 2.9. ",
        "original_sentence": "요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 99,
        "word_count": 22,
        "page_number": 5,
        "window_text": "안정성\n\n안정성\n\n평가는‘생물의약품\n\n안전성\n\n시험\n\n가이드라인(식약처,\n\n2015)’에\n\n따라\n\n수행해야 한다.  수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n 요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n 원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다.  만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n <!-- PAGE_41 -->\n### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2. ",
        "original_sentence": "원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 8,
        "window_text": "수행한 연구의 종류 및 준수한 연구계획서, 연구 결과를 구연식\n\n문서와\n\n함께\n\n도표나\n\n그래프와\n\n같은\n\n적절한\n\n서식으로\n\n요약해야\n\n한다.\n\n 요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n 원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다.  만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n <!-- PAGE_41 -->\n### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다. ",
        "original_sentence": "만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "<!-- PAGE_41 -->\n### 2.9. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 41,
        "window_text": "요약\n\n자료에는 적절한 보관조건 또는 유효기간에 관한 결론뿐 아니라 결과를 포함해야\n\n한다.\n\n 원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다.  만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n <!-- PAGE_41 -->\n### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다.  지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다. ",
        "original_sentence": "<!-- PAGE_41 -->\n### 2.9. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 8,
        "window_text": "원액(혹은\n\n보관된\n\n중간체)의\n\n유효기간\n\n및\n\n차후\n\n유효기간의\n\n연장을\n\n뒷받침하기 위한 안정성 자료는 실제 조건 하에서 실시간 장기 안정성 연구를\n\n기반으로 해야 한다.  만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n <!-- PAGE_41 -->\n### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다.  지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다.  원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다. ",
        "original_sentence": "최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2. "
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 116,
        "word_count": 29,
        "page_number": 2,
        "window_text": "만일 중간체나 원료의약품의 운송이 있다면 적절한 온도와\n\n조건 하에서 수행된 운송 밸리데이션이 요구된다.\n\n <!-- PAGE_41 -->\n### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다.  지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다.  원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다.  이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다. ",
        "original_sentence": "제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 20,
        "window_text": "<!-- PAGE_41 -->\n### 2.9.  최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다.  지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다.  원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다.  이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다.  최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n",
        "original_sentence": "지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 73,
        "word_count": 12,
        "page_number": 8,
        "window_text": "최종 제형화 백신(완제의약품)의 제조 및 관리\n\n앞서 ‘2.2.  제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다.  지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다.  원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다.  이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다.  최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.1. ",
        "original_sentence": "원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 52,
        "word_count": 14,
        "page_number": 8,
        "window_text": "제조에 관한 사항’에서 기술한 바와 같이, 백신의 개발 및 제조에\n\n관한 개요에는 제조 및 공정 중 관리, 출하시험에 대해 도해식의 주석을 첨부한\n\n42/72\n\n흐름도, 그리고 구연식 서술을 포함해야 한다.  지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다.  원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다.  이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다.  최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.1.  조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n",
        "original_sentence": "이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 8,
        "window_text": "지질나노입자의 적절한 제형화를\n\n확인하기 위해 사용한 방법을 자세히 설명해야 한다.  원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다.  이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다.  최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.1.  조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n 각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n",
        "original_sentence": "최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "<!-- PAGE_42 -->\n### 2.9.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 42,
        "window_text": "원액 제형화 또는 원액\n\n지질나노입자에\n\n대해\n\n제안한\n\n정치시간(hold-time)을\n\n적절히\n\n명시하고\n\n밸리데에션해야 한다.  이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다.  최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.1.  조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n 각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.2. ",
        "original_sentence": "<!-- PAGE_42 -->\n### 2.9.1. "
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 138,
        "word_count": 31,
        "page_number": 8,
        "window_text": "이 정치 시간 중의 이화학적 안정성 및 미생물 관리를\n\n보장하는 데 적절한 고려가 필요하다.  최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.1.  조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n 각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.2.  지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n",
        "original_sentence": "조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 14,
        "window_text": "최종 제형화 및 충전, 마감에 사용한 방법을\n\n설명하고 적절히 밸리데이션해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.1.  조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n 각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.2.  지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n 제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n",
        "original_sentence": "각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "<!-- PAGE_42 -->\n### 2.9.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 42,
        "window_text": "<!-- PAGE_42 -->\n### 2.9.1.  조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n 각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.2.  지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n 제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n 지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다. ",
        "original_sentence": "<!-- PAGE_42 -->\n### 2.9.2. "
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 71,
        "word_count": 15,
        "page_number": 8,
        "window_text": "조성\n\n원료의약품(mRNA) 및 모든 첨가제(예: 지질)를 포함하여 백신의 최종 조성에\n\n대해 - 특히 두 가지 이상의 용량이나 제형에 대해 품목허가를 계획하고 있다면 -\n\n각\n\n포장단위\n\n내의\n\n구성성분들의\n\n함량과\n\n함께\n\n기술해야\n\n한다.\n\n 각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.2.  지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n 제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n 지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다.  적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다. ",
        "original_sentence": "지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 8,
        "window_text": "각\n\n구성성분의\n\n기능에 대해서도 기술해야 한다.\n\n <!-- PAGE_42 -->\n### 2.9.2.  지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n 제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n 지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다.  적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다.  이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다. ",
        "original_sentence": "제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 51,
        "word_count": 9,
        "page_number": 8,
        "window_text": "<!-- PAGE_42 -->\n### 2.9.2.  지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n 제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n 지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다.  적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다.  이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다.  그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다. ",
        "original_sentence": "지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 52,
        "word_count": 9,
        "page_number": 8,
        "window_text": "지질나노입자의 제조와 관리 그리고 mRNA 봉입\n\n지질나노입자의 적절한 제형화를 보장하기 위해 사용한 방법을 설명해야 한다.\n\n 제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n 지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다.  적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다.  이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다.  그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다.  이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다. ",
        "original_sentence": "적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": "이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 139,
        "word_count": 28,
        "page_number": 8,
        "window_text": "제안한\n\n지질나노입자의\n\n제형화\n\n및\n\n제조공정에\n\n대한\n\n근거를\n\n뒷받침하기\n\n위해\n\n적절한\n\n제품\n\n개발\n\n자료를\n\n제공해야\n\n한다.\n\n 지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다.  적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다.  이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다.  그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다.  이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다.  원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다. ",
        "original_sentence": "이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다. "
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 149,
        "word_count": 23,
        "page_number": 8,
        "window_text": "지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자의 모든 주요품질특성에 대해 조사해야 한다.  적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다.  이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다.  그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다.  이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다.  원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다.  보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다. ",
        "original_sentence": "그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 18,
        "window_text": "적합한 경우,\n\n실험설계(Design of Experiment) 접근법을 채택할 수도 있다.  이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다.  그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다.  이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다.  원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다.  보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다.  이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n",
        "original_sentence": "이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다. "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 8,
        "window_text": "이들의 크기 및\n\n다분산, 그리고 이에 따른 안정성은 모두 지질과 수용성 상(aqueous phase)의\n\n유동 역학(flow mechanics) 그리고 제조공정 중 유도되는 전단응력(shear stress),\n\n이 두 가지 모두의 영향을 받는다.  그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다.  이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다.  원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다.  보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다.  이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n 지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다. ",
        "original_sentence": "원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 17,
        "window_text": "그러므로 mRNA-지질나노입자 제형화 및 최종\n\n제형화 백신의 안정성에 관한 주요 가공 파라미터(critical processing parameter)와\n\n이들의\n\n최적\n\n운영범위(operational\n\nrange)를\n\n탐색하는\n\n관련된\n\n연구를\n\n수행해야\n\n한다.  이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다.  원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다.  보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다.  이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n 지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다.  지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n",
        "original_sentence": "보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 3,
        "window_text": "이를 통해 제품이 요구되는 품질에 맞추어 일관성 있게 제조되도록 보장할\n\n것이다.  원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다.  보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다.  이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n 지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다.  지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n 지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n",
        "original_sentence": "이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 111,
        "word_count": 25,
        "page_number": 8,
        "window_text": "원액 지질나노입자 또는 원액의 제형화에 대하여 제안한 정치 시간을\n\n적절하게 명시하고 밸리데이션해야 한다.  보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다.  이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n 지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다.  지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n 지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n 마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다. ",
        "original_sentence": "지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 95,
        "word_count": 14,
        "page_number": 8,
        "window_text": "보관할 경우 최종 백신 생산의 중요한\n\n중간체이므로 적절하게 관리해야 한다.  이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n 지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다.  지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n 지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n 마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다.  해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n",
        "original_sentence": "지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 182,
        "word_count": 34,
        "page_number": 8,
        "window_text": "이러한 정치 시간 중의 이화학적 안정성\n\n43/72\n\n및 미생물 관리에 대해 적절한 고려가 필요하다.\n\n 지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다.  지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n 지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n 마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다.  해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n 지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다. ",
        "original_sentence": "지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 76,
        "word_count": 11,
        "page_number": 8,
        "window_text": "지질 준비, 지질과 함께 mRNA의 봉입, 희석 및 정제 단계, 그리고 이후 적합한\n\n용기로의\n\n충전에\n\n대해\n\n기술하고,\n\n공정이\n\n필수적인\n\n공정\n\n중\n\n규격을\n\n충족함을\n\n밸리데이션해야 한다.  지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n 지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n 마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다.  해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n 지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다.  (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율. ",
        "original_sentence": "마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 8,
        "window_text": "지질나노입자 준비에 사용한 원료약품의 제거를 위해 다양한\n\n여과\n\n기법(예:\n\n접선유동여과(tangential\n\nflow\n\nfiltration))을\n\n고려해야\n\n한다.\n\n 지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n 마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다.  해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n 지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다.  (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율.  일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n",
        "original_sentence": "해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 2,
        "window_text": "지질나노입자를\n\n사용한\n\n봉입\n\n중\n\n그리고\n\n지질나노입자\n\n및\n\n최종\n\nmRNA-지질나노입자\n\n백신\n\n제품의\n\n안정성에\n\n영향을\n\n준다고\n\n알려진\n\n제조\n\n조건하에서(예: mRNA의 해동 그리고 지질나노입자나 mRNA-지질나노입자의 동결\n\n속도에 따른 영향) mRNA의 분해를 최소화하는 데 특정한 관심을 기울여야 한다.\n\n 마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다.  해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n 지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다.  (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율.  일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n",
        "original_sentence": "지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다. "
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "(1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 4,
        "window_text": "마찬가지로,\n\n동결건조한다면,\n\n동결건조\n\n및\n\n용해(reconstitution)를\n\n위한\n\n조건을\n\n고려하고 타당성을 입증해야 한다.  해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n 지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다.  (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율.  일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n 마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n",
        "original_sentence": "(1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율. "
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 109,
        "word_count": 28,
        "page_number": 8,
        "window_text": "해당되는 경우 희석제 또는 재구성 용액을\n\n설명해야 한다.\n\n 지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다.  (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율.  일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n 마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n <!-- PAGE_43 -->\n### 2.9.3. ",
        "original_sentence": "일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 182,
        "word_count": 43,
        "page_number": 5,
        "window_text": "지질나노입자를 위한 적절한 관리에 대해서도 상술해야 하며, 일반적으로 다음\n\n사항을 포함하게 될 것이다.  (1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율.  일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n 마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n <!-- PAGE_43 -->\n### 2.9.3.  최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다. ",
        "original_sentence": "mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 23,
        "window_text": "(1) 지질의 확인 및 함량, 순도(불순물 포함), (2)\n\n입자크기 및 분포, 다분산, (3) RNA 봉입 효율/봉입된 비율.  일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n 마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n <!-- PAGE_43 -->\n### 2.9.3.  최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다.  흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다. ",
        "original_sentence": "마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "<!-- PAGE_43 -->\n### 2.9.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 43,
        "window_text": "일부 경우에는 제품의\n\n일관성 및 안정성을 보장하기 위해 표면 특성(예: 전하), 지질 분자 비율 혹은\n\nmRNA 대 양이온성 지질 비율(예, 질소 대 인산염의 비율)도 명시해야 할 수 있다.\n\n mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n 마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n <!-- PAGE_43 -->\n### 2.9.3.  최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다.  흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다.  흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다. ",
        "original_sentence": "<!-- PAGE_43 -->\n### 2.9.3. "
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 96,
        "word_count": 20,
        "page_number": 8,
        "window_text": "mRNA 원료의약품에 대한 변경(예: 서열 또는 길이, 이차구조의 변경)이 차후\n\n지질나노입자의 주요품질특성에 미칠 수 있는 영향(예: 입자크기와 분포, 형태학\n\n및 표면 특성) 그리고 궁극적으로 최종 백신 제품에 미칠 수 있는 영향(예: 봉입\n\n비율 및 세포와의 상호작용/세포 내 흡입)에 대한 고려 역시 중요할 것이다.\n\n 마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n <!-- PAGE_43 -->\n### 2.9.3.  최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다.  흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다.  흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다.  정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n",
        "original_sentence": "최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 108,
        "word_count": 24,
        "page_number": 8,
        "window_text": "마찬가지로 플랫폼 데이터가 새로운 후보 백신 개발을 지지하기 위한 것이라면\n\n이러한 요소의 영향을 결정해야 한다.\n\n <!-- PAGE_43 -->\n### 2.9.3.  최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다.  흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다.  흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다.  정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n 멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n",
        "original_sentence": "흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 17,
        "window_text": "<!-- PAGE_43 -->\n### 2.9.3.  최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다.  흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다.  흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다.  정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n 멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n 모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다. ",
        "original_sentence": "흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 164,
        "word_count": 31,
        "page_number": 8,
        "window_text": "최종 백신의 제조, 충전 및 용기\n\n원액 정제 mRNA(원료의약품)로부터 최종 백신(완제의약품)까지의 제조 단계를\n\n도해로 제시하는 주석을 첨부한 흐름도를 제공해야 한다.  흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다.  흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다.  정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n 멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n 모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다.  용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다. ",
        "original_sentence": "정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 8,
        "window_text": "흐름도에는 최종 제형화\n\n원액의 희석, 재료 및 중간체의 확인, 공정 중 시험 및 품질관리 시험과 같은 모든\n\n44/72\n\n단계(즉, 단위 작업(unit operation))를 포함해야 한다.  흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다.  정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n 멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n 모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다.  용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다.  이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n",
        "original_sentence": "멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 84,
        "word_count": 15,
        "page_number": 8,
        "window_text": "흐름도에서 묘사한 각 공정\n\n단계에 대한 구연식 서술을 제공해야 한다.  정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n 멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n 모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다.  용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다.  이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n 다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다. ",
        "original_sentence": "모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 85,
        "word_count": 20,
        "page_number": 6,
        "window_text": "정보로는, 예를 들어, 각 공정 단계의\n\n규모, 완충액 및 기타 첨가제, 주요 장비, 공정관리(관련된 개발 자료로 타당성을\n\n입증한\n\n허용기준이\n\n설정된\n\n공정\n\n중\n\n시험\n\n및\n\n주요\n\n공정운영변수(process\n\noperational\n\nparameter)를\n\n포함)를\n\n포함해야\n\n한다.\n\n 멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n 모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다.  용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다.  이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n 다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다.  또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n",
        "original_sentence": "용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 111,
        "word_count": 27,
        "page_number": 8,
        "window_text": "멸균공정\n\n및\n\n미생물\n\n관리도\n\n포함해야 한다.\n\n 모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다.  용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다.  이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n 다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다.  또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n 제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다. ",
        "original_sentence": "이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 169,
        "word_count": 26,
        "page_number": 8,
        "window_text": "모든\n\n주요품질특성이\n\n유지되며\n\n필요한\n\n규격을\n\n충족함을\n\n보장하기\n\n위해\n\nmRNA-지질나노입자의 무균 충전 공정을 적절히 밸리데이션해야 한다.  용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다.  이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n 다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다.  또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n 제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다.  다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다. ",
        "original_sentence": "다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": "또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 69,
        "word_count": 12,
        "page_number": 16,
        "window_text": "용기 및\n\n마개(그리고, 해당되는 경우, 전달 기기)를 구성하는 물질이 백신의 품질에 유해한\n\n영향을 주지 않음을 보장하기 위해 주의를 기울여야 한다.  이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n 다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다.  또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n 제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다.  다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다.  다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n",
        "original_sentence": "또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 103,
        "word_count": 17,
        "page_number": 17,
        "window_text": "이를 위해, 최종 용기\n\n및 마개 시스템에 대한 용기/마개 무결성 시험과 추출물 및/또는 용출물 평가는\n\n일반적으로 용기의 적격성 입증을 위해 요구되며, 안정성 평가의 일부로서 필요할\n\n수 있다.\n\n 다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다.  또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n 제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다.  다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다.  다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n 다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n",
        "original_sentence": "제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 29,
        "window_text": "다회 투여용량 백신 바이알을 사용하며 백신이 보존제를 함유하고 있지 않다면,\n\nBCG(bacillus\n\nCalmette–Guérin)\n\n및\n\n홍역-함유 백신의\n\n예시처럼\n\n용해(재구성)한\n\n백신의\n\n경우와\n\n같이,\n\n이러한\n\n백신은\n\n시간\n\n제한적(time-restricted)으로\n\n사용해야\n\n한다.  또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n 제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다.  다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다.  다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n 다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n 다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다. ",
        "original_sentence": "다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 117,
        "word_count": 23,
        "page_number": 8,
        "window_text": "또한, 다회 투여용량 용기(multi-dose container)는 개봉 후 내용물의 미생물\n\n오염을\n\n방지해야\n\n한다.\n\n 제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다.  다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다.  다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n 다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n 다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다.  희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n",
        "original_sentence": "다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 43,
        "word_count": 8,
        "page_number": 27,
        "window_text": "제안한\n\n용기-마개\n\n시스템의\n\n적합성을\n\n증명하기\n\n위하여\n\n용기-마개 시스템에 대한 적절한 시뮬레이션 연구(예: 다회-천자(multi-puncture)\n\n시험)가 필요할 수 있다.  다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다.  다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n 다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n 다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다.  희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n 제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n",
        "original_sentence": "다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 114,
        "word_count": 21,
        "page_number": 24,
        "window_text": "다회 투여용량 바이알은 정확한 투약이 가능하도록 허용\n\n가능한 과충전량과 함께, 라벨 표시량을 충족하도록 설계해야 한다.  다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n 다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n 다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다.  희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n 제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n 최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n",
        "original_sentence": "다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 27,
        "window_text": "다회 투여용량\n\n백신 바이알은 바이알 무결성 손상의 위험 및 바이알 오염 가능성을 평가하기\n\n위해\n\n예상되는\n\n최대\n\n격막\n\n천자(maximum\n\nseptum\n\npuncture)에\n\n대해\n\n평가해야\n\n한다.\n\n 다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n 다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다.  희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n 제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n 최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n 이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n",
        "original_sentence": "희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 5,
        "window_text": "다회\n\n투여용량\n\n바이알의\n\n추출\n\n가능\n\n함량을\n\n밸리데이션해야\n\n한다.\n\n 다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다.  희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n 제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n 최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n 이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n 다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다. ",
        "original_sentence": "제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 118,
        "word_count": 26,
        "page_number": 8,
        "window_text": "다회\n\n투여용량 백신 바이알이 농축액으로 제공된다면, 제안한 재구성 용액을 사용하여\n\n적합성(comparability)\n\n연구를\n\n추가로\n\n진행하며\n\n적절한\n\n희석\n\n후\n\n정치\n\n시간을\n\n확립해야 한다.  희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n 제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n 최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n 이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n 다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다.  둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n",
        "original_sentence": "최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 119,
        "word_count": 26,
        "page_number": 2,
        "window_text": "희석 전과 희석 후 규격을 설정하고 타당성을 입증해야 한다.\n\n 제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n 최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n 이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n 다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다.  둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n <!-- PAGE_45 -->\n### 2.9.4. ",
        "original_sentence": "이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 106,
        "word_count": 20,
        "page_number": 2,
        "window_text": "제조사는 적절한 보관 및 유통 조건 하에서 그리고 사용 중 제품의 안정성을\n\n45/72\n\n증명하는 적합한 자료를 식약처에 제공해야 한다.\n\n 최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n 이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n 다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다.  둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n <!-- PAGE_45 -->\n### 2.9.4.  최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다. ",
        "original_sentence": "다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다. "
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 14,
        "window_text": "최종 백신이 두 종류 이상의 mRNA를 함유하고 있다면(예 : 다가 백신 또는\n\n별도의\n\nmRNA들로\n\n구성된\n\nsa-mRNA),\n\n이\n\n최종\n\n백신의\n\n제조\n\n시\n\n추가적인\n\n고려사항이\n\n있을\n\n수\n\n있다.\n\n 이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n 다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다.  둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n <!-- PAGE_45 -->\n### 2.9.4.  최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다.  모든 기준 및 시험법은\n\n식약처의 승인이 필요하다. ",
        "original_sentence": "둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "<!-- PAGE_45 -->\n### 2.9.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 45,
        "window_text": "이\n\n중\n\n한\n\n가지\n\n고려사항은\n\n각\n\nmRNA의\n\n발현을\n\n최적화하고 면역 간섭을 최소화하기 위하여(다가 백신의 경우) 제형화 시 각기\n\n다른\n\nmRNA의\n\n적절한\n\n비율을\n\n보장하는\n\n것이\n\n될\n\n것이다.\n\n 다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다.  둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n <!-- PAGE_45 -->\n### 2.9.4.  최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다.  모든 기준 및 시험법은\n\n식약처의 승인이 필요하다.  제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n",
        "original_sentence": "<!-- PAGE_45 -->\n### 2.9.4. "
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 17,
        "window_text": "다른\n\n고려사항은\n\nmRNA들을 지질나노입자 제형화 이전에 혼합할 것인가 아니면 각각의 mRNA를\n\n지질나노입자로 봉입한 후에 mRNA-지질나노입자의 혼합물을 준비할 것인가가 될\n\n것이다.  둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n <!-- PAGE_45 -->\n### 2.9.4.  최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다.  모든 기준 및 시험법은\n\n식약처의 승인이 필요하다.  제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n 원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다. ",
        "original_sentence": "최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "모든 기준 및 시험법은\n\n식약처의 승인이 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 8,
        "window_text": "둘 중 어느 경우라도 선택한 접근법에 대해 기술해야 한다.\n\n <!-- PAGE_45 -->\n### 2.9.4.  최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다.  모든 기준 및 시험법은\n\n식약처의 승인이 필요하다.  제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n 원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다.  분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다. ",
        "original_sentence": "모든 기준 및 시험법은\n\n식약처의 승인이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 8,
        "window_text": "<!-- PAGE_45 -->\n### 2.9.4.  최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다.  모든 기준 및 시험법은\n\n식약처의 승인이 필요하다.  제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n 원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다.  분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다.  시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다. ",
        "original_sentence": "제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 77,
        "word_count": 17,
        "page_number": 17,
        "window_text": "최종 백신의 관리\n\n각 최종 백신 로트에서 채취한 검체를 평가해야 한다.  모든 기준 및 시험법은\n\n식약처의 승인이 필요하다.  제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n 원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다.  분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다.  시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다.  개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n",
        "original_sentence": "원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 8,
        "window_text": "모든 기준 및 시험법은\n\n식약처의 승인이 필요하다.  제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n 원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다.  분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다.  시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다.  개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n 또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n",
        "original_sentence": "분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 17,
        "window_text": "제조사는 최종 백신에 관한 규격을 수립하고 근거를\n\n제시해야\n\n한다.\n\n 원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다.  분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다.  시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다.  개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n 또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n 상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n",
        "original_sentence": "시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 97,
        "word_count": 22,
        "page_number": 8,
        "window_text": "원칙적으로,\n\n최종\n\n규격은\n\n임상\n\n연구를\n\n통해\n\n성능이\n\n허용\n\n가능하다고 입증된 로트에 대한 시험 결과를 기반으로 정의해야 한다.  분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다.  시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다.  개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n 또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n 상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n 개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n",
        "original_sentence": "개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 16,
        "window_text": "분석법\n\n밸리데이션에 대한 정보를 포함하여 백신에 대한 분석법 및 허용 한도에 대해\n\n기술해야 한다.  시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다.  개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n 또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n 상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n 개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n 제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다. ",
        "original_sentence": "또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 45,
        "window_text": "시험에는 확인, 순도, 함량, 안전성, 추가적 품질 파라미터, 역가에\n\n대한 평가를 포함할 것을 권고한다.  개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n 또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n 상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n 개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n 제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다.  앞서 ‘2.6. ",
        "original_sentence": "상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 121,
        "word_count": 30,
        "page_number": 8,
        "window_text": "개발 초기에는 규격이 제한적이며 허용기준이\n\n다소 넓을 수 있으나, 제조공정 및 분석법 부문의 경험을 획득함에 따라, 적절한\n\n경우,\n\n이를\n\n검토하고\n\n강화해야\n\n한다.\n\n 또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n 상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n 개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n 제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다.  앞서 ‘2.6.  제품 특성 분석’, ‘2.7. ",
        "original_sentence": "개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 58,
        "word_count": 16,
        "page_number": 8,
        "window_text": "또한\n\n요구된\n\n유효기간을\n\n증명하기\n\n위해\n\n안정성을 확립해야 한다.\n\n 상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n 개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n 제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다.  앞서 ‘2.6.  제품 특성 분석’, ‘2.7.  제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n",
        "original_sentence": "제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다. "
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "앞서 ‘2.6. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 36,
        "window_text": "상업적 규모로 생산한 모든 로트에 대한 시험 결과를 요약하여 제공해야 한다.\n\n 개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n 제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다.  앞서 ‘2.6.  제품 특성 분석’, ‘2.7.  제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n 제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다. ",
        "original_sentence": "앞서 ‘2.6. "
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "제품 특성 분석’, ‘2.7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 34,
        "window_text": "개발 초기에는, 임상시험 승인을 뒷받침하기 위해, GMP를 준수하여 제조한 로트\n\n시험의 결과, 그리고 가용한 경우, 제조 절차 확립을 위해 실시한 생산 점검용\n\n로트 생산 가동에 대한 요약 정보를 제공해야 한다.\n\n 제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다.  앞서 ‘2.6.  제품 특성 분석’, ‘2.7.  제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n 제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다.  한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n",
        "original_sentence": "제품 특성 분석’, ‘2.7. "
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 126,
        "word_count": 27,
        "page_number": 8,
        "window_text": "제품 개발 중 수행하는 모든 시험을 상업적 규모로 생산한 모든 백신 로트에\n\n대해 실시할 필요는 없다.  앞서 ‘2.6.  제품 특성 분석’, ‘2.7.  제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n 제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다.  한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n 다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다. ",
        "original_sentence": "제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 75,
        "word_count": 16,
        "page_number": 17,
        "window_text": "앞서 ‘2.6.  제품 특성 분석’, ‘2.7.  제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n 제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다.  한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n 다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다.  그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n",
        "original_sentence": "제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 5,
        "window_text": "제품 특성 분석’, ‘2.7.  제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n 제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다.  한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n 다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다.  그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n 최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다. ",
        "original_sentence": "한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 162,
        "word_count": 36,
        "page_number": 23,
        "window_text": "제조의 일관성’에서 논한\n\n바와 같이, 일부 시험은 생산 방법 및 생산의 일관성을 확립하기 위하여 제한적인\n\n46/72\n\n일련의\n\n배치에\n\n대해\n\n제품과\n\n공정에\n\n관한\n\n지식을\n\n획득하기\n\n위한\n\n목적으로서만\n\n필요하다.\n\n 제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다.  한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n 다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다.  그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n 최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다.  이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다. ",
        "original_sentence": "다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 159,
        "word_count": 36,
        "page_number": 8,
        "window_text": "제조\n\n일관성\n\n확증을\n\n위하여\n\n최종\n\n제형인\n\n백신의\n\n몇몇\n\n연속\n\n로트를\n\n밸리데이션된 방법을 사용해 시험하고 분석해야 한다.  한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n 다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다.  그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n 최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다.  이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다.  이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다. ",
        "original_sentence": "그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 103,
        "word_count": 25,
        "page_number": 8,
        "window_text": "한 로트와 다른 로트 간의\n\n통계적으로 유의하거나 과학적으로 의미가 있는 차이에 주목하고 조사해야 한다.\n\n 다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다.  그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n 최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다.  이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다.  이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다.  추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다. ",
        "original_sentence": "최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 123,
        "word_count": 25,
        "page_number": 2,
        "window_text": "다양한 로트를 사용한 임상시험 결과뿐 아니라, 이러한 연구에서 획득한 자료를,\n\n제품과 공정에 대한 지식 그리고 특정한 속성의 변동에 대한 위험도(criticality)\n\n평가와 더불어, 일상적인 로트 출하를 위해 사용되는 백신 규격 및 허용기준을\n\n정의하기 위한 기반으로 사용해야 한다.  그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n 최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다.  이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다.  이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다.  추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다.  총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n",
        "original_sentence": "이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 6,
        "window_text": "그러므로 mRNA 백신의 확인 및 순도,\n\n농도/분량/함량, 안전성, 추가적 품질 파라미터, 역가, 안정성과 관련하여 일관성\n\n확립을 위해 초기 상업적 생산 로트에 대한 광범위한 분석을 실시해야 하지만,\n\n식약처가 동의한다면, 이후에는 보다 제한적인 일련의 시험이 적절할 수 있다.\n\n 최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다.  이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다.  이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다.  추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다.  총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n 확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n",
        "original_sentence": "이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 89,
        "word_count": 16,
        "page_number": 8,
        "window_text": "최종 백신이 두 종 이상의 mRNA를 함유하고 있다면(예: 다가 백신 또는 별도의\n\nmRNA들로 구성된 sa-mRNA), 이 최종 백신의 제조 시 추가적인 고려사항이\n\n있을 수 있다.  이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다.  이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다.  추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다.  총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n 확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n 한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n",
        "original_sentence": "추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 8,
        "window_text": "이러한 고려사항 중 일부는, 예를 들어, mRNA들을 혼합물로서\n\n함께\n\n봉입했는가\n\n또는\n\n개별적으로\n\n봉입한\n\n후\n\n각각의\n\nmRNA-지질나노입자을\n\n혼합하였는가와 같이, 제조 시 취한 접근법을 기반으로 할 것이다.  이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다.  추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다.  총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n 확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n 한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n 제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n",
        "original_sentence": "총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 90,
        "word_count": 15,
        "page_number": 17,
        "window_text": "이것은 이후\n\n지질나노입자 크기 및 전하, 다분산에 영향을 줄 수 있다.  추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다.  총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n 확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n 한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n 제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n 47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1. ",
        "original_sentence": "확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 122,
        "word_count": 23,
        "page_number": 8,
        "window_text": "추가로, 혼합(mixing)의\n\n일관성\n\n밸리데이션은\n\n각\n\n용량에\n\n각각의\n\nmRNA가\n\n적절한\n\n비율로\n\n함유되어\n\n있는가를 확인하는 데 대단히 중요하다.  총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n 확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n 한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n 제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n 47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1.  확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다. ",
        "original_sentence": "한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 122,
        "word_count": 27,
        "page_number": 17,
        "window_text": "총 mRNA 함량은 용량 설정의 기반이\n\n되므로, 최종 백신의 전체 mRNA 함량 중 적절한 비율을 확인하는 것은 대단히\n\n중요하다.\n\n 확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n 한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n 제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n 47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1.  확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다.  백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다. ",
        "original_sentence": "제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 37,
        "word_count": 6,
        "page_number": 47,
        "window_text": "확인시험에서는\n\n제조소에서\n\n제조한\n\n다른\n\n제품으로부터\n\n이\n\n백신을\n\n종전처럼\n\n구별하는\n\n한편,\n\n각각의\n\nmRNA가\n\n포함되었는가를\n\n다루어야\n\n한다.\n\n 한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n 제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n 47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1.  확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다.  백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다.  염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n",
        "original_sentence": "47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1. "
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 102,
        "word_count": 23,
        "page_number": 17,
        "window_text": "한\n\n가지 원료의약품이나 구성성분(예 : replicon을 코딩하는 mRNA)이 이 제조소에서\n\n생산하는\n\n두\n\n가지\n\n이상의\n\n백신이나\n\n제품에\n\n사용된다면,\n\n확인시험은\n\n혼동을\n\n방지하기 위해 대단히 중요하다.\n\n 제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n 47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1.  확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다.  백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다.  염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.2. ",
        "original_sentence": "확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 75,
        "word_count": 17,
        "page_number": 8,
        "window_text": "제조\n\n일관성에\n\n대한\n\n경험을\n\n획득함에\n\n따라,\n\n허가\n\n후\n\n변경\n\n시에는\n\n공정\n\n밸리데이션, 제품 특성분석 및/또는 비교동등성 시험계획서를 사용하여 필요한\n\n시험 및 보조자료 축소를 허용하게 될 수도 있다.\n\n 47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1.  확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다.  백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다.  염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.2.  순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다. ",
        "original_sentence": "백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 27,
        "window_text": "47/72\n\n<!-- PAGE_47 -->\n### 2.9.4.1.  확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다.  백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다.  염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.2.  순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다.  전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다. ",
        "original_sentence": "염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "<!-- PAGE_47 -->\n### 2.9.4.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 47,
        "window_text": "확인\n\n각\n\n백신\n\n로트는\n\n최종\n\n제품의\n\n확인\n\n그리고\n\n동일\n\n시설에서\n\n제조했거나\n\n동일\n\n장비를 이용해 제조한 다른 제품으로부터의 구분을 위해 적절한 시험을 거쳐야\n\n한다.  백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다.  염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.2.  순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다.  전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다.  모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다. ",
        "original_sentence": "<!-- PAGE_47 -->\n### 2.9.4.2. "
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 8,
        "window_text": "백신에 2개 이상의 mRNA가 포함되어 있는 경우(예: sa-mRNA, 혼합 또는\n\n다가 백신) 각 mRNA의 식별을 확인해야 한다.  염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.2.  순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다.  전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다.  모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다.  mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다. ",
        "original_sentence": "순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": "전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 79,
        "word_count": 19,
        "page_number": 8,
        "window_text": "염기서열 분석을 통한 확인을\n\n고려해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.2.  순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다.  전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다.  모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다.  mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다.  품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2. ",
        "original_sentence": "전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 18,
        "window_text": "<!-- PAGE_47 -->\n### 2.9.4.2.  순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다.  전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다.  모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다.  mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다.  품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2.  순도 및 불순물’\n\n참조). ",
        "original_sentence": "모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다. "
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 78,
        "word_count": 14,
        "page_number": 8,
        "window_text": "순도 및 불순물\n\n최종 백신의 각 로트의 순도를 평가하고 명시한 한도 내에 있음을 증명해야\n\n한다.  전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다.  모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다.  mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다.  품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2.  순도 및 불순물’\n\n참조).  백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n",
        "original_sentence": "mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 5,
        "window_text": "전달 시스템의 구성성분에서 기인하는 잠재적 불순물 그리고 최종 백신의\n\n산화 및 분해에서 유래하는 불순물의 관리 측면에 대해 고려해야 한다.  모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다.  mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다.  품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2.  순도 및 불순물’\n\n참조).  백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.3. ",
        "original_sentence": "품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2. "
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "순도 및 불순물’\n\n참조). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 8,
        "window_text": "모든\n\n불순물을 검출하려면 단회 시험으로는 충분하지 않을 것이다.  mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다.  품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2.  순도 및 불순물’\n\n참조).  백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.3.  함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n",
        "original_sentence": "순도 및 불순물’\n\n참조). "
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 119,
        "word_count": 28,
        "page_number": 8,
        "window_text": "mRNA 완전성 및\n\n입자크기,\n\n지질/폴리머\n\n불순물,\n\n지질나노입자로\n\n봉입한\n\nmRNA의\n\n비율/효율에\n\n관한 시험을 고려해야 한다.  품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2.  순도 및 불순물’\n\n참조).  백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.3.  함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n 따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n",
        "original_sentence": "백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "<!-- PAGE_47 -->\n### 2.9.4.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 47,
        "window_text": "품목허가 신청 시에는 용기-마개 시스템의 적합성\n\n그리고 용출물 및 추출물에 대한 평가와 논의가 필요하다(‘2.8.1.2.  순도 및 불순물’\n\n참조).  백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.3.  함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n 따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.4. ",
        "original_sentence": "<!-- PAGE_47 -->\n### 2.9.4.3. "
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 8,
        "window_text": "순도 및 불순물’\n\n참조).  백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.3.  함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n 따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.4.  안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다. ",
        "original_sentence": "함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 47,
        "window_text": "백신에 하나 이상의 mRNA(예: sa-mRNA, 홉합 또는 다가 백신)가 포함된\n\n경우 각 mRNA의 함량 및 각 mRNA에 대한 비율이 의도한 대로이고 총 mRNA\n\n용량을 초과하지 않았는지 확인해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.3.  함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n 따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.4.  안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다.  백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다. ",
        "original_sentence": "따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "<!-- PAGE_47 -->\n### 2.9.4.4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 47,
        "window_text": "<!-- PAGE_47 -->\n### 2.9.4.3.  함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n 따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.4.  안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다.  백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다.  더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n",
        "original_sentence": "<!-- PAGE_47 -->\n### 2.9.4.4. "
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 80,
        "word_count": 17,
        "page_number": 8,
        "window_text": "함량 또는 농도\n\nmRNA 백신은 무게 단위의 mRNA 함량을 기반으로 투여 용량을 산출한다.\n\n 따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.4.  안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다.  백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다.  더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n 식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음). ",
        "original_sentence": "안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 93,
        "word_count": 18,
        "page_number": 8,
        "window_text": "따라서, 역가 평가에 추가로, mRNA의 정량화 방법에 대해 기술해야 한다.\n\n <!-- PAGE_47 -->\n### 2.9.4.4.  안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다.  백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다.  더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n 식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음).  그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n",
        "original_sentence": "백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 27,
        "window_text": "<!-- PAGE_47 -->\n### 2.9.4.4.  안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다.  백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다.  더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n 식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음).  그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n",
        "original_sentence": "더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 76,
        "word_count": 11,
        "page_number": 8,
        "window_text": "안전성 특성\n\n각\n\n백신\n\n로트에\n\n대하여\n\n세균\n\n및\n\n곰팡이\n\n무균시험(시험물질의\n\n살균\n\n활성도\n\n부족의 제시를 포함)을 수행해야 한다.  백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다.  더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n 식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음).  그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_48 -->\n### 2.9.4.5. ",
        "original_sentence": "식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음). "
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 8,
        "window_text": "백신을 비경구 외(non-parenteral) 투여하는\n\n경우, 무균시험 생략 및 적절한 대체 미생물한도시험 포함에 대해 적절한 근거\n\n48/72\n\n제시가 필요하다.  더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n 식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음).  그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_48 -->\n### 2.9.4.5.  추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다. ",
        "original_sentence": "그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 142,
        "word_count": 33,
        "page_number": 8,
        "window_text": "더 나아가, 엔도톡신 시험을 각 로트에 대하여 실시하고, 적절한\n\n규격을\n\n설정해야\n\n한다.\n\n 식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음).  그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_48 -->\n### 2.9.4.5.  추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다.  여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n",
        "original_sentence": "과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "<!-- PAGE_48 -->\n### 2.9.4.5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 48,
        "window_text": "식약처가\n\n요구한다면\n\n발열성\n\n시험을\n\n수행할\n\n수\n\n있다(단핵구활성시험(monocyte activation test)일 수 있음).  그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_48 -->\n### 2.9.4.5.  추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다.  여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n 제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다. ",
        "original_sentence": "<!-- PAGE_48 -->\n### 2.9.4.5. "
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 16,
        "window_text": "그러나 실시 및 허용\n\n가능한 납득할 만한 대체 시험이 있는 경우라면 언제나 동물시험을 피해야 한다.\n\n 과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_48 -->\n### 2.9.4.5.  추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다.  여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n 제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다.  최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n",
        "original_sentence": "추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 8,
        "window_text": "과학\n\n및 윤리적 이유로,\n\n시험\n\n시\n\n동물 사용을\n\n최소화하기\n\n위해\n\n“대체,\n\n감소,\n\n개선”의 3R 원칙을 적용하는 것이 바람직하며, 안전성 평가 그리고 기타 제품\n\n시험을 위해서도 적절한 in vitro 대체 시험법의 사용을 고려해야 한다.\n\n <!-- PAGE_48 -->\n### 2.9.4.5.  추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다.  여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n 제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다.  최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n 나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다. ",
        "original_sentence": "여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 67,
        "word_count": 11,
        "page_number": 8,
        "window_text": "<!-- PAGE_48 -->\n### 2.9.4.5.  추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다.  여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n 제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다.  최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n 나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다.  비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n",
        "original_sentence": "제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 121,
        "word_count": 15,
        "page_number": 17,
        "window_text": "추가적인 품질 파라미터\n\n다른 중요한 품질 파라미터 또한 확립하고 관리해야 한다.  여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n 제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다.  최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n 나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다.  비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n 최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다. ",
        "original_sentence": "최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 139,
        "word_count": 25,
        "page_number": 26,
        "window_text": "여기에는 성상(가시성\n\n및 비가시성의 불용성 미립자 두 가지 존재를 모두 포함) 및 추출 가능 용량,\n\npH를\n\n포함할\n\n수\n\n있다.\n\n 제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다.  최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n 나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다.  비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n 최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다.  순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n",
        "original_sentence": "나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 77,
        "word_count": 14,
        "page_number": 8,
        "window_text": "제품\n\n특성에\n\n따라,\n\n삼투압\n\n농도(osmolality)\n\n또는\n\n점성도(viscosity) 역시 중요할 수 있다.  최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n 나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다.  비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n 최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다.  순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n 제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n",
        "original_sentence": "비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 8,
        "window_text": "최종 백신(완제의약품)의 경우, 추가적인\n\n파라미터에는\n\n지질/폴리머\n\n동정(identification)\n\n및\n\n함량,\n\nmRNA-지질나노입자\n\n비율, 다분산 지수(polydisperity index)가 포함된다.\n\n 나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다.  비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n 최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다.  순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n 제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n 제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n",
        "original_sentence": "최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 8,
        "window_text": "나노입자\n\n크기와\n\n관련하여,\n\n나노입자-기반\n\n치료제의\n\n관리와\n\n유사하게\n\n다지점\n\n관리(multiple point control)를 채택하고, 입자크기 측정을 위해 사용하는 시험은\n\n채택한 분석법에 따라 그 결과가 달라지므로 명시가 필요하다.  비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n 최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다.  순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n 제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n 제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n 49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6. ",
        "original_sentence": "순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 85,
        "word_count": 18,
        "page_number": 8,
        "window_text": "비봉입 mRNA는\n\n불안정하다고 간주하기 때문에, 지질나노입자를 사용한 mRNA의 봉입 정도 역시\n\n주요품질특성으로\n\n간주해야\n\n한다.\n\n 최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다.  순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n 제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n 제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n 49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6.  역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다. ",
        "original_sentence": "제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n"
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 66,
        "word_count": 13,
        "page_number": 17,
        "window_text": "최종\n\n제품의\n\n구조가\n\n동결-해동\n\n및\n\n희석으로\n\n인해 변경되지 않음을 확증해야 한다.  순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n 제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n 제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n 49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6.  역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다.  질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n",
        "original_sentence": "제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 37,
        "word_count": 6,
        "page_number": 49,
        "window_text": "순도나 확인을 위해 이미 수행 중인 겔\n\n또는 모세관 전기영동 및/또는 HPLC와 같은 기법이 일부 품질 기준 평가 시\n\n유용할 수 있다.\n\n 제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n 제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n 49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6.  역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다.  질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n 백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n",
        "original_sentence": "49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6. "
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 80,
        "word_count": 15,
        "page_number": 31,
        "window_text": "제형화뿐만 아니라 제품의 물리적 특성을 확인하기 위해 다른 시험이 필요할 수\n\n있다(예:\n\n백신을\n\n동결건조한다면,\n\n잔여\n\n수분에\n\n관한\n\n시험).\n\n 제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n 49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6.  역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다.  질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n 백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n 따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n",
        "original_sentence": "역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_698",
      "text": "질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 697,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 8,
        "window_text": "제품의\n\n확인된\n\n주요품질특성에 대한 관리를 보장하기 위하여, 사용되는 분석법의 밸리데이션에\n\n대해 기술해야 한다.\n\n 49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6.  역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다.  질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n 백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n 따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n 이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다. ",
        "original_sentence": "질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_699",
      "text": "백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 698,
        "window_size": 3,
        "char_count": 147,
        "word_count": 25,
        "page_number": 23,
        "window_text": "49/72\n\n<!-- PAGE_49 -->\n### 2.9.4.6.  역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다.  질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n 백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n 따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n 이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다.  그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n",
        "original_sentence": "백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_700",
      "text": "따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 699,
        "window_size": 3,
        "char_count": 104,
        "word_count": 16,
        "page_number": 23,
        "window_text": "역가\n\n적절히 정량적이며 밸리데이션된 기능적 방법(functional method)을 사용하여\n\n최종 백신의 각 로트의 역가를 결정해야 한다.  질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n 백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n 따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n 이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다.  그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n 제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n",
        "original_sentence": "따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_701",
      "text": "이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 700,
        "window_size": 3,
        "char_count": 82,
        "word_count": 12,
        "page_number": 23,
        "window_text": "질환 특이적일 수 있는 (기능성을\n\n포함한) 역가의 다양한 측면을 관리하기 위해 서로 다른 시험들이 필요할 수\n\n있다.\n\n 백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n 따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n 이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다.  그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n 제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n 새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n",
        "original_sentence": "이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다. "
      }
    },
    {
      "chunk_id": "chunk_702",
      "text": "그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 701,
        "window_size": 3,
        "char_count": 128,
        "word_count": 27,
        "page_number": 8,
        "window_text": "백신\n\n피접종자의\n\n면역원성은,\n\n(self-amplifying\n\nreplicon\n\n구성성분\n\n포함이\n\n가능한) mRNA로 코딩된 단백질의 발현뿐만 아니라 백신 제형화를 통한 표적\n\n세포로의\n\n전달을\n\n포함하여,\n\n최종\n\n백신\n\n특성들의\n\n복합적인\n\n기능이다.\n\n 따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n 이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다.  그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n 제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n 새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n",
        "original_sentence": "그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_703",
      "text": "제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 702,
        "window_size": 3,
        "char_count": 71,
        "word_count": 18,
        "page_number": 8,
        "window_text": "따라서,\n\n잠재적인 in vitro 역가 분석시험에는 세포-기반 형질주입(transfection) 시스템 또는\n\n무세포\n\n분석(cell-free\n\nassay)을\n\n포함할\n\n수\n\n있다.\n\n 이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다.  그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n 제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n 새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n 사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n",
        "original_sentence": "제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_704",
      "text": "새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 703,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 10,
        "window_text": "이러한\n\n방법은\n\n정확히\n\n확인된(correct\n\nidentity)\n\n올바른\n\n크기의\n\n단백질이\n\nmRNA로부터\n\n발현되었음을\n\n증명해줄 것이다.  그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n 제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n 새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n 사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n 동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다. ",
        "original_sentence": "새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_705",
      "text": "mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 704,
        "window_size": 3,
        "char_count": 92,
        "word_count": 19,
        "page_number": 8,
        "window_text": "그러나 역가는 제품 종류(이 경우에는 mRNA 백신)뿐 아니라\n\n예방하고자\n\n하는\n\n질환의\n\n임상\n\n적응증을\n\n기반으로\n\n분석해야\n\n하므로,\n\n역가를\n\n측정하기 위해 사용해야 하는 특정 분석시험을 지정하는 것은 가능하지 않다.\n\n 제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n 새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n 사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n 동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다.  시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다. ",
        "original_sentence": "mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_706",
      "text": "사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 705,
        "window_size": 3,
        "char_count": 53,
        "word_count": 11,
        "page_number": 16,
        "window_text": "제품 관리를 위해 선택한 역가 시험에 대하여 과학적 근거와 임상 결과 및 모든\n\n품질 검사항목과의 상관관계를 제시해야 한다.\n\n 새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n 사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n 동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다.  시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다.  따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다. ",
        "original_sentence": "사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_707",
      "text": "동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 706,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 6,
        "window_text": "새로운 균주에 대한 신규 후보 백신을 개발하는 경우, 역가시험이 균주변경에\n\n대해 유효한지에 대해 확실히 확인하여야 한다.\n\n mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n 사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n 동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다.  시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다.  따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다.  플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다. ",
        "original_sentence": "동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다. "
      }
    },
    {
      "chunk_id": "chunk_708",
      "text": "시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 707,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 10,
        "window_text": "mRNA에 대한 역가 규격은, 임상시험에서 유효성 증명을 위해 사용하는 최소\n\n용량에\n\n인간\n\n면역원성\n\n자료를\n\n추가하여,\n\n이를\n\n기반으로\n\n설정해야\n\n한다.\n\n 사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n 동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다.  시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다.  따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다.  플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다.  제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다. ",
        "original_sentence": "시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다. "
      }
    },
    {
      "chunk_id": "chunk_709",
      "text": "따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 708,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 23,
        "window_text": "사용\n\n가능한 인간 안전성 자료를 기반으로 상한(upper limit) 또한 정의해야 한다.\n\n 동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다.  시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다.  따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다.  플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다.  제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다.  그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다. ",
        "original_sentence": "따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_710",
      "text": "플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 709,
        "window_size": 3,
        "char_count": 143,
        "word_count": 29,
        "page_number": 8,
        "window_text": "동물-기반 분석시험은 변동성이 높으며 밸리데이션이 어려운 경향이 있다.  시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다.  따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다.  플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다.  제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다.  그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다.  그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n",
        "original_sentence": "플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_711",
      "text": "제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 710,
        "window_size": 3,
        "char_count": 62,
        "word_count": 13,
        "page_number": 5,
        "window_text": "시험\n\n시 동물 사용을 최소화하기 위해 “대체, 감소, 개선”의 3R 원칙을 적용하는 것이\n\n또한 바람직하다.  따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다.  플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다.  제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다.  그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다.  그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n <!-- PAGE_50 -->\n### 2.9.4.7. ",
        "original_sentence": "제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다. "
      }
    },
    {
      "chunk_id": "chunk_712",
      "text": "그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 711,
        "window_size": 3,
        "char_count": 130,
        "word_count": 28,
        "page_number": 8,
        "window_text": "따라서 역가시험을 위해서 적절한 in vitro 대체 시험법의 사용을\n\n고려해야 한다.  플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다.  제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다.  그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다.  그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n <!-- PAGE_50 -->\n### 2.9.4.7.  표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n",
        "original_sentence": "그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다. "
      }
    },
    {
      "chunk_id": "chunk_713",
      "text": "그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 712,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 25,
        "window_text": "플라스미드 DNA 백신과 마찬가지로, mRNA 백신의 역가 확립 및\n\n모니터링을\n\n위하여\n\n생화학\n\n또는\n\n생물물리학적\n\n척도들(measure)(예:\n\n핵산\n\n함량,\n\nmRNA 완전성 및 유전자 서열)을 조합하여 사용할 수도 있을 것이라 예견하고\n\n있다.  제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다.  그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다.  그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n <!-- PAGE_50 -->\n### 2.9.4.7.  표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n 이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n",
        "original_sentence": "그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_714",
      "text": "<!-- PAGE_50 -->\n### 2.9.4.7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 713,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 50,
        "window_text": "제조사는 적절하게 정량적이며 기능을 측정하는 in vitro 분석시험의 실시를\n\n목표로 노력할 것을 독려한다.  그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다.  그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n <!-- PAGE_50 -->\n### 2.9.4.7.  표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n 이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n 향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다. ",
        "original_sentence": "<!-- PAGE_50 -->\n### 2.9.4.7. "
      }
    },
    {
      "chunk_id": "chunk_715",
      "text": "표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 714,
        "window_size": 3,
        "char_count": 109,
        "word_count": 25,
        "page_number": 8,
        "window_text": "그러나 이러한 척도는 mRNA에만 해당되며, 제형\n\n50/72\n\n및 면역증강제, 면역조절인자 등의 영향에 대해서는 설명해주지 못한다는 점을\n\n인정해야 하며, 따라서 mRNA 백신의 역가 평가는 사례별 기반으로 고려해야 할\n\n것이다.  그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n <!-- PAGE_50 -->\n### 2.9.4.7.  표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n 이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n 향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다.  이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다. ",
        "original_sentence": "표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_716",
      "text": "이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 715,
        "window_size": 3,
        "char_count": 52,
        "word_count": 11,
        "page_number": 17,
        "window_text": "그러므로, 적절한 역가 척도에 대해 논의하고 식약처의 동의를 구할 것을\n\n권한다.\n\n <!-- PAGE_50 -->\n### 2.9.4.7.  표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n 이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n 향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다.  이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다.  이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다. ",
        "original_sentence": "이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_717",
      "text": "향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 716,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 8,
        "window_text": "<!-- PAGE_50 -->\n### 2.9.4.7.  표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n 이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n 향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다.  이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다.  이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다.  추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n",
        "original_sentence": "향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_718",
      "text": "이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 717,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 8,
        "window_text": "표준물질\n\n임상적으로 평가한 적합한 최종 백신 로트를 화학적 조성 및 순도, 생물학적\n\n활성, 전체 서열과 관련하여 완전히 특성을 분석하고, 내부 표준물질로 사용하기\n\n위해\n\n보관해야\n\n한다.\n\n 이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n 향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다.  이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다.  이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다.  추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n <!-- PAGE_50 -->\n### 2.9.4.8. ",
        "original_sentence": "이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다. "
      }
    },
    {
      "chunk_id": "chunk_719",
      "text": "이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 718,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 23,
        "window_text": "이\n\n물질을\n\n상업적\n\n생산\n\n로트에\n\n대한\n\n품질관리\n\n평가의\n\n기반으로 사용해야 한다.\n\n 향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다.  이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다.  이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다.  추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n <!-- PAGE_50 -->\n### 2.9.4.8.  안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n",
        "original_sentence": "이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_720",
      "text": "추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 719,
        "window_size": 3,
        "char_count": 170,
        "word_count": 40,
        "page_number": 8,
        "window_text": "향후 WHO로부터 국제 표준품 사용이 가능해질 수 있는 한편, 식약처에서는 국가\n\n표준품을 개발하여 제공할 수 있다.  이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다.  이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다.  추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n <!-- PAGE_50 -->\n### 2.9.4.8.  안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n 추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다. ",
        "original_sentence": "추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_721",
      "text": "<!-- PAGE_50 -->\n### 2.9.4.8. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 720,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 50,
        "window_text": "이러한 국제 표준품의 사용이 가능해진다면,\n\n내부 또는 국가 표준물질을 이들에 대해 교정하는 것이 중요해질 것이다.  이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다.  추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n <!-- PAGE_50 -->\n### 2.9.4.8.  안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n 추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다.  일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다. ",
        "original_sentence": "<!-- PAGE_50 -->\n### 2.9.4.8. "
      }
    },
    {
      "chunk_id": "chunk_722",
      "text": "안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 721,
        "window_size": 3,
        "char_count": 165,
        "word_count": 35,
        "page_number": 8,
        "window_text": "이러한\n\n방식으로,\n\n새로운 표준물질을 준비해야 할 때마다, 더욱 신뢰성 높은 방식으로\n\n비교를 할 수 있다.  추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n <!-- PAGE_50 -->\n### 2.9.4.8.  안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n 추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다.  일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다.  백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n",
        "original_sentence": "안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_723",
      "text": "추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 722,
        "window_size": 3,
        "char_count": 79,
        "word_count": 14,
        "page_number": 10,
        "window_text": "추가적으로 해당하는 경우에는 공통 단위(예: IU)를 사용해\n\n결과를 표기함으로써, 서로 다른 실험실에서 획득한 시험 결과 및 동일한 병원체에\n\n대한 그리고 같거나 유사한 기술을 기반으로 한 서로 다른 제품(예,\n\n코로나19\n\nmRNA 백신 간에, 독감 백신 간에)에 대한 비교 역시 가능해질 것이다.\n\n <!-- PAGE_50 -->\n### 2.9.4.8.  안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n 추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다.  일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다.  백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n 51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1. ",
        "original_sentence": "추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_724",
      "text": "일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 723,
        "window_size": 3,
        "char_count": 87,
        "word_count": 22,
        "page_number": 5,
        "window_text": "<!-- PAGE_50 -->\n### 2.9.4.8.  안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n 추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다.  일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다.  백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n 51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1.  안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n",
        "original_sentence": "일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_725",
      "text": "백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 724,
        "window_size": 3,
        "char_count": 87,
        "word_count": 15,
        "page_number": 23,
        "window_text": "안전성 시험, 보관 및 유효일자\n\n각각의 mRNA에 대하여 ‘의약품 등의 안전에 관한 규칙 [별표 1] 의약품 제조\n\n및 품질관리기준, [별표 3] 생물학적제제등 제조 및 품질관리기준’, ‘생물의약품\n\n안정성시험 가이드라인(식약처, 2015)에서 제시하는 적합한 관련 지침을 적용해야\n\n한다.\n\n 추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다.  일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다.  백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n 51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1.  안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n 상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다. ",
        "original_sentence": "백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n"
      }
    },
    {
      "chunk_id": "chunk_726",
      "text": "51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 725,
        "window_size": 3,
        "char_count": 39,
        "word_count": 6,
        "page_number": 51,
        "window_text": "추가로\n\n’확장\n\n보관온도\n\n조건(ECTC)에서\n\n사용하는\n\n백신의\n\n안정성\n\n평가\n\n가이드라인(식약처, 2016) 역시 적용될 수도 있다.  일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다.  백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n 51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1.  안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n 상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다.  안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다. ",
        "original_sentence": "51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1. "
      }
    },
    {
      "chunk_id": "chunk_727",
      "text": "안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 726,
        "window_size": 3,
        "char_count": 46,
        "word_count": 9,
        "page_number": 24,
        "window_text": "일차 및 이차 포장재에 표기된\n\n보관 온도 및 유효일자와 관련된 문구는 시험에서 획득한 증거를 기반으로 해야\n\n하며, 승인을 위해 식약처에 제출해야 한다.  백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n 51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1.  안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n 상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다.  안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다.  측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다. ",
        "original_sentence": "안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_728",
      "text": "상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 727,
        "window_size": 3,
        "char_count": 91,
        "word_count": 21,
        "page_number": 17,
        "window_text": "백신 바이알 모니터링에 관한 지침은\n\nWHO Getting started with vaccine vial monitors를 참고해야 한다(42, 43).\n\n 51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1.  안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n 상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다.  안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다.  측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다.  높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다. ",
        "original_sentence": "상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_729",
      "text": "안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 728,
        "window_size": 3,
        "char_count": 164,
        "word_count": 34,
        "page_number": 8,
        "window_text": "51/72\n\n<!-- PAGE_51 -->\n### 2.9.4.8.1.  안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n 상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다.  안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다.  측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다.  높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다.  동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n",
        "original_sentence": "안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_730",
      "text": "측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 729,
        "window_size": 3,
        "char_count": 41,
        "word_count": 9,
        "page_number": 25,
        "window_text": "안정성\n\n적절한\n\n안정성\n\n연구는\n\n백신\n\n개발의\n\n핵심적\n\n부분을\n\n구성한다.\n\n 상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다.  안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다.  측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다.  높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다.  동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n 추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다. ",
        "original_sentence": "측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_731",
      "text": "높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 730,
        "window_size": 3,
        "char_count": 171,
        "word_count": 34,
        "page_number": 41,
        "window_text": "상업적\n\n사용을\n\n보장하기 위해, 사용을 제안한 용기에 담긴 최종 제품의 안정성을 측정하고, 그\n\n결과를 적절한 보관 조건하에서의 유효기간 설정에 사용해야 한다.  안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다.  측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다.  높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다.  동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n 추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다.  고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n",
        "original_sentence": "높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_732",
      "text": "동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 731,
        "window_size": 3,
        "char_count": 129,
        "word_count": 33,
        "page_number": 8,
        "window_text": "안정성을 지시해\n\n줄 수 있는(stability-indicating) 파라미터를 측정해야 하며, 여기에는 성상(가시성 및\n\n비가시성의 불용성 미립자 포함) 및 mRNA 함량, 백신 역가, mRNA 완전성, 봉입\n\n정도, 입자크기, 다분산, mRNA 및 지질과 관련된 불순물이 포함될 수 있다.  측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다.  높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다.  동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n 추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다.  고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n 다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n",
        "original_sentence": "동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_733",
      "text": "추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 732,
        "window_size": 3,
        "char_count": 81,
        "word_count": 15,
        "page_number": 8,
        "window_text": "측정할\n\n파라미터에 대해 설명하고 규격을 설정하며 근거를 제시해야 한다.  높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다.  동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n 추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다.  고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n 다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n 초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다. ",
        "original_sentence": "추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_734",
      "text": "고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 733,
        "window_size": 3,
        "char_count": 69,
        "word_count": 17,
        "page_number": 8,
        "window_text": "높은 온도에서의\n\n가속 안정성 연구(accelerated stability study)는 제품의 안정성에 대하여 보완하는\n\n추가적인 보조자료를 제공하고 안정성 측정을 위해 채택한 분석시험이 안전성을\n\n지시해주는 특성을 확인할 수 있기는 하지만, 앞서 설명한 목적으로 실시간 안정성\n\n연구를 수행해야 한다.  동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n 추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다.  고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n 다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n 초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다.  예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다. ",
        "original_sentence": "고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_735",
      "text": "다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 734,
        "window_size": 3,
        "char_count": 110,
        "word_count": 23,
        "page_number": 24,
        "window_text": "동결 이상의 온도에서 장기간(예 : 6개월 이상) 보관하는 것이\n\n고려되는 경우, 잠재적인 지질 산화 또는 기타 그러한 변화와 이러한 변화가 효능에\n\n미치는 결과적인 영향을 처리하기 위한 추가 분석 방법을 포함해야 할 수 있다.\n\n 추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다.  고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n 다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n 초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다.  예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다.  가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다. ",
        "original_sentence": "다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_736",
      "text": "초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 735,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 22,
        "window_text": "추가로,\n\n유효기간을\n\n뒷받침하기\n\n위해\n\n플랫폼\n\n자료뿐\n\n아니라\n\n가속\n\n및\n\n가혹시험(stress testing) 자료를 고려할 수 있다.  고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n 다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n 초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다.  예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다.  가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다.  마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n",
        "original_sentence": "초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다. "
      }
    },
    {
      "chunk_id": "chunk_737",
      "text": "예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 736,
        "window_size": 3,
        "char_count": 177,
        "word_count": 41,
        "page_number": 2,
        "window_text": "고온에서의 단기 보관 및 조제 시\n\n안정성에 관한 자료와 같이 임상적 사용을 뒷받침해주는 안정성 자료를 생성해야\n\n한다.\n\n 다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n 초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다.  예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다.  가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다.  마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n 52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n",
        "original_sentence": "예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_738",
      "text": "가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 737,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 28,
        "window_text": "다회 투여용량 바이알의 경우,\n\n요구되는,\n\n사용\n\n중 조건 하에서의 백신의\n\n미생물 품질 및 안정성을 보장하기 위하여, 사용 중 안정성(in-use stability) 자료가\n\n필요할 것이다.\n\n 초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다.  예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다.  가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다.  마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n 52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n 이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다. ",
        "original_sentence": "가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_739",
      "text": "마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 738,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 10,
        "window_text": "초기 임상 개발 중에는, 안정성 정보가 제한적일 것으로 예상한다.  예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다.  가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다.  마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n 52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n 이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다.  보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다. ",
        "original_sentence": "마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_740",
      "text": "52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 739,
        "window_size": 3,
        "char_count": 106,
        "word_count": 22,
        "page_number": 2,
        "window_text": "예를 들면,\n\n임상시험 승인 신청 시점에서 일부 규제담당자는 임상시험에서 사용될 용기에서\n\n제안한 임상시험에서 사용할 최종 백신의 로트 또는 동일한 용기 타입 및 크기에\n\n있어서 이와 동일한 방식으로 제조하였으며 동일 규격을 충족하는 로트의 3개월\n\n실시간 안정성을 수용하지만, 이에 대해 식약처의 동의가 필요하다.  가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다.  마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n 52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n 이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다.  보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다.  안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n",
        "original_sentence": "52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_741",
      "text": "이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 740,
        "window_size": 3,
        "char_count": 64,
        "word_count": 11,
        "page_number": 8,
        "window_text": "가속 안정성\n\n평가 프로그램을 활용한 예측 안정성 모델링의 결과를 포함함으로써 초기 임상\n\n개발을 뒷받침할 수도 있습니다.  마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n 52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n 이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다.  보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다.  안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n 열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n",
        "original_sentence": "이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다. "
      }
    },
    {
      "chunk_id": "chunk_742",
      "text": "보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 741,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 8,
        "window_text": "마찬가지로 플랫폼 기술에 대한 안정성 데이터는\n\n해당 플랫폼을 기반으로 하는 새로운 후보 백신을 뒷받침할 수 있다.\n\n 52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n 이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다.  보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다.  안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n 열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.2. ",
        "original_sentence": "보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_743",
      "text": "안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 742,
        "window_size": 3,
        "char_count": 49,
        "word_count": 8,
        "page_number": 4,
        "window_text": "52/72\n\n장기 보관을 위해 초저온(deep-freeze) 조건을 권고한다면, 백신의 유통 및 조제를\n\n뒷받침하기 위해 대체 단기 보관 조건(예: 냉동 및/또는 냉장)을 탐색해야 한다.\n\n 이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다.  보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다.  안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n 열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.2.  보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n",
        "original_sentence": "안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_744",
      "text": "열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 743,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 24,
        "window_text": "이와 유사하게, 온도 일탈(temperature excursion) 연구 또는 운송 시뮬레이션 연구도\n\n기대한다.  보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다.  안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n 열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.2.  보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n 백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다. ",
        "original_sentence": "열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_745",
      "text": "<!-- PAGE_52 -->\n### 2.9.4.8.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 744,
        "window_size": 3,
        "char_count": 32,
        "word_count": 5,
        "page_number": 52,
        "window_text": "보관 안정성과 용기-마개 시스템의 적합성((예: 침출물 및 추출물 관련\n\n적합성 포함)을 평가하고 논해야 한다.  안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n 열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.2.  보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n 백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다.  최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다. ",
        "original_sentence": "<!-- PAGE_52 -->\n### 2.9.4.8.2. "
      }
    },
    {
      "chunk_id": "chunk_746",
      "text": "보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 745,
        "window_size": 3,
        "char_count": 27,
        "word_count": 4,
        "page_number": 27,
        "window_text": "안정성 평가는 ‘생물의약품 안정성 시험\n\n가이드라인(2015)’를\n\n준수해야\n\n한다.\n\n 열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.2.  보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n 백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다.  최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다.  임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n",
        "original_sentence": "보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_747",
      "text": "백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 746,
        "window_size": 3,
        "char_count": 107,
        "word_count": 24,
        "page_number": 8,
        "window_text": "열\n\n안정성이\n\n더\n\n높은\n\n백신\n\n제형화\n\n개발을\n\n고려해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.2.  보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n 백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다.  최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다.  임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.3. ",
        "original_sentence": "백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_748",
      "text": "최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 747,
        "window_size": 3,
        "char_count": 140,
        "word_count": 34,
        "page_number": 17,
        "window_text": "<!-- PAGE_52 -->\n### 2.9.4.8.2.  보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n 백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다.  최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다.  임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.3.  유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n",
        "original_sentence": "최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_749",
      "text": "임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 748,
        "window_size": 3,
        "char_count": 81,
        "word_count": 19,
        "page_number": 10,
        "window_text": "보관조건\n\n보관조건을\n\n밸리데이션해야\n\n한다.\n\n 백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다.  최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다.  임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.3.  유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n 유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n",
        "original_sentence": "임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_750",
      "text": "<!-- PAGE_52 -->\n### 2.9.4.8.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 749,
        "window_size": 3,
        "char_count": 32,
        "word_count": 5,
        "page_number": 52,
        "window_text": "백신은\n\n제조시설에서\n\n유통을\n\n개시하기\n\n전\n\n또는 보관시설에서 출하하기 전에, 백신 제조사가 역가의 최소 손실에 적합하다고\n\n증명한 기간 및 온도를 상회하는 조건에서 보관해서는 안 된다.  최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다.  임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.3.  유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n 유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n <!-- PAGE_52 -->\n### 2.10. ",
        "original_sentence": "<!-- PAGE_52 -->\n### 2.9.4.8.3. "
      }
    },
    {
      "chunk_id": "chunk_751",
      "text": "유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 750,
        "window_size": 3,
        "char_count": 93,
        "word_count": 16,
        "page_number": 10,
        "window_text": "최대 보관 기간은\n\n안정성 연구 결과를 기반으로 식약처의 승인을 받아 확정해야 하며, 용기 및\n\n포장에\n\n명시한\n\n최소\n\n역가를\n\n포함하여,\n\n최종\n\n제품에\n\n대한\n\n모든\n\n품질\n\n규격이\n\n유효기간 만료 시까지 유지됨을 보장할 수 있도록 해야 한다.  임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.3.  유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n 유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n <!-- PAGE_52 -->\n### 2.10.  기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n",
        "original_sentence": "유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_752",
      "text": "유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 751,
        "window_size": 3,
        "char_count": 101,
        "word_count": 24,
        "page_number": 8,
        "window_text": "임상시험 실시 중,\n\n이 기간은 이상적으로는 참가자 등록을 완료한 임상시험에서 예상하는 백신 투여\n\n단계의 지속 기간과 최소한 동일해야 한다.\n\n <!-- PAGE_52 -->\n### 2.9.4.8.3.  유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n 유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n <!-- PAGE_52 -->\n### 2.10.  기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n <!-- PAGE_53 -->\n### 2.11. ",
        "original_sentence": "유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_753",
      "text": "<!-- PAGE_52 -->\n### 2.10. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 752,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 52,
        "window_text": "<!-- PAGE_52 -->\n### 2.9.4.8.3.  유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n 유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n <!-- PAGE_52 -->\n### 2.10.  기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n <!-- PAGE_53 -->\n### 2.11.  보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다. ",
        "original_sentence": "<!-- PAGE_52 -->\n### 2.10. "
      }
    },
    {
      "chunk_id": "chunk_754",
      "text": "기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 753,
        "window_size": 3,
        "char_count": 120,
        "word_count": 23,
        "page_number": 8,
        "window_text": "유효기간\n\n유효기간은 실시간 안정성 연구가 뒷받침하는 최종 용기의 유효기간(shelf-life)을\n\n기반으로\n\n정의해야\n\n하고\n\n식약처의\n\n승인을\n\n받아야\n\n한다.\n\n 유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n <!-- PAGE_52 -->\n### 2.10.  기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n <!-- PAGE_53 -->\n### 2.11.  보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다.  보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n",
        "original_sentence": "기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_755",
      "text": "<!-- PAGE_53 -->\n### 2.11. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 754,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 53,
        "window_text": "유효일자는,\n\n해당되는\n\n경우, 최종 제형화 원액의 혼합 일자 또는 충전 일자, 최종 로트에 대한 최초의\n\n유효한 역가시험 일자를 기반으로 해야 하며, 식약처의 동의가 필요하다.\n\n <!-- PAGE_52 -->\n### 2.10.  기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n <!-- PAGE_53 -->\n### 2.11.  보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다.  보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n 핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다. ",
        "original_sentence": "<!-- PAGE_53 -->\n### 2.11. "
      }
    },
    {
      "chunk_id": "chunk_756",
      "text": "보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 755,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 8,
        "window_text": "<!-- PAGE_52 -->\n### 2.10.  기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n <!-- PAGE_53 -->\n### 2.11.  보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다.  보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n 핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다.  적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n",
        "original_sentence": "보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_757",
      "text": "보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 756,
        "window_size": 3,
        "char_count": 77,
        "word_count": 18,
        "page_number": 8,
        "window_text": "기록\n\n후보백신의 개발 단계에 맞추어 ‘의약품 제조 및 품질관리기준’, ‘생물학적제제등\n\n제조 및 품질관리기준, ’임상시험용의약품 제조 및 품질관리기준‘에서 제시하는\n\n53/72\n\n관련 권고사항을 적용해야 한다.\n\n <!-- PAGE_53 -->\n### 2.11.  보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다.  보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n 핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다.  적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n 54/72\n\n<!-- PAGE_54 -->\n## 3. ",
        "original_sentence": "보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_758",
      "text": "핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 757,
        "window_size": 3,
        "char_count": 83,
        "word_count": 18,
        "page_number": 5,
        "window_text": "<!-- PAGE_53 -->\n### 2.11.  보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다.  보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n 핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다.  적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n 54/72\n\n<!-- PAGE_54 -->\n## 3.  비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다. ",
        "original_sentence": "핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_759",
      "text": "적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 758,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 8,
        "window_text": "보관검체\n\n향후 연구 및 필요에 대비하여 충분한 수의 검체를 보관해야 한다.  보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n 핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다.  적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n 54/72\n\n<!-- PAGE_54 -->\n## 3.  비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다.  제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n",
        "original_sentence": "적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_760",
      "text": "54/72\n\n<!-- PAGE_54 -->\n## 3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 759,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 54,
        "window_text": "보관 검체가\n\n필요한 경우로는 제조와 관련된 연구 및 개발, 비임상 연구, 향후 가교 임상시험이\n\n포함되나\n\n이에\n\n국한되지\n\n않는다.\n\n 핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다.  적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n 54/72\n\n<!-- PAGE_54 -->\n## 3.  비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다.  제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다. ",
        "original_sentence": "54/72\n\n<!-- PAGE_54 -->\n## 3. "
      }
    },
    {
      "chunk_id": "chunk_761",
      "text": "비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 760,
        "window_size": 3,
        "char_count": 66,
        "word_count": 15,
        "page_number": 8,
        "window_text": "핵심\n\n임상시험에서\n\n사용한\n\n백신\n\n로트는\n\n표준물질로서 사용이 가능하며, 이러한 목적으로 충분한 수의 바이알을 적절히\n\n비축 및 보관해야 한다.  적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n 54/72\n\n<!-- PAGE_54 -->\n## 3.  비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다.  제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다.  이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다. ",
        "original_sentence": "비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_762",
      "text": "제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 761,
        "window_size": 3,
        "char_count": 113,
        "word_count": 23,
        "page_number": 8,
        "window_text": "적당한 수의 핵심 임상시험 로트의 용기를 보유할 수\n\n있도록 사전 계획이 필요하다.\n\n 54/72\n\n<!-- PAGE_54 -->\n## 3.  비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다.  제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다.  이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다.  그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다. ",
        "original_sentence": "제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_763",
      "text": "mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 762,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 2,
        "window_text": "54/72\n\n<!-- PAGE_54 -->\n## 3.  비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다.  제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다.  이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다.  그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다.  mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다. ",
        "original_sentence": "mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다. "
      }
    },
    {
      "chunk_id": "chunk_764",
      "text": "이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 763,
        "window_size": 3,
        "char_count": 89,
        "word_count": 23,
        "page_number": 8,
        "window_text": "비임상 평가\n\nmRNA 후보백신의 비임상 평가는 의도한 임상적 사용을 감안하여 제품 특이적\n\n기반으로 고려해야 한다.  제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다.  이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다.  그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다.  mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다.  그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다. ",
        "original_sentence": "이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다. "
      }
    },
    {
      "chunk_id": "chunk_765",
      "text": "그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 764,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 6,
        "window_text": "제품의 약리학(면역원성 및 효력) 및 독성학과 관련된\n\n적절한 연구의 선택을 포함하여, 비임상 연구의 설계 및 실시, 분석은 ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’을 참고해야 한다.\n\n mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다.  이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다.  그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다.  mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다.  그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다.  예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n",
        "original_sentence": "그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_766",
      "text": "mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 765,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 8,
        "window_text": "mRNA 백신의 안전성 및 효력 평가에서 몇 가지 고려해야 할 잠재적 우려\n\n사항이 있다.  이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다.  그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다.  mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다.  그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다.  예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n <!-- PAGE_54 -->\n### 3.1. ",
        "original_sentence": "mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다. "
      }
    },
    {
      "chunk_id": "chunk_767",
      "text": "그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 766,
        "window_size": 3,
        "char_count": 115,
        "word_count": 24,
        "page_number": 8,
        "window_text": "이 제품 유형의 신규성 때문에 이 항에는 핵심 평가변수를 고려하는\n\n수많은 쟁점이 나열되어 있으며 그중 일부는 주어진 mRNA 백신과 관련이 있을\n\n수 있다.  그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다.  mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다.  그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다.  예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n <!-- PAGE_54 -->\n### 3.1.  약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n",
        "original_sentence": "그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_768",
      "text": "예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 767,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 8,
        "window_text": "그러나 추후 추가적으로 논의가 필요한 부분이 있을 수 있다.  mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다.  그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다.  예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n <!-- PAGE_54 -->\n### 3.1.  약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n - (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n",
        "original_sentence": "예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_769",
      "text": "<!-- PAGE_54 -->\n### 3.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 768,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 54,
        "window_text": "mRNA\n\n백신의 설계에 따라, 이러한 문제들 전체가 반드시 mRNA 백신에 관련되지는\n\n않을 것이다.  그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다.  예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n <!-- PAGE_54 -->\n### 3.1.  약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n - (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n 면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2. ",
        "original_sentence": "<!-- PAGE_54 -->\n### 3.1. "
      }
    },
    {
      "chunk_id": "chunk_770",
      "text": "약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 769,
        "window_size": 3,
        "char_count": 117,
        "word_count": 22,
        "page_number": 4,
        "window_text": "그러나 백신 개발사/제조사는 그들의 후보 백신에 대하여 효력(예:\n\n면역원성\n\n시험,\n\n만일\n\n적절한\n\n모델\n\n동물이\n\n있다면,\n\n면역접종\n\n후\n\n공격시험)\n\n및\n\n안전성을 입증하는 증거를 제공해야 한다.  예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n <!-- PAGE_54 -->\n### 3.1.  약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n - (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n 면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2.  독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n",
        "original_sentence": "약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_771",
      "text": "- (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 770,
        "window_size": 3,
        "char_count": 90,
        "word_count": 17,
        "page_number": 4,
        "window_text": "예상하는 연구의 종류 및 설계, 수는\n\n식약처의 동의가 필요하다.\n\n <!-- PAGE_54 -->\n### 3.1.  약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n - (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n 면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2.  독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n - (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n",
        "original_sentence": "- (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n"
      }
    },
    {
      "chunk_id": "chunk_772",
      "text": "면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 771,
        "window_size": 3,
        "char_count": 195,
        "word_count": 37,
        "page_number": 55,
        "window_text": "<!-- PAGE_54 -->\n### 3.1.  약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n - (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n 면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2.  독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n - (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n 이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다. ",
        "original_sentence": "면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2. "
      }
    },
    {
      "chunk_id": "chunk_773",
      "text": "독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 772,
        "window_size": 3,
        "char_count": 84,
        "word_count": 14,
        "page_number": 4,
        "window_text": "약리작용\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n식약처가\n\n예방용\n\nmRNA 백신의 비임상시험에서 다룰 것으로 기대할 수도 있는 추가적인 문제에는\n\n다음이 포함될 수 있다.\n\n - (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n 면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2.  독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n - (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n 이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다.  식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다. ",
        "original_sentence": "독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_774",
      "text": "- (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 773,
        "window_size": 3,
        "char_count": 122,
        "word_count": 27,
        "page_number": 4,
        "window_text": "- (1) 면역반응의 지속성(durability)을 시사하는 면역세포 표현형, 특히 후보 백신의\n방어\n\n효과\n\n유도와\n\n관련이\n\n있다고\n\n제안된\n\n면역반응들.\n\n 면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2.  독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n - (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n 이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다.  식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다.  식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다. ",
        "original_sentence": "- (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n"
      }
    },
    {
      "chunk_id": "chunk_775",
      "text": "이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 774,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 8,
        "window_text": "면역반응의\n\n지속성\n\n평가를\n\n위해,\n\n면역세포\n\n표현형\n\n및/또는\n\n사이토카인\n\n발현의\n\n특성\n\n분석은\n\n- (2) RNA에 의한 선천성 면역반응의 유도(예: 1형 인터페론(type I interferon)),\n이러한 면역반응은 표적 항원의 번역을 감소시키는 것으로 보고되었거나, 또는\n\n55/72\n\n<!-- PAGE_55 -->\n### 3.2.  독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n - (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n 이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다.  식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다.  식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다.  mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n",
        "original_sentence": "이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_776",
      "text": "식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 775,
        "window_size": 3,
        "char_count": 128,
        "word_count": 28,
        "page_number": 8,
        "window_text": "독성\n\n‘생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)’\n\n이외에\n\n연구에서\n\n다음\n\n사항들을 다루도록 설계해야 하는가를 고려해야 한다.\n\n - (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n 이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다.  식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다.  식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다.  mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n 이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다. ",
        "original_sentence": "식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_777",
      "text": "식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 776,
        "window_size": 3,
        "char_count": 90,
        "word_count": 22,
        "page_number": 8,
        "window_text": "- (1) 생체\n분포\n\n및\n\n잔존도\n\n:\n\n이러한\n\n잠재적\n\n우려에\n\n대한\n\n증거\n\n데이터베이스\n\n개발을\n\n통해\n\n향후\n\n임상\n\n후보\n\n백신을\n\n더욱\n\n신속히\n\n개발할\n\n수\n\n있게\n\n될\n\n것이다(3,\n\n44~49).\n\n 이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다.  식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다.  식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다.  mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n 이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다.  비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51). ",
        "original_sentence": "식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다. "
      }
    },
    {
      "chunk_id": "chunk_778",
      "text": "mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 777,
        "window_size": 3,
        "char_count": 121,
        "word_count": 29,
        "page_number": 8,
        "window_text": "이\n\n잠재적\n\n문제는\n\n또한\n\n백신이\n\n특정\n\n세포나\n\n조직으로\n\n이동하는가에 따라 달라질 수 있다.  식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다.  식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다.  mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n 이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다.  비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51).  추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55). ",
        "original_sentence": "mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n"
      }
    },
    {
      "chunk_id": "chunk_779",
      "text": "이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 778,
        "window_size": 3,
        "char_count": 91,
        "word_count": 21,
        "page_number": 8,
        "window_text": "식약처는 mRNA 및 지질나노입자(또는\n\n지질 구성성분)가 백신을 투여한 조직으로부터 멀리 떨어진 곳에 분포하고\n\n있는가, 이들이 어떤 조직에 분포하는가, 그리고 얼마나 오래 잔존하는가를\n\n다루는 비임상 연구를 기대할 수 있다.  식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다.  mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n 이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다.  비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51).  추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55).  따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n",
        "original_sentence": "이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_780",
      "text": "비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 779,
        "window_size": 3,
        "char_count": 113,
        "word_count": 25,
        "page_number": 8,
        "window_text": "식약처로부터 이러한 연구에 대한\n\n- (2) 염증 : RNA는 다수의 경로, 특히 RNA를 감지하는 수많은 센서를 지닌\n선천성 면역체계를 통해 염증을 유발한다.  mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n 이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다.  비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51).  추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55).  따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n 동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다. ",
        "original_sentence": "비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51). "
      }
    },
    {
      "chunk_id": "chunk_781",
      "text": "추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 780,
        "window_size": 3,
        "char_count": 116,
        "word_count": 27,
        "page_number": 23,
        "window_text": "mRNA 백신 내의 mRNA 분자 및\n\n(성공적인 전달과 세포 내 유입을 가능하게 해주는) 지질나노입자, 두 가지\n\n모두는 선천성 면역반응에 영향을 주고 이를 촉발할 수 있는 성질을 지니고\n\n있다(50,\n\n51).\n\n 이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다.  비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51).  추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55).  따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n 동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다.  그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n",
        "original_sentence": "추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55). "
      }
    },
    {
      "chunk_id": "chunk_782",
      "text": "따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 781,
        "window_size": 3,
        "char_count": 103,
        "word_count": 25,
        "page_number": 8,
        "window_text": "이러한\n\n활성\n\n중\n\n일부는\n\n백신에\n\n대한\n\n면역반응에\n\n유리하게\n\n작용할 수 있는 한편, 전신/국소 독성 및 염증반응을 모두 모니터하는 것이\n\n중요할 것이다.  비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51).  추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55).  따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n 동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다.  그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n 개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다. ",
        "original_sentence": "따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_783",
      "text": "동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 782,
        "window_size": 3,
        "char_count": 390,
        "word_count": 59,
        "page_number": 8,
        "window_text": "비임상 연구 설계에서는 인체에 발생하는 심각한 이상사례\n\n또는 특별 관심의 대상인 이상사례(AESI)에 대한 지표를 예측할 수 있는\n\n면역반응 또는 반응원성, 독성에 대해 고려해야 한다(50, 51).  추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55).  따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n 동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다.  그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n 개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다.  그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다. ",
        "original_sentence": "동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다. "
      }
    },
    {
      "chunk_id": "chunk_784",
      "text": "그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 783,
        "window_size": 3,
        "char_count": 56,
        "word_count": 11,
        "page_number": 23,
        "window_text": "추가적으로,\n\nPEG와 같이 전달을 돕기 위해 첨가한 기타 구성성분은 상대적으로 무해\n\n함에도 불구하고, 이들 역시 이화학적 성질에 영향을 주어 그 결과 안전성\n\n프로파일에 영향을 줄 수 있다(52~55).  따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n 동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다.  그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n 개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다.  그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다.  더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n",
        "original_sentence": "그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_785",
      "text": "개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 784,
        "window_size": 3,
        "char_count": 95,
        "word_count": 21,
        "page_number": 4,
        "window_text": "따라서 제형화를 포함한 전반적인\n\n제품 프로파일 그리고 (변동이 발생할 수 있는) 이화학적 성질이 어떻게\n\n염증 및 안전성 프로파일에 영향을 줄 수 있는가를 이해하는 것이 중요하다.\n\n 동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다.  그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n 개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다.  그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다.  더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n",
        "original_sentence": "개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_786",
      "text": "그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 785,
        "window_size": 3,
        "char_count": 450,
        "word_count": 92,
        "page_number": 8,
        "window_text": "동물모델의 선택은 항상 그렇듯이 동물모델의 항-RNA 선천성 면역 반응이\n\n일반적으로 인간에서 관찰된 것보다 훨씬 더 약하다는 점을 이해하는 것이\n\n56/72\n\n- (3) 변형된 뉴클레오시드로 인한 예상하지 못한 심각한 독성 : 변형된 구조를\n가진 특정 비자연적인 뉴클레오시드 유사체(unnatural nucleoside analogue)를\n\n함유한\n\n일부\n\n항바이러스제\n\n및\n\n항암제는\n\n미토콘드리아\n\n독성을\n\n유발하여,\n\n근질환(myopathy), 다발성신경병증(polyneuropathy), 젖산산증(lactic acidosis),\n\n간지방증(liver\n\nsteatosis),\n\n췌장염(pancreatitis),\n\n지방이영양증(lipodystropy),\n\n그리고 심지어는 사망으로 이어진다.  그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n 개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다.  그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다.  더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다. ",
        "original_sentence": "그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_787",
      "text": "더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 786,
        "window_size": 3,
        "char_count": 337,
        "word_count": 72,
        "page_number": 4,
        "window_text": "그러나 임상적으로 관찰된 이러한 독성\n\n중\n\n일부는\n\n비임상\n\n동물모델에서는\n\n관찰되지\n\n않았다.\n\n 개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다.  그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다.  더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다.  추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n",
        "original_sentence": "더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_788",
      "text": "Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 787,
        "window_size": 3,
        "char_count": 116,
        "word_count": 19,
        "page_number": 8,
        "window_text": "개발이\n\n가장\n\n진전된\n\n(코로나19) mRNA 백신에 사용된 변형된 뉴클레오시드는 자연 발생적인 것인\n\n반면, 미래의 후보 백신은 비자연적인 변형물을 포함할 수 있다.  그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다.  더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다.  추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n 이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n",
        "original_sentence": "Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_789",
      "text": "Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 788,
        "window_size": 3,
        "char_count": 108,
        "word_count": 24,
        "page_number": 2,
        "window_text": "그러므로,\n\n특히\n\n비자연적\n\n뉴클레오시드\n\n변형물을\n\n포함한\n\nmRNA\n\n백신의\n\n경우(다른\n\n개발되는 핵산 기반 제품에서 이미 특성분석이 잘되지 않은), 안전성 평가 중\n\n적절한 동물모델 및 비임상 연구에서 이러한 잠재적 독성을 어떻게 관찰할\n\n- (4) 새로운\n지질\n\n및\n\n새로운\n\n지질나노입자\n\n:\n\n지질나노입자를\n\n제형화하는\n\n데\n\n사용한\n\n지질이\n\n입자의\n\n전반적인\n\n전하에\n\n영향을\n\n줄\n\n수\n\n있으므로,\n\n새로운\n\n지질로\n\n제작한 지질나노입자를\n\n사용하는\n\n경우 또는\n\n지질나노입자\n\n자체가\n\n변형된 것이고(예: 비율 변경 또는 공정 변경) 이어 이러한 지질나노입자가\n\n이전에\n\n지질나노입자로\n\n봉입한\n\nmRNA\n\n제품에서\n\n비임상이나\n\n임상적으로\n\n시험된\n\n적이\n\n없는\n\n경우에는,\n\n새로운\n\n지질(또는\n\n새로운\n\n첨가제)을\n\n함유한\n\n새로운 제형화에 대하여 독성 평가를 실시해야 한다.  더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다.  추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n 이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n 임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n",
        "original_sentence": "Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_790",
      "text": "추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 789,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 8,
        "window_text": "더 나아가, ‘생물의약품\n\n비임상시험 가이드라인(식약처, 2018)’에서 제시하고 있는 새로운 면역증강제\n\n및/또는\n\nICH\n\n가이드라인\n\nS2(R1)(58)의\n\n새로운\n\n화학적\n\n물질에\n\n대한\n\n기대사항과 유사하게, 식약처는 새로운 지질 구성성분의 유전독성 및 전신\n\n- (5) 새로운 제형화 : 마찬가지로, (지질나노입자 이외의) 새로운 첨가제를 함유한\n제형화의 경우, 새로운 제형화에 따른 전신 독성 및 유전독성에 대한 자료\n\n플라스미드 DNA 백신 개발 중 백신 핵산의 숙주 유전체 내 삽입 가능성과\n\n57/72\n\n관련된 초기의 이론적 우려는 다음을 이유로 mRNA 백신에는 적용되지 않는다.\n\n Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다.  추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n 이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n 임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n 이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다. ",
        "original_sentence": "추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_791",
      "text": "이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 790,
        "window_size": 3,
        "char_count": 119,
        "word_count": 28,
        "page_number": 8,
        "window_text": "Ÿ RNA의 숙주 유전체 내 삽입이 발생할 수 있는 유일하게 알려진 기전에는\n\n역전사효소(reverse\n\ntranscriptase)와\n\n통합효소(integrase)를\n\n함유한\n\n복합체의\n\n존재가 필요하다.\n\n Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다.  추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n 이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n 임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n 이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다.  종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다. ",
        "original_sentence": "이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_792",
      "text": "임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 791,
        "window_size": 3,
        "char_count": 119,
        "word_count": 19,
        "page_number": 8,
        "window_text": "Ÿ 더 나아가, mRNA 후보백신의 설계 시 고려해야 할 사항은 역전사효소가\n\n전사를\n\n개시하는\n\n데\n\n필요한\n\n프라이머에\n\n대한\n\n특정\n\nRNA-결합\n\n부위를\n\n포함하지 않도록 하는 것이다.  추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n 이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n 임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n 이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다.  종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다.  예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n",
        "original_sentence": "임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_793",
      "text": "이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 792,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 17,
        "window_text": "추가로, 결과 산물이 삽입되도록 역전사 후\n\nŸ 마지막으로, 백신 mRNA는, 세포 자체의 mRNA와 같이, 일단 체내 세포\n\n속으로\n\n들어가면\n\n비교적\n\n짧은\n\n기간\n\n내에\n\n분해된다.\n\n 이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n 임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n 이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다.  종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다.  예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n 동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n",
        "original_sentence": "이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_794",
      "text": "종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 793,
        "window_size": 3,
        "char_count": 86,
        "word_count": 22,
        "page_number": 8,
        "window_text": "이\n\n전체\n\n시간\n\n동안,\n\nmRNA 백신은 세포질 내에 머무는 것으로 예상되며, 이곳에서 mRNA가\n\n따라서 mRNA 백신에 있어서 삽입 및 유전적 위험성을 다루기 위해서 비임상\n\n연구를 실시할 필요는 없다.\n\n 임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n 이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다.  종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다.  예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n 동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n 동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다. ",
        "original_sentence": "종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_795",
      "text": "예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 794,
        "window_size": 3,
        "char_count": 84,
        "word_count": 21,
        "page_number": 5,
        "window_text": "임신부\n\n또는\n\n가임기\n\n여성에서\n\n광범위하게\n\n사용할\n\n것으로\n\n예상되는\n\n다른\n\n백신들과\n\n마찬가지로\n\n‘생물의약품\n\n비암상시험\n\n가이드라인(식약처,\n\n2014)’에서\n\n제공하는\n\n지침을\n\n참조해야\n\n한다.\n\n 이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다.  종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다.  예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n 동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n 동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다.  마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n",
        "original_sentence": "예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_796",
      "text": "동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 795,
        "window_size": 3,
        "char_count": 113,
        "word_count": 26,
        "page_number": 8,
        "window_text": "이러한\n\n연구의\n\n필요성은\n\n백신의\n\n해당\n\n임상\n\n적응증에 대하여 표적 인구를 기반으로 할 것이다.  종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다.  예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n 동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n 동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다.  마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n 여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n",
        "original_sentence": "동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_797",
      "text": "동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 796,
        "window_size": 3,
        "char_count": 131,
        "word_count": 28,
        "page_number": 10,
        "window_text": "종종, 필요한 경우, 이러한\n\n연구는 상업적 제조 방법 및 규모로 생산한 후보백신을 사용한 핵심 임상시험을\n\n수행하는 중 또는 시험 완료 후에 실시한다.  예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n 동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n 동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다.  마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n 여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n <!-- PAGE_58 -->\n### 3.3. ",
        "original_sentence": "동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_798",
      "text": "마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 797,
        "window_size": 3,
        "char_count": 122,
        "word_count": 28,
        "page_number": 8,
        "window_text": "예를 들어, 가임 여성이 포함된\n\n모집단에서 데이터는 품목허가 신청 시 및 임신 여성을 임상 연구에 의도적으로\n\n등록하기 전에 이용 가능해야 한다.\n\n 동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n 동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다.  마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n 여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n <!-- PAGE_58 -->\n### 3.3.  비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n",
        "original_sentence": "마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_799",
      "text": "여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 798,
        "window_size": 3,
        "char_count": 134,
        "word_count": 29,
        "page_number": 8,
        "window_text": "동일 플랫폼 기술을 기반으로 한 유사한 후보 백신을 확보할 수 있다면, 이러한\n\n자료가 추가적인 비임상 연구의 필요성을 배제하는 데 과학적으로 충분한가에\n\n대하여\n\n식약처의\n\n승인을\n\n얻어야\n\n한다.\n\n 동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다.  마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n 여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n <!-- PAGE_58 -->\n### 3.3.  비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n",
        "original_sentence": "여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_800",
      "text": "<!-- PAGE_58 -->\n### 3.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 799,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 58,
        "window_text": "동일한\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n유사한\n\n후보\n\n백신의\n\n비임상\n\n안전성\n\n데이터를\n\n사용할\n\n수\n\n있는\n\n경우\n\n이러한\n\n데이터가 추가 비임상 안전성 연구의 필요성을 배제하기에 과학적으로 충분하다는\n\n데 동의해야 한다.  마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n 여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n <!-- PAGE_58 -->\n### 3.3.  비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n 그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다. ",
        "original_sentence": "<!-- PAGE_58 -->\n### 3.3. "
      }
    },
    {
      "chunk_id": "chunk_801",
      "text": "비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 800,
        "window_size": 3,
        "char_count": 128,
        "word_count": 32,
        "page_number": 17,
        "window_text": "마찬가지로, 단가 의약품 제제의 비임상 안전성 데이터는 예를\n\n58/72\n\n들어 동일한 질병 항원(다른 균주) 또는 다른 질병 항원(혼합 백신)에 대한 다가\n\n의약품\n\n제제의\n\n임상\n\n개발을\n\n뒷받침할\n\n수\n\n있다.\n\n 여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n <!-- PAGE_58 -->\n### 3.3.  비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n 그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다.  관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다. ",
        "original_sentence": "비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_802",
      "text": "Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 801,
        "window_size": 3,
        "char_count": 400,
        "word_count": 79,
        "page_number": 8,
        "window_text": "여기에는\n\n동일한\n\n몰\n\n및\n\n지질/mRNA 비를 갖는 동일한 지질나노입자, 다가 의약품 제형의 모든 mRNA의\n\n합이 단가 비임상 안전성 연구(가능하다면 임상 데이터)에서 결정된 최대내성용량\n\n이하일 것이라는 것을 아는 것이 포함된다.\n\n <!-- PAGE_58 -->\n### 3.3.  비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n 그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다.  관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다.  사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n",
        "original_sentence": "Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_803",
      "text": "그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 802,
        "window_size": 3,
        "char_count": 116,
        "word_count": 24,
        "page_number": 8,
        "window_text": "<!-- PAGE_58 -->\n### 3.3.  비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n 그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다.  관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다.  사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n 어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다. ",
        "original_sentence": "그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_804",
      "text": "관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 803,
        "window_size": 3,
        "char_count": 70,
        "word_count": 18,
        "page_number": 10,
        "window_text": "비임상 평가의 가속화\n\n공중보건 긴급상황 중 우선순위 병원체에 대한 신속한 백신 개발의 경우 그리고\n\n새로운 후보 백신이 특정 제조사의 플랫폼 기술을 기반으로 하는 경우, 다음과\n\n같은 단축 비임상 프로그램을 고려할 수 있다.\n\n Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n 그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다.  관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다.  사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n 어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다.  만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다. ",
        "original_sentence": "관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_805",
      "text": "사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 804,
        "window_size": 3,
        "char_count": 198,
        "word_count": 42,
        "page_number": 8,
        "window_text": "Ÿ 이미 임상적으로 시험한 mRNA 백신에 코딩된 표적 항원의 서열이 변경된\n\n경우(예: 계절성 또는 다른 잠재적인 대유행 균주 항원에 대해 시험이 진행된\n\n대유행 독감 균주의 경우, 또는 SARS-CoV-2 spike 단백질 변이체가 발생한\n\n경우),\n\n동일한\n\n지질나노입자를\n\n사용한\n\n경우(즉,\n\n동일한\n\n지질\n\n조성\n\n및\n\nmRNA-지질\n\n비율,\n\n그리고\n\n도즈\n\n당\n\nmRNA와\n\n지질나노입자의\n\n총량이\n\n임상적으로 시험한 총량 이하로 유지되는 경우), 그리고 승인된 제조공정을\n\n이후 사용하는 경우 식약처의 요건에 따라, 비임상 프로그램은 면역원성 연구\n\n또는,\n\n가용한\n\n경우라면,\n\n적절한\n\n동물모델을\n\n사용하는\n\n공격-방어(challenge-protection)\n\n연구로\n\n제한될\n\n수도\n\n있다.\n\n 그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다.  관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다.  사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n 어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다.  만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다.  자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n",
        "original_sentence": "사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_806",
      "text": "어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 805,
        "window_size": 3,
        "char_count": 102,
        "word_count": 22,
        "page_number": 18,
        "window_text": "그러나\n\n이러한\n\n비임상 효력시험은 일반적으로 우수실험실운영기준(GLP)을 완전히 준수하지\n\n않고 수행됨을 감안할 때, 이러한 면역원성 및 공격-방어 연구 중에는 가능한\n\n많은 안전성 자료를 수집해야 한다.  관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다.  사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n 어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다.  만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다.  자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n 자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n",
        "original_sentence": "어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다. "
      }
    },
    {
      "chunk_id": "chunk_807",
      "text": "만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 806,
        "window_size": 3,
        "char_count": 230,
        "word_count": 33,
        "page_number": 5,
        "window_text": "관련된 항원을 발현하는 동물용 백신에\n\n관한 안전성 정보가 있다면, 이 정보 역시 유용할 수도 있으며 이를 제공해야\n\n한다.  사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n 어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다.  만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다.  자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n 자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n 따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다. ",
        "original_sentence": "만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_808",
      "text": "자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 807,
        "window_size": 3,
        "char_count": 64,
        "word_count": 10,
        "page_number": 8,
        "window_text": "사용한 플랫폼 기술의 안전성에 관한 기타 정보(예: 이전의 독성학 및\n\nŸ 지질나노입자를 관련이 없는 mRNA와 함께 임상적으로 시험하였고 따라서\n\n표적 항원이 새로운(즉, 임상적으로 시험을 실시한 다른 항원과는 관련이\n\n없는) 것이라면, 비임상 연구를 면역원성이나 공격-방어 연구로만 제한하는\n\n59/72\n\n접근법은\n\n충분하지\n\n않을\n\n수도\n\n있다.\n\n 어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다.  만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다.  자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n 자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n 따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다.  그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다. ",
        "original_sentence": "자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n"
      }
    },
    {
      "chunk_id": "chunk_809",
      "text": "자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 808,
        "window_size": 3,
        "char_count": 221,
        "word_count": 50,
        "page_number": 8,
        "window_text": "어떤\n\n종류의\n\n비임상\n\n안전성/독성학\n\n정보가 필요한가를 결정 시에는, 병리학의 견지에서 자연적 질환에 대하여\n\n무엇이, 얼마만큼 알려져 있는가를 지침으로 삼을 수도 있을 것이다.  만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다.  자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n 자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n 따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다.  그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다.  관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n",
        "original_sentence": "자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_810",
      "text": "따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 809,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 8,
        "window_text": "만일\n\n자연적 질환이 교차-반응성 및 분자적 모방(molecular mimicry), 자가면역,\n\n알레르기원성(allergenicity)\n\n또는\n\n면역-연관\n\n질환강화(immune-associated\n\ndisease\n\nenhancement)로\n\n인해\n\n면역병리(immunopathology)와\n\n관련되어\n\n있다면, 새로운 표적 항원이 이러한 효과들과 관련이 없음을 확증하기 위해\n\n독성 연구가 필요할 수 있다.  자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n 자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n 따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다.  그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다.  관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n 60/72\n\n<!-- PAGE_60 -->\n## 4. ",
        "original_sentence": "따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_811",
      "text": "그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 810,
        "window_size": 3,
        "char_count": 153,
        "word_count": 37,
        "page_number": 8,
        "window_text": "자가면역은 비임상 연구에서 평가되지 않을 수\n\n있다(생물의약품\n\n비임상시험\n\n가이드라인(식약처,\n\n2018)).\n\n 자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n 따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다.  그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다.  관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n 60/72\n\n<!-- PAGE_60 -->\n## 4.  임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n",
        "original_sentence": "그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_812",
      "text": "관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 811,
        "window_size": 3,
        "char_count": 121,
        "word_count": 29,
        "page_number": 8,
        "window_text": "자연적\n\n질환이\n\n면역병리와\n\n관련이\n\n없거나\n\n또는\n\n자연적\n\n질환에\n\n대해\n\n알려진\n\n바가\n\n거의\n\n없다면,\n\n비임상\n\n프로그램을\n\n어떻게\n\n단축할\n\n수\n\n있는가에\n\n대하여\n\n식약처와\n\nŸ 마지막으로, 지질나노입자 및 코딩된 표적 항원 (그리고 mRNA 구조 및\n\n서열) 두 가지가 모두 새로운 경우, 비임상 평가는 더욱 복잡할 수 있으며\n\n한층\n\n광범위한\n\n연구가\n\n필요할\n\n수\n\n있다.\n\n 따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다.  그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다.  관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n 60/72\n\n<!-- PAGE_60 -->\n## 4.  임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n 만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n",
        "original_sentence": "관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_813",
      "text": "60/72\n\n<!-- PAGE_60 -->\n## 4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 812,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 60,
        "window_text": "따라서\n\n식약처와의\n\n논의가\n\n또한\n\n필요할 수 있으며, 비임상 프로그램 단축이 상당히 불가능할 수 있다.  그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다.  관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n 60/72\n\n<!-- PAGE_60 -->\n## 4.  임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n 만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n 임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다. ",
        "original_sentence": "60/72\n\n<!-- PAGE_60 -->\n## 4. "
      }
    },
    {
      "chunk_id": "chunk_814",
      "text": "임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 813,
        "window_size": 3,
        "char_count": 161,
        "word_count": 29,
        "page_number": 2,
        "window_text": "그러나,\n\n필요한 비임상 연구를 임상 개발과 동시에 (또는 조금 앞서서) 실시하면서,\n\n비임상 프로그램 단축에 대한 결정 시에는, 특히 동일 플랫폼 기술을 기반으로\n\n하는 경우라면, 관련성이 있으며 기존에 시험을 실시한 제품에 대해 이미 알려진\n\n바를 항상 고려해야 한다.  관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n 60/72\n\n<!-- PAGE_60 -->\n## 4.  임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n 만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n 임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다.  또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다. ",
        "original_sentence": "임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_815",
      "text": "만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 814,
        "window_size": 3,
        "char_count": 113,
        "word_count": 21,
        "page_number": 8,
        "window_text": "관련된 제품(들)에서 도출한 임상 자료를 확보할 수\n\n있다면, 이러한 자료는 동물모델이나 in vitro 인간 모델에서 획득한 자료보다도\n\n인체 적용 시 후보백신의 안전성 평가에 관하여 더욱 유의한 것일 수 있다.\n\n 60/72\n\n<!-- PAGE_60 -->\n## 4.  임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n 만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n 임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다.  또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다.  더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n",
        "original_sentence": "만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_816",
      "text": "임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 815,
        "window_size": 3,
        "char_count": 115,
        "word_count": 22,
        "page_number": 23,
        "window_text": "60/72\n\n<!-- PAGE_60 -->\n## 4.  임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n 만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n 임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다.  또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다.  더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n 다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n",
        "original_sentence": "임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_817",
      "text": "또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 816,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 6,
        "window_text": "임상 평가\n\n임상시험\n\n승인\n\n또는\n\n품목허가를\n\n위한\n\n임상\n\n평가\n\n기대사항은\n\n개발이\n\n진행\n\n중이거나 완료된 mRNA 백신이 목표로 하는 질환 및 백신의 작용기전(mode of\n\naction)(또는\n\n작용기작(mechanism\n\nof\n\nmechanism))을\n\n기반으로\n\n한다.\n\n 만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n 임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다.  또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다.  더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n 다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n <!-- PAGE_60 -->\n### 4.1. ",
        "original_sentence": "또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_818",
      "text": "더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 817,
        "window_size": 3,
        "char_count": 166,
        "word_count": 40,
        "page_number": 8,
        "window_text": "만일\n\n방어효과에 관한 ICP(immune correlate of protection)가 확인되었다면, 이러한\n\nICP 미확립의 경우에 기대할 수도 있는 사항과 비교하여 기대사항이 변경될 수\n\n있다.\n\n 임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다.  또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다.  더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n 다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n <!-- PAGE_60 -->\n### 4.1.  안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n",
        "original_sentence": "더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_819",
      "text": "다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 818,
        "window_size": 3,
        "char_count": 176,
        "word_count": 41,
        "page_number": 8,
        "window_text": "임상\n\n연구는\n\n‘의약품\n\n등의\n\n안전에\n\n관한\n\n규칙(총리령)\n\n[별표\n\n4]\n\n의약품\n\n임상시험 관리기준’, ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있는\n\n원칙을 준수해야 한다.  또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다.  더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n 다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n <!-- PAGE_60 -->\n### 4.1.  안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n - (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59). ",
        "original_sentence": "다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_820",
      "text": "<!-- PAGE_60 -->\n### 4.1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 819,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 60,
        "window_text": "또한 시판 후 약물감시는 위의 두 번째 가이드라인에서는\n\n논하고 있다.  더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n 다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n <!-- PAGE_60 -->\n### 4.1.  안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n - (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59).  이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n",
        "original_sentence": "<!-- PAGE_60 -->\n### 4.1. "
      }
    },
    {
      "chunk_id": "chunk_821",
      "text": "안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 820,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 8,
        "window_text": "더 나아가, 이들 두 가이드라인에서는 백신 투여 계획 및 임상 개발\n\n계획, 안전성 정보 수집, 핵심 유효성 연구를 위한 설계(잠재적 평가변수 포함),\n\n면역원성 분석시험의 표준화(IS 사용 및 IU로 작성한 자료의 보고를 포함), 유효성\n\n추론을 위한 면역가교의 평가 시 고려사항을 제공한다.\n\n 다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n <!-- PAGE_60 -->\n### 4.1.  안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n - (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59).  이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64). ",
        "original_sentence": "안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_822",
      "text": "- (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 821,
        "window_size": 3,
        "char_count": 176,
        "word_count": 33,
        "page_number": 4,
        "window_text": "다른 종류의 백신에 대하여 기대하는 바와 같이, 하지만 이미 허가되었을 수\n\n있는 다른 종류의 백신보다 mRNA 백신과 연관성이 더 깊을 수 있으므로 아래\n\n개략적으로\n\n서술하고\n\n있는\n\n잠재적\n\n우려\n\n사항에\n\n대한\n\n특별한\n\n고려와\n\n함께,\n\n임상시험에서는 안전성 및 면역원성, 유효성 자료를 포착해야 한다.\n\n <!-- PAGE_60 -->\n### 4.1.  안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n - (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59).  이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64).  그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다. ",
        "original_sentence": "- (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59). "
      }
    },
    {
      "chunk_id": "chunk_823",
      "text": "이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 822,
        "window_size": 3,
        "char_count": 83,
        "word_count": 16,
        "page_number": 17,
        "window_text": "<!-- PAGE_60 -->\n### 4.1.  안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n - (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59).  이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64).  그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다.  따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n",
        "original_sentence": "이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n"
      }
    },
    {
      "chunk_id": "chunk_824",
      "text": "RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 823,
        "window_size": 3,
        "char_count": 128,
        "word_count": 29,
        "page_number": 4,
        "window_text": "안전성 및 면역원성 평가\n\nmRNA 백신과 특히 연관성 있을 수 있는 다음의 안전성 및 면역학적 측면의\n\n평가를 가능하게 해주는 충분한 자료를 획득해야 한다.\n\n - (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59).  이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64).  그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다.  따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n - (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n",
        "original_sentence": "RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64). "
      }
    },
    {
      "chunk_id": "chunk_825",
      "text": "그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 824,
        "window_size": 3,
        "char_count": 121,
        "word_count": 27,
        "page_number": 8,
        "window_text": "- (1) 유해한 면역효과\nmRNA\n\n백신의\n\n인체\n\n투여\n\n임상시험\n\n중간결과에서\n\n백신\n\n접종\n\n수일\n\n경과\n\n후\n\n일시적인\n\n림프구의\n\n일시적\n\n감소(1~3등급)가\n\n보고되었는데,\n\n림프구는\n\n모든\n\n참가자에게서 6~8일 이내에 기저 수치로 회복되었으며 관련된 임상적 관찰사항은\n\n61/72\n\n없었다(59).  이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64).  그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다.  따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n - (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n",
        "original_sentence": "그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_826",
      "text": "따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 825,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 24,
        "window_text": "이러한 일시적 감소는 다른 백신에 대해서도 관찰되었으며 면역반응에\n\n영향을\n\n주는\n\n유의한\n\n유해\n\n효과로\n\n이어지지는\n\n않았다(60,\n\n61).\n\n RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64).  그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다.  따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n - (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n 현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23). ",
        "original_sentence": "따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_827",
      "text": "- (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 826,
        "window_size": 3,
        "char_count": 157,
        "word_count": 34,
        "page_number": 4,
        "window_text": "RNA는\n\n제1형\n\n인터페론을 유도하며, 이것은 백혈구의 일시적인 조직 내로의 이동과 관련이 있기\n\n때문에 초기 임상시험에서는 혈중 림프구 수에 영향을 주는 모든 현상에 특정한\n\n관심을 기울여야 할 수 있다(46, 62~64).  그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다.  따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n - (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n 현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23).  이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n",
        "original_sentence": "- (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_828",
      "text": "Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 827,
        "window_size": 3,
        "char_count": 81,
        "word_count": 20,
        "page_number": 8,
        "window_text": "그렇기는 하지만, 이러한 현상이 후보\n\n백신에\n\n대한\n\n면역반응에\n\n중요할\n\n수\n\n있으므로,\n\n백혈구\n\n수나\n\n하위군에\n\n발생한\n\n변화가 유해한 임상적 징후나 증상과 관련이 있는가를 관찰하는 것이 중요할 수\n\n있다.  따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n - (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n 현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23).  이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n 이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다. ",
        "original_sentence": "Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n"
      }
    },
    {
      "chunk_id": "chunk_829",
      "text": "현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 828,
        "window_size": 3,
        "char_count": 65,
        "word_count": 12,
        "page_number": 4,
        "window_text": "따라서, 백신 접종 직후 기간 중 적절한 반응원성 파라미터의 모니터링이\n\n무엇보다 중요하다.\n\n - (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n 현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23).  이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n 이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다.  그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n",
        "original_sentence": "현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23). "
      }
    },
    {
      "chunk_id": "chunk_830",
      "text": "이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 829,
        "window_size": 3,
        "char_count": 178,
        "word_count": 38,
        "page_number": 10,
        "window_text": "- (2) 면역반응의 종류 및 범위\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 설명하고 있는 면역원성의 종류\n\n및\n\n범위\n\n외에도,\n\n면역원성을\n\n측정하는\n\n연구에서는,\n\nmRNA\n\n백신의\n\n안전성\n\n및\n\n면역원성에 관한 추가적 측면으로 다음 사항을 포함할 수 있다.\n\n Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n 현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23).  이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n 이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다.  그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n 플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n",
        "original_sentence": "이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_831",
      "text": "이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 830,
        "window_size": 3,
        "char_count": 155,
        "word_count": 32,
        "page_number": 8,
        "window_text": "Ÿ 자연적 질병 및 백신 작용기전에 대해 아는 것에 따라 mRNA 후보 백신이\n\n특정\n\n종류의\n\n면역반응에\n\n대하여\n\n성향이\n\n있는가\n\n여부.\n\n 현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23).  이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n 이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다.  그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n 플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n 유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n",
        "original_sentence": "이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_832",
      "text": "그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 831,
        "window_size": 3,
        "char_count": 192,
        "word_count": 33,
        "page_number": 2,
        "window_text": "현재까지,\n\n두\n\n건의\n\n코로나19 mRNA 백신 임상 연구에서는 Th1-유형의 성향에 주목하였다(17,\n\n23).  이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n 이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다.  그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n 플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n 유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n 모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다. ",
        "original_sentence": "그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_833",
      "text": "플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 832,
        "window_size": 3,
        "char_count": 89,
        "word_count": 22,
        "page_number": 17,
        "window_text": "이러한 정보는 특정 질병에 대한 면역반응의 영향을 예측하고 이해하는\n\nŸ 다른\n\n새로운\n\n백신과\n\n마찬가지로\n\n‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에서 정의하고 있는 특별 관심의 대상인 이상사례(AESI)의 실례나 증거\n\n또는 기타 새로운 이상사례를 임상시험 및 시판 후 평가에서 확인해야 한다.\n\n 이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다.  그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n 플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n 유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n 모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다.  이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n",
        "original_sentence": "플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_834",
      "text": "유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 833,
        "window_size": 3,
        "char_count": 88,
        "word_count": 21,
        "page_number": 8,
        "window_text": "이를 확인했다면, 백신 구성성분(예: RNA 또는 지질)에 대하여 원치 않은\n\n면역반응이\n\n발생하는가,\n\n또는\n\n이것이\n\n백신\n\n피접종자의\n\n기존\n\n면역에\n\n따른\n\n결과라면,\n\n증가\n\n또는\n\n악화되는가와\n\n같이,\n\n관련성\n\n및\n\n잠재적\n\n원인에\n\n대한\n\n조사를 실시해야 한다.  그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n 플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n 유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n 모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다.  이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n 특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n",
        "original_sentence": "유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_835",
      "text": "모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 834,
        "window_size": 3,
        "char_count": 138,
        "word_count": 31,
        "page_number": 17,
        "window_text": "그렇지 않으면, 발현된 항원에 대한 반응으로 인한\n\n62/72\n\nmRNA\n\n개발\n\n중에는\n\n최대내성용량(maximally\n\ntolerable\n\ndose)과\n\n관련하여\n\nmRNA의\n\n전체\n\n용량(특히\n\n백신이\n\n다가\n\n백신이거나\n\nsa-mRNA\n\n백신에\n\n별도의\n\nmRNA들을 사용한다면) 그리고 지질나노입자의 전체 용량 역시 고려해야 한다.\n\n 플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n 유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n 모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다.  이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n 특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65). ",
        "original_sentence": "모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다. "
      }
    },
    {
      "chunk_id": "chunk_836",
      "text": "이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 835,
        "window_size": 3,
        "char_count": 62,
        "word_count": 11,
        "page_number": 4,
        "window_text": "플랫폼\n\n기술의\n\n경우\n\n주어진\n\n인구에\n\n대한\n\n최대\n\n허용\n\n용량은\n\n해당\n\n플랫폼을\n\n기반으로 하는 이전 백신 또는 후보 백신에 의해 제한될 수 있다.\n\n 유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n 모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다.  이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n 특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65).  아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n",
        "original_sentence": "이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_837",
      "text": "특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 836,
        "window_size": 3,
        "char_count": 77,
        "word_count": 20,
        "page_number": 8,
        "window_text": "유용성 감소로 인해 기초 접종 후 추가접종을 고려한다면, 국소 및 전신 반응의\n\n빈도\n\n또는\n\n중증도\n\n증가에\n\n대한\n\n면밀한\n\n평가를\n\n수행해야\n\n한다.\n\n 모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다.  이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n 특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65).  아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n 제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69). ",
        "original_sentence": "특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_838",
      "text": "mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 837,
        "window_size": 3,
        "char_count": 159,
        "word_count": 31,
        "page_number": 4,
        "window_text": "모든\n\n백신과\n\n마찬가지로\n\n유효성\n\n임상의\n\n가장\n\n효율적인\n\n설계를\n\n제시하기\n\n위해\n\n예비\n\n임상\n\n시험에서 용량, 시기 및 예방 접종\n\n횟수(필요하다면 기초접종 및 추가 접종),\n\n면역반응의 변화 및 지속성을 신중하게 조사하는 것이 좋다.  이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n 특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65).  아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n 제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69).  비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n",
        "original_sentence": "mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65). "
      }
    },
    {
      "chunk_id": "chunk_839",
      "text": "아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 838,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 8,
        "window_text": "이러한 문제에 대한\n\n논의는\n\n‘백신\n\n임상평가\n\n가이드라인(식약처,\n\n2017)’에서\n\n찾을\n\n수\n\n있다.\n\n 특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65).  아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n 제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69).  비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n 유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n",
        "original_sentence": "아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_840",
      "text": "제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 839,
        "window_size": 3,
        "char_count": 140,
        "word_count": 29,
        "page_number": 17,
        "window_text": "특정\n\n상황에서는 면역 또는 보호 약화와 같은 시판 후 데이터가 수집될 때까지 추가\n\n접종이 필요하다는 결정이 내려지지 않을 수 있다.\n\n mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65).  아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n 제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69).  비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n 유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n ‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다. ",
        "original_sentence": "제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69). "
      }
    },
    {
      "chunk_id": "chunk_841",
      "text": "비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 840,
        "window_size": 3,
        "char_count": 111,
        "word_count": 21,
        "page_number": 24,
        "window_text": "mRNA 기반 코로나19 백신의 임상시험 수행 시 또는 폭넓은 사용 시, 특별히\n\n주목해야 하는 면역학적으로 관련성 있는 두 건의 이상사례(예: 급성 알레르기성\n\n쇼크(anaphylaxis 또는 anaphylactoid case))가 드물게 관찰되었다는 점에 주목해야\n\n한다(65).  아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n 제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69).  비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n 유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n ‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다.  공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다. ",
        "original_sentence": "비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_842",
      "text": "유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 841,
        "window_size": 3,
        "char_count": 157,
        "word_count": 27,
        "page_number": 8,
        "window_text": "아나필락시스는 모든 백신에 대하여 매우 드물게 발생한다고 알려져\n\n있으며,\n\nmRNA\n\n백신에\n\n특유한\n\n것이\n\n아니다.\n\n 제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69).  비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n 유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n ‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다.  공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다.  코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n",
        "original_sentence": "유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_843",
      "text": "‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 842,
        "window_size": 3,
        "char_count": 74,
        "word_count": 13,
        "page_number": 4,
        "window_text": "제형화의\n\n어떤\n\n측면이\n\n면역학적\n\n이상사례와 관련이 있는가는 파악되지 않았으며, 다른 백신과 마찬가지로, 특정\n\n백신 구성성분에 대해 알려진 알레르기가 있는 사람들은 이러한 성분을 함유한\n\n백신을 접종해서는 안 된다고 조언하고 있다(66~69).  비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n 유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n ‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다.  공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다.  코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n 현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n",
        "original_sentence": "‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_844",
      "text": "공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 843,
        "window_size": 3,
        "char_count": 96,
        "word_count": 21,
        "page_number": 3,
        "window_text": "비록 생물학적 기전과 관련된\n\n요소들은\n\n아직\n\n밝혀지지\n\n않았지만\n\n심근염과\n\n심낭염은\n\n또한\n\n코로나19\n\nmRNA\n\n백신의\n\n약물감시\n\n동안\n\n관찰되었으며\n\n관련이\n\n있는\n\n것으로\n\n보인다.\n\n 유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n ‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다.  공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다.  코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n 현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n 식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다. ",
        "original_sentence": "공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_845",
      "text": "코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 844,
        "window_size": 3,
        "char_count": 66,
        "word_count": 15,
        "page_number": 4,
        "window_text": "유럽\n\n의약품청(EMA)(49, 70), 영국 의약품 및 건강관리제품규제청(MHRA)(66, 71), 미국\n\n의약품청(US\n\nFDA)(72,\n\n73)의\n\n간행물을\n\n포함하여,\n\n몇몇\n\n규제당국의\n\n최근\n\n출간물들이 유용한 관련 정보를 제공하고 있다는 점도 추가로 주목해야 한다.\n\n ‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다.  공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다.  코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n 현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n 식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다.  추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다. ",
        "original_sentence": "코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_846",
      "text": "현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 845,
        "window_size": 3,
        "char_count": 227,
        "word_count": 51,
        "page_number": 4,
        "window_text": "‘백신\n\n임상\n\n평가\n\n가이드라인(식약처,\n\n2017)’에\n\n의거하여\n\n능동적인\n\n약물감시\n\n계획을 수립하여 실시할 것을 권고한다.  공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다.  코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n 현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n 식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다.  추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다.  앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n",
        "original_sentence": "현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_847",
      "text": "식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 846,
        "window_size": 3,
        "char_count": 125,
        "word_count": 30,
        "page_number": 8,
        "window_text": "공중보건 긴급상황의 맥락에서 보급한\n\n63/72\n\n코로나19 백신이나 다른 백신의 특정한 경우에는, 잠재적 이상사례에 대한 공공\n\n의식 제고 캠페인 운영을 고려해야 한다.  코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n 현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n 식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다.  추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다.  앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n 백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n",
        "original_sentence": "식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_848",
      "text": "추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 847,
        "window_size": 3,
        "char_count": 119,
        "word_count": 31,
        "page_number": 8,
        "window_text": "코로나19 백신과 잠재적으로 관련된\n\n모든 이상사례는 현재 약물감시 활동의 일환으로서 더욱 심도 있게 평가 중이다.\n\n 현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n 식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다.  추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다.  앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n 백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n <!-- PAGE_63 -->\n### 4.2. ",
        "original_sentence": "추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_849",
      "text": "앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 848,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 25,
        "window_text": "현재 임상시험용 mRNA 코로나19 백신의 폭넓은 사용을 이끌어 낸 유효성\n\n연구의 일부로서 안전성 연구의 짧은 기간 및 제한적인 범위, 그리고 mRNA와\n\n함께 제형화한 지질나노입자에 대하여 대규모 인구를 대상으로는 아직 파악되지\n\n못한 장기적인 안전성 영향을 고려할 때, 이러한 백신 사용과의 관계가 알려지지\n\n않은\n\n희귀한\n\n이상사례를\n\n계속하여\n\n모니터\n\n및\n\n기록하는\n\n것이\n\n중요할\n\n것이다.\n\n 식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다.  추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다.  앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n 백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n <!-- PAGE_63 -->\n### 4.2.  유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다. ",
        "original_sentence": "앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_850",
      "text": "백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 849,
        "window_size": 3,
        "char_count": 228,
        "word_count": 44,
        "page_number": 10,
        "window_text": "식약처는 현재의 제형화 설계로 제작한 서로 다른 mRNA 백신에 대하여 임상적\n\n이해를 증진하고 더욱 정밀한 안전성 프로파일을 제공하기 위하여, 각기 다른\n\n제조사가 제조한 백신들에 대하여 위와 같은 자료를 분석해야 한다.  추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다.  앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n 백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n <!-- PAGE_63 -->\n### 4.2.  유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다.  백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n",
        "original_sentence": "백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_851",
      "text": "<!-- PAGE_63 -->\n### 4.2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 850,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 63,
        "window_text": "추가적으로\n\n제조사 및 공중보건기관은 특정 위험군들 사이의 유용성, 그리고 방어 효과 지속,\n\n감염 및 전파 두 가지 모두에 대한 유용성에 관한 질문들을 다루는 도입 후 백신\n\n유용성 연구 수행을 고려해야 한다.  앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n 백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n <!-- PAGE_63 -->\n### 4.2.  유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다.  백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다. ",
        "original_sentence": "<!-- PAGE_63 -->\n### 4.2. "
      }
    },
    {
      "chunk_id": "chunk_852",
      "text": "유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 851,
        "window_size": 3,
        "char_count": 77,
        "word_count": 16,
        "page_number": 8,
        "window_text": "앞서 기술한 바와 같이, 이 영역은 빠르게\n\n진화하고 있으며 중요한 새로운 자료가 지속해서 도출되고 있다.\n\n 백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n <!-- PAGE_63 -->\n### 4.2.  유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다.  백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다.  위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76). ",
        "original_sentence": "유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다. "
      }
    },
    {
      "chunk_id": "chunk_853",
      "text": "백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 852,
        "window_size": 3,
        "char_count": 64,
        "word_count": 14,
        "page_number": 4,
        "window_text": "백신의 임상 평가 시에 사용하는 면역 분석시험의 표준화를 위해 IU로 표기한\n\n국제\n\n표준품의\n\n사용이\n\n가능해진다면,\n\n이를\n\n내부\n\n표준물질\n\n또는\n\n기타\n\n작업용\n\n표준물질(working\n\nstandard)을\n\n교정하는\n\n데\n\n사용해야\n\n하며,\n\n획득한\n\n결과의\n\n비교가능성을\n\n백신들,\n\n연구들,\n\n그리고\n\n상이한\n\n분석\n\n플랫폼들에\n\n걸쳐\n\n향상하기\n\n위하여 IU로 표기한 결과를 보고해야 한다.\n\n <!-- PAGE_63 -->\n### 4.2.  유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다.  백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다.  위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76).  (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다. ",
        "original_sentence": "백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_854",
      "text": "mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 853,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 8,
        "window_text": "<!-- PAGE_63 -->\n### 4.2.  유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다.  백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다.  위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76).  (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다.  모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n",
        "original_sentence": "mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_855",
      "text": "위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 854,
        "window_size": 3,
        "char_count": 92,
        "word_count": 18,
        "page_number": 2,
        "window_text": "유효성 평가\n\n유효성\n\n평가는\n\n후보백신을\n\n통해\n\n방어하고자\n\n하는\n\n질환\n\n및\n\n임상시험에서\n\n결정되는 임상 적응증에 따라 달라진다.  백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다.  위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76).  (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다.  모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n <!-- PAGE_64 -->\n### 4.3. ",
        "original_sentence": "위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76). "
      }
    },
    {
      "chunk_id": "chunk_856",
      "text": "(적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 855,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 24,
        "window_text": "백신 유효성 평가 시 고려해야 할 요소는\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’에서 기술하고 있다.\n\n mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다.  위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76).  (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다.  모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n <!-- PAGE_64 -->\n### 4.3.  공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n",
        "original_sentence": "(적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_857",
      "text": "모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 856,
        "window_size": 3,
        "char_count": 147,
        "word_count": 31,
        "page_number": 2,
        "window_text": "mRNA 기반 백신이 널리 사용되고 있는 국가에서 임상시험 시 위약 대조군의\n\n사용할 때 특별한 고려가 요구된다는 점을 인지해야 한다.  위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76).  (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다.  모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n <!-- PAGE_64 -->\n### 4.3.  공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n 면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n",
        "original_sentence": "모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n"
      }
    },
    {
      "chunk_id": "chunk_858",
      "text": "<!-- PAGE_64 -->\n### 4.3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 857,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 64,
        "window_text": "위약군을 설정한 진행\n\n중인 코로나19 백신 시험의 실시와 관련된 윤리적 고려사항은 2020년 12월에\n\n64/72\n\n개최된 공개 회의에서 논의되었다(74~76).  (적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다.  모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n <!-- PAGE_64 -->\n### 4.3.  공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n 면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n 다음의 두 가지 시나리오를 반드시 고려해야 한다. ",
        "original_sentence": "<!-- PAGE_64 -->\n### 4.3. "
      }
    },
    {
      "chunk_id": "chunk_859",
      "text": "공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 858,
        "window_size": 3,
        "char_count": 213,
        "word_count": 46,
        "page_number": 4,
        "window_text": "(적절한 대조군 선정을 포함한) 시험\n\n설계 문제는 ‘백신 임상 평가 가이드라인(식약처, 2017)’에서 논하고 있다.  모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n <!-- PAGE_64 -->\n### 4.3.  공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n 면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n 다음의 두 가지 시나리오를 반드시 고려해야 한다.  (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다. ",
        "original_sentence": "공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_860",
      "text": "면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 859,
        "window_size": 3,
        "char_count": 94,
        "word_count": 20,
        "page_number": 24,
        "window_text": "모든\n\n후보\n\n백신과\n\n마찬가지로,\n\n과학적\n\n이점과\n\n윤리적\n\n고려사항\n\n두\n\n부문\n\n모두는\n\n임상시험\n\n설계에\n\n정보를\n\n제공하며,\n\n결정은\n\n반드시\n\n규제\n\n승인\n\n신청을\n\n제출한\n\n국가의 현재 안전성 및 위해성 맥락을 기반으로 해야 한다(77, 78).\n\n <!-- PAGE_64 -->\n### 4.3.  공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n 면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n 다음의 두 가지 시나리오를 반드시 고려해야 한다.  (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다.  이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다. ",
        "original_sentence": "면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_861",
      "text": "다음의 두 가지 시나리오를 반드시 고려해야 한다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 860,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 27,
        "window_text": "<!-- PAGE_64 -->\n### 4.3.  공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n 면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n 다음의 두 가지 시나리오를 반드시 고려해야 한다.  (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다.  이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다.  전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n",
        "original_sentence": "다음의 두 가지 시나리오를 반드시 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_862",
      "text": "(1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 861,
        "window_size": 3,
        "char_count": 98,
        "word_count": 23,
        "page_number": 4,
        "window_text": "공중 위기 맥락에서의 유효성 평가\n\n‘백신 임상 평가 가이드라인(식약처, 2017)’의 5.6.2 항에서 논하고 있는 바와\n\n같이,\n\n제조사의 모체\n\n백신(또는 시판\n\n백신)에\n\n대해 임상적\n\n유효성 평가변수를\n\n증명한\n\n해당\n\n플랫폼\n\n기술을\n\n기반으로\n\n하는\n\n변이\n\n백신의\n\n유효성을\n\n유추하기\n\n위해서, 제조사의 모체 백신과 변이 백신 사이의 면역가교를 고려할 수 있다.\n\n 면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n 다음의 두 가지 시나리오를 반드시 고려해야 한다.  (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다.  이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다.  전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n 코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n",
        "original_sentence": "(1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_863",
      "text": "이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 862,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 8,
        "window_text": "면역가교는\n\n모체\n\n백신과\n\n변이\n\n백신의\n\n동등한\n\n항체\n\n역가가\n\n어떻게\n\n유사한\n\n유효성으로 전환될 것인가에 대해 타당성을 제시함으로써 뒷받침해야 할 수 있다.\n\n 다음의 두 가지 시나리오를 반드시 고려해야 한다.  (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다.  이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다.  전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n 코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n 현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n",
        "original_sentence": "이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_864",
      "text": "전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 863,
        "window_size": 3,
        "char_count": 103,
        "word_count": 25,
        "page_number": 2,
        "window_text": "다음의 두 가지 시나리오를 반드시 고려해야 한다.  (1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다.  이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다.  전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n 코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n 현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n ‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n",
        "original_sentence": "전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_865",
      "text": "코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 864,
        "window_size": 3,
        "char_count": 144,
        "word_count": 24,
        "page_number": 64,
        "window_text": "(1) 변이 백신이 모체 백신을\n\n대체할 것, (2) 변이 백신과 모체 백신을 결합하거나(즉, 2가 또는 다가 백신으로),\n\n또는 동시에 투여하거나 순차적으로 투여할 것이다.  이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다.  전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n 코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n 현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n ‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n 65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1. ",
        "original_sentence": "코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n"
      }
    },
    {
      "chunk_id": "chunk_866",
      "text": "현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 865,
        "window_size": 3,
        "char_count": 114,
        "word_count": 27,
        "page_number": 8,
        "window_text": "이러한 면역가교 연구 중의\n\n비교 안전성 자료 수집 역시 기대할 것이다.  전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n 코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n 현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n ‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n 65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1.  Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n",
        "original_sentence": "현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_867",
      "text": "‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 866,
        "window_size": 3,
        "char_count": 47,
        "word_count": 7,
        "page_number": 24,
        "window_text": "전반적으로, 면역가교 연구에 대한\n\n고려사항은 질환 및 병원체, 유도한 면역반응과 같은 요소에 따라 달라질 수\n\n있으므로, 시험 설계 및 자료 요건은 사례별 기반으로 결정해야 한다.\n\n 코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n 현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n ‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n 65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1.  Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n Nat\n\nRev\n\nDrug\n\nDiscov.\n\n",
        "original_sentence": "‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_868",
      "text": "65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 867,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 65,
        "window_text": "코로나19 백신의 특정한 경우에는, 유럽 의약품청(EMA)(49, 70), 영국 의약품 및\n\n건강관리제품규제청(MHRA)(66, 71), 미국 의약품청(US FDA)(72, 73), 그리고 다른\n\n규제당국들이 제공하는 지침을 고려할 수 있다(79~81).\n\n 현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n ‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n 65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1.  Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n Nat\n\nRev\n\nDrug\n\nDiscov.\n\n 2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n",
        "original_sentence": "65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_869",
      "text": "Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 868,
        "window_size": 3,
        "char_count": 88,
        "word_count": 15,
        "page_number": 8,
        "window_text": "현재 독감 바이러스에 대한 mRNA 백신이 개발 중에 있으며, 제안한 균주 변경\n\n시에는\n\n불활화\n\n또는\n\n약독화\n\n생\n\n독감\n\n바이러스\n\n백신에\n\n대한\n\n현재의\n\n관행을\n\n고려해야\n\n할\n\n수\n\n있다.\n\n ‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n 65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1.  Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n Nat\n\nRev\n\nDrug\n\nDiscov.\n\n 2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n - 2. ",
        "original_sentence": "Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n"
      }
    },
    {
      "chunk_id": "chunk_870",
      "text": "Nat\n\nRev\n\nDrug\n\nDiscov.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 869,
        "window_size": 3,
        "char_count": 25,
        "word_count": 4,
        "page_number": 65,
        "window_text": "‘인플루엔자\n\n백신\n\n평가\n\n가이드라인(식약처,\n\n2020)’을\n\n참조해야 한다.\n\n 65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1.  Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n Nat\n\nRev\n\nDrug\n\nDiscov.\n\n 2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n - 2.  Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. ",
        "original_sentence": "Nat\n\nRev\n\nDrug\n\nDiscov.\n\n"
      }
    },
    {
      "chunk_id": "chunk_871",
      "text": "2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 870,
        "window_size": 3,
        "char_count": 102,
        "word_count": 8,
        "page_number": 4,
        "window_text": "65/72\n\n<!-- PAGE_65 -->\n### [참고문헌]\n\n- 1.  Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n Nat\n\nRev\n\nDrug\n\nDiscov.\n\n 2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n - 2.  Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al.  Direct gene\ntransfer into mouse muscle in vivo. ",
        "original_sentence": "2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n"
      }
    },
    {
      "chunk_id": "chunk_872",
      "text": "- 2. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 871,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs.\n Nat\n\nRev\n\nDrug\n\nDiscov.\n\n 2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n - 2.  Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al.  Direct gene\ntransfer into mouse muscle in vivo.  Science. ",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_873",
      "text": "Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 872,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Nat\n\nRev\n\nDrug\n\nDiscov.\n\n 2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n - 2.  Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al.  Direct gene\ntransfer into mouse muscle in vivo.  Science.  1990 Mar 23;247(4949 Pt 1):1465–8.\n\n",
        "original_sentence": "Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. "
      }
    },
    {
      "chunk_id": "chunk_874",
      "text": "Direct gene\ntransfer into mouse muscle in vivo. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 873,
        "window_size": 3,
        "char_count": 48,
        "word_count": 8,
        "page_number": 23,
        "window_text": "2014;13(10):759–80\n\n(abstract:\n\nhttps://pubmed.ncbi.nlm.nih.gov/\n\n25233993/, accessed 15 June 2021).\n\n - 2.  Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al.  Direct gene\ntransfer into mouse muscle in vivo.  Science.  1990 Mar 23;247(4949 Pt 1):1465–8.\n\n - 3. ",
        "original_sentence": "Direct gene\ntransfer into mouse muscle in vivo. "
      }
    },
    {
      "chunk_id": "chunk_875",
      "text": "Science. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 874,
        "window_size": 3,
        "char_count": 9,
        "word_count": 1,
        "page_number": 65,
        "window_text": "- 2.  Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al.  Direct gene\ntransfer into mouse muscle in vivo.  Science.  1990 Mar 23;247(4949 Pt 1):1465–8.\n\n - 3.  Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology. ",
        "original_sentence": "Science. "
      }
    },
    {
      "chunk_id": "chunk_876",
      "text": "1990 Mar 23;247(4949 Pt 1):1465–8.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 875,
        "window_size": 3,
        "char_count": 36,
        "word_count": 5,
        "page_number": 4,
        "window_text": "Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al.  Direct gene\ntransfer into mouse muscle in vivo.  Science.  1990 Mar 23;247(4949 Pt 1):1465–8.\n\n - 3.  Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology.  Nat Rev Drug Discov. ",
        "original_sentence": "1990 Mar 23;247(4949 Pt 1):1465–8.\n\n"
      }
    },
    {
      "chunk_id": "chunk_877",
      "text": "- 3. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 876,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Direct gene\ntransfer into mouse muscle in vivo.  Science.  1990 Mar 23;247(4949 Pt 1):1465–8.\n\n - 3.  Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology.  Nat Rev Drug Discov.  2018 Apr;17(4):261–79.\n\n",
        "original_sentence": "- 3. "
      }
    },
    {
      "chunk_id": "chunk_878",
      "text": "Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 877,
        "window_size": 3,
        "char_count": 94,
        "word_count": 17,
        "page_number": 65,
        "window_text": "Science.  1990 Mar 23;247(4949 Pt 1):1465–8.\n\n - 3.  Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology.  Nat Rev Drug Discov.  2018 Apr;17(4):261–79.\n\n - 4. ",
        "original_sentence": "Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology. "
      }
    },
    {
      "chunk_id": "chunk_879",
      "text": "Nat Rev Drug Discov. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 878,
        "window_size": 3,
        "char_count": 21,
        "word_count": 4,
        "page_number": 65,
        "window_text": "1990 Mar 23;247(4949 Pt 1):1465–8.\n\n - 3.  Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology.  Nat Rev Drug Discov.  2018 Apr;17(4):261–79.\n\n - 4.  Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. ",
        "original_sentence": "Nat Rev Drug Discov. "
      }
    },
    {
      "chunk_id": "chunk_880",
      "text": "2018 Apr;17(4):261–79.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 879,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 4,
        "window_text": "- 3.  Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology.  Nat Rev Drug Discov.  2018 Apr;17(4):261–79.\n\n - 4.  Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al.  Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability. ",
        "original_sentence": "2018 Apr;17(4):261–79.\n\n"
      }
    },
    {
      "chunk_id": "chunk_881",
      "text": "- 4. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 880,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Pardi\nN,\n\nHogan MJ,\n\nPorter\n\nFW,\n\nWeissman D.\n\nmRNA vaccines\n\n- - a\nnew era\n\nin\n\nvaccinology.  Nat Rev Drug Discov.  2018 Apr;17(4):261–79.\n\n - 4.  Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al.  Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability.  Mol Ther J Am Soc Gene Ther. ",
        "original_sentence": "- 4. "
      }
    },
    {
      "chunk_id": "chunk_882",
      "text": "Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 881,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Nat Rev Drug Discov.  2018 Apr;17(4):261–79.\n\n - 4.  Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al.  Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability.  Mol Ther J Am Soc Gene Ther.  200810\n\nNov;16(11):1833–40.\n\n",
        "original_sentence": "Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. "
      }
    },
    {
      "chunk_id": "chunk_883",
      "text": "Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 882,
        "window_size": 3,
        "char_count": 144,
        "word_count": 16,
        "page_number": 8,
        "window_text": "2018 Apr;17(4):261–79.\n\n - 4.  Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al.  Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability.  Mol Ther J Am Soc Gene Ther.  200810\n\nNov;16(11):1833–40.\n\n - 5. ",
        "original_sentence": "Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability. "
      }
    },
    {
      "chunk_id": "chunk_884",
      "text": "Mol Ther J Am Soc Gene Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 883,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 65,
        "window_text": "- 4.  Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al.  Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability.  Mol Ther J Am Soc Gene Ther.  200810\n\nNov;16(11):1833–40.\n\n - 5.  Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n",
        "original_sentence": "Mol Ther J Am Soc Gene Ther. "
      }
    },
    {
      "chunk_id": "chunk_885",
      "text": "200810\n\nNov;16(11):1833–40.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 884,
        "window_size": 3,
        "char_count": 29,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al.  Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability.  Mol Ther J Am Soc Gene Ther.  200810\n\nNov;16(11):1833–40.\n\n - 5.  Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals. ",
        "original_sentence": "200810\n\nNov;16(11):1833–40.\n\n"
      }
    },
    {
      "chunk_id": "chunk_886",
      "text": "- 5. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 885,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Incorporation\nof pseudouridine into mRNA yields superior nonimmunogenic vector with increased\n\ntranslational capacity and biological stability.  Mol Ther J Am Soc Gene Ther.  200810\n\nNov;16(11):1833–40.\n\n - 5.  Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals.  Mol Ther J Am Soc Gene Ther. ",
        "original_sentence": "- 5. "
      }
    },
    {
      "chunk_id": "chunk_887",
      "text": "Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 886,
        "window_size": 3,
        "char_count": 83,
        "word_count": 14,
        "page_number": 8,
        "window_text": "Mol Ther J Am Soc Gene Ther.  200810\n\nNov;16(11):1833–40.\n\n - 5.  Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals.  Mol Ther J Am Soc Gene Ther.  2015\n\nSep;23(9):1456–1464.\n\n",
        "original_sentence": "Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n"
      }
    },
    {
      "chunk_id": "chunk_888",
      "text": "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 887,
        "window_size": 3,
        "char_count": 123,
        "word_count": 14,
        "page_number": 8,
        "window_text": "200810\n\nNov;16(11):1833–40.\n\n - 5.  Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals.  Mol Ther J Am Soc Gene Ther.  2015\n\nSep;23(9):1456–1464.\n\n - 6. ",
        "original_sentence": "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals. "
      }
    },
    {
      "chunk_id": "chunk_889",
      "text": "Mol Ther J Am Soc Gene Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 888,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 65,
        "window_text": "- 5.  Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals.  Mol Ther J Am Soc Gene Ther.  2015\n\nSep;23(9):1456–1464.\n\n - 6.  Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines. ",
        "original_sentence": "Mol Ther J Am Soc Gene Ther. "
      }
    },
    {
      "chunk_id": "chunk_890",
      "text": "2015\n\nSep;23(9):1456–1464.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 889,
        "window_size": 3,
        "char_count": 28,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Thess\nA,\n\nGrund\n\nS,\n\nMui\n\nBL,\n\nHope\n\nMJ,\n\nBaumhof\n\nP,\n\nFotin-Mleczek\n\nM,\n\net\n\nal.\n\n Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals.  Mol Ther J Am Soc Gene Ther.  2015\n\nSep;23(9):1456–1464.\n\n - 6.  Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines.  Methods Mol\n\nBiol Clifton NJ. ",
        "original_sentence": "2015\n\nSep;23(9):1456–1464.\n\n"
      }
    },
    {
      "chunk_id": "chunk_891",
      "text": "- 6. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 890,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an\n\nEffective Protein Therapy in Large Animals.  Mol Ther J Am Soc Gene Ther.  2015\n\nSep;23(9):1456–1464.\n\n - 6.  Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines.  Methods Mol\n\nBiol Clifton NJ.  2017;1499:89–107.\n\n",
        "original_sentence": "- 6. "
      }
    },
    {
      "chunk_id": "chunk_892",
      "text": "Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 891,
        "window_size": 3,
        "char_count": 142,
        "word_count": 21,
        "page_number": 65,
        "window_text": "Mol Ther J Am Soc Gene Ther.  2015\n\nSep;23(9):1456–1464.\n\n - 6.  Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines.  Methods Mol\n\nBiol Clifton NJ.  2017;1499:89–107.\n\n - 7. ",
        "original_sentence": "Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_893",
      "text": "Methods Mol\n\nBiol Clifton NJ. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 892,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 65,
        "window_text": "2015\n\nSep;23(9):1456–1464.\n\n - 6.  Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines.  Methods Mol\n\nBiol Clifton NJ.  2017;1499:89–107.\n\n - 7.  Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al. ",
        "original_sentence": "Methods Mol\n\nBiol Clifton NJ. "
      }
    },
    {
      "chunk_id": "chunk_894",
      "text": "2017;1499:89–107.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 893,
        "window_size": 3,
        "char_count": 19,
        "word_count": 1,
        "page_number": 4,
        "window_text": "- 6.  Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines.  Methods Mol\n\nBiol Clifton NJ.  2017;1499:89–107.\n\n - 7.  Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al.  The European\nRegulatory Environment of RNA-Based Vaccines. ",
        "original_sentence": "2017;1499:89–107.\n\n"
      }
    },
    {
      "chunk_id": "chunk_895",
      "text": "- 7. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 894,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R. RNActive® Technology:\nGeneration and Testing of Stable and Immunogenic mRNA Vaccines.  Methods Mol\n\nBiol Clifton NJ.  2017;1499:89–107.\n\n - 7.  Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al.  The European\nRegulatory Environment of RNA-Based Vaccines.  In: Kramps T, Elbers K, editors.\n\n",
        "original_sentence": "- 7. "
      }
    },
    {
      "chunk_id": "chunk_896",
      "text": "Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 895,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 23,
        "window_text": "Methods Mol\n\nBiol Clifton NJ.  2017;1499:89–107.\n\n - 7.  Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al.  The European\nRegulatory Environment of RNA-Based Vaccines.  In: Kramps T, Elbers K, editors.\n\n RNA Vaccines: Methods and Protocols [Internet]. ",
        "original_sentence": "Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al. "
      }
    },
    {
      "chunk_id": "chunk_897",
      "text": "The European\nRegulatory Environment of RNA-Based Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 896,
        "window_size": 3,
        "char_count": 59,
        "word_count": 7,
        "page_number": 8,
        "window_text": "2017;1499:89–107.\n\n - 7.  Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al.  The European\nRegulatory Environment of RNA-Based Vaccines.  In: Kramps T, Elbers K, editors.\n\n RNA Vaccines: Methods and Protocols [Internet].  New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n",
        "original_sentence": "The European\nRegulatory Environment of RNA-Based Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_898",
      "text": "In: Kramps T, Elbers K, editors.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 897,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 8,
        "window_text": "- 7.  Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al.  The European\nRegulatory Environment of RNA-Based Vaccines.  In: Kramps T, Elbers K, editors.\n\n RNA Vaccines: Methods and Protocols [Internet].  New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n p.\n\n",
        "original_sentence": "In: Kramps T, Elbers K, editors.\n\n"
      }
    },
    {
      "chunk_id": "chunk_899",
      "text": "RNA Vaccines: Methods and Protocols [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 898,
        "window_size": 3,
        "char_count": 48,
        "word_count": 6,
        "page_number": 8,
        "window_text": "Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, et al.  The European\nRegulatory Environment of RNA-Based Vaccines.  In: Kramps T, Elbers K, editors.\n\n RNA Vaccines: Methods and Protocols [Internet].  New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n p.\n\n 203–22.\n\n",
        "original_sentence": "RNA Vaccines: Methods and Protocols [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_900",
      "text": "New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 899,
        "window_size": 3,
        "char_count": 55,
        "word_count": 9,
        "page_number": 4,
        "window_text": "The European\nRegulatory Environment of RNA-Based Vaccines.  In: Kramps T, Elbers K, editors.\n\n RNA Vaccines: Methods and Protocols [Internet].  New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n p.\n\n 203–22.\n\n (Methods\n\nin\n\nMolecular\n\nBiology).\n\n",
        "original_sentence": "New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n"
      }
    },
    {
      "chunk_id": "chunk_901",
      "text": "p.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 900,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 65,
        "window_text": "In: Kramps T, Elbers K, editors.\n\n RNA Vaccines: Methods and Protocols [Internet].  New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n p.\n\n 203–22.\n\n (Methods\n\nin\n\nMolecular\n\nBiology).\n\n Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8. ",
        "original_sentence": "p.\n\n"
      }
    },
    {
      "chunk_id": "chunk_902",
      "text": "203–22.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 901,
        "window_size": 3,
        "char_count": 9,
        "word_count": 1,
        "page_number": 65,
        "window_text": "RNA Vaccines: Methods and Protocols [Internet].  New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n p.\n\n 203–22.\n\n (Methods\n\nin\n\nMolecular\n\nBiology).\n\n Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8.  Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective. ",
        "original_sentence": "203–22.\n\n"
      }
    },
    {
      "chunk_id": "chunk_903",
      "text": "(Methods\n\nin\n\nMolecular\n\nBiology).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 902,
        "window_size": 3,
        "char_count": 36,
        "word_count": 4,
        "page_number": 23,
        "window_text": "New York, NY: Springer; 2017 [cited\n\n202121\n\nJan\n\n5].\n\n p.\n\n 203–22.\n\n (Methods\n\nin\n\nMolecular\n\nBiology).\n\n Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8.  Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective.  NPJ Vaccines. ",
        "original_sentence": "(Methods\n\nin\n\nMolecular\n\nBiology).\n\n"
      }
    },
    {
      "chunk_id": "chunk_904",
      "text": "Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 903,
        "window_size": 3,
        "char_count": 69,
        "word_count": 5,
        "page_number": 4,
        "window_text": "p.\n\n 203–22.\n\n (Methods\n\nin\n\nMolecular\n\nBiology).\n\n Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8.  Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective.  NPJ Vaccines.  2020 Feb 4;5(1):11.\n\n",
        "original_sentence": "Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_905",
      "text": "Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 904,
        "window_size": 3,
        "char_count": 142,
        "word_count": 20,
        "page_number": 65,
        "window_text": "203–22.\n\n (Methods\n\nin\n\nMolecular\n\nBiology).\n\n Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8.  Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective.  NPJ Vaccines.  2020 Feb 4;5(1):11.\n\n - 9. ",
        "original_sentence": "Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective. "
      }
    },
    {
      "chunk_id": "chunk_906",
      "text": "NPJ Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 905,
        "window_size": 3,
        "char_count": 14,
        "word_count": 2,
        "page_number": 23,
        "window_text": "(Methods\n\nin\n\nMolecular\n\nBiology).\n\n Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8.  Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective.  NPJ Vaccines.  2020 Feb 4;5(1):11.\n\n - 9.  Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n",
        "original_sentence": "NPJ Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_907",
      "text": "2020 Feb 4;5(1):11.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 906,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Available\n\nfrom:\n\nhttps://doi.org/10.1007/978-1-4939-6481-9_13\n\n- 8.  Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective.  NPJ Vaccines.  2020 Feb 4;5(1):11.\n\n - 9.  Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n Curr Top Microbiol Immunol. ",
        "original_sentence": "2020 Feb 4;5(1):11.\n\n"
      }
    },
    {
      "chunk_id": "chunk_908",
      "text": "- 9. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 907,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Jackson\nNAC,\n\nKester\n\nKE,\n\nCasimiro\n\nD,\n\nGurunathan\n\nS,\n\nDeRosa\n\nF.\n\nThe\n\npromise\n\nof\n\nmRNA24 vaccines: a biotech and industrial perspective.  NPJ Vaccines.  2020 Feb 4;5(1):11.\n\n - 9.  Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n Curr Top Microbiol Immunol.  2020 Jul 8;27\n\n- 10. ",
        "original_sentence": "- 9. "
      }
    },
    {
      "chunk_id": "chunk_909",
      "text": "Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 908,
        "window_size": 3,
        "char_count": 80,
        "word_count": 12,
        "page_number": 65,
        "window_text": "NPJ Vaccines.  2020 Feb 4;5(1):11.\n\n - 9.  Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n Curr Top Microbiol Immunol.  2020 Jul 8;27\n\n- 10.  Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials. ",
        "original_sentence": "Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n"
      }
    },
    {
      "chunk_id": "chunk_910",
      "text": "Curr Top Microbiol Immunol. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 909,
        "window_size": 3,
        "char_count": 28,
        "word_count": 4,
        "page_number": 65,
        "window_text": "2020 Feb 4;5(1):11.\n\n - 9.  Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n Curr Top Microbiol Immunol.  2020 Jul 8;27\n\n- 10.  Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials.  Methods\n- 11. ",
        "original_sentence": "Curr Top Microbiol Immunol. "
      }
    },
    {
      "chunk_id": "chunk_911",
      "text": "2020 Jul 8;27\n\n- 10. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 910,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 4,
        "window_text": "- 9.  Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n Curr Top Microbiol Immunol.  2020 Jul 8;27\n\n- 10.  Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials.  Methods\n- 11.  Hager G. Nonclinical Safety Testing of RNA Vaccines. ",
        "original_sentence": "2020 Jul 8;27\n\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_912",
      "text": "Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 911,
        "window_size": 3,
        "char_count": 74,
        "word_count": 10,
        "page_number": 8,
        "window_text": "Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines.\n Curr Top Microbiol Immunol.  2020 Jul 8;27\n\n- 10.  Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials.  Methods\n- 11.  Hager G. Nonclinical Safety Testing of RNA Vaccines.  Methods Mol Biol Clifton NJ.\n",
        "original_sentence": "Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials. "
      }
    },
    {
      "chunk_id": "chunk_913",
      "text": "Methods\n- 11. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 912,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Curr Top Microbiol Immunol.  2020 Jul 8;27\n\n- 10.  Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials.  Methods\n- 11.  Hager G. Nonclinical Safety Testing of RNA Vaccines.  Methods Mol Biol Clifton NJ.\n - 12. ",
        "original_sentence": "Methods\n- 11. "
      }
    },
    {
      "chunk_id": "chunk_914",
      "text": "Hager G. Nonclinical Safety Testing of RNA Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 913,
        "window_size": 3,
        "char_count": 53,
        "word_count": 8,
        "page_number": 8,
        "window_text": "2020 Jul 8;27\n\n- 10.  Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials.  Methods\n- 11.  Hager G. Nonclinical Safety Testing of RNA Vaccines.  Methods Mol Biol Clifton NJ.\n - 12.  Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n",
        "original_sentence": "Hager G. Nonclinical Safety Testing of RNA Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_915",
      "text": "Methods Mol Biol Clifton NJ.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 914,
        "window_size": 3,
        "char_count": 29,
        "word_count": 5,
        "page_number": 65,
        "window_text": "Schmid A. Considerations for Producing mRNA Vaccines for Clinical Trials.  Methods\n- 11.  Hager G. Nonclinical Safety Testing of RNA Vaccines.  Methods Mol Biol Clifton NJ.\n - 12.  Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n Sixty-Fourth\n\nReport. ",
        "original_sentence": "Methods Mol Biol Clifton NJ.\n"
      }
    },
    {
      "chunk_id": "chunk_916",
      "text": "- 12. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 915,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Methods\n- 11.  Hager G. Nonclinical Safety Testing of RNA Vaccines.  Methods Mol Biol Clifton NJ.\n - 12.  Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n Sixty-Fourth\n\nReport.  Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec. ",
        "original_sentence": "- 12. "
      }
    },
    {
      "chunk_id": "chunk_917",
      "text": "Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 916,
        "window_size": 3,
        "char_count": 160,
        "word_count": 18,
        "page_number": 8,
        "window_text": "Hager G. Nonclinical Safety Testing of RNA Vaccines.  Methods Mol Biol Clifton NJ.\n - 12.  Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n Sixty-Fourth\n\nReport.  Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec.  2020)\n\n66/72\n\n- 13. ",
        "original_sentence": "Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n"
      }
    },
    {
      "chunk_id": "chunk_918",
      "text": "Sixty-Fourth\n\nReport. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 917,
        "window_size": 3,
        "char_count": 22,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Methods Mol Biol Clifton NJ.\n - 12.  Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n Sixty-Fourth\n\nReport.  Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec.  2020)\n\n66/72\n\n- 13.  Krammer F. SARS-CoV-2 vaccines in development. ",
        "original_sentence": "Sixty-Fourth\n\nReport. "
      }
    },
    {
      "chunk_id": "chunk_919",
      "text": "Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 918,
        "window_size": 3,
        "char_count": 172,
        "word_count": 16,
        "page_number": 4,
        "window_text": "- 12.  Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n Sixty-Fourth\n\nReport.  Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec.  2020)\n\n66/72\n\n- 13.  Krammer F. SARS-CoV-2 vaccines in development.  Nature. ",
        "original_sentence": "Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec. "
      }
    },
    {
      "chunk_id": "chunk_920",
      "text": "2020)\n\n66/72\n\n- 13. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 919,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 4,
        "window_text": "Guidelines\non\n\nthe\n\nNonclinical\n\nEvaluation\n\nof\n\nVaccine\n\nAdjuvants\n\nand\n\nAdjuvanted\n\nVaccines,\n\nIn:\n\nWHO\n\nExpert\n\nCommittee\n\non\n\nBiological\n\nStandardization.\n\n Sixty-Fourth\n\nReport.  Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec.  2020)\n\n66/72\n\n- 13.  Krammer F. SARS-CoV-2 vaccines in development.  Nature.  2020 Oct;586(7830):516–27.\n",
        "original_sentence": "2020)\n\n66/72\n\n- 13. "
      }
    },
    {
      "chunk_id": "chunk_921",
      "text": "Krammer F. SARS-CoV-2 vaccines in development. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 920,
        "window_size": 3,
        "char_count": 47,
        "word_count": 6,
        "page_number": 23,
        "window_text": "Sixty-Fourth\n\nReport.  Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec.  2020)\n\n66/72\n\n- 13.  Krammer F. SARS-CoV-2 vaccines in development.  Nature.  2020 Oct;586(7830):516–27.\n - 14. ",
        "original_sentence": "Krammer F. SARS-CoV-2 vaccines in development. "
      }
    },
    {
      "chunk_id": "chunk_922",
      "text": "Nature. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 921,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 65,
        "window_text": "Geneva, World Health Organization, 2014, Annex 2 (WHO Technical Report\n\nSeries 987; http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua=1,\n\naccessed 1 Dec.  2020)\n\n66/72\n\n- 13.  Krammer F. SARS-CoV-2 vaccines in development.  Nature.  2020 Oct;586(7830):516–27.\n - 14.  Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n",
        "original_sentence": "Nature. "
      }
    },
    {
      "chunk_id": "chunk_923",
      "text": "2020 Oct;586(7830):516–27.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 922,
        "window_size": 3,
        "char_count": 27,
        "word_count": 2,
        "page_number": 4,
        "window_text": "2020)\n\n66/72\n\n- 13.  Krammer F. SARS-CoV-2 vaccines in development.  Nature.  2020 Oct;586(7830):516–27.\n - 14.  Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n mRNA therapeutics deliver a hopeful message. ",
        "original_sentence": "2020 Oct;586(7830):516–27.\n"
      }
    },
    {
      "chunk_id": "chunk_924",
      "text": "- 14. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 923,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Krammer F. SARS-CoV-2 vaccines in development.  Nature.  2020 Oct;586(7830):516–27.\n - 14.  Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n mRNA therapeutics deliver a hopeful message.  Nano Today [Internet]. ",
        "original_sentence": "- 14. "
      }
    },
    {
      "chunk_id": "chunk_925",
      "text": "Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 924,
        "window_size": 3,
        "char_count": 80,
        "word_count": 16,
        "page_number": 65,
        "window_text": "Nature.  2020 Oct;586(7830):516–27.\n - 14.  Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n mRNA therapeutics deliver a hopeful message.  Nano Today [Internet].  2018 Dec 1\n\n[cited 2021 May 1];23:16–39. ",
        "original_sentence": "Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n"
      }
    },
    {
      "chunk_id": "chunk_926",
      "text": "mRNA therapeutics deliver a hopeful message. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 925,
        "window_size": 3,
        "char_count": 45,
        "word_count": 6,
        "page_number": 8,
        "window_text": "2020 Oct;586(7830):516–27.\n - 14.  Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n mRNA therapeutics deliver a hopeful message.  Nano Today [Internet].  2018 Dec 1\n\n[cited 2021 May 1];23:16–39.  Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15. ",
        "original_sentence": "mRNA therapeutics deliver a hopeful message. "
      }
    },
    {
      "chunk_id": "chunk_927",
      "text": "Nano Today [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 926,
        "window_size": 3,
        "char_count": 23,
        "word_count": 3,
        "page_number": 65,
        "window_text": "- 14.  Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n mRNA therapeutics deliver a hopeful message.  Nano Today [Internet].  2018 Dec 1\n\n[cited 2021 May 1];23:16–39.  Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15.  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. ",
        "original_sentence": "Nano Today [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_928",
      "text": "2018 Dec 1\n\n[cited 2021 May 1];23:16–39. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 927,
        "window_size": 3,
        "char_count": 41,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Zhong Z, Mc Cafferty S, Combes F, Huysmans H, De Temmerman J, Gitsels A, et al.\n mRNA therapeutics deliver a hopeful message.  Nano Today [Internet].  2018 Dec 1\n\n[cited 2021 May 1];23:16–39.  Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15.  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. ",
        "original_sentence": "2018 Dec 1\n\n[cited 2021 May 1];23:16–39. "
      }
    },
    {
      "chunk_id": "chunk_929",
      "text": "Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 928,
        "window_size": 3,
        "char_count": 93,
        "word_count": 6,
        "page_number": 8,
        "window_text": "mRNA therapeutics deliver a hopeful message.  Nano Today [Internet].  2018 Dec 1\n\n[cited 2021 May 1];23:16–39.  Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15.  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  N Engl J Med [Internet].\n\n",
        "original_sentence": "Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15. "
      }
    },
    {
      "chunk_id": "chunk_930",
      "text": "Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 929,
        "window_size": 3,
        "char_count": 74,
        "word_count": 14,
        "page_number": 23,
        "window_text": "Nano Today [Internet].  2018 Dec 1\n\n[cited 2021 May 1];23:16–39.  Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15.  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  N Engl J Med [Internet].\n\n 2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n",
        "original_sentence": "Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. "
      }
    },
    {
      "chunk_id": "chunk_931",
      "text": "Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 930,
        "window_size": 3,
        "char_count": 59,
        "word_count": 9,
        "page_number": 4,
        "window_text": "2018 Dec 1\n\n[cited 2021 May 1];23:16–39.  Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15.  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  N Engl J Med [Internet].\n\n 2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16. ",
        "original_sentence": "Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. "
      }
    },
    {
      "chunk_id": "chunk_932",
      "text": "N Engl J Med [Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 931,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 65,
        "window_text": "Available from: https://www.sciencedirect.com/science/\n\narticle/pii/S1748013218301099\n\n- 15.  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  N Engl J Med [Internet].\n\n 2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16.  Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. ",
        "original_sentence": "N Engl J Med [Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_933",
      "text": "2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 932,
        "window_size": 3,
        "char_count": 55,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  N Engl J Med [Internet].\n\n 2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16.  Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.  Efficacy and Safety\n- 17. ",
        "original_sentence": "2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n"
      }
    },
    {
      "chunk_id": "chunk_934",
      "text": "Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 933,
        "window_size": 3,
        "char_count": 42,
        "word_count": 5,
        "page_number": 4,
        "window_text": "Safety\nand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  N Engl J Med [Internet].\n\n 2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16.  Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.  Efficacy and Safety\n- 17.  Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n",
        "original_sentence": "Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16. "
      }
    },
    {
      "chunk_id": "chunk_935",
      "text": "Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 934,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 8,
        "window_text": "N Engl J Med [Internet].\n\n 2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16.  Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.  Efficacy and Safety\n- 17.  Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n",
        "original_sentence": "Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. "
      }
    },
    {
      "chunk_id": "chunk_936",
      "text": "Efficacy and Safety\n- 17. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 935,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 4,
        "window_text": "2020\n\nDec\n\n31\n\n[cited\n\n2021\n\nJan\n\n5];383(27):2603–15.\n\n Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16.  Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.  Efficacy and Safety\n- 17.  Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n - 18. ",
        "original_sentence": "Efficacy and Safety\n- 17. "
      }
    },
    {
      "chunk_id": "chunk_937",
      "text": "Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 936,
        "window_size": 3,
        "char_count": 86,
        "word_count": 14,
        "page_number": 23,
        "window_text": "Available\n\nfrom:\n\nhttps://doi.org/\n\n- 16.  Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.  Efficacy and Safety\n- 17.  Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n - 18.  Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA. ",
        "original_sentence": "Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n"
      }
    },
    {
      "chunk_id": "chunk_938",
      "text": "COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 937,
        "window_size": 3,
        "char_count": 86,
        "word_count": 11,
        "page_number": 4,
        "window_text": "Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.  Efficacy and Safety\n- 17.  Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n - 18.  Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA.  Gene Ther. ",
        "original_sentence": "COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n"
      }
    },
    {
      "chunk_id": "chunk_939",
      "text": "- 18. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 938,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Efficacy and Safety\n- 17.  Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n - 18.  Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA.  Gene Ther.  2020\n- 19. ",
        "original_sentence": "- 18. "
      }
    },
    {
      "chunk_id": "chunk_940",
      "text": "Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 939,
        "window_size": 3,
        "char_count": 65,
        "word_count": 7,
        "page_number": 8,
        "window_text": "Sahin\nU,\n\nMuik\n\nA,\n\nDerhovanessian\n\nE,\n\nVogler\n\nI,\n\nKranz\n\nLM,\n\nVormehr\n\nM,\n\net\n\nal.\n\n COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n - 18.  Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA.  Gene Ther.  2020\n- 19.  Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n",
        "original_sentence": "Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA. "
      }
    },
    {
      "chunk_id": "chunk_941",
      "text": "Gene Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 940,
        "window_size": 3,
        "char_count": 11,
        "word_count": 2,
        "page_number": 65,
        "window_text": "COVID-19\n\nvaccine\n\nBNT162b1\n\nelicits\n\nhuman\n\nantibody\n\nand\n\nTH1\n\nT\n\ncell\n\nresponses.\n\n - 18.  Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA.  Gene Ther.  2020\n- 19.  Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective. ",
        "original_sentence": "Gene Ther. "
      }
    },
    {
      "chunk_id": "chunk_942",
      "text": "2020\n- 19. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 941,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 4,
        "window_text": "- 18.  Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA.  Gene Ther.  2020\n- 19.  Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective.  J Control Release Off J Control Release Soc. ",
        "original_sentence": "2020\n- 19. "
      }
    },
    {
      "chunk_id": "chunk_943",
      "text": "Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 942,
        "window_size": 3,
        "char_count": 27,
        "word_count": 4,
        "page_number": 26,
        "window_text": "Lundstrom K. Nanoparticle-based delivery of self-amplifying RNA.  Gene Ther.  2020\n- 19.  Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective.  J Control Release Off J Control Release Soc.  2012\n\nJul 20;161(2):152–63.\n\n",
        "original_sentence": "Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n"
      }
    },
    {
      "chunk_id": "chunk_944",
      "text": "The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 943,
        "window_size": 3,
        "char_count": 90,
        "word_count": 11,
        "page_number": 8,
        "window_text": "Gene Ther.  2020\n- 19.  Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective.  J Control Release Off J Control Release Soc.  2012\n\nJul 20;161(2):152–63.\n\n - 20. ",
        "original_sentence": "The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective. "
      }
    },
    {
      "chunk_id": "chunk_945",
      "text": "J Control Release Off J Control Release Soc. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 944,
        "window_size": 3,
        "char_count": 45,
        "word_count": 8,
        "page_number": 65,
        "window_text": "2020\n- 19.  Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective.  J Control Release Off J Control Release Soc.  2012\n\nJul 20;161(2):152–63.\n\n - 20.  Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. ",
        "original_sentence": "J Control Release Off J Control Release Soc. "
      }
    },
    {
      "chunk_id": "chunk_946",
      "text": "2012\n\nJul 20;161(2):152–63.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 945,
        "window_size": 3,
        "char_count": 29,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Bertrand\nN,\n\nLeroux\n\nJ-C.\n\n The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective.  J Control Release Off J Control Release Soc.  2012\n\nJul 20;161(2):152–63.\n\n - 20.  Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al.  Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21. ",
        "original_sentence": "2012\n\nJul 20;161(2):152–63.\n\n"
      }
    },
    {
      "chunk_id": "chunk_947",
      "text": "- 20. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 946,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "The\n\njourney\n\nof\n\na\n\ndrug-carrier\n\nin\n\nthe\n\nbody:\n\nan\n\nanatomo-physiological perspective.  J Control Release Off J Control Release Soc.  2012\n\nJul 20;161(2):152–63.\n\n - 20.  Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al.  Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21.  Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. ",
        "original_sentence": "- 20. "
      }
    },
    {
      "chunk_id": "chunk_948",
      "text": "Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 947,
        "window_size": 3,
        "char_count": 61,
        "word_count": 14,
        "page_number": 65,
        "window_text": "J Control Release Off J Control Release Soc.  2012\n\nJul 20;161(2):152–63.\n\n - 20.  Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al.  Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21.  Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles.  Mol Pharm\n[Internet].\n\n",
        "original_sentence": "Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. "
      }
    },
    {
      "chunk_id": "chunk_949",
      "text": "Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 948,
        "window_size": 3,
        "char_count": 110,
        "word_count": 14,
        "page_number": 8,
        "window_text": "2012\n\nJul 20;161(2):152–63.\n\n - 20.  Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al.  Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21.  Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles.  Mol Pharm\n[Internet].\n\n 2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n",
        "original_sentence": "Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21. "
      }
    },
    {
      "chunk_id": "chunk_950",
      "text": "Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 949,
        "window_size": 3,
        "char_count": 72,
        "word_count": 9,
        "page_number": 23,
        "window_text": "- 20.  Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al.  Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21.  Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles.  Mol Pharm\n[Internet].\n\n 2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n Available\n\nfrom:\n\n- 22. ",
        "original_sentence": "Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. "
      }
    },
    {
      "chunk_id": "chunk_951",
      "text": "Mol Pharm\n[Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 950,
        "window_size": 3,
        "char_count": 23,
        "word_count": 3,
        "page_number": 65,
        "window_text": "Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al.  Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21.  Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles.  Mol Pharm\n[Internet].\n\n 2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n Available\n\nfrom:\n\n- 22.  Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al. ",
        "original_sentence": "Mol Pharm\n[Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_952",
      "text": "2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 951,
        "window_size": 3,
        "char_count": 51,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Safety Evaluation of\nLipid\n\nNanoparticle-Formulated\n\nModified\n\nmRNA\n\nin\n\nthe\n\nSprague-Dawley\n\nRat\n\nand\n\n- 21.  Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles.  Mol Pharm\n[Internet].\n\n 2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n Available\n\nfrom:\n\n- 22.  Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al.  Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles. ",
        "original_sentence": "2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n"
      }
    },
    {
      "chunk_id": "chunk_953",
      "text": "Available\n\nfrom:\n\n- 22. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 952,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 8,
        "window_text": "Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles.  Mol Pharm\n[Internet].\n\n 2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n Available\n\nfrom:\n\n- 22.  Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al.  Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles.  Mol Ther Nucleic Acids. ",
        "original_sentence": "Available\n\nfrom:\n\n- 22. "
      }
    },
    {
      "chunk_id": "chunk_954",
      "text": "Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 953,
        "window_size": 3,
        "char_count": 62,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Mol Pharm\n[Internet].\n\n 2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n Available\n\nfrom:\n\n- 22.  Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al.  Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles.  Mol Ther Nucleic Acids.  2013 Dec 17;2:e139.\n\n",
        "original_sentence": "Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al. "
      }
    },
    {
      "chunk_id": "chunk_955",
      "text": "Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 954,
        "window_size": 3,
        "char_count": 128,
        "word_count": 15,
        "page_number": 8,
        "window_text": "2008\n\nAug\n\n1\n\n[cited\n\n2021\n\nMay\n\n1];5(4):496–504.\n\n Available\n\nfrom:\n\n- 22.  Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al.  Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles.  Mol Ther Nucleic Acids.  2013 Dec 17;2:e139.\n\n - 23. ",
        "original_sentence": "Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles. "
      }
    },
    {
      "chunk_id": "chunk_956",
      "text": "Mol Ther Nucleic Acids. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 955,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 65,
        "window_text": "Available\n\nfrom:\n\n- 22.  Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al.  Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles.  Mol Ther Nucleic Acids.  2013 Dec 17;2:e139.\n\n - 23.  Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n",
        "original_sentence": "Mol Ther Nucleic Acids. "
      }
    },
    {
      "chunk_id": "chunk_957",
      "text": "2013 Dec 17;2:e139.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 956,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YYC, et al.  Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles.  Mol Ther Nucleic Acids.  2013 Dec 17;2:e139.\n\n - 23.  Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. ",
        "original_sentence": "2013 Dec 17;2:e139.\n\n"
      }
    },
    {
      "chunk_id": "chunk_958",
      "text": "- 23. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 957,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Influence of\nPolyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics\n\nof siRNA Lipid Nanoparticles.  Mol Ther Nucleic Acids.  2013 Dec 17;2:e139.\n\n - 23.  Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.  N Engl J Med. ",
        "original_sentence": "- 23. "
      }
    },
    {
      "chunk_id": "chunk_959",
      "text": "Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 958,
        "window_size": 3,
        "char_count": 78,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Mol Ther Nucleic Acids.  2013 Dec 17;2:e139.\n\n - 23.  Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.  N Engl J Med.  2020\n\nNov 12;383(20):1920–31.\n\n",
        "original_sentence": "Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n"
      }
    },
    {
      "chunk_id": "chunk_960",
      "text": "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 959,
        "window_size": 3,
        "char_count": 57,
        "word_count": 8,
        "page_number": 8,
        "window_text": "2013 Dec 17;2:e139.\n\n - 23.  Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.  N Engl J Med.  2020\n\nNov 12;383(20):1920–31.\n\n - 24. ",
        "original_sentence": "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. "
      }
    },
    {
      "chunk_id": "chunk_961",
      "text": "N Engl J Med. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 960,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 66,
        "window_text": "- 23.  Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.  N Engl J Med.  2020\n\nNov 12;383(20):1920–31.\n\n - 24.  Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25. ",
        "original_sentence": "N Engl J Med. "
      }
    },
    {
      "chunk_id": "chunk_962",
      "text": "2020\n\nNov 12;383(20):1920–31.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 961,
        "window_size": 3,
        "char_count": 31,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.\n An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.  N Engl J Med.  2020\n\nNov 12;383(20):1920–31.\n\n - 24.  Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25.  Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26. ",
        "original_sentence": "2020\n\nNov 12;383(20):1920–31.\n\n"
      }
    },
    {
      "chunk_id": "chunk_963",
      "text": "- 24. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 962,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.  N Engl J Med.  2020\n\nNov 12;383(20):1920–31.\n\n - 24.  Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25.  Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26.  Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n",
        "original_sentence": "- 24. "
      }
    },
    {
      "chunk_id": "chunk_964",
      "text": "Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 963,
        "window_size": 3,
        "char_count": 171,
        "word_count": 21,
        "page_number": 26,
        "window_text": "N Engl J Med.  2020\n\nNov 12;383(20):1920–31.\n\n - 24.  Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25.  Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26.  Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines. ",
        "original_sentence": "Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25. "
      }
    },
    {
      "chunk_id": "chunk_965",
      "text": "Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 964,
        "window_size": 3,
        "char_count": 93,
        "word_count": 14,
        "page_number": 66,
        "window_text": "2020\n\nNov 12;383(20):1920–31.\n\n - 24.  Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25.  Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26.  Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines.  Mol Ther Nucleic Acids. ",
        "original_sentence": "Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26. "
      }
    },
    {
      "chunk_id": "chunk_966",
      "text": "Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 965,
        "window_size": 3,
        "char_count": 86,
        "word_count": 14,
        "page_number": 23,
        "window_text": "- 24.  Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25.  Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26.  Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines.  Mol Ther Nucleic Acids.  2019 Apr 15;15:1–11.\n\n",
        "original_sentence": "Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n"
      }
    },
    {
      "chunk_id": "chunk_967",
      "text": "Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 966,
        "window_size": 3,
        "char_count": 96,
        "word_count": 10,
        "page_number": 8,
        "window_text": "Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured\nlipid\n\ncarriers\n\nas\n\nnovel\n\ndrug\n\ndelivery\n\nsystems:\n\napplications,\n\nadvantages\n\nand\n\n- 25.  Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26.  Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines.  Mol Ther Nucleic Acids.  2019 Apr 15;15:1–11.\n\n - 27. ",
        "original_sentence": "Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines. "
      }
    },
    {
      "chunk_id": "chunk_968",
      "text": "Mol Ther Nucleic Acids. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 967,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 65,
        "window_text": "Guevara\nML,\n\nPersano\n\nF,\n\nPersano\n\nS.\n\nAdvances\n\nin\n\nLipid\n\nNanoparticles\n\nfor\n\n67/72\n\n- 26.  Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines.  Mol Ther Nucleic Acids.  2019 Apr 15;15:1–11.\n\n - 27.  Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines. ",
        "original_sentence": "Mol Ther Nucleic Acids. "
      }
    },
    {
      "chunk_id": "chunk_969",
      "text": "2019 Apr 15;15:1–11.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 968,
        "window_size": 3,
        "char_count": 22,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Hassett\nKJ,\n\nBenenato\n\nKE,\n\nJacquinet\n\nE,\n\nLee\n\nA,\n\nWoods\n\nA,\n\nYuzhakov\n\nO,\n\net\n\nal.\n\n Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines.  Mol Ther Nucleic Acids.  2019 Apr 15;15:1–11.\n\n - 27.  Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines.  Vaccines. ",
        "original_sentence": "2019 Apr 15;15:1–11.\n\n"
      }
    },
    {
      "chunk_id": "chunk_970",
      "text": "- 27. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 969,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Optimization\n\nof\n\nLipid\n\nNanoparticles\n\nfor\n\nIntramuscular\n\nAdministration\n\nof\n\nmRNA\n\nVaccines.  Mol Ther Nucleic Acids.  2019 Apr 15;15:1–11.\n\n - 27.  Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines.  Vaccines.  2021 Jan 19;9(1).\n\n",
        "original_sentence": "- 27. "
      }
    },
    {
      "chunk_id": "chunk_971",
      "text": "Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 970,
        "window_size": 3,
        "char_count": 121,
        "word_count": 18,
        "page_number": 65,
        "window_text": "Mol Ther Nucleic Acids.  2019 Apr 15;15:1–11.\n\n - 27.  Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines.  Vaccines.  2021 Jan 19;9(1).\n\n - 28. ",
        "original_sentence": "Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_972",
      "text": "Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 971,
        "window_size": 3,
        "char_count": 10,
        "word_count": 1,
        "page_number": 67,
        "window_text": "2019 Apr 15;15:1–11.\n\n - 27.  Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines.  Vaccines.  2021 Jan 19;9(1).\n\n - 28.  Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. ",
        "original_sentence": "Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_973",
      "text": "2021 Jan 19;9(1).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 972,
        "window_size": 3,
        "char_count": 19,
        "word_count": 3,
        "page_number": 4,
        "window_text": "- 27.  Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines.  Vaccines.  2021 Jan 19;9(1).\n\n - 28.  Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM.  Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n",
        "original_sentence": "2021 Jan 19;9(1).\n\n"
      }
    },
    {
      "chunk_id": "chunk_974",
      "text": "- 28. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 973,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.\nNanomaterial Delivery Systems for mRNA Vaccines.  Vaccines.  2021 Jan 19;9(1).\n\n - 28.  Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM.  Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n Pharmaceutics\n\n[Internet].\n\n",
        "original_sentence": "- 28. "
      }
    },
    {
      "chunk_id": "chunk_975",
      "text": "Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 974,
        "window_size": 3,
        "char_count": 63,
        "word_count": 10,
        "page_number": 65,
        "window_text": "Vaccines.  2021 Jan 19;9(1).\n\n - 28.  Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM.  Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n Pharmaceutics\n\n[Internet].\n\n 2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n",
        "original_sentence": "Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. "
      }
    },
    {
      "chunk_id": "chunk_976",
      "text": "Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 975,
        "window_size": 3,
        "char_count": 84,
        "word_count": 9,
        "page_number": 39,
        "window_text": "2021 Jan 19;9(1).\n\n - 28.  Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM.  Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n Pharmaceutics\n\n[Internet].\n\n 2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n Available\n\nfrom:\n\n- 29. ",
        "original_sentence": "Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n"
      }
    },
    {
      "chunk_id": "chunk_977",
      "text": "Pharmaceutics\n\n[Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 976,
        "window_size": 3,
        "char_count": 28,
        "word_count": 2,
        "page_number": 65,
        "window_text": "- 28.  Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM.  Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n Pharmaceutics\n\n[Internet].\n\n 2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n Available\n\nfrom:\n\n- 29.  Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation. ",
        "original_sentence": "Pharmaceutics\n\n[Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_978",
      "text": "2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 977,
        "window_size": 3,
        "char_count": 44,
        "word_count": 6,
        "page_number": 4,
        "window_text": "Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM.  Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n Pharmaceutics\n\n[Internet].\n\n 2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n Available\n\nfrom:\n\n- 29.  Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation.  Biomaterials.\n\n",
        "original_sentence": "2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n"
      }
    },
    {
      "chunk_id": "chunk_979",
      "text": "Available\n\nfrom:\n\n- 29. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 978,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 8,
        "window_text": "Nanoparticles as\nAdjuvants\n\nand\n\nNanodelivery\n\nSystems\n\nfor\n\nmRNA-Based\n\nVaccines.\n\n Pharmaceutics\n\n[Internet].\n\n 2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n Available\n\nfrom:\n\n- 29.  Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation.  Biomaterials.\n\n 2010 Sep;31(26):6867–75.\n\n",
        "original_sentence": "Available\n\nfrom:\n\n- 29. "
      }
    },
    {
      "chunk_id": "chunk_980",
      "text": "Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 979,
        "window_size": 3,
        "char_count": 152,
        "word_count": 24,
        "page_number": 26,
        "window_text": "Pharmaceutics\n\n[Internet].\n\n 2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n Available\n\nfrom:\n\n- 29.  Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation.  Biomaterials.\n\n 2010 Sep;31(26):6867–75.\n\n - 30. ",
        "original_sentence": "Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation. "
      }
    },
    {
      "chunk_id": "chunk_981",
      "text": "Biomaterials.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 980,
        "window_size": 3,
        "char_count": 15,
        "word_count": 1,
        "page_number": 66,
        "window_text": "2021\n\nJan\n\n[cited\n\n2021\n\nMay\n\n1];13(1):45.\n\n Available\n\nfrom:\n\n- 29.  Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation.  Biomaterials.\n\n 2010 Sep;31(26):6867–75.\n\n - 30.  Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n",
        "original_sentence": "Biomaterials.\n\n"
      }
    },
    {
      "chunk_id": "chunk_982",
      "text": "2010 Sep;31(26):6867–75.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 981,
        "window_size": 3,
        "char_count": 26,
        "word_count": 2,
        "page_number": 67,
        "window_text": "Available\n\nfrom:\n\n- 29.  Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation.  Biomaterials.\n\n 2010 Sep;31(26):6867–75.\n\n - 30.  Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n",
        "original_sentence": "2010 Sep;31(26):6867–75.\n\n"
      }
    },
    {
      "chunk_id": "chunk_983",
      "text": "- 30. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 982,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid\nnanoparticles and the role of Toll-like receptor 4 in immune activation.  Biomaterials.\n\n 2010 Sep;31(26):6867–75.\n\n - 30.  Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n J Control Release Off J Control Release Soc. ",
        "original_sentence": "- 30. "
      }
    },
    {
      "chunk_id": "chunk_984",
      "text": "Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 983,
        "window_size": 3,
        "char_count": 81,
        "word_count": 14,
        "page_number": 8,
        "window_text": "Biomaterials.\n\n 2010 Sep;31(26):6867–75.\n\n - 30.  Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n J Control Release Off J Control Release Soc.  2018 Oct 10;287:67–77.\n\n",
        "original_sentence": "Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n"
      }
    },
    {
      "chunk_id": "chunk_985",
      "text": "Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 984,
        "window_size": 3,
        "char_count": 86,
        "word_count": 11,
        "page_number": 23,
        "window_text": "2010 Sep;31(26):6867–75.\n\n - 30.  Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n J Control Release Off J Control Release Soc.  2018 Oct 10;287:67–77.\n\n - 31. ",
        "original_sentence": "Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n"
      }
    },
    {
      "chunk_id": "chunk_986",
      "text": "J Control Release Off J Control Release Soc. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 985,
        "window_size": 3,
        "char_count": 45,
        "word_count": 8,
        "page_number": 65,
        "window_text": "- 30.  Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n J Control Release Off J Control Release Soc.  2018 Oct 10;287:67–77.\n\n - 31.  Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32. ",
        "original_sentence": "J Control Release Off J Control Release Soc. "
      }
    },
    {
      "chunk_id": "chunk_987",
      "text": "2018 Oct 10;287:67–77.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 986,
        "window_size": 3,
        "char_count": 24,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Pizzuto M, Bigey P, Lachagès A-M, Hoffmann C, Ruysschaert J-M, Escriou V, et al.\n Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n J Control Release Off J Control Release Soc.  2018 Oct 10;287:67–77.\n\n - 31.  Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32.  Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33. ",
        "original_sentence": "2018 Oct 10;287:67–77.\n\n"
      }
    },
    {
      "chunk_id": "chunk_988",
      "text": "- 31. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 987,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum.\n\n J Control Release Off J Control Release Soc.  2018 Oct 10;287:67–77.\n\n - 31.  Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32.  Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33.  Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al. ",
        "original_sentence": "- 31. "
      }
    },
    {
      "chunk_id": "chunk_989",
      "text": "Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 988,
        "window_size": 3,
        "char_count": 88,
        "word_count": 15,
        "page_number": 26,
        "window_text": "J Control Release Off J Control Release Soc.  2018 Oct 10;287:67–77.\n\n - 31.  Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32.  Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33.  Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al.  The INN global nomenclature of biological medicines: A continuous\n\nchallenge. ",
        "original_sentence": "Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32. "
      }
    },
    {
      "chunk_id": "chunk_990",
      "text": "Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 989,
        "window_size": 3,
        "char_count": 112,
        "word_count": 14,
        "page_number": 8,
        "window_text": "2018 Oct 10;287:67–77.\n\n - 31.  Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32.  Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33.  Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al.  The INN global nomenclature of biological medicines: A continuous\n\nchallenge.  Biologicals [Internet]. ",
        "original_sentence": "Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33. "
      }
    },
    {
      "chunk_id": "chunk_991",
      "text": "Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 990,
        "window_size": 3,
        "char_count": 96,
        "word_count": 18,
        "page_number": 26,
        "window_text": "- 31.  Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32.  Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33.  Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al.  The INN global nomenclature of biological medicines: A continuous\n\nchallenge.  Biologicals [Internet].  2019 Jul 1 [cited 2021 May 1];60:15–23. ",
        "original_sentence": "Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al. "
      }
    },
    {
      "chunk_id": "chunk_992",
      "text": "The INN global nomenclature of biological medicines: A continuous\n\nchallenge. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 991,
        "window_size": 3,
        "char_count": 78,
        "word_count": 10,
        "page_number": 8,
        "window_text": "Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious\n- 32.  Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33.  Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al.  The INN global nomenclature of biological medicines: A continuous\n\nchallenge.  Biologicals [Internet].  2019 Jul 1 [cited 2021 May 1];60:15–23.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34. ",
        "original_sentence": "The INN global nomenclature of biological medicines: A continuous\n\nchallenge. "
      }
    },
    {
      "chunk_id": "chunk_993",
      "text": "Biologicals [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 992,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 65,
        "window_text": "Guidance\non\n\nthe\n\nUse\n\nof\n\nInternational\n\nNonproprietary\n\nNames\n\n(INNs)\n\nfor\n\nPharmaceutical\n\nSubstances\n\n- 33.  Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al.  The INN global nomenclature of biological medicines: A continuous\n\nchallenge.  Biologicals [Internet].  2019 Jul 1 [cited 2021 May 1];60:15–23.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34.  Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n",
        "original_sentence": "Biologicals [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_994",
      "text": "2019 Jul 1 [cited 2021 May 1];60:15–23. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 993,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Robertson JS, Chui W-K, Genazzani AA, Malan SF, López de la Rica Manjavacas A,\nMignot G, et al.  The INN global nomenclature of biological medicines: A continuous\n\nchallenge.  Biologicals [Internet].  2019 Jul 1 [cited 2021 May 1];60:15–23.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34.  Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n - 35. ",
        "original_sentence": "2019 Jul 1 [cited 2021 May 1];60:15–23. "
      }
    },
    {
      "chunk_id": "chunk_995",
      "text": "Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 994,
        "window_size": 3,
        "char_count": 92,
        "word_count": 5,
        "page_number": 8,
        "window_text": "The INN global nomenclature of biological medicines: A continuous\n\nchallenge.  Biologicals [Internet].  2019 Jul 1 [cited 2021 May 1];60:15–23.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34.  Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n - 35.  Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n",
        "original_sentence": "Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34. "
      }
    },
    {
      "chunk_id": "chunk_996",
      "text": "Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 995,
        "window_size": 3,
        "char_count": 161,
        "word_count": 23,
        "page_number": 65,
        "window_text": "Biologicals [Internet].  2019 Jul 1 [cited 2021 May 1];60:15–23.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34.  Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n - 35.  Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n RNA\n\n2020,\n\n25:507–518.\n\n",
        "original_sentence": "Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n"
      }
    },
    {
      "chunk_id": "chunk_997",
      "text": "- 35. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 996,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "2019 Jul 1 [cited 2021 May 1];60:15–23.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34.  Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n - 35.  Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n RNA\n\n2020,\n\n25:507–518.\n\n - 36. ",
        "original_sentence": "- 35. "
      }
    },
    {
      "chunk_id": "chunk_998",
      "text": "Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 997,
        "window_size": 3,
        "char_count": 202,
        "word_count": 27,
        "page_number": 39,
        "window_text": "Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/S104510561930048X\n\n- 34.  Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n - 35.  Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n RNA\n\n2020,\n\n25:507–518.\n\n - 36.  Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability. ",
        "original_sentence": "Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n"
      }
    },
    {
      "chunk_id": "chunk_999",
      "text": "RNA\n\n2020,\n\n25:507–518.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 998,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Arbuthnot P, Ely\nA, Bloom K. A convenient method to generate and maintain\n\npoly(A)-encoding\n\nDNA\n\nsequences\n\nrequired\n\nfor\n\nin\n\nvitro\n\ntranscription\n\nof\n\nmRNA.\n\n - 35.  Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n RNA\n\n2020,\n\n25:507–518.\n\n - 36.  Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability.  J Pharm Sci [Internet]. ",
        "original_sentence": "RNA\n\n2020,\n\n25:507–518.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1000",
      "text": "- 36. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 999,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "- 35.  Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n RNA\n\n2020,\n\n25:507–518.\n\n - 36.  Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability.  J Pharm Sci [Internet].  2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n",
        "original_sentence": "- 36. "
      }
    },
    {
      "chunk_id": "chunk_1001",
      "text": "Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1000,
        "window_size": 3,
        "char_count": 126,
        "word_count": 18,
        "page_number": 23,
        "window_text": "Trepotec Z, Geiger J, Plank C, Aneja M, and Rudolph C. Segmented poly(A) tails\nsignificantly\n\nreduce\n\nrecombination\n\nof\n\nplasmid\n\nDNA\n\nwithout\n\naffecting\n\nmRNA\n\ntranslation\n\nefficiency\n\nor\n\nhalf-life.\n\n RNA\n\n2020,\n\n25:507–518.\n\n - 36.  Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability.  J Pharm Sci [Internet].  2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n Available\n\nfrom:\n\n68/72\n\n- 37. ",
        "original_sentence": "Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability. "
      }
    },
    {
      "chunk_id": "chunk_1002",
      "text": "J Pharm Sci [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1001,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 65,
        "window_text": "RNA\n\n2020,\n\n25:507–518.\n\n - 36.  Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability.  J Pharm Sci [Internet].  2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n Available\n\nfrom:\n\n68/72\n\n- 37.  Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products. ",
        "original_sentence": "J Pharm Sci [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_1003",
      "text": "2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1002,
        "window_size": 3,
        "char_count": 70,
        "word_count": 8,
        "page_number": 4,
        "window_text": "- 36.  Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability.  J Pharm Sci [Internet].  2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n Available\n\nfrom:\n\n68/72\n\n- 37.  Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products.  Drug\n\nDiscov Today. ",
        "original_sentence": "2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1004",
      "text": "Available\n\nfrom:\n\n68/72\n\n- 37. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1003,
        "window_size": 3,
        "char_count": 31,
        "word_count": 5,
        "page_number": 8,
        "window_text": "Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing\nthe Cold Reality of mRNA Vaccine Stability.  J Pharm Sci [Internet].  2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n Available\n\nfrom:\n\n68/72\n\n- 37.  Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products.  Drug\n\nDiscov Today.  2016 Mar;21(3):430–44.\n\n",
        "original_sentence": "Available\n\nfrom:\n\n68/72\n\n- 37. "
      }
    },
    {
      "chunk_id": "chunk_1005",
      "text": "Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1004,
        "window_size": 3,
        "char_count": 159,
        "word_count": 22,
        "page_number": 65,
        "window_text": "J Pharm Sci [Internet].  2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n Available\n\nfrom:\n\n68/72\n\n- 37.  Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products.  Drug\n\nDiscov Today.  2016 Mar;21(3):430–44.\n\n - 38. ",
        "original_sentence": "Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products. "
      }
    },
    {
      "chunk_id": "chunk_1006",
      "text": "Drug\n\nDiscov Today. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1005,
        "window_size": 3,
        "char_count": 20,
        "word_count": 3,
        "page_number": 65,
        "window_text": "2021 Mar 1 [cited\n\nWHO/BS/2021.2402\n\n2021\n\nFeb\n\n19];110(3):997–1001.\n\n Available\n\nfrom:\n\n68/72\n\n- 37.  Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products.  Drug\n\nDiscov Today.  2016 Mar;21(3):430–44.\n\n - 38.  Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens. ",
        "original_sentence": "Drug\n\nDiscov Today. "
      }
    },
    {
      "chunk_id": "chunk_1007",
      "text": "2016 Mar;21(3):430–44.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1006,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Available\n\nfrom:\n\n68/72\n\n- 37.  Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products.  Drug\n\nDiscov Today.  2016 Mar;21(3):430–44.\n\n - 38.  Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens.  Vaccines. ",
        "original_sentence": "2016 Mar;21(3):430–44.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1008",
      "text": "- 38. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1007,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Muralidhara\nBK,\n\nBaid\n\nR,\n\nBishop\n\nSM,\n\nHuang\n\nM,\n\nWang\n\nW,\n\nNema\n\nS.\n\nCritical\n\nconsiderations for developing nucleic acid macromolecule based drug products.  Drug\n\nDiscov Today.  2016 Mar;21(3):430–44.\n\n - 38.  Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens.  Vaccines.  2019 Sep 27;7(4).\n\n",
        "original_sentence": "- 38. "
      }
    },
    {
      "chunk_id": "chunk_1009",
      "text": "Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1008,
        "window_size": 3,
        "char_count": 145,
        "word_count": 19,
        "page_number": 66,
        "window_text": "Drug\n\nDiscov Today.  2016 Mar;21(3):430–44.\n\n - 38.  Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens.  Vaccines.  2019 Sep 27;7(4).\n\n - 39. ",
        "original_sentence": "Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens. "
      }
    },
    {
      "chunk_id": "chunk_1010",
      "text": "Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1009,
        "window_size": 3,
        "char_count": 10,
        "word_count": 1,
        "page_number": 67,
        "window_text": "2016 Mar;21(3):430–44.\n\n - 38.  Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens.  Vaccines.  2019 Sep 27;7(4).\n\n - 39.  ICH Q3C(R6). ",
        "original_sentence": "Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_1011",
      "text": "2019 Sep 27;7(4).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1010,
        "window_size": 3,
        "char_count": 19,
        "word_count": 3,
        "page_number": 4,
        "window_text": "- 38.  Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens.  Vaccines.  2019 Sep 27;7(4).\n\n - 39.  ICH Q3C(R6).  Impurities: guideline for residual solvents. ",
        "original_sentence": "2019 Sep 27;7(4).\n\n"
      }
    },
    {
      "chunk_id": "chunk_1012",
      "text": "- 39. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1011,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Poveda\nC,\n\nBiter\n\nAB,\n\nBottazzi\n\nME,\n\nStrych\n\nU.\n\nEstablishing\n\nPreferred\n\nProduct\n\nCharacterization for the Evaluation of RNA Vaccine Antigens.  Vaccines.  2019 Sep 27;7(4).\n\n - 39.  ICH Q3C(R6).  Impurities: guideline for residual solvents.  2016. https://database.ich.org/\n- 40. ",
        "original_sentence": "- 39. "
      }
    },
    {
      "chunk_id": "chunk_1013",
      "text": "ICH Q3C(R6). ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1012,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 56,
        "window_text": "Vaccines.  2019 Sep 27;7(4).\n\n - 39.  ICH Q3C(R6).  Impurities: guideline for residual solvents.  2016. https://database.ich.org/\n- 40.  ICH\nQ3D(R1).\n\n",
        "original_sentence": "ICH Q3C(R6). "
      }
    },
    {
      "chunk_id": "chunk_1014",
      "text": "Impurities: guideline for residual solvents. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1013,
        "window_size": 3,
        "char_count": 45,
        "word_count": 5,
        "page_number": 8,
        "window_text": "2019 Sep 27;7(4).\n\n - 39.  ICH Q3C(R6).  Impurities: guideline for residual solvents.  2016. https://database.ich.org/\n- 40.  ICH\nQ3D(R1).\n\n Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n",
        "original_sentence": "Impurities: guideline for residual solvents. "
      }
    },
    {
      "chunk_id": "chunk_1015",
      "text": "2016. https://database.ich.org/\n- 40. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1014,
        "window_size": 3,
        "char_count": 38,
        "word_count": 4,
        "page_number": 4,
        "window_text": "- 39.  ICH Q3C(R6).  Impurities: guideline for residual solvents.  2016. https://database.ich.org/\n- 40.  ICH\nQ3D(R1).\n\n Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n - 2019.\nhttps://database.ich.org/\n\n- 41. ",
        "original_sentence": "2016. https://database.ich.org/\n- 40. "
      }
    },
    {
      "chunk_id": "chunk_1016",
      "text": "ICH\nQ3D(R1).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1015,
        "window_size": 3,
        "char_count": 14,
        "word_count": 2,
        "page_number": 4,
        "window_text": "ICH Q3C(R6).  Impurities: guideline for residual solvents.  2016. https://database.ich.org/\n- 40.  ICH\nQ3D(R1).\n\n Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n - 2019.\nhttps://database.ich.org/\n\n- 41.  ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n",
        "original_sentence": "ICH\nQ3D(R1).\n\n"
      }
    },
    {
      "chunk_id": "chunk_1017",
      "text": "Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1016,
        "window_size": 3,
        "char_count": 40,
        "word_count": 4,
        "page_number": 23,
        "window_text": "Impurities: guideline for residual solvents.  2016. https://database.ich.org/\n- 40.  ICH\nQ3D(R1).\n\n Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n - 2019.\nhttps://database.ich.org/\n\n- 41.  ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n - 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42. ",
        "original_sentence": "Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1018",
      "text": "- 2019.\nhttps://database.ich.org/\n\n- 41. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1017,
        "window_size": 3,
        "char_count": 41,
        "word_count": 5,
        "page_number": 4,
        "window_text": "2016. https://database.ich.org/\n- 40.  ICH\nQ3D(R1).\n\n Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n - 2019.\nhttps://database.ich.org/\n\n- 41.  ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n - 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42.  WHO Getting started with vaccine vial monitors. ",
        "original_sentence": "- 2019.\nhttps://database.ich.org/\n\n- 41. "
      }
    },
    {
      "chunk_id": "chunk_1019",
      "text": "ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1018,
        "window_size": 3,
        "char_count": 129,
        "word_count": 16,
        "page_number": 4,
        "window_text": "ICH\nQ3D(R1).\n\n Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n - 2019.\nhttps://database.ich.org/\n\n- 41.  ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n - 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42.  WHO Getting started with vaccine vial monitors.  2002. https://apps.who.int/iris/\n- 43. ",
        "original_sentence": "ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1020",
      "text": "- 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1019,
        "window_size": 3,
        "char_count": 45,
        "word_count": 5,
        "page_number": 4,
        "window_text": "Guideline\n\nfor\n\nelemental\n\nimpurities.\n\n - 2019.\nhttps://database.ich.org/\n\n- 41.  ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n - 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42.  WHO Getting started with vaccine vial monitors.  2002. https://apps.who.int/iris/\n- 43.  WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n",
        "original_sentence": "- 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42. "
      }
    },
    {
      "chunk_id": "chunk_1021",
      "text": "WHO Getting started with vaccine vial monitors. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1020,
        "window_size": 3,
        "char_count": 48,
        "word_count": 7,
        "page_number": 23,
        "window_text": "- 2019.\nhttps://database.ich.org/\n\n- 41.  ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n - 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42.  WHO Getting started with vaccine vial monitors.  2002. https://apps.who.int/iris/\n- 43.  WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n 2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44. ",
        "original_sentence": "WHO Getting started with vaccine vial monitors. "
      }
    },
    {
      "chunk_id": "chunk_1022",
      "text": "2002. https://apps.who.int/iris/\n- 43. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1021,
        "window_size": 3,
        "char_count": 39,
        "word_count": 4,
        "page_number": 8,
        "window_text": "ICH\nguideline\n\nS2\n\n(R1)\n\non\n\ngenotoxicity\n\ntesting\n\nand\n\ndata\n\ninterpretation\n\nfor\n\npharmaceuticals\n\nintended\n\nfor\n\nhuman\n\nuse.\n\n - 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42.  WHO Getting started with vaccine vial monitors.  2002. https://apps.who.int/iris/\n- 43.  WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n 2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44.  Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al. ",
        "original_sentence": "2002. https://apps.who.int/iris/\n- 43. "
      }
    },
    {
      "chunk_id": "chunk_1023",
      "text": "WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1022,
        "window_size": 3,
        "char_count": 88,
        "word_count": 14,
        "page_number": 23,
        "window_text": "- 2012.\nhttps://www.ema.europa.eu/en/\n\n- 42.  WHO Getting started with vaccine vial monitors.  2002. https://apps.who.int/iris/\n- 43.  WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n 2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44.  Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al.  Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45. ",
        "original_sentence": "WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1024",
      "text": "2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1023,
        "window_size": 3,
        "char_count": 77,
        "word_count": 4,
        "page_number": 8,
        "window_text": "WHO Getting started with vaccine vial monitors.  2002. https://apps.who.int/iris/\n- 43.  WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n 2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44.  Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al.  Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45.  Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. ",
        "original_sentence": "2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44. "
      }
    },
    {
      "chunk_id": "chunk_1025",
      "text": "Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1024,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 23,
        "window_text": "2002. https://apps.who.int/iris/\n- 43.  WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n 2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44.  Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al.  Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45.  Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al.  Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection. ",
        "original_sentence": "Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al. "
      }
    },
    {
      "chunk_id": "chunk_1026",
      "text": "Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1025,
        "window_size": 3,
        "char_count": 111,
        "word_count": 14,
        "page_number": 8,
        "window_text": "WHO Bar-codes, QR codes and Vaccine Vial Monitors in the context of COVID-19\nvaccines.\n\n 2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44.  Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al.  Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45.  Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al.  Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection.  J Control Release Off J Control Release Soc. ",
        "original_sentence": "Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45. "
      }
    },
    {
      "chunk_id": "chunk_1027",
      "text": "Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1026,
        "window_size": 3,
        "char_count": 74,
        "word_count": 14,
        "page_number": 23,
        "window_text": "2020\n\nhttps://www.who.int/publications/m/item/bar-codes-qr-codes-and-\n\n- 44.  Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al.  Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45.  Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al.  Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection.  J Control Release Off J Control Release Soc.  2020 Sep 10;325:370–9.\n\n",
        "original_sentence": "Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. "
      }
    },
    {
      "chunk_id": "chunk_1028",
      "text": "Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1027,
        "window_size": 3,
        "char_count": 116,
        "word_count": 15,
        "page_number": 8,
        "window_text": "Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, et al.  Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45.  Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al.  Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection.  J Control Release Off J Control Release Soc.  2020 Sep 10;325:370–9.\n\n - 46. ",
        "original_sentence": "Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection. "
      }
    },
    {
      "chunk_id": "chunk_1029",
      "text": "J Control Release Off J Control Release Soc. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1028,
        "window_size": 3,
        "char_count": 45,
        "word_count": 8,
        "page_number": 65,
        "window_text": "Nonclinical safety\nassessment\n\nof\n\nrepeated\n\nadministration\n\nand\n\nbiodistribution\n\nof\n\na\n\nnovel\n\nrabies\n\n- 45.  Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al.  Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection.  J Control Release Off J Control Release Soc.  2020 Sep 10;325:370–9.\n\n - 46.  Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. ",
        "original_sentence": "J Control Release Off J Control Release Soc. "
      }
    },
    {
      "chunk_id": "chunk_1030",
      "text": "2020 Sep 10;325:370–9.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1029,
        "window_size": 3,
        "char_count": 24,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al.  Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection.  J Control Release Off J Control Release Soc.  2020 Sep 10;325:370–9.\n\n - 46.  Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al.  Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses. ",
        "original_sentence": "2020 Sep 10;325:370–9.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1031",
      "text": "- 46. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1030,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Delivery of\nself-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic\n\nlipid selection.  J Control Release Off J Control Release Soc.  2020 Sep 10;325:370–9.\n\n - 46.  Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al.  Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses.  Mol Ther J Am Soc Gene Ther. ",
        "original_sentence": "- 46. "
      }
    },
    {
      "chunk_id": "chunk_1032",
      "text": "Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1031,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 65,
        "window_text": "J Control Release Off J Control Release Soc.  2020 Sep 10;325:370–9.\n\n - 46.  Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al.  Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses.  Mol Ther J Am Soc Gene Ther.  2017 Jun 7;25(6):1316–27.\n\n",
        "original_sentence": "Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. "
      }
    },
    {
      "chunk_id": "chunk_1033",
      "text": "Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1032,
        "window_size": 3,
        "char_count": 117,
        "word_count": 15,
        "page_number": 8,
        "window_text": "2020 Sep 10;325:370–9.\n\n - 46.  Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al.  Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses.  Mol Ther J Am Soc Gene Ther.  2017 Jun 7;25(6):1316–27.\n\n - 47. ",
        "original_sentence": "Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses. "
      }
    },
    {
      "chunk_id": "chunk_1034",
      "text": "Mol Ther J Am Soc Gene Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1033,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 65,
        "window_text": "- 46.  Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al.  Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses.  Mol Ther J Am Soc Gene Ther.  2017 Jun 7;25(6):1316–27.\n\n - 47.  Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al. ",
        "original_sentence": "Mol Ther J Am Soc Gene Ther. "
      }
    },
    {
      "chunk_id": "chunk_1035",
      "text": "2017 Jun 7;25(6):1316–27.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1034,
        "window_size": 3,
        "char_count": 27,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al.  Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses.  Mol Ther J Am Soc Gene Ther.  2017 Jun 7;25(6):1316–27.\n\n - 47.  Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al.  Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques. ",
        "original_sentence": "2017 Jun 7;25(6):1316–27.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1036",
      "text": "- 47. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1035,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Preclinical and\nClinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and\n\nH7N9 Influenza Viruses.  Mol Ther J Am Soc Gene Ther.  2017 Jun 7;25(6):1316–27.\n\n - 47.  Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al.  Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques.  Mol Ther J Am\n\nSoc Gene Ther. ",
        "original_sentence": "- 47. "
      }
    },
    {
      "chunk_id": "chunk_1037",
      "text": "Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1036,
        "window_size": 3,
        "char_count": 64,
        "word_count": 14,
        "page_number": 23,
        "window_text": "Mol Ther J Am Soc Gene Ther.  2017 Jun 7;25(6):1316–27.\n\n - 47.  Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al.  Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques.  Mol Ther J Am\n\nSoc Gene Ther.  2017 Dec\n\n- 48. ",
        "original_sentence": "Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al. "
      }
    },
    {
      "chunk_id": "chunk_1038",
      "text": "Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1037,
        "window_size": 3,
        "char_count": 136,
        "word_count": 17,
        "page_number": 8,
        "window_text": "2017 Jun 7;25(6):1316–27.\n\n - 47.  Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al.  Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques.  Mol Ther J Am\n\nSoc Gene Ther.  2017 Dec\n\n- 48.  Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. ",
        "original_sentence": "Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques. "
      }
    },
    {
      "chunk_id": "chunk_1039",
      "text": "Mol Ther J Am\n\nSoc Gene Ther. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1038,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 65,
        "window_text": "- 47.  Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al.  Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques.  Mol Ther J Am\n\nSoc Gene Ther.  2017 Dec\n\n- 48.  Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.  Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes. ",
        "original_sentence": "Mol Ther J Am\n\nSoc Gene Ther. "
      }
    },
    {
      "chunk_id": "chunk_1040",
      "text": "2017 Dec\n\n- 48. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1039,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 4,
        "window_text": "Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, et al.  Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques.  Mol Ther J Am\n\nSoc Gene Ther.  2017 Dec\n\n- 48.  Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.  Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes.  J Controlled Release [Internet]. ",
        "original_sentence": "2017 Dec\n\n- 48. "
      }
    },
    {
      "chunk_id": "chunk_1041",
      "text": "Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1040,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Efficient Targeting\nand Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine\n\nAdministration in Rhesus\n\nMacaques.  Mol Ther J Am\n\nSoc Gene Ther.  2017 Dec\n\n- 48.  Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.  Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes.  J Controlled Release [Internet].  2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51. ",
        "original_sentence": "Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. "
      }
    },
    {
      "chunk_id": "chunk_1042",
      "text": "Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1041,
        "window_size": 3,
        "char_count": 110,
        "word_count": 14,
        "page_number": 8,
        "window_text": "Mol Ther J Am\n\nSoc Gene Ther.  2017 Dec\n\n- 48.  Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.  Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes.  J Controlled Release [Internet].  2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51.  Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49. ",
        "original_sentence": "Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes. "
      }
    },
    {
      "chunk_id": "chunk_1043",
      "text": "J Controlled Release [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1042,
        "window_size": 3,
        "char_count": 33,
        "word_count": 4,
        "page_number": 65,
        "window_text": "2017 Dec\n\n- 48.  Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.  Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes.  J Controlled Release [Internet].  2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51.  Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49.  EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50. ",
        "original_sentence": "J Controlled Release [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_1044",
      "text": "2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1043,
        "window_size": 3,
        "char_count": 47,
        "word_count": 9,
        "page_number": 4,
        "window_text": "Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.  Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes.  J Controlled Release [Internet].  2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51.  Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49.  EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50.  Obeid MA, Tate RJ, Mullen AB, Ferro VA. ",
        "original_sentence": "2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51. "
      }
    },
    {
      "chunk_id": "chunk_1045",
      "text": "Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1044,
        "window_size": 3,
        "char_count": 90,
        "word_count": 5,
        "page_number": 8,
        "window_text": "Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\n\nto mice by\n\nvarious routes.  J Controlled Release [Internet].  2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51.  Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49.  EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50.  Obeid MA, Tate RJ, Mullen AB, Ferro VA.  Chapter 8 - Lipid-based nanoparticles for\ncancer treatment. ",
        "original_sentence": "Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49. "
      }
    },
    {
      "chunk_id": "chunk_1046",
      "text": "EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1045,
        "window_size": 3,
        "char_count": 81,
        "word_count": 12,
        "page_number": 4,
        "window_text": "J Controlled Release [Internet].  2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51.  Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49.  EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50.  Obeid MA, Tate RJ, Mullen AB, Ferro VA.  Chapter 8 - Lipid-based nanoparticles for\ncancer treatment.  In: Grumezescu AM, editor. ",
        "original_sentence": "EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50. "
      }
    },
    {
      "chunk_id": "chunk_1047",
      "text": "Obeid MA, Tate RJ, Mullen AB, Ferro VA. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1046,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 65,
        "window_text": "2015 Nov 10 [cited 2021 May 1];217:345–\n\n- 51.  Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49.  EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50.  Obeid MA, Tate RJ, Mullen AB, Ferro VA.  Chapter 8 - Lipid-based nanoparticles for\ncancer treatment.  In: Grumezescu AM, editor.  Lipid Nanocarriers for Drug Targeting\n\n[Internet]. ",
        "original_sentence": "Obeid MA, Tate RJ, Mullen AB, Ferro VA. "
      }
    },
    {
      "chunk_id": "chunk_1048",
      "text": "Chapter 8 - Lipid-based nanoparticles for\ncancer treatment. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1047,
        "window_size": 3,
        "char_count": 60,
        "word_count": 8,
        "page_number": 26,
        "window_text": "Available from: https://www.sciencedirect.com/science/article/pii/S0168365915300535\n- 49.  EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50.  Obeid MA, Tate RJ, Mullen AB, Ferro VA.  Chapter 8 - Lipid-based nanoparticles for\ncancer treatment.  In: Grumezescu AM, editor.  Lipid Nanocarriers for Drug Targeting\n\n[Internet].  William Andrew Publishing; 2018 [cited 2021 May 27]. ",
        "original_sentence": "Chapter 8 - Lipid-based nanoparticles for\ncancer treatment. "
      }
    },
    {
      "chunk_id": "chunk_1049",
      "text": "In: Grumezescu AM, editor. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1048,
        "window_size": 3,
        "char_count": 27,
        "word_count": 4,
        "page_number": 8,
        "window_text": "EMA\nAssessment\n\nreport\n\nComirnaty,\n\nDecember\n\n21,\n\n2020,\n\npage\n\n47\n\n69/72\n\n- 50.  Obeid MA, Tate RJ, Mullen AB, Ferro VA.  Chapter 8 - Lipid-based nanoparticles for\ncancer treatment.  In: Grumezescu AM, editor.  Lipid Nanocarriers for Drug Targeting\n\n[Internet].  William Andrew Publishing; 2018 [cited 2021 May 27].  p. ",
        "original_sentence": "In: Grumezescu AM, editor. "
      }
    },
    {
      "chunk_id": "chunk_1050",
      "text": "Lipid Nanocarriers for Drug Targeting\n\n[Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1049,
        "window_size": 3,
        "char_count": 51,
        "word_count": 6,
        "page_number": 23,
        "window_text": "Obeid MA, Tate RJ, Mullen AB, Ferro VA.  Chapter 8 - Lipid-based nanoparticles for\ncancer treatment.  In: Grumezescu AM, editor.  Lipid Nanocarriers for Drug Targeting\n\n[Internet].  William Andrew Publishing; 2018 [cited 2021 May 27].  p.  313–59. ",
        "original_sentence": "Lipid Nanocarriers for Drug Targeting\n\n[Internet]. "
      }
    },
    {
      "chunk_id": "chunk_1051",
      "text": "William Andrew Publishing; 2018 [cited 2021 May 27]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1050,
        "window_size": 3,
        "char_count": 53,
        "word_count": 8,
        "page_number": 4,
        "window_text": "Chapter 8 - Lipid-based nanoparticles for\ncancer treatment.  In: Grumezescu AM, editor.  Lipid Nanocarriers for Drug Targeting\n\n[Internet].  William Andrew Publishing; 2018 [cited 2021 May 27].  p.  313–59.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51. ",
        "original_sentence": "William Andrew Publishing; 2018 [cited 2021 May 27]. "
      }
    },
    {
      "chunk_id": "chunk_1052",
      "text": "p. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1051,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 65,
        "window_text": "In: Grumezescu AM, editor.  Lipid Nanocarriers for Drug Targeting\n\n[Internet].  William Andrew Publishing; 2018 [cited 2021 May 27].  p.  313–59.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51.  Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52. ",
        "original_sentence": "p. "
      }
    },
    {
      "chunk_id": "chunk_1053",
      "text": "313–59. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1052,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 4,
        "window_text": "Lipid Nanocarriers for Drug Targeting\n\n[Internet].  William Andrew Publishing; 2018 [cited 2021 May 27].  p.  313–59.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51.  Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52.  CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n",
        "original_sentence": "313–59. "
      }
    },
    {
      "chunk_id": "chunk_1054",
      "text": "Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1053,
        "window_size": 3,
        "char_count": 95,
        "word_count": 5,
        "page_number": 8,
        "window_text": "William Andrew Publishing; 2018 [cited 2021 May 27].  p.  313–59.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51.  Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52.  CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n - 53. ",
        "original_sentence": "Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51. "
      }
    },
    {
      "chunk_id": "chunk_1055",
      "text": "Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1054,
        "window_size": 3,
        "char_count": 245,
        "word_count": 30,
        "page_number": 65,
        "window_text": "p.  313–59.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51.  Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52.  CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n - 53.  Turecek PL, Bossard MJ, Schoetens F, Ivens IA. ",
        "original_sentence": "Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52. "
      }
    },
    {
      "chunk_id": "chunk_1056",
      "text": "CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1055,
        "window_size": 3,
        "char_count": 280,
        "word_count": 26,
        "page_number": 23,
        "window_text": "313–59.  Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51.  Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52.  CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n - 53.  Turecek PL, Bossard MJ, Schoetens F, Ivens IA.  PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n",
        "original_sentence": "CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1057",
      "text": "- 53. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1056,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Available\n\nfrom: https://www.sciencedirect.com/science/article/pii/B9780128136874000086\n\n- 51.  Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52.  CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n - 53.  Turecek PL, Bossard MJ, Schoetens F, Ivens IA.  PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n J\n\n- 54. ",
        "original_sentence": "- 53. "
      }
    },
    {
      "chunk_id": "chunk_1058",
      "text": "Turecek PL, Bossard MJ, Schoetens F, Ivens IA. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1057,
        "window_size": 3,
        "char_count": 47,
        "word_count": 8,
        "page_number": 65,
        "window_text": "Marlowe\nJL,\n\nAkopian\n\nV,\n\nKarmali\n\nP,\n\nKornbrust\n\nD,\n\nLockridge\n\nJ,\n\nSemple\n\nS.\n\nRecommendations\n\nof\n\nthe\n\nOligonucleotide\n\nSafety\n\nWorking\n\nGroup’s\n\nFormulated\n\nOligonucleotide\n\nSubcommittee\n\nfor\n\nthe\n\nSafety\n\nAssessment\n\nof\n\nFormulated\n\n- 52.  CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n - 53.  Turecek PL, Bossard MJ, Schoetens F, Ivens IA.  PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n J\n\n- 54.  Turecek PL, Siekmann J. ",
        "original_sentence": "Turecek PL, Bossard MJ, Schoetens F, Ivens IA. "
      }
    },
    {
      "chunk_id": "chunk_1059",
      "text": "PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1058,
        "window_size": 3,
        "char_count": 120,
        "word_count": 14,
        "page_number": 8,
        "window_text": "CHMP Safety Working Party's resopnse to the PDCO regarding the use of PEGylated\ndrug\n\nproducts\n\nin\n\nthe\n\npediatric\n\npopulation\n\nhttps://www.ema.europa.eu/en/\n\nchmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-\n\ndrug-products Accessed June 1, 2021.\n\n - 53.  Turecek PL, Bossard MJ, Schoetens F, Ivens IA.  PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n J\n\n- 54.  Turecek PL, Siekmann J.  4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations. ",
        "original_sentence": "PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1060",
      "text": "J\n\n- 54. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1059,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 26,
        "window_text": "- 53.  Turecek PL, Bossard MJ, Schoetens F, Ivens IA.  PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n J\n\n- 54.  Turecek PL, Siekmann J.  4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations.  In: Pasut G, Zalipsky S, editors. ",
        "original_sentence": "J\n\n- 54. "
      }
    },
    {
      "chunk_id": "chunk_1061",
      "text": "Turecek PL, Siekmann J. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1060,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 66,
        "window_text": "Turecek PL, Bossard MJ, Schoetens F, Ivens IA.  PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n J\n\n- 54.  Turecek PL, Siekmann J.  4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations.  In: Pasut G, Zalipsky S, editors.  Polymer-Protein Conjugates [Internet].\n\n",
        "original_sentence": "Turecek PL, Siekmann J. "
      }
    },
    {
      "chunk_id": "chunk_1062",
      "text": "4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1061,
        "window_size": 3,
        "char_count": 78,
        "word_count": 9,
        "page_number": 8,
        "window_text": "PEGylation of Biopharmaceuticals: A\nReview\n\nof\n\nChemistry\n\nand\n\nNonclinical\n\nSafety\n\nInformation\n\nof\n\nApproved\n\nDrugs.\n\n J\n\n- 54.  Turecek PL, Siekmann J.  4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations.  In: Pasut G, Zalipsky S, editors.  Polymer-Protein Conjugates [Internet].\n\n Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n",
        "original_sentence": "4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations. "
      }
    },
    {
      "chunk_id": "chunk_1063",
      "text": "In: Pasut G, Zalipsky S, editors. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1062,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 8,
        "window_text": "J\n\n- 54.  Turecek PL, Siekmann J.  4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations.  In: Pasut G, Zalipsky S, editors.  Polymer-Protein Conjugates [Internet].\n\n Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n p.\n\n",
        "original_sentence": "In: Pasut G, Zalipsky S, editors. "
      }
    },
    {
      "chunk_id": "chunk_1064",
      "text": "Polymer-Protein Conjugates [Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1063,
        "window_size": 3,
        "char_count": 40,
        "word_count": 3,
        "page_number": 23,
        "window_text": "Turecek PL, Siekmann J.  4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations.  In: Pasut G, Zalipsky S, editors.  Polymer-Protein Conjugates [Internet].\n\n Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n p.\n\n 61–101.\n\n",
        "original_sentence": "Polymer-Protein Conjugates [Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1065",
      "text": "Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1064,
        "window_size": 3,
        "char_count": 42,
        "word_count": 6,
        "page_number": 4,
        "window_text": "4 - PEG–protein conjugates: nonclinical and clinical toxicity\nconsiderations.  In: Pasut G, Zalipsky S, editors.  Polymer-Protein Conjugates [Internet].\n\n Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n p.\n\n 61–101.\n\n Available\n\nfrom:\n\n- 55. ",
        "original_sentence": "Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1066",
      "text": "p.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1065,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 65,
        "window_text": "In: Pasut G, Zalipsky S, editors.  Polymer-Protein Conjugates [Internet].\n\n Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n p.\n\n 61–101.\n\n Available\n\nfrom:\n\n- 55.  Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al. ",
        "original_sentence": "p.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1067",
      "text": "61–101.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1066,
        "window_size": 3,
        "char_count": 9,
        "word_count": 1,
        "page_number": 69,
        "window_text": "Polymer-Protein Conjugates [Internet].\n\n Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n p.\n\n 61–101.\n\n Available\n\nfrom:\n\n- 55.  Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al.  Cytotoxicity study of polyethylene\nglycol derivatives. ",
        "original_sentence": "61–101.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1068",
      "text": "Available\n\nfrom:\n\n- 55. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1067,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 8,
        "window_text": "Elsevier;\n\n2020\n\n[cited\n\n2021\n\nMay\n\n27].\n\n p.\n\n 61–101.\n\n Available\n\nfrom:\n\n- 55.  Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al.  Cytotoxicity study of polyethylene\nglycol derivatives.  RSC Adv [Internet]. ",
        "original_sentence": "Available\n\nfrom:\n\n- 55. "
      }
    },
    {
      "chunk_id": "chunk_1069",
      "text": "Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1068,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 65,
        "window_text": "p.\n\n 61–101.\n\n Available\n\nfrom:\n\n- 55.  Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al.  Cytotoxicity study of polyethylene\nglycol derivatives.  RSC Adv [Internet].  2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n",
        "original_sentence": "Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al. "
      }
    },
    {
      "chunk_id": "chunk_1070",
      "text": "Cytotoxicity study of polyethylene\nglycol derivatives. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1069,
        "window_size": 3,
        "char_count": 55,
        "word_count": 6,
        "page_number": 8,
        "window_text": "61–101.\n\n Available\n\nfrom:\n\n- 55.  Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al.  Cytotoxicity study of polyethylene\nglycol derivatives.  RSC Adv [Internet].  2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56. ",
        "original_sentence": "Cytotoxicity study of polyethylene\nglycol derivatives. "
      }
    },
    {
      "chunk_id": "chunk_1071",
      "text": "RSC Adv [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1070,
        "window_size": 3,
        "char_count": 20,
        "word_count": 3,
        "page_number": 65,
        "window_text": "Available\n\nfrom:\n\n- 55.  Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al.  Cytotoxicity study of polyethylene\nglycol derivatives.  RSC Adv [Internet].  2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56.  Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. ",
        "original_sentence": "RSC Adv [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_1072",
      "text": "2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1071,
        "window_size": 3,
        "char_count": 48,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Liu G, Li Y, Yang L, Wei Y, Wang X, Wang Z, et al.  Cytotoxicity study of polyethylene\nglycol derivatives.  RSC Adv [Internet].  2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56.  Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al.  Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase. ",
        "original_sentence": "2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1073",
      "text": "Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1072,
        "window_size": 3,
        "char_count": 90,
        "word_count": 6,
        "page_number": 8,
        "window_text": "Cytotoxicity study of polyethylene\nglycol derivatives.  RSC Adv [Internet].  2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56.  Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al.  Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase.  J Biol\n\nChem. ",
        "original_sentence": "Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56. "
      }
    },
    {
      "chunk_id": "chunk_1074",
      "text": "Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1073,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 23,
        "window_text": "RSC Adv [Internet].  2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56.  Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al.  Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase.  J Biol\n\nChem.  2001 Nov 2;276(44):40847–57.\n\n",
        "original_sentence": "Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. "
      }
    },
    {
      "chunk_id": "chunk_1075",
      "text": "Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1074,
        "window_size": 3,
        "char_count": 85,
        "word_count": 11,
        "page_number": 8,
        "window_text": "2017 Mar 24 [cited 2021 May 27];7(30):18252–9.\n\n Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56.  Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al.  Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase.  J Biol\n\nChem.  2001 Nov 2;276(44):40847–57.\n\n - 57. ",
        "original_sentence": "Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase. "
      }
    },
    {
      "chunk_id": "chunk_1076",
      "text": "J Biol\n\nChem. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1075,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 69,
        "window_text": "Available from: https://pubs.rsc.org/en/content/articlelanding/ 2017/ra/c7ra00861a\n\n- 56.  Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al.  Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase.  J Biol\n\nChem.  2001 Nov 2;276(44):40847–57.\n\n - 57.  Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58. ",
        "original_sentence": "J Biol\n\nChem. "
      }
    },
    {
      "chunk_id": "chunk_1077",
      "text": "2001 Nov 2;276(44):40847–57.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1076,
        "window_size": 3,
        "char_count": 30,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al.  Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase.  J Biol\n\nChem.  2001 Nov 2;276(44):40847–57.\n\n - 57.  Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58.  Nucleoside\nAnalogues.\n\n",
        "original_sentence": "2001 Nov 2;276(44):40847–57.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1078",
      "text": "- 57. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1077,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Toxicity of\nantiviral nucleoside analogs and the human mitochondrial DNA polymerase.  J Biol\n\nChem.  2001 Nov 2;276(44):40847–57.\n\n - 57.  Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58.  Nucleoside\nAnalogues.\n\n In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet]. ",
        "original_sentence": "- 57. "
      }
    },
    {
      "chunk_id": "chunk_1079",
      "text": "Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1078,
        "window_size": 3,
        "char_count": 91,
        "word_count": 12,
        "page_number": 8,
        "window_text": "J Biol\n\nChem.  2001 Nov 2;276(44):40847–57.\n\n - 57.  Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58.  Nucleoside\nAnalogues.\n\n In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet].  Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n",
        "original_sentence": "Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58. "
      }
    },
    {
      "chunk_id": "chunk_1080",
      "text": "Nucleoside\nAnalogues.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1079,
        "window_size": 3,
        "char_count": 23,
        "word_count": 2,
        "page_number": 66,
        "window_text": "2001 Nov 2;276(44):40847–57.\n\n - 57.  Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58.  Nucleoside\nAnalogues.\n\n In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet].  Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n Available\n\nfrom:\n\n- 59. ",
        "original_sentence": "Nucleoside\nAnalogues.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1081",
      "text": "In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1080,
        "window_size": 3,
        "char_count": 96,
        "word_count": 11,
        "page_number": 8,
        "window_text": "- 57.  Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58.  Nucleoside\nAnalogues.\n\n In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet].  Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n Available\n\nfrom:\n\n- 59.  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. ",
        "original_sentence": "In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_1082",
      "text": "Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1081,
        "window_size": 3,
        "char_count": 118,
        "word_count": 16,
        "page_number": 8,
        "window_text": "Moyle\nG.\n\nToxicity\n\nof\n\nantiretroviral\n\nnucleoside\n\nand\n\nnucleotide\n\nanalogues:\n\nis\n\n- 58.  Nucleoside\nAnalogues.\n\n In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet].  Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n Available\n\nfrom:\n\n- 59.  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults. ",
        "original_sentence": "Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1083",
      "text": "Available\n\nfrom:\n\n- 59. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1082,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 8,
        "window_text": "Nucleoside\nAnalogues.\n\n In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet].  Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n Available\n\nfrom:\n\n- 59.  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults.  Nature [Internet]. ",
        "original_sentence": "Available\n\nfrom:\n\n- 59. "
      }
    },
    {
      "chunk_id": "chunk_1084",
      "text": "Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1083,
        "window_size": 3,
        "char_count": 74,
        "word_count": 14,
        "page_number": 23,
        "window_text": "In:\n\nLiverTox:\n\nClinical\n\nand\n\nResearch\n\nInformation\n\non\n\nDrug-Induced Liver Injury [Internet].  Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n Available\n\nfrom:\n\n- 59.  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults.  Nature [Internet].  2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n",
        "original_sentence": "Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. "
      }
    },
    {
      "chunk_id": "chunk_1085",
      "text": "Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1084,
        "window_size": 3,
        "char_count": 61,
        "word_count": 10,
        "page_number": 4,
        "window_text": "Bethesda (MD): National Institute of Diabetes\n\nand\n\nDigestive\n\nand\n\nKidney\n\nDiseases;\n\n2012\n\n[cited\n\n2021\n\nMay\n\n27].\n\n Available\n\nfrom:\n\n- 59.  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults.  Nature [Internet].  2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60. ",
        "original_sentence": "Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults. "
      }
    },
    {
      "chunk_id": "chunk_1086",
      "text": "Nature [Internet]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1085,
        "window_size": 3,
        "char_count": 19,
        "word_count": 2,
        "page_number": 65,
        "window_text": "Available\n\nfrom:\n\n- 59.  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults.  Nature [Internet].  2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60.  Bovay A, Speiser DE, Marraco SAF. ",
        "original_sentence": "Nature [Internet]. "
      }
    },
    {
      "chunk_id": "chunk_1087",
      "text": "2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1086,
        "window_size": 3,
        "char_count": 52,
        "word_count": 6,
        "page_number": 4,
        "window_text": "Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.  Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults.  Nature [Internet].  2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60.  Bovay A, Speiser DE, Marraco SAF.  Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination. ",
        "original_sentence": "2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1088",
      "text": "Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1087,
        "window_size": 3,
        "char_count": 49,
        "word_count": 5,
        "page_number": 8,
        "window_text": "Phase\nI/II study of COVID-19 RNA vaccine BNT162b1 in adults.  Nature [Internet].  2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60.  Bovay A, Speiser DE, Marraco SAF.  Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination.  Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n",
        "original_sentence": "Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60. "
      }
    },
    {
      "chunk_id": "chunk_1089",
      "text": "Bovay A, Speiser DE, Marraco SAF. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1088,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 65,
        "window_text": "Nature [Internet].  2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60.  Bovay A, Speiser DE, Marraco SAF.  Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination.  Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n 2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n",
        "original_sentence": "Bovay A, Speiser DE, Marraco SAF. "
      }
    },
    {
      "chunk_id": "chunk_1090",
      "text": "Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1089,
        "window_size": 3,
        "char_count": 121,
        "word_count": 17,
        "page_number": 8,
        "window_text": "2020 Oct\n\n[cited\n\n2021\n\nMay\n\n27];586(7830):589–93.\n\n Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60.  Bovay A, Speiser DE, Marraco SAF.  Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination.  Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n 2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n 70/72\n\n- 61. ",
        "original_sentence": "Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination. "
      }
    },
    {
      "chunk_id": "chunk_1091",
      "text": "Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1090,
        "window_size": 3,
        "char_count": 40,
        "word_count": 4,
        "page_number": 23,
        "window_text": "Available\n\nfrom:\n\nhttps://www.nature.com/\n\n- 60.  Bovay A, Speiser DE, Marraco SAF.  Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination.  Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n 2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n 70/72\n\n- 61.  Faguet GB. ",
        "original_sentence": "Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1092",
      "text": "2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1091,
        "window_size": 3,
        "char_count": 54,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Bovay A, Speiser DE, Marraco SAF.  Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination.  Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n 2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n 70/72\n\n- 61.  Faguet GB.  The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes. ",
        "original_sentence": "2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1093",
      "text": "70/72\n\n- 61. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1092,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Early drop of circulating T cells negatively\ncorrelates with the protective immune response to Yellow Fever vaccination.  Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n 2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n 70/72\n\n- 61.  Faguet GB.  The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes.  J Infect Dis. ",
        "original_sentence": "70/72\n\n- 61. "
      }
    },
    {
      "chunk_id": "chunk_1094",
      "text": "Faguet GB. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1093,
        "window_size": 3,
        "char_count": 11,
        "word_count": 2,
        "page_number": 65,
        "window_text": "Hum\n\nVaccines\n\nImmunother\n\n[Internet].\n\n 2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n 70/72\n\n- 61.  Faguet GB.  The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes.  J Infect Dis.  1981 Feb;143(2):252–8.\n\n",
        "original_sentence": "Faguet GB. "
      }
    },
    {
      "chunk_id": "chunk_1095",
      "text": "The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1094,
        "window_size": 3,
        "char_count": 90,
        "word_count": 14,
        "page_number": 8,
        "window_text": "2020\n\nDec\n\n1\n\n[cited\n\n2021\n\nMar\n\n20];16(12):3103–10.\n\n 70/72\n\n- 61.  Faguet GB.  The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes.  J Infect Dis.  1981 Feb;143(2):252–8.\n\n - 62. ",
        "original_sentence": "The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes. "
      }
    },
    {
      "chunk_id": "chunk_1096",
      "text": "J Infect Dis. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1095,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 69,
        "window_text": "70/72\n\n- 61.  Faguet GB.  The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes.  J Infect Dis.  1981 Feb;143(2):252–8.\n\n - 62.  Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. ",
        "original_sentence": "J Infect Dis. "
      }
    },
    {
      "chunk_id": "chunk_1097",
      "text": "1981 Feb;143(2):252–8.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1096,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 4,
        "window_text": "Faguet GB.  The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes.  J Infect Dis.  1981 Feb;143(2):252–8.\n\n - 62.  Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al.  Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial. ",
        "original_sentence": "1981 Feb;143(2):252–8.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1098",
      "text": "- 62. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1097,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "The effect of killed influenza virus vaccine on the kinetics of normal\nhuman lymphocytes.  J Infect Dis.  1981 Feb;143(2):252–8.\n\n - 62.  Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al.  Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial.  Lancet Lond Engl.\n\n",
        "original_sentence": "- 62. "
      }
    },
    {
      "chunk_id": "chunk_1099",
      "text": "Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1098,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 26,
        "window_text": "J Infect Dis.  1981 Feb;143(2):252–8.\n\n - 62.  Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al.  Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial.  Lancet Lond Engl.\n\n 2017 Sep 23;390(10101):1511–20.\n\n",
        "original_sentence": "Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. "
      }
    },
    {
      "chunk_id": "chunk_1100",
      "text": "Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1099,
        "window_size": 3,
        "char_count": 164,
        "word_count": 20,
        "page_number": 8,
        "window_text": "1981 Feb;143(2):252–8.\n\n - 62.  Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al.  Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial.  Lancet Lond Engl.\n\n 2017 Sep 23;390(10101):1511–20.\n\n - 63. ",
        "original_sentence": "Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial. "
      }
    },
    {
      "chunk_id": "chunk_1101",
      "text": "Lancet Lond Engl.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1100,
        "window_size": 3,
        "char_count": 19,
        "word_count": 3,
        "page_number": 65,
        "window_text": "- 62.  Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al.  Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial.  Lancet Lond Engl.\n\n 2017 Sep 23;390(10101):1511–20.\n\n - 63.  Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. ",
        "original_sentence": "Lancet Lond Engl.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1102",
      "text": "2017 Sep 23;390(10101):1511–20.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1101,
        "window_size": 3,
        "char_count": 33,
        "word_count": 3,
        "page_number": 70,
        "window_text": "Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al.  Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial.  Lancet Lond Engl.\n\n 2017 Sep 23;390(10101):1511–20.\n\n - 63.  Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al.  Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease. ",
        "original_sentence": "2017 Sep 23;390(10101):1511–20.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1103",
      "text": "- 63. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1102,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Safety and\nimmunogenicity\n\nof\n\na\n\nmRNA\n\nrabies\n\nvaccine\n\nin\n\nhealthy\n\nadults:\n\nan\n\nopen-label,\n\nnon-randomised, prospective, first-in-human phase 1 clinical trial.  Lancet Lond Engl.\n\n 2017 Sep 23;390(10101):1511–20.\n\n - 63.  Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al.  Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease.  Cell. ",
        "original_sentence": "- 63. "
      }
    },
    {
      "chunk_id": "chunk_1104",
      "text": "Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1103,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Lancet Lond Engl.\n\n 2017 Sep 23;390(10101):1511–20.\n\n - 63.  Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al.  Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease.  Cell.  2017 Jul\n\n13;170(2):273–283.e12.\n\n",
        "original_sentence": "Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. "
      }
    },
    {
      "chunk_id": "chunk_1105",
      "text": "Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1104,
        "window_size": 3,
        "char_count": 75,
        "word_count": 8,
        "page_number": 23,
        "window_text": "2017 Sep 23;390(10101):1511–20.\n\n - 63.  Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al.  Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease.  Cell.  2017 Jul\n\n13;170(2):273–283.e12.\n\n - 64. ",
        "original_sentence": "Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease. "
      }
    },
    {
      "chunk_id": "chunk_1106",
      "text": "Cell. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1105,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 70,
        "window_text": "- 63.  Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al.  Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease.  Cell.  2017 Jul\n\n13;170(2):273–283.e12.\n\n - 64.  Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al. ",
        "original_sentence": "Cell. "
      }
    },
    {
      "chunk_id": "chunk_1107",
      "text": "2017 Jul\n\n13;170(2):273–283.e12.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1106,
        "window_size": 3,
        "char_count": 34,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al.  Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease.  Cell.  2017 Jul\n\n13;170(2):273–283.e12.\n\n - 64.  Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.  A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile. ",
        "original_sentence": "2017 Jul\n\n13;170(2):273–283.e12.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1108",
      "text": "- 64. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1107,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Vaccine\nMediated Protection Against Zika Virus-Induced Congenital Disease.  Cell.  2017 Jul\n\n13;170(2):273–283.e12.\n\n - 64.  Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.  A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile.  Int J Cancer. ",
        "original_sentence": "- 64. "
      }
    },
    {
      "chunk_id": "chunk_1109",
      "text": "Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1108,
        "window_size": 3,
        "char_count": 73,
        "word_count": 14,
        "page_number": 65,
        "window_text": "Cell.  2017 Jul\n\n13;170(2):273–283.e12.\n\n - 64.  Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.  A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile.  Int J Cancer.  2015 Jul 15;137(2):372–84.\n\n",
        "original_sentence": "Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al. "
      }
    },
    {
      "chunk_id": "chunk_1110",
      "text": "A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1109,
        "window_size": 3,
        "char_count": 106,
        "word_count": 13,
        "page_number": 8,
        "window_text": "2017 Jul\n\n13;170(2):273–283.e12.\n\n - 64.  Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.  A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile.  Int J Cancer.  2015 Jul 15;137(2):372–84.\n\n - 65. ",
        "original_sentence": "A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile. "
      }
    },
    {
      "chunk_id": "chunk_1111",
      "text": "Int J Cancer. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1110,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 66,
        "window_text": "- 64.  Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.  A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile.  Int J Cancer.  2015 Jul 15;137(2):372–84.\n\n - 65.  Shimabukuro TT, Cole M, Su JR. ",
        "original_sentence": "Int J Cancer. "
      }
    },
    {
      "chunk_id": "chunk_1112",
      "text": "2015 Jul 15;137(2):372–84.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1111,
        "window_size": 3,
        "char_count": 28,
        "word_count": 3,
        "page_number": 4,
        "window_text": "Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.  A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile.  Int J Cancer.  2015 Jul 15;137(2):372–84.\n\n - 65.  Shimabukuro TT, Cole M, Su JR.  Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. ",
        "original_sentence": "2015 Jul 15;137(2):372–84.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1113",
      "text": "- 65. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1112,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "A novel\nRNA-based adjuvant combines strong immunostimulatory capacities with a favorable\n\nsafety profile.  Int J Cancer.  2015 Jul 15;137(2):372–84.\n\n - 65.  Shimabukuro TT, Cole M, Su JR.  Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021.  JAMA [Internet].\n\n",
        "original_sentence": "- 65. "
      }
    },
    {
      "chunk_id": "chunk_1114",
      "text": "Shimabukuro TT, Cole M, Su JR. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1113,
        "window_size": 3,
        "char_count": 31,
        "word_count": 6,
        "page_number": 65,
        "window_text": "Int J Cancer.  2015 Jul 15;137(2):372–84.\n\n - 65.  Shimabukuro TT, Cole M, Su JR.  Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021.  JAMA [Internet].\n\n 2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n",
        "original_sentence": "Shimabukuro TT, Cole M, Su JR. "
      }
    },
    {
      "chunk_id": "chunk_1115",
      "text": "Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1114,
        "window_size": 3,
        "char_count": 109,
        "word_count": 16,
        "page_number": 8,
        "window_text": "2015 Jul 15;137(2):372–84.\n\n - 65.  Shimabukuro TT, Cole M, Su JR.  Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021.  JAMA [Internet].\n\n 2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n Available\n\nfrom:\n\n- 66. ",
        "original_sentence": "Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. "
      }
    },
    {
      "chunk_id": "chunk_1116",
      "text": "JAMA [Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1115,
        "window_size": 3,
        "char_count": 18,
        "word_count": 2,
        "page_number": 65,
        "window_text": "- 65.  Shimabukuro TT, Cole M, Su JR.  Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021.  JAMA [Internet].\n\n 2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n Available\n\nfrom:\n\n- 66.  Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L. ",
        "original_sentence": "JAMA [Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1117",
      "text": "2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1116,
        "window_size": 3,
        "char_count": 52,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Shimabukuro TT, Cole M, Su JR.  Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021.  JAMA [Internet].\n\n 2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n Available\n\nfrom:\n\n- 66.  Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L.  [cited 2021 May 1]. ",
        "original_sentence": "2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1118",
      "text": "Available\n\nfrom:\n\n- 66. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1117,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 8,
        "window_text": "Reports of Anaphylaxis After Receipt of mRNA\nCOVID-19 Vaccines in the US—December 14, 2020-January 18, 2021.  JAMA [Internet].\n\n 2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n Available\n\nfrom:\n\n- 66.  Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L.  [cited 2021 May 1].  Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67. ",
        "original_sentence": "Available\n\nfrom:\n\n- 66. "
      }
    },
    {
      "chunk_id": "chunk_1119",
      "text": "Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1118,
        "window_size": 3,
        "char_count": 213,
        "word_count": 24,
        "page_number": 8,
        "window_text": "JAMA [Internet].\n\n 2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n Available\n\nfrom:\n\n- 66.  Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L.  [cited 2021 May 1].  Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67.  Castells MC, Phillips EJ. ",
        "original_sentence": "Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L. "
      }
    },
    {
      "chunk_id": "chunk_1120",
      "text": "[cited 2021 May 1]. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1119,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 4,
        "window_text": "2021\n\nMar\n\n16\n\n[cited\n\n2021\n\nMay\n\n1];325(11):1101.\n\n Available\n\nfrom:\n\n- 66.  Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L.  [cited 2021 May 1].  Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67.  Castells MC, Phillips EJ.  Maintaining Safety with SARS-CoV-2 Vaccines. ",
        "original_sentence": "[cited 2021 May 1]. "
      }
    },
    {
      "chunk_id": "chunk_1121",
      "text": "Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1120,
        "window_size": 3,
        "char_count": 204,
        "word_count": 7,
        "page_number": 8,
        "window_text": "Available\n\nfrom:\n\n- 66.  Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L.  [cited 2021 May 1].  Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67.  Castells MC, Phillips EJ.  Maintaining Safety with SARS-CoV-2 Vaccines.  N Engl J\nMed\n\n[Internet].\n\n",
        "original_sentence": "Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67. "
      }
    },
    {
      "chunk_id": "chunk_1122",
      "text": "Castells MC, Phillips EJ. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1121,
        "window_size": 3,
        "char_count": 26,
        "word_count": 4,
        "page_number": 66,
        "window_text": "Public\nAssessment\n\nReport\n\nNational\n\nProcedure:\n\nCOVID-19\n\nVaccine\n\nModerna,\n\n- 0.20\nmg/mL dispersion for\n\ninjection\n\n(COVID-19 mRNA\n\nVaccine\n\n[nucleoside-modified]),\n\nPLGB 53720/0002, Moderna Biotech Spain, S.L.  [cited 2021 May 1].  Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67.  Castells MC, Phillips EJ.  Maintaining Safety with SARS-CoV-2 Vaccines.  N Engl J\nMed\n\n[Internet].\n\n 2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n",
        "original_sentence": "Castells MC, Phillips EJ. "
      }
    },
    {
      "chunk_id": "chunk_1123",
      "text": "Maintaining Safety with SARS-CoV-2 Vaccines. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1122,
        "window_size": 3,
        "char_count": 45,
        "word_count": 5,
        "page_number": 23,
        "window_text": "[cited 2021 May 1].  Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67.  Castells MC, Phillips EJ.  Maintaining Safety with SARS-CoV-2 Vaccines.  N Engl J\nMed\n\n[Internet].\n\n 2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n Available\n\nfrom:\n\n- 68. ",
        "original_sentence": "Maintaining Safety with SARS-CoV-2 Vaccines. "
      }
    },
    {
      "chunk_id": "chunk_1124",
      "text": "N Engl J\nMed\n\n[Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1123,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 65,
        "window_text": "Available from:\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme\n\nnt_data/file/977367/UKPAR_COVID_19_Vaccine_Moderna_07.04.2021_CMA_Reliance_P\n\nAR__-__final.pdf\n\n- 67.  Castells MC, Phillips EJ.  Maintaining Safety with SARS-CoV-2 Vaccines.  N Engl J\nMed\n\n[Internet].\n\n 2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n Available\n\nfrom:\n\n- 68.  Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69. ",
        "original_sentence": "N Engl J\nMed\n\n[Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1125",
      "text": "2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1124,
        "window_size": 3,
        "char_count": 52,
        "word_count": 7,
        "page_number": 4,
        "window_text": "Castells MC, Phillips EJ.  Maintaining Safety with SARS-CoV-2 Vaccines.  N Engl J\nMed\n\n[Internet].\n\n 2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n Available\n\nfrom:\n\n- 68.  Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69.  FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n",
        "original_sentence": "2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1126",
      "text": "Available\n\nfrom:\n\n- 68. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1125,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 8,
        "window_text": "Maintaining Safety with SARS-CoV-2 Vaccines.  N Engl J\nMed\n\n[Internet].\n\n 2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n Available\n\nfrom:\n\n- 68.  Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69.  FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n",
        "original_sentence": "Available\n\nfrom:\n\n- 68. "
      }
    },
    {
      "chunk_id": "chunk_1127",
      "text": "Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1126,
        "window_size": 3,
        "char_count": 93,
        "word_count": 12,
        "page_number": 65,
        "window_text": "N Engl J\nMed\n\n[Internet].\n\n 2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n Available\n\nfrom:\n\n- 68.  Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69.  FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n - 70. ",
        "original_sentence": "Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69. "
      }
    },
    {
      "chunk_id": "chunk_1128",
      "text": "FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1127,
        "window_size": 3,
        "char_count": 163,
        "word_count": 20,
        "page_number": 23,
        "window_text": "2021\n\nFeb\n\n18\n\n[cited\n\n2021\n\nMay\n\n1];384(7):643–9.\n\n Available\n\nfrom:\n\n- 68.  Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69.  FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n - 70.  EMA\nAssessment\n\nReport.\n\n",
        "original_sentence": "FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1129",
      "text": "https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1128,
        "window_size": 3,
        "char_count": 67,
        "word_count": 5,
        "page_number": 4,
        "window_text": "Available\n\nfrom:\n\n- 68.  Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69.  FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n - 70.  EMA\nAssessment\n\nReport.\n\n COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n",
        "original_sentence": "https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1130",
      "text": "- 70. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1129,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Sellaturay\nP,\n\nNasser\n\nS,\n\nEwan\n\nP.\n\nPolyethylene\n\nGlycol-Induced\n\nSystemic\n\nAllergic\n\n- 69.  FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n - 70.  EMA\nAssessment\n\nReport.\n\n COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n 6\n\nJan\n\n- 2021.\n",
        "original_sentence": "- 70. "
      }
    },
    {
      "chunk_id": "chunk_1131",
      "text": "EMA\nAssessment\n\nReport.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1130,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 67,
        "window_text": "FDA\npresentation\n\nto\n\ntheir\n\nVaccines\n\nand\n\nRelated\n\nBiological\n\nProducts\n\nAdvisory\n\nCommittee on December 17, 2020 regarding Moderna COVID-19 candidate vaccine.\n\n https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n - 70.  EMA\nAssessment\n\nReport.\n\n COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n 6\n\nJan\n\n- 2021.\n - 71. ",
        "original_sentence": "EMA\nAssessment\n\nReport.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1132",
      "text": "COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1131,
        "window_size": 3,
        "char_count": 37,
        "word_count": 4,
        "page_number": 4,
        "window_text": "https://www.fda.gov/media/144585/download, accessed June 1, 2021.\n\n - 70.  EMA\nAssessment\n\nReport.\n\n COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n 6\n\nJan\n\n- 2021.\n - 71.  UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72. ",
        "original_sentence": "COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1133",
      "text": "6\n\nJan\n\n- 2021.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1132,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 4,
        "window_text": "- 70.  EMA\nAssessment\n\nReport.\n\n COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n 6\n\nJan\n\n- 2021.\n - 71.  UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72.  US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n",
        "original_sentence": "6\n\nJan\n\n- 2021.\n"
      }
    },
    {
      "chunk_id": "chunk_1134",
      "text": "- 71. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1133,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 4,
        "window_text": "EMA\nAssessment\n\nReport.\n\n COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n 6\n\nJan\n\n- 2021.\n - 71.  UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72.  US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73. ",
        "original_sentence": "- 71. "
      }
    },
    {
      "chunk_id": "chunk_1135",
      "text": "UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1134,
        "window_size": 3,
        "char_count": 83,
        "word_count": 13,
        "page_number": 4,
        "window_text": "COVID-19\n\nVaccine\n\nReport\n\nModerna.\n\n 6\n\nJan\n\n- 2021.\n - 71.  UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72.  US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73.  US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n",
        "original_sentence": "UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72. "
      }
    },
    {
      "chunk_id": "chunk_1136",
      "text": "US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1135,
        "window_size": 3,
        "char_count": 66,
        "word_count": 7,
        "page_number": 8,
        "window_text": "6\n\nJan\n\n- 2021.\n - 71.  UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72.  US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73.  US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74. ",
        "original_sentence": "US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1137",
      "text": "2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1136,
        "window_size": 3,
        "char_count": 99,
        "word_count": 12,
        "page_number": 4,
        "window_text": "- 71.  UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72.  US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73.  US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. ",
        "original_sentence": "2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73. "
      }
    },
    {
      "chunk_id": "chunk_1138",
      "text": "US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1137,
        "window_size": 3,
        "char_count": 58,
        "word_count": 7,
        "page_number": 4,
        "window_text": "UK MHRA Public Assessment Report: COVID-19 mRNA Vaccine BNT162b2 2020\n71/72\n\n- 72.  US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73.  US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n",
        "original_sentence": "US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1139",
      "text": "2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1138,
        "window_size": 3,
        "char_count": 55,
        "word_count": 4,
        "page_number": 4,
        "window_text": "US\nFDA\n\nReview\n\nMemorandum:\n\nPfizer-BioNTech\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73.  US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n - 75. ",
        "original_sentence": "2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74. "
      }
    },
    {
      "chunk_id": "chunk_1140",
      "text": "Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1139,
        "window_size": 3,
        "char_count": 115,
        "word_count": 13,
        "page_number": 26,
        "window_text": "2020\n\nhttps://www.fda.gov/media/144416/download Accessed June 1, 2021 Accessed June 1, 2021\n\n- 73.  US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n - 75.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. ",
        "original_sentence": "Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. "
      }
    },
    {
      "chunk_id": "chunk_1141",
      "text": "Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1140,
        "window_size": 3,
        "char_count": 114,
        "word_count": 16,
        "page_number": 23,
        "window_text": "US\nFDA\n\nReview\n\nMemorandum:\n\nModerna\n\nCOVID-19\n\nvaccine.\n\n 2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n - 75.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n",
        "original_sentence": "Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n"
      }
    },
    {
      "chunk_id": "chunk_1142",
      "text": "- 75. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1141,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "2020\n\nhttps://www.fda.gov/media/144673/download\n\n- 74.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n - 75.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n - 76. ",
        "original_sentence": "- 75. "
      }
    },
    {
      "chunk_id": "chunk_1143",
      "text": "Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1142,
        "window_size": 3,
        "char_count": 115,
        "word_count": 13,
        "page_number": 26,
        "window_text": "Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n - 75.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n - 76.  Expert consultation on the use of placebos in vaccine trials. ",
        "original_sentence": "Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available. "
      }
    },
    {
      "chunk_id": "chunk_1144",
      "text": "Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1143,
        "window_size": 3,
        "char_count": 114,
        "word_count": 16,
        "page_number": 23,
        "window_text": "Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n10,\n\n- 2020.\n - 75.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n - 76.  Expert consultation on the use of placebos in vaccine trials.  Meeting report. ",
        "original_sentence": "Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n"
      }
    },
    {
      "chunk_id": "chunk_1145",
      "text": "- 76. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1144,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "- 75.  Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n - 76.  Expert consultation on the use of placebos in vaccine trials.  Meeting report.  Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77. ",
        "original_sentence": "- 76. "
      }
    },
    {
      "chunk_id": "chunk_1146",
      "text": "Expert consultation on the use of placebos in vaccine trials. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1145,
        "window_size": 3,
        "char_count": 62,
        "word_count": 10,
        "page_number": 8,
        "window_text": "Goodman\nS.\n\nConsiderations\n\nfor\n\nplacebo-controlled\n\ntrial\n\ndesign\n\nif\n\nan\n\nunlicensed\n\nvaccine becomes available.  Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n - 76.  Expert consultation on the use of placebos in vaccine trials.  Meeting report.  Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77.  Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n",
        "original_sentence": "Expert consultation on the use of placebos in vaccine trials. "
      }
    },
    {
      "chunk_id": "chunk_1147",
      "text": "Meeting report. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1146,
        "window_size": 3,
        "char_count": 16,
        "word_count": 2,
        "page_number": 23,
        "window_text": "Presentation to US FDA Vaccines and Related Biological\n\nProducts\n\nAdvisory\n\nCommittee\n\non\n\nDecember\n\n17,\n\n- 2020.\n - 76.  Expert consultation on the use of placebos in vaccine trials.  Meeting report.  Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77.  Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n :31.\n\n",
        "original_sentence": "Meeting report. "
      }
    },
    {
      "chunk_id": "chunk_1148",
      "text": "Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1147,
        "window_size": 3,
        "char_count": 143,
        "word_count": 13,
        "page_number": 4,
        "window_text": "- 76.  Expert consultation on the use of placebos in vaccine trials.  Meeting report.  Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77.  Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n :31.\n\n - 78. ",
        "original_sentence": "Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77. "
      }
    },
    {
      "chunk_id": "chunk_1149",
      "text": "Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1148,
        "window_size": 3,
        "char_count": 77,
        "word_count": 10,
        "page_number": 23,
        "window_text": "Expert consultation on the use of placebos in vaccine trials.  Meeting report.  Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77.  Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n :31.\n\n - 78.  Weir JP, Gruber MF. ",
        "original_sentence": "Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1150",
      "text": ":31.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1149,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 71,
        "window_text": "Meeting report.  Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77.  Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n :31.\n\n - 78.  Weir JP, Gruber MF.  An overview of the regulation of influenza vaccines in the\n- 79. ",
        "original_sentence": ":31.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1151",
      "text": "- 78. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1150,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 26,
        "window_text": "Geneva:\nWorld Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/94056/1/\n\n9789241506250_eng.pdf Accessed June 1, 2021\n\n- 77.  Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n :31.\n\n - 78.  Weir JP, Gruber MF.  An overview of the regulation of influenza vaccines in the\n- 79.  Marta DJ. ",
        "original_sentence": "- 78. "
      }
    },
    {
      "chunk_id": "chunk_1152",
      "text": "Weir JP, Gruber MF. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1151,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 65,
        "window_text": "Guideline\non\n\nInfluenza\n\nVaccines\n\n- -\nNon-clinical\n\nand\n\nClinical\n\nModule.\n\n :31.\n\n - 78.  Weir JP, Gruber MF.  An overview of the regulation of influenza vaccines in the\n- 79.  Marta DJ.  Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n",
        "original_sentence": "Weir JP, Gruber MF. "
      }
    },
    {
      "chunk_id": "chunk_1153",
      "text": "An overview of the regulation of influenza vaccines in the\n- 79. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1152,
        "window_size": 3,
        "char_count": 65,
        "word_count": 12,
        "page_number": 8,
        "window_text": ":31.\n\n - 78.  Weir JP, Gruber MF.  An overview of the regulation of influenza vaccines in the\n- 79.  Marta DJ.  Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n :7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80. ",
        "original_sentence": "An overview of the regulation of influenza vaccines in the\n- 79. "
      }
    },
    {
      "chunk_id": "chunk_1154",
      "text": "Marta DJ. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1153,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 66,
        "window_text": "- 78.  Weir JP, Gruber MF.  An overview of the regulation of influenza vaccines in the\n- 79.  Marta DJ.  Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n :7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80.  Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n",
        "original_sentence": "Marta DJ. "
      }
    },
    {
      "chunk_id": "chunk_1155",
      "text": "Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1154,
        "window_size": 3,
        "char_count": 140,
        "word_count": 17,
        "page_number": 65,
        "window_text": "Weir JP, Gruber MF.  An overview of the regulation of influenza vaccines in the\n- 79.  Marta DJ.  Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n :7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80.  Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n HSA.\n\n",
        "original_sentence": "Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1156",
      "text": ":7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1155,
        "window_size": 3,
        "char_count": 185,
        "word_count": 6,
        "page_number": 8,
        "window_text": "An overview of the regulation of influenza vaccines in the\n- 79.  Marta DJ.  Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n :7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80.  Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n HSA.\n\n [cited\n\n2021\n\nMay\n\n2].\n\n",
        "original_sentence": ":7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80. "
      }
    },
    {
      "chunk_id": "chunk_1157",
      "text": "Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1156,
        "window_size": 3,
        "char_count": 92,
        "word_count": 11,
        "page_number": 23,
        "window_text": "Marta DJ.  Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n :7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80.  Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n HSA.\n\n [cited\n\n2021\n\nMay\n\n2].\n\n Available\n\nfrom:\n\n- 81. ",
        "original_sentence": "Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1158",
      "text": "HSA.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1157,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 71,
        "window_text": "Reflection paper on the regulatory requirements for vaccines intended to\nprovide\n\nprotection\n\nagainst\n\nvariant\n\nstrain(s)\n\nof\n\nSARS-CoV-2.\n\n :7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80.  Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n HSA.\n\n [cited\n\n2021\n\nMay\n\n2].\n\n Available\n\nfrom:\n\n- 81.  ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n",
        "original_sentence": "HSA.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1159",
      "text": "[cited\n\n2021\n\nMay\n\n2].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1158,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 4,
        "window_text": ":7.\n\nhttps://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulat\n\nory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf\n\nAccessed\n\n- 80.  Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n HSA.\n\n [cited\n\n2021\n\nMay\n\n2].\n\n Available\n\nfrom:\n\n- 81.  ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n [cited\n\n2021\n\nMay\n\n1].\n\n",
        "original_sentence": "[cited\n\n2021\n\nMay\n\n2].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1160",
      "text": "Available\n\nfrom:\n\n- 81. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1159,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 4,
        "window_text": "Access Consortium’s guidance on strain changes in authorised COVID-19 vaccines\n[Internet].\n\n HSA.\n\n [cited\n\n2021\n\nMay\n\n2].\n\n Available\n\nfrom:\n\n- 81.  ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n [cited\n\n2021\n\nMay\n\n1].\n\n Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n",
        "original_sentence": "Available\n\nfrom:\n\n- 81. "
      }
    },
    {
      "chunk_id": "chunk_1161",
      "text": "ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1160,
        "window_size": 3,
        "char_count": 125,
        "word_count": 14,
        "page_number": 4,
        "window_text": "HSA.\n\n [cited\n\n2021\n\nMay\n\n2].\n\n Available\n\nfrom:\n\n- 81.  ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n [cited\n\n2021\n\nMay\n\n1].\n\n Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n (Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n",
        "original_sentence": "ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1162",
      "text": "[cited\n\n2021\n\nMay\n\n1].\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1161,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 4,
        "window_text": "[cited\n\n2021\n\nMay\n\n2].\n\n Available\n\nfrom:\n\n- 81.  ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n [cited\n\n2021\n\nMay\n\n1].\n\n Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n (Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n 2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n",
        "original_sentence": "[cited\n\n2021\n\nMay\n\n1].\n\n"
      }
    },
    {
      "chunk_id": "chunk_1163",
      "text": "Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1162,
        "window_size": 3,
        "char_count": 100,
        "word_count": 6,
        "page_number": 8,
        "window_text": "Available\n\nfrom:\n\n- 81.  ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n [cited\n\n2021\n\nMay\n\n1].\n\n Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n (Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n 2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n 72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n",
        "original_sentence": "Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1164",
      "text": "(Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1163,
        "window_size": 3,
        "char_count": 66,
        "word_count": 7,
        "page_number": 4,
        "window_text": "ICMRA COVID-19 Virus Variants Workshop | International Coalition of Medicines\nRegulatory\n\nAuthorities\n\n(ICMRA)\n\n[Internet].\n\n [cited\n\n2021\n\nMay\n\n1].\n\n Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n (Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n 2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n 72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n 식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다. ",
        "original_sentence": "(Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1165",
      "text": "2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1164,
        "window_size": 3,
        "char_count": 139,
        "word_count": 16,
        "page_number": 4,
        "window_text": "[cited\n\n2021\n\nMay\n\n1].\n\n Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n (Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n 2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n 72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n 식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다.  신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n",
        "original_sentence": "2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n"
      }
    },
    {
      "chunk_id": "chunk_1166",
      "text": "72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1165,
        "window_size": 3,
        "char_count": 476,
        "word_count": 91,
        "page_number": 72,
        "window_text": "Available\n\nfrom:\n\nhttp://www.icmra.info/drupal/en/covid-19/10february2021.Gruber\n\nM,\n\nCavileri\n\nM.\n\n (Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n 2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n 72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n 식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다.  신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n 공익신고자 보호제도란?\n\n",
        "original_sentence": "72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1167",
      "text": "식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다. ",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1166,
        "window_size": 3,
        "char_count": 69,
        "word_count": 15,
        "page_number": 29,
        "window_text": "(Co-chairs)\n\nICMRA\n\nCOVID-19\n\nVirus\n\nVariants\n\nWorkshop\n\nreport.\n\n 2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n 72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n 식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다.  신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n 공익신고자 보호제도란?\n\n 공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n",
        "original_sentence": "식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_1168",
      "text": "신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1167,
        "window_size": 3,
        "char_count": 71,
        "word_count": 16,
        "page_number": 31,
        "window_text": "2021\n\nICMRA\n\nCOVID-19 Virus Variants Workshop | International Coalition of Medicines Regulatory\n\nAuthorities (ICMRA) (accessed 3/8/2021).\n\n 72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n 식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다.  신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n 공익신고자 보호제도란?\n\n 공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n",
        "original_sentence": "신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_1169",
      "text": "공익신고자 보호제도란?\n\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1168,
        "window_size": 3,
        "char_count": 14,
        "word_count": 2,
        "page_number": 72,
        "window_text": "72/72\n\n<!-- PAGE_72 -->\n#### 예방용 mRNA 백신 평가 가이드라인\n\n발\n\n행\n\n일\n\n2022년 01월 27일\n\n발\n\n행\n\n인\n\n식품의약품안전처 식품의약품안전평가원장 서경원\n\n편집위 원장\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부장 박인숙\n\n편 집 위 원\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n김재옥, 김영훈, 임재현, 김연희, 진미령, 배창준, 송주경, 이은경, 박소영,\n\n신진영, 이\n\n현, 방서영, 박종식, 신숙진, 송민지, 이경윤, 권혜진, 천수정\n\n도움주신 분\n\n(실무작업반)\n\n발 행 부 서\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n연\n\n락\n\n처\n\n식품의약품안전처 식품의약품안전평가원 바이오생약심사부 생물제제과\n\n전 화 번 호\n\n043) 719-3451\n\n팩 스 번 호\n\n043) 719-3450\n\n공익신고자 보호법이 항상 당신의 양심을 지켜드립니다.\n\n 식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다.  신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n 공익신고자 보호제도란?\n\n 공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n",
        "original_sentence": "공익신고자 보호제도란?\n\n"
      }
    },
    {
      "chunk_id": "chunk_1170",
      "text": "공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n",
      "metadata": {
        "source": "예방용+mRNA+백신+평가+가이드라인.pdf",
        "chunk_index": 1169,
        "window_size": 3,
        "char_count": 148,
        "word_count": 27,
        "page_number": 8,
        "window_text": "식약처의 공무원이나 관계자가 부조리한 행위를 하거나 부당하게 처리한 경우가 있을 때는 다음으로\n\n신고하여 주시기 바랍니다.  신고자의 신원은 절대 보장하겠으며 향후 민원처리에 있어 추호의 불편\n\n함이 없도록 최선을 다하여 도와드릴 것을 약속드립니다.\n\n 공익신고자 보호제도란?\n\n 공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n",
        "original_sentence": "공익신고자등(친족 또는 동거인 포함)이 공익신고 등으로 인하여 피해를 받지 않도록 비밀보장, 불이익\n\n보호조치, 신변보호조치 등을 통하여 보호하는 제도\n\n※보호조치요구방법\n\n식약처 홈페이지(www.mfds.go.kr) > 국민소통 >국민신문고 > 공직자 부조리신고\n"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 1170,
    "avg_chunk_length": 81.8068376068376,
    "min_chunk_length": 3,
    "max_chunk_length": 532,
    "total_characters": 95714,
    "total_words": 18229,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 4723,
    "heading_count": 96,
    "paragraph_count": 4338,
    "list_item_count": 104,
    "table_cell_count": 185,
    "tables_detected": 2,
    "chunks_generated": 1170
  }
}